0001140361-22-017906.txt : 20220506 0001140361-22-017906.hdr.sgml : 20220506 20220505171430 ACCESSION NUMBER: 0001140361-22-017906 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220505 DATE AS OF CHANGE: 20220505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHEMBIO DIAGNOSTICS, INC. CENTRAL INDEX KEY: 0001092662 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 880425691 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35569 FILM NUMBER: 22897670 BUSINESS ADDRESS: STREET 1: 555 WIRELESS BLVD. CITY: HAUPPAUGE STATE: NY ZIP: 11788 BUSINESS PHONE: (631) 924-1135 MAIL ADDRESS: STREET 1: 555 WIRELESS BLVD. CITY: HAUPPAUGE STATE: NY ZIP: 11788 FORMER COMPANY: FORMER CONFORMED NAME: Chembio Diagnostics Inc. DATE OF NAME CHANGE: 20040607 FORMER COMPANY: FORMER CONFORMED NAME: TRADING SOLUTIONS COM INC DATE OF NAME CHANGE: 19990805 10-Q 1 brhc10037126_10q.htm 10-Q
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

For the quarterly period ended March 31, 2022

OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from: ______ to ________

000-30379
(Commission File Number)

graphic

Chembio Diagnostics, Inc.
(Exact name of registrant as specified in its charter)

Nevada
 
88-0425691
(State or other jurisdiction of incorporation)
 
(IRS Employer Identification Number)

555 Wireless Blvd.
Hauppauge, NY 11788
(Address of principal executive offices including zip code)

(631) 924-1135
(Registrant’s telephone number, including area code)

N/A
(Former Name or Former Address, if Changed Since Last Report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 
Large accelerated filer ☐
Accelerated filer ☒
 
Non-accelerated filer ☐
Smaller reporting company ☒
 
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Yes ☐ No ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
 
Trading Symbol
 
Name of each exchange on which registered
Common Stock, $0.01 par value
 
CEMI
 
The NASDAQ Stock Market LLC

As of April 29, 2022, the registrant had 30,221,859 shares outstanding of its common stock, $.01 par value.


Quarterly Report on Form 10-Q
For The Quarterly Period Ended
March 31, 2022

Table of Contents

Chembio Diagnostics, Inc.

   
Page
     
Part I. FINANCIAL INFORMATION:
  
   
 
Item 1. Financial Statements:
  
     
 
4
     
 
5
     
  6
     
  7
     
  9
     
  10
     
  27
     
 
36
     
Part II. OTHER INFORMATION:
  
     
  36
     
  36
     
  43
     
44

2
Unless the context requires otherwise, the words ‘‘we,’’ ‘‘us,’’ ‘‘our,’’ ‘‘our company,’’ ‘‘Chembio’’ and similar terms refer to Chembio Diagnostics, Inc. and its consolidated subsidiaries.

DPP, STAT-PAK, STAT-VIEW and SURE CHECK are our registered trademarks, and CHEMBIO and MICRO READER are our trademarks. For convenience, these trademarks appear in this report without ® and ™ symbols, and that practice does not mean that we will not assert, to the fullest extent under applicable law, our rights to the trademarks.

FORWARD-LOOKING STATEMENTS AND STATISTICAL ESTIMATES

This report contains statements reflecting our views about our future performance that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are generally identified through the inclusion of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “objective,” “outlook,” “plan,” “potential,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would” or variations of such words or similar expressions. All statements addressing our future operating performance, and statements addressing events and developments that we expect or anticipate will occur in the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon currently available information, operating plans, and projections about future events and trends.

This report contains estimates, projections and other data concerning our industry, our business and the markets for our products. Where expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by the World Health Organization, or WHO. We also include data that we have compiled, obtained, identified or otherwise derived from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. Other than WHO, we do not expressly refer to the sources from which this data is derived.

Forward-looking statements and statistical estimates inherently involve risks and uncertainties that could cause actual results to differ materially from those predicted or expressed in this report. These risks and uncertainties include those described in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December31, 2021 or our 2021 Form 10-K, as filed with the Securities and Exchange Commission or the SEC, on March 3, 2022, and in Part II, Item 1A, “Risk Factors,” of this report. You should interpret many of the risks identified in these reports as being heightened as a result of the ongoing and numerous adverse impacts of COVID-19. Investors are cautioned not to place undue reliance on any forward-looking statements or statistical estimates, which speak only as of the date they are made. We undertake no obligation to update any forward-looking statement or statistical estimate, whether as a result of new information, future events or otherwise.
 

3
PART I
Item 1.
FINANCIAL STATEMENTS
 CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS

 
(Unaudited)
March 31,
2022
    
December 31,
2021
  
- ASSETS -
            
CURRENT ASSETS:
            
Cash and cash equivalents
  
$
24,399,388
    
$
28,772,892
  
Accounts receivable, net of allowance for doubtful accounts of $242,981 and $243,042 at March 31, 2022 and December 31, 2021, respectively
    
9,879,954
      
11,441,107
  
Inventories, net
    
11,844,121
      
12,920,451
  
Prepaid expenses and other current assets
    
2,097,491
      
2,096,399
  
TOTAL CURRENT ASSETS
    
48,220,954
      
55,230,849
  
                 
FIXED ASSETS:
                
Property, plant and equipment, net
    
8,414,313
      
8,556,773
  
Finance lease right-of-use asset, net
    
190,526
      
191,870
  
                 
OTHER ASSETS:
                
Operating lease right-of-use assets, net
    
5,693,482
      
5,891,906
  
Goodwill
    
-
      
3,022,787
  
Deposits and other assets
    
370,940
      
358,010
  
                 
TOTAL ASSETS
  
$
62,890,215
    
$
73,252,195
  
                 
- LIABILITIES AND STOCKHOLDERS’ EQUITY -
                
CURRENT LIABILITIES:
                
Accounts payable and accrued liabilities
  
$
10,542,851
    
$
13,127,993
  
Current portion of long-term debt
    
2,100,000
      
1,200,000
  
Operating lease liabilities
    
916,524
      
886,294
  
Finance lease liabilities
    
72,203
      
68,176
  
TOTAL CURRENT LIABILITIES
    
13,631,578
      
15,282,463
  
                 
OTHER LIABILITIES:
                
Long-term operating lease liabilities
    
5,733,214
      
5,976,151
  
Long-term finance lease liabilities
    
134,955
      
139,678
  
Long-term debt, net
    
16,855,322
      
17,589,003
  
                 
TOTAL LIABILITIES
    
36,355,069
      
38,987,295
  
                 
COMMITMENTS AND CONTINGENCIES
           
                 
STOCKHOLDERS’ EQUITY:
                
Preferred stock - 10,000,000 shares authorized; none outstanding
    
-
      
-
  
Common stock - $0.01 par value; 100,000,000 shares authorized; 30,269,916 shares and 30,104,986 shares issued at March 31, 2022 and December 31, 2021, respectively
    
302,699
      
301,050
  
Additional paid-in capital
    
166,483,376
      
165,772,636
  
Accumulated deficit
    
(139,800,154
)
    
(131,009,860
)
Treasury Stock, 48,057  shares at cost, at March 31, 2022 and December 31, 2021
    
(206,554
)
    
(206,554
)
Accumulated other comprehensive (loss)
    
(244,221
)
    
(592,372
)
TOTAL STOCKHOLDERS’ EQUITY
    
26,535,146
      
34,264,900
  
                 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
  
$
62,890,215
    
$
73,252,195
  

See accompanying notes to condensed consolidated financial statements

4
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

 
For the three months
ended March 31,
  
   
2022
    
2021
  
REVENUES:
            
Product revenue
  
$
18,527,456
    
$
4,024,662
  
R&D revenue
    
18,173
      
1,106,639
  
Government grant income
    
-
      
3,350,000
  
License and royalty revenue
    
270,982
      
243,058
  
TOTAL REVENUES
    
18,816,611
      
8,724,359
  
                 
COSTS AND EXPENSES:
                
Cost of product revenue
    
15,223,861
      
3,548,441
  
Research and development expenses
    
1,653,706
      
2,863,338
  
Selling, general and administrative expenses
    
6,946,271
      
6,085,067
  
Impairment, restructuring, severance and related costs
    
3,043,179
      
83,087
  
TOTAL COSTS AND EXPENSES
    
26,867,017
      
12,579,933
  
                 
LOSS FROM OPERATIONS
    
(8,050,406
)
    
(3,855,574
)
                 
OTHER EXPENSE:
                
Interest expense, net
    
(733,561
)
    
(712,477
)
                 
LOSS BEFORE INCOME TAXES
    
(8,783,967
)
    
(4,568,051
)
                 
Income tax (expense)/benefit
    
(6,327
)
    
67,888
  
                 
NET LOSS
  
$
(8,790,294
)
  
$
(4,500,163
)
                 
Basic and diluted loss per share
  
$
(0.29
)
  
$
(0.22
)
                 
Weighted average number of shares outstanding, basic and diluted
    
30,090,045
      
20,163,386
  

See accompanying notes to condensed consolidated financial statements
5

CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)

 
  
For the three months
ended March 31,
  
 
  
2022
    
2021
  
Net loss
  
$
(8,790,294
)
  
$
(4,500,163
)
Other comprehensive income (loss):
                
Foreign currency translation adjustments, net of tax
    
348,151
      
(455,722
)
Comprehensive loss
  
$
(8,442,143
)
  
$
(4,955,885
)

See accompanying notes to condensed consolidated financial statements
6
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(Unaudited)


  
For the three months ended March 31, 2022
  
   
Common Stock
    
Additional
Paid-in-
Capital
    
Treasury
Stock
    
Accumulated
Deficit
    
AOCI
    
Total
  
   
Shares
    
Amount
    
Shares
    
Amount
  
Balance at December 31, 2021
    
30,104,986
    
$
301,050
    
$
165,772,636
      
(48,057
)
  
$
(206,554
)
  
$
(131,009,860
)
  
$
(592,372
)
  
$
34,264,900
  
                                                                 
Common Stock:
                                                                
Restricted stock issued
    
164,930
      
1,649
      
264,437
      
-
      
-
      
-
      
-
      
266,086
  
Restricted stock compensation, net 
    
-
      
-
      
229,563
      
-
      
-
      
-
      
-
      
229,563
  
Shares tendered for withholding taxes
    
-
      
-
      
(38,514
)
    
-
      
-
      
-
      
-
      
(38,514
)
                                                                 
Options:
                                                                
Stock option compensation
    
-
      
-
      
255,254
      
-
      
-
      
-
      
-
      
255,254
  
                                                                 
Comprehensive income
    
-
      
-
      
-
      
-
      
-
      
-
      
348,151
      
348,151
  
                                                                 
Net loss
    
-
      
-
      
-
      
-
      
-
      
(8,790,294
)
    
-
      
(8,790,294
)
                                                                 
Balance at March 31, 2022
    
30,269,916
    
$
302,699
    
$
166,483,376
      
(48,057
)
  
$
(206,554
)
  
$
(139,800,154
)
  
$
(244,221
)
  
$
26,535,146
  

7
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(Unaudited)

   
For the three months ended March 31, 2021
  
   
Common Stock
    
Additional
Paid-in-Capital
    
Treasury
Stock
    
Accumulated
Deficit
    
AOCI
    
Total
  
   
Shares
    
Amount
    
Shares
    
Amount
  
Balance at December 31, 2020
    
20,223,498
    
$
202,235
    
$
124,961,514
      
(41,141
)
  
$
(190,093
)
  
$
(97,106,331
)
  
$
(90,916
)
  
$
27,776,409
  
                                                                 
Common Stock:
                                                                
  Restricted stock issued
    
62,197
      
622
      
58,909
      
-
      
-
      
-
      
-
      
59,531
  
  Restricted stock compensation, net
    
-
      
-
      
309,010
      
-
      
-
      
-
      
-
      
309,010
  
  Shares tendered for withholding taxes
    
-
      
-
      
(115,059
)
    
-
      
-
      
-
      
-
      
(115,059
)
                                                                 
Options:
                                                                
  Stock option compensation
    
-
      
-
      
211,140
      
-
      
-
      
-
      
-
      
211,140
  
                                                                 
Comprehensive loss
    
-
      
-
      
-
      
-
      
-
      
-
      
(455,722
)
    
(455,722
)
                                                                 
Net loss
    
-
      
-
      
-
      
-
      
-
      
(4,500,163
)
    
-
      
(4,500,163
)
                                                                 
Balance at March 31, 2021
    
20,285,695
    
$
202,857
    
$
125,425,514
      
(41,141
)
  
$
(190,093
)
  
$
(101,606,494
)
  
$
(546,638
)
  
$
23,285,146
  

See accompanying notes to condensed consolidated financial statements
8
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED
(Unaudited)

 
March 31,
2022
    
March 31,
2021
  
             
CASH FLOWS FROM OPERATING ACTIVITIES:
            
Cash received from customers and grants
  
$
20,377,703
    
$
8,485,683
  
Cash paid to suppliers and employees
    
(23,810,426
)
    
(14,830,243
)
Cash paid for operating leases
    
(360,878
)
    
(347,871
)
Cash paid for finance leases
    
(4,686
)
    
(4,944
)
Interest and taxes, net
    
(570,672
)
    
(563,885
)
Net cash used in operating activities
    
(4,368,959
)
    
(7,261,260
)
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
                
Patent application costs
    
-
      
(4,130
)
Acquisition of and deposits on fixed assets
    
(286,544
)
    
(1,235,038
)
Net cash used in investing activities
    
(286,544
)
    
(1,239,168
)
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
                
Payments of tax withholding on stock award
    
(38,514
)
    
(115,059
)
Payments on finance lease
    
(16,930
)
    
(14,282
)
Net cash used in financing activities
    
(55,444
)
    
(129,341
)
                 
Effect of exchange rate changes on cash
    
337,443
      
(85,579
)
DECREASE IN CASH AND CASH EQUIVALENTS
    
(4,373,504
)
    
(8,715,348
)
Cash and cash equivalents - beginning of the period
    
28,772,892
      
23,066,301
  
                 
Cash and cash equivalents - end of the period
  
$
24,399,388
    
$
14,350,953
  
                 
RECONCILIATION OF NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:
                
                 
Net loss
  
$
(8,790,294
)
  
$
(4,500,163
)
Adjustments:
                
Depreciation and amortization
    
598,548
      
687,227
  
Share based compensation
    
750,903
      
579,789
  
Benefit from deferred tax liability
    
-
      
(69,941
)
Provision of (recovery of) doubtful accounts
    
(61
)
    
57,735
  
Impairment
    
3,033,565
      
-
  
Changes in assets and liabilities:
                
Accounts receivable
    
1,561,214
      
906,100
  
Inventories
    
1,076,330
      
(2,174,225
)
Prepaid expenses and other current assets
    
(387,297
)
    
(33,955
)
Deposits and other assets
    
373,275
      
134,480
  
Accounts payable and accrued liabilities
    
(2,585,142
)
    
(1,645,796
)
Deferred revenue
    
-
      
(1,202,511
)
Net cash used in operating activities
  
$
(4,368,959
)
  
$
(7,261,260
)

See accompanying notes to condensed consolidated financial statements
9
CHEMBIO DIAGNOSTICS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
March 31, 2022
(Unaudited)

NOTE 1 — DESCRIPTION OF BUSINESS:

Chembio Diagnostics, Inc. (“Chembio”) and its subsidiaries (collectively with Chembio, the “Company”) develop and commercialize point-of-care diagnostic tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment.

The Company’s product portfolio is based upon our proprietary DPP technology, a diagnostic platform that provides high-quality, cost-effective results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as STIs and HIV, Gastroenterology and Women’s Health. Compared with traditional lateral flow technology, the DPP technology platform can provide:
 

10
 
•
Enhanced sensitivity and specificity: This is achieved via the Company’s proprietary approach to separating the sample path from the buffer path, together with patent and other proprietary strategies, which differ significantly from traditional lateral flow test.
 
•
Advanced multiplexing capabilities: Through advanced multiplexing, the DPP platform can detect and differentiate up to eight distinct test results from a single patient sample, which can deliver greater clinical value than other rapid tests currently on the market.
 
•
Objective results: For some diagnostic applications, the Company’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzers can report accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still onsite. Objective results produced by the DPP Micro Reader can reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

The Company targets the market for rapid diagnostic test solutions for infectious diseases, which is driven by the high prevalence of infectious diseases globally, an increase in the geriatric population, growing demand for rapid test results, and advancements in multiplexing. The Company has a broad portfolio of infectious disease products, which prior to 2020 were focused principally on sexually transmitted disease and fever and tropical disease. In February 2020 the Company began the process of shifting substantially all of its resources to seek to leverage the DPP technology platform to address the acute and escalating need for diagnostic testing for COVID-19. The Company is continuing to pursue:

 
•
an emergency use authorization (“EUA”), from the U.S. Food and Drug Administration (the “FDA”), as well as 510(k) clearance from the FDA, for the DPP SARS-CoV-2 Antigen test system;
 
•
an EUA from the FDA for the DPP Respiratory Antigen Panel; and
 
•
a Clinical Laboratory Improvement Amendment (“CLIA”), waiver from the FDA for the DPP HIV-Syphilis test system.

NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES:


(a)
Basis of presentation:

The accompanying unaudited condensed consolidated financial statements include the accounts of Chembio and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Certain reclassifications have been made to the unaudited condensed consolidated balance sheet of the prior year to conform to the current year presentation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Chembio’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC.

Going Concern Considerations

The Company continued to experience market, clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of COVID-19 test systems during the continuing, but evolving, uncertainty resulting from COVID‑19. For the three months ended March 31, 2022, the Company continued to incur significant expenses in connection with pending legal matters (see Note 6 – Commitments, Contingencies, and Concentrations: Litigation).
 
The Company performed an assessment to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are being issued. Initially, this assessment did not consider the potential mitigating effect of management’s plans that had not been fully implemented. Because, as described below, substantial doubt was determined to exist as the result of this initial assessment, management then assessed the mitigating effect of its plans to determine if it is probable that the plans (1) would be effectively implemented within one year after the date the accompanying unaudited condensed consolidated financial statements are issued and (2) when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern.
 
11
The Company achieved significant revenue growth in recent years while profitability has not been at levels as expected. It has taken steps including investments in automation to mitigate headwinds such as labor availability, volatile capacity planning and implementation of operational efficiency targets to proactively monitor production with the overarching goal for profitable growth. During the three months ended March 31, 2022, the Company undertook measures to increase its total revenues and improve its liquidity position by implementing the Global Competitiveness Program. The main pillars of the Global Competitiveness Program include the following:

•
Focus on higher margin business in growth markets

•
Lower manufacturing costs

•
Reduce infrastructure costs

•
Strategic review of non-core businesses and assets:

In addition, the Company will continue to focus on regulatory approvals for its DPP SARS-CoV-2 Antigen test system, DPP Respiratory Antigen Panel, and DPP HIV-Syphilis test system. These measures and other plans and initiatives have been designed to provide the Company with adequate liquidity to meet its obligations for at least the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are being issued. The Company’s execution of those measures and its other plans and initiative continue to depend, however, on factors and uncertainties that are beyond the Company’s control, or that may not be addressable on terms acceptable to the Company or at all. The Company considered in particular how:

•
The ongoing healthcare and economic impacts of COVID-19 on the global customer base for the Company’s non‑COVID-19 products continue to negatively affect the timing and rate of recovery of the Company’s revenues from those products by, for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect the Company’s liquidity.

•
Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products.

12
The Company further considered how these factors and uncertainties could impact its ability over the next year to meet the obligations specified in the Credit Agreement with the Lender (both as defined in Note 7 – Long-Term Debt). Those obligations include covenants requiring: i) minimum cash balance of $3.0 million and ii) minimum total revenue amounts for the twelve months preceding each quarter end. For the next year, the minimum total revenue requirements range from $43.8 million for the twelve months ending June 30, 2022 to $48.8 million for the twelve months ending March 31, 2023. Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that the Company would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement or that, if such liquidity were not available, the Company would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern. The Company’s inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for its operations, could have a material adverse effect on its business, prospects, results of operations, liquidity and financial condition.

Accordingly, management determined the Company could not be certain that the Company’s plans and initiatives would be effectively implemented within one year after the date on which the accompanying unaudited condensed consolidated financial statements are being issued. Without giving effect to the prospect of raising additional capital pursuant to the Company’s At the Market Offering Agreement dated July 19, 2021 with Chembio Diagnostics, Inc. and Craig-Hallum Capital Group LLC, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond the Company’s control, it is unlikely that the Company will be able to generate sufficient cash flows to meet its required financial obligations, including its debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited condensed consolidated financial statements are being issued.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are issued. As such, the accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.


(b)
Significant Accounting Policies:

During the three months ended March 31, 2022, there has been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.


(c)
Fair Value of Financial Instruments:

The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate fair value due to the immediate or short-term maturity of these financial instruments. Included in cash and cash equivalents were $ 17.1 million and $25.0 million as of March 31, 2022 and December 31, 2021, respectively, of money market funds that are Level 1 fair value measurements under the hierarchy. The fair value of the Company’s total debt of $20.0 million (carrying value of $18.9 million) and $20.0 million (carrying value of $18.8 million) as of March 31, 2022 and December 31, 2021 respectively, is a Level 2 fair value measurement under the hierarchy and the Company’s debt face value approximates the recorded value, as the rate is based upon the current rates available to the Company for similar financial instruments.

Fair value measurements of all financial assets and liabilities that are measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:


Level 1:
Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

13

Level 2:
Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,


Level 3:
Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).


(d)
Cash and Cash Equivalents:

Cash and cash equivalents are defined as short-term, highly liquid investments, such as money market funds, with original maturities of three months or less at date of purchase.


(e)
Loss Per Share:

Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period excluding unvested restricted stock. Diluted loss per share for the three months ended March 31, 2022 and 2021 reflects the potential dilution from the exercise or conversion of other securities into common stock, if dilutive.

There were 3,760,787 and 1,848,286 options outstanding as of March 31, 2022 and 2021, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.

There were 1,739,944 and 847,795 shares of restricted stock outstanding as of March 31, 2022 and 2020, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.


(f)
Income Taxes:

At the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis, and may change in subsequent interim periods. Accordingly, the Company’s effective tax rate for the three months ended March 31, 2022 was (0.1)%, compared to the effective tax rate of 1.6% for the three months ended March 31, 2021. The Company’s effective tax rates for both periods were affected primarily by a full valuation allowance on domestic net deferred tax assets.


(g)
Recently Issued Accounting Standards Affecting the Company:

Recently Adopted

ASU 2021-10 - Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance

In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which creates Accounting Standards Codification (“ASC”) 832 and aims to provide increased transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. The disclosure requirements in ASC 832 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model (for example, in ASC 958-605, Not-for-Profit Entities – Revenue Recognition). The FASB broadly defined “government assistance” in ASC 832 to ensure that assistance received from most types of governmental entities or other related organizations would be disclosed.  Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The Company adopted the standard effective January 1, 2022 and has determined that the adoption did not have a material impact on the Company’s consolidated financial statements.

14
Not Yet Adopted

ASU 2020-06 - Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity

On August 5, 2020, the FASB issued ASU 2020-06, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. ASU 2020-06 simplifies the guidance in GAAP on the issuer’s accounting for convertible debt instruments, requires entities to provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance. The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.

ASU 2021-08—Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
  
On October 28, 2021, the FASB issued ASU 2021-08,1 which amends ASC 805 to “require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination.” Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. ASU 2021-08 amends ASC 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to “require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606.” While primarily related to contract assets and contract liabilities that were accounted for by the acquiree in accordance with ASC 606, “the amendments also apply to contract assets and contract liabilities from other contracts to which the provisions of Topic 606 apply, such as contract liabilities from the sale of nonfinancial assets within the scope of Subtopic 610-20.” The ASU’s amendments are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.

15
NOTE 3 — REVENUE:

Disaggregation of Revenue

The following table disaggregates Total Revenues by revenue type:

 
March 31, 2022
    
March 31, 2021
  
   
Exchange
Transactions
    
Non-Exchange
Transactions
    
Total
    
Exchange
Transactions
    
Non-Exchange
Transactions
    
Total
  
Net product revenue
  
$
18,527,456
    
$
-
    
$
18,527,456
    
$
4,024,662
    
$
-
    
$
4,024,662
  
R&D Revenue
    
18,173
      
-
      
18,173
      
1,106,639
      
-
      
1,106,639
  
Government grant revenue
    
–
      
–
      
–
      
–
      
3,350,000
      
3,350,000
  
License and royalty revenue
    
270,982
      
-
      
270,982
      
243,058
      
-
      
243,058
  
   
$
18,816,611
    
$
-
    
$
18,816,611
    
$
5,374,359
    
$
3,350,000
    
$
8,724,359
  

Exchange transactions are recognized in accordance with ASC 606, while non-exchange transactions are recognized in accordance with ASU No. 2018-08.

The following table disaggregates Total Revenues by geographic location:

 
For the three months ended
  
   
March 31, 2022
    
March 31, 2021
  
Africa
  
$
767,352
    
$
1,344,858
  
Asia
    
15,558
      
216,954
  
Europe & Middle East
    
723,745
      
2,600,274
  
Latin America
    
12,557,390
      
258,019
  
United States
    
4,752,566
      
4,304,254
  
   
$
18,816,611
    
$
8,724,359
  

NOTE 4 — INVENTORY:

Inventories are presented net of reserves and consist of the following at:

 
March 31,
2022
    
December 31,
2021
  
Raw materials
  
$
7,197,257
    
$
7,306,095
  
Work in process
    
1,932,069
      
3,556,878
  
Finished goods
    
2,714,795
      
2,057,478
  
   
$
11,844,121
    
$
12,920,451
  

NOTE 5 — STOCKHOLDERS’ EQUITY:

(a)
Common Stock

During the first three months of 2022 and 2021, there were no options exercised.

(b)
Preferred Stock

Chembio has 10,000,000 shares of preferred stock authorized and none outstanding. These shares can become issuable upon an approved resolution by the board of directors of Chembio (the “Board”) and the filing of a Certificate of Designation with the state of Nevada.

16
(c)
Treasury Stock

Chembio has 48,057 shares of treasury stock acquired upon the vesting of restricted stock awards related to the tax withholding requirements paid on behalf of the employees.

(d)
Options, Restricted Stock, and Restricted Stock Units

The Board or its Compensation Committee may issue options, restricted stock, and restricted stock units pursuant to equity incentive plans that have been approved by Chembio’s stockholders.

NOTE 6 — COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS:

a)
Concentrations:

The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company’s net product sales for the periods indicated:

   
For the three months ended
    
Accounts Receivable as of
  
   
March 31, 2022
   
March 31, 2021
   
March 31,
2022
    
December
31, 2021
  
   
Product
Sales
    
% of
Product
Sales
    
Product
Sales
    
% of
Product
Sales
              
Customer 1
   $ 11,856,024       64 %  
$
 *      
*
     $ 5,930,162    
$
7,672,845
  

Revenue includes product sales only, while accounts receivable reflects the total due from the customer, including freight.

The following table discloses purchases the Company had to each vendor that purchased in excess of 10% of the Company’s net purchases for the periods indicated:

 
For the three months ended
    
Accounts Payable as of
  
   
March 31, 2022
   
March 31, 2021
   
March 31,
2022
    
December
31, 2021
  
   
Purchases
    
% of
Purchases
    
Purchases
    
% of
Purchases
              
Vendor 1
  
$
2,323,605
      
34
%
  
$
*
      
*
    
$
224,500
     $ *
  
Vendor 2
    
1,088,251
      
16
%
    
469,635
      
11
%
    
164,983
      
353,097
  


In the tables above, an asterisk (*) indicates that indicates that sales, accounts receivable, purchases or accounts payable, as applicable to the tabular column, did not exceed 10% for the period indicated.

The Company purchases materials pursuant to intellectual property rights agreements that are important components in its products.  Management believes that other suppliers could provide similar materials on comparable terms.  A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which could adversely affect operating results.

b)
Employment Contracts:

The Company has multi-year contracts with three key employees. The contracts call for salaries presently aggregating $1,178,000 per year. The contracts expire in December 2022 and December 31, 2024. The following table is a schedule of future minimum salary commitments:

17
2022
  
$
883,500
  
2023
    
383,000
  
2024
     383,000  

c)
Benefit Plan:

Chembio has a 401(k) plan established for the Company’s employees whereby it matches 40% of the first 5% of salary (or up to 2% of salary) that an employee contributes to the plan. Matching contribution expenses totaled approximately $67,135 and $35,456 for the three months ended March 31, 2022 and 2021, respectively.

d)
Leases:

The Company leases facilities in New York, Germany, Malaysia, and Brazil, and certain equipment.

The Company’s facility leases generally include optional renewal periods. Upon entering into a new facility lease, the Company evaluates the leasehold improvements and regulatory requirements related to its operations in that location. To the extent that the initial lease term of the related facility lease is less than the useful life of the leasehold improvements and potential regulatory costs associated with moving the facility, the Company concludes that it is reasonably certain that a renewal option will be exercised, and thus that renewal period is included in the lease term and the related payments are reflected in the right-of-use asset and lease liability.

The Company’s leases generally include fixed rental payments with defined annual increases. While certain of the Company’s leases are gross leases, the majority of the Company’s leases are net leases in which the Company makes separate payments to the lessor based on the lessor’s property and casualty insurance costs, the property taxes assessed on the property, and a portion of the common area maintenance where applicable. The Company has elected the practical expedient not to separate lease and non-lease components for all of the Company’s facility leases.

The components of lease expense were as follows:

 
Three Months Ended
March 31
  
   
2022
    
2021
  
Operating lease expense
  
$
403,385
    
$
408,466
  
                 
Finance lease cost
                
Amortization of right-of-use assets
  
$
17,579
    
$
15,758
  
Interest on lease liabilities
    
4,686
      
4,944
  
Total finance lease expense
  
$
22,265
    
$
20,702
  

Supplemental cash flow information related to leases was as follows.

 
  
Three Months Ended
March 31
  
 
  
2022
    
2021
  
Cash paid for amounts included in the measurement of lease liabilities:
            
Operating cash flows for operating leases
  
$
360,878
    
$
347,871
  
Operating cash flows for finance leases
    
4,686
      
4,944
  
Financing cash flows for finance leases
    
16,930
      
14,282
  
Right-of-use assets obtained in exchange for lease obligations:
                
Finance leases
    
16,234
      
-
  

18
Supplemental balance sheet information related to leases was as follows:

 
  
March 31, 2022
    
March 31, 2021
  
Finance Leases
            
Finance lease right of use asset
  
$
356,997
    
$
315,153
  
Accumulated depreciation
    
(166,471
)
    
(97,777
)
Finance lease right of use asset, net
  
$
190,526
    
$
217,376
  
 
                
Weighted Average Remaining Lease Term
                
Operating leases
  
7.4 years
    
8.6 years
  
Finance leases
  
2.8 years
    
3.5 years
  
 
                
Weighted Average Discount Rate
                
Operating leases
    
9.32
%
    
9.30
%
Finance leases
    
8.56
%
    
8.18
%

Maturities of lease liabilities were as follows.

 
  
March 31, 2022
    
March 31, 2021
  
 
  
Operating
Leases
    
Finance
Leases
    
Operating
Leases
    
Finance
Leases
  
2022
  
$
1,086,370
    
$
65,913
    
$
861,916
    
$
57,678
  
2023
    
1,221,017
      
87,884
      
1,057,757
      
76,904
  
2024
    
1,018,875
      
60,116
      
1,026,272
      
76,904
  
2025
    
1,049,442
      
16,731
      
1,018,875
      
49,136
  
2026
    
1,080,925
      
5,940
      
1,049,442
      
5,751
  
Thereafter
    
3,643,521
      
355
      
4,724,446
      
-
  
Total lease payments
  
$
9,100,150
    
$
236,939
    
$
9,738,708
    
$
266,373
  
Less: imputed interest
    
2,450,412
      
29,781
      
2,968,703
      
36,544
  
Total
  
$
6,649,738
    
$
207,158
    
$
6,770,005
    
$
229,829
  

e)
Litigation:

SEC Investigation

The SEC is conducting a non-public, fact-finding investigation relating to the public offering of common stock that Chembio completed in May 2020 (the “May 2020 Offering”) and to the FDA’s revocation in June 2020 of an emergency use authorization for the DPP COVID-19 IgM/IgG system that was issued by the FDA in April 2020. Chembio received subpoenas from the SEC in July 2020 and April 2021 seeking the production of documents in connection with this investigation. In addition, the SEC delivered subpoenas in April 2021 to five of Chembio’s employees (including its three executive officers, who consist of its Chief Executive Officer and President, its former Executive Vice President and Chief Financial Officer, and its Executive Vice President and Chief Scientific and Technology Officer). An additional subpoena was issued in June 2021 to Chembio’s former Interim Chief Executive Officer and Executive Chair. Each subpoena requested the production of documents relating to the same matters as are the subject of the subpoenas Chembio received. Chembio and the six individuals are cooperating fully in the SEC’s investigation and expect to continue to do so.

The SEC’s letters transmitting the subpoenas expressly provide that the inquiry does not mean that the SEC or its staff have concluded that anyone has violated the federal securities laws or have a negative opinion of any person, entity or security. The Company cannot predict the scope, duration or outcome of the investigation or the impact, if any, of the investigation on its results of operations.

19
Legal Proceedings


Stockholder Litigation

Putative Stockholder Securities Class-Action Litigation

In 2020 four purported securities class-action lawsuits were filed in the United States District Court for the Eastern District of New York by alleged stockholders of Chembio:

•
Sergey Chernysh v. Chembio Diagnostics, Inc., Richard L. Eberly, and Gail S. Page, filed on June 18, 2020;

•
James Gowen v. Chembio Diagnostics, Inc., Richard L. Eberly, and Gail S. Page, filed on June 22, 2020;

•
Anthony Bailey v. Chembio Diagnostics, Inc. Richard J. Eberly, Gail S. Page, and Neil A. Goldman, filed on July 3, 2020; and;

•
Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P., and Special Situations Private Equity Fund, L.P. v. Chembio Diagnostics, Inc., Richard Eberly, Gail S. Page, Robert W. Baird & Co. Inc. and Dougherty & Company LLC, filed August 17, 2020.

The plaintiffs in each of the above cases alleged claims under Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), Rule 10b-5 thereunder and Section 20(a) of the Exchange Act. Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P. and Special Situations Private Equity Fund, L.P. (collectively, the “Special Situations Funds”) also asserted claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “Securities Act”) relating to the May 2020 Offering.

Chembio and the plaintiffs entered into Court-approved stipulations relieving Chembio and the other defendants of the obligation to respond to the complaints in these cases pending the designation of a lead plaintiff pursuant to the Private Securities Litigation Reform Act of 1995. Eight motions for appointment as lead plaintiff were filed by various prospective lead plaintiffs. However, all but two of these motions were withdrawn or otherwise abandoned, leaving before the Court two motions for appointment as lead plaintiff - one filed by the Special Situations Funds and one by Municipal Employees’ Retirement System of Michigan. By order entered December 29, 2020, Magistrate Judge Lindsay consolidated the cases and appointed the Special Situations Funds and Municipal Employees’ Retirement System of Michigan (together, the “Lead Plaintiffs”), as co-lead plaintiffs and their respective counsel as co-lead counsel. The consolidated cases are now pending under the caption “In re Chembio Diagnostics, Inc. Securities Litigation.”

The Lead Plaintiffs filed their Consolidated Amended Complaint (the “CAC”) on February 12, 2021. In summary, the CAC purported to allege claims based on assertedly false and misleading statements and omissions concerning the performance of the DPP COVID-19 IgM/IgG System, as well as an asserted failure to timely disclose that the emergency use authorization that had been granted by the FDA with respect to the DPP COVID-19 IgM/IgG System “was - or was at an increased risk of - being revoked.” The CAC named as defendants Chembio, Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan, John Potthoff (together, the “Chembio Defendants”) and the underwriters for the May 2020 Offering, Robert W. Baird & Co., Inc. and Dougherty & Company LLC (the “Underwriter Defendants”).

The CAC purported to assert five counts under the Securities Act and the Exchange Act. Counts I through III were brought under the Securities Act, allegedly on behalf of a purported class consisting of all persons who purchased Chembio common stock directly in or traceable to the May 2020 Offering pursuant to Chembio’s shelf registration statement on Form S 3 (File No. 333-227398) and the related prospectus, as supplemented by a prospectus supplement dated May 7, 2020 (the “Securities Act Class”). Count I purported to allege a claim for violation of Section 11 of the Securities Act against all defendants other than Messrs. Eberly and Esfandiari. Count II purported to allege a claim for violation of Section 12 of the Securities Act against all defendants other than Messrs. Eberly and Esfandiari. Count III purported to allege a claim under Section 15 of the Securities Act against Ms. Davis, Dr. Polan, Dr. Potthoff, Ms. Page and Mr. Goldman.

20
Counts IV and V alleged claims under the Exchange Act on behalf of a purported class consisting of all persons who purchased Chembio common stock on the open market from March 12, 2020 through June 16, 2020 (the “Exchange Act Class”). Count IV purported to allege a claim for violation of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder against Chembio, Mr. Eberly, Ms. Page, Mr. Goldman and Mr. Esfandiari. Count V purported to allege a claim under Section 20(a) of the Exchange Act against Mr. Eberly, Ms. Page, Mr. Goldman and Mr. Esfandiari.

In their CAC, the Lead Plaintiffs sought, on behalf of the Securities Act Class and the Exchange Act Class, among other things, an award of damages in an amount to be proven at trial, as well as an award of reasonable costs, including attorneys’ fees and expenses, expert fees, pre-judgment and post-judgment interest, and such other relief as the Court deems just and proper. The Lead Plaintiffs also sought rescission “or a rescissory measure of damages” on behalf of the Securities Act Class as to Count II.

Pursuant to an order entered by the Court on January 29, 2021, any defendant wishing to move against the amended complaint was required to file, by February 18, 2021, a letter requesting a pre-motion conference. On that date, the defendants submitted letters to the Court requesting a pre-motion conference regarding anticipated motions to dismiss the CAC, and the Lead Plaintiffs responded on February 24, 2021. In its January 29, 2021 order, the Court indicated that it would consider a briefing schedule on motions to dismiss after it had received and reviewed the parties’ correspondence.

On March 5, 2021, the Court entered an order in which it advised the parties that it had determined a pre motion conference was not necessary and established a briefing schedule on the defendants’ anticipated motions to dismiss. However, the defendants subsequently agreed with the Lead Plaintiffs’ counsel to a modification of the schedule, which was then approved by the Court. Pursuant to that schedule, defendants’ motions and supporting papers were filed on March 26, 2021, the Lead Plaintiffs’ opposition papers were filed on April 16, 2021, and the defendants’ reply papers were filed on April 30, 2021.

The Court issued its Opinion and Order (the “Order”) on the defendants’ motions to dismiss on February 23, 2022.  In its Order, the Court: (i) dismissed Counts I and II without prejudice as to all defendants named in those Counts except the Underwriter Defendants as to which Counts I and II were not dismissed; (ii) dismissed Count III without prejudice as to all defendants named in that Count; and (iii) dismissed Counts IV and V with prejudice as to all defendants named in those Counts.  The Court gave Lead Plaintiffs fourteen days within which to attempt to replead their claims under the Securities Act against Chembio, Ms. Page, Mr. Goldman, Ms. Davis, Ms. Polan and Mr. Potthoff.

On March 4, 2022, Lead Plaintiffs filed a letter motion in which they advised the Court that they intended to file an amended complaint, but that they wished to first seek reconsideration of the Court’s February 23 order.  They accordingly requested, and the Court granted, an adjournment of the deadline for filing an amended complaint until three business days after the Court’s ruling on Lead Plaintiffs’ anticipated motion for reconsideration.  The Court also granted a request by the Underwriter Defendants to extend the time for them to file their answer to the CAC, and set May 2, 2022 as the date for the filing of that answer.

On March 7, 2022, Magistrate Judge John Wicks entered an order requiring that the parties meet and confer regarding the scheduling of discovery in the case, requiring that the parties submit a Proposed Scheduling Order by March 23, and setting a hearing (via zoom) on March 30.  The Chembio Defendants filed a letter motion requesting that the Court adjourn the initial conference and suspend the other requirements in the March 7, 2022 order.  Magistrate Judge Wicks granted the letter motion on March 14, and further ordered that the initial conference would be rescheduled “following the resolution of all preliminary dispositive issues.”

On March 9, 2022, Lead Plaintiffs filed a motion for partial reconsideration of the Court’s February 23 Order.  In their motion, Lead Plaintiffs requested that the Court reconsider and reverse its dismissal of Counts IV and V with prejudice, and its dismissal of Counts I, II and III without prejudice.  The Chembio Defendants filed their memorandum in opposition to this motion on March 23, 2022; Lead Plaintiffs filed their reply memorandum in support of the motion on March 30, 2022.  The Court has not yet ruled upon the motion for partial reconsideration.

21
On April 26, 2022, the Court entered an order canceling the previously-set May 2 date by which the Underwriter Defendants were required to file their answer to the CAC, and providing that the Underwriter Defendants’ answer to an amended complaint shall be due within three weeks after such amended complaint has been served.

Putative Stockholder Derivative Litigation

On September 11, 2020, a putative stockholder derivative action captioned Karen Wong, derivatively on behalf of Chembio Diagnostics, Inc., Plaintiff v. Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan and John G. Potthoff, Defendants, and Chembio Diagnostics, Inc., Nominal Defendant (the “Wong complaint”) was filed purportedly on Chembio’s behalf in the United States District Court for the Eastern District of New York. The Wong complaint purports to assert a claim for violation of Section 14(a) of the Exchange Act and Rule 14a-9 thereunder based on ostensibly false and misleading statements and omissions concerning the Company’s rapid COVID-19 antibody test in the proxy statement disseminated in advance of Chembio’s Annual Meeting of Stockholders held on July 28, 2020. The Wong complaint also asserts claims against the individual defendants for purported breaches of fiduciary duties owed to Chembio, as well as unjust enrichment.

The Wong complaint requests a declaration that the individual defendants have breached or aided and abetted the breach of their fiduciary duties to Chembio, an award of damages to us, restitution, and an award of the plaintiff’s costs and disbursements in the action, including reasonable attorneys’ and experts’ fees, costs and expenses, and improvements to Chembio’s corporate governance and internal procedures regarding compliance with laws. Pursuant to a stipulation by which the individual defendants named in the Wong complaint agreed to waive service of process, the Court ordered that the time for defendants to answer or otherwise respond to the complaint be extended to November 19, 2020. The parties subsequently entered into a stipulation for a stay of proceedings in the action relating to the Wong complaint pending final disposition of motions to dismiss the pending putative class-action litigation, subject to certain conditions. The Court entered an order granting the requested stay on November 3, 2020. At this stage of the litigation, the Company is not able to predict the probability of a favorable or unfavorable outcome.

On March 31, 2022, a second putative stockholder derivative action captioned Michelle Chen, derivatively on behalf of Chembio Diagnostics, Inc., Plaintiff v. Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan and John G. Potthoff, Defendants, and Chembio Diagnostics, Inc., Nominal Defendant (the “Chen complaint”) was filed purportedly on behalf of Chembio in the Supreme Court for the State of New York, County of Suffolk.  The Chen complaint purports to assert a claim for breach of fiduciary duty against the defendants based on ostensibly false and misleading statements and omissions concerning the Company’s rapid COVID-19 antibody test.  The Chen complaint goes on to allege that the misconduct asserted in the complaint gave rise to the filing of the consolidated securities litigation described above.

Counsel for the defendants in the Chen action are engaged in discussions with counsel for Chen concerning a possible stay of the Chen action.


Employee Litigation

On March 19, 2021, John J. Sperzel III, Chembio’s former chief executive officer, filed a fifteen-count complaint in the United States District Court for the Eastern District of New York. The complaint was filed following the dismissal of an action previously filed by Mr. Sperzel in the United States District Court in Maine, which was dismissed for lack of personal jurisdiction over Chembio. In summary, the complaint filed in the Eastern District of New York alleges that Chembio wrongfully refused to allow Mr. Sperzel to exercise certain options to purchase, for an aggregate exercise price of $943,126, a total of 266,666 shares of common stock that were allegedly vested as of the date of his separation from Chembio, on January 3, 2020. The complaint alleges that under the terms of the applicable stock incentive plans, Mr. Sperzel had thirty days after the date on which he ceased to qualify as an “Eligible Person” under the plans within which to exercise the options, and asserts that by reason of his alleged continued service to us, he remained an “Eligible Person” and ostensibly retained the right to exercise the options. The Compensation Committee of the Board determined that the options expired on February 3, 2020, thirty days after Mr. Sperzel’s separation from Chembio, and that a purported attempt by Mr. Sperzel to exercise the options after that date was not valid.

22
Count I of the complaint purports to allege that Chembio breached Mr. Sperzel’s separation agreement by refusing to allow him to exercise the stock options. Counts II through XI of the complaint purport to allege claims for breach of each of ten separate stock option agreements, collectively asserting damages of “at least” $3,190,198. Count XII of the complaint alleges a breach of Mr. Sperzel’s separation agreement based on Chembio’s purported failure to pay Mr. Sperzel consulting fees to which he claims to be entitled for consulting services allegedly performed following his separation. Count XIII of the complaint alleges a claim for breach of an implied covenant of good faith and fair dealing under Nevada common law based on the allegation that Chembio prevented Mr. Sperzel from obtaining the benefits of the stock option agreements and separation agreement. Mr. Sperzel alleges that he suffered damages in excess of $3 million as a result of the purported breach of the covenant of good faith and fair dealing. Count XIV of the complaint purports to assert a claim for quantum meruit, alleging that “it is reasonable for Sperzel to expect payment in exchange for ... services” he allegedly provided to us and, based on allegations that upon his separation Mr. Sperzel was not informed as to the pending expiration of the stock options he later sought to exercise, that Chembio has been unjustly enriched. Finally, Count XV of the complaint seeks a declaratory judgment that Mr. Sperzel is relieved from performance under his separation agreement due to asserted material breaches of the agreement based on the allegations summarized above. The complaint seeks compensatory damages in an unspecified amount, a declaration, as described above, and an award of Mr. Sperzel’s costs and expenses in the litigation, including reasonable attorneys’ fees, expert costs and disbursements. The complaint requests a trial by jury. In his initial disclosures served in discovery, Mr. Sperzel claims entitlement to recover damages in a total amount not less than $10 million, together with prejudgment interest at the rate of 9% per annum.

On May 20, 2021, Chembio filed its answer and affirmative defenses denying the material allegations of Mr. Sperzel’s complaint. Chembio and Mr. Sperzel are presently engaged in discovery. Under the present case schedule, all fact discovery was completed on April 28, 2022, and the parties are currently in the midst of an additional period of expert witness discovery, concluding on June 28, 2022. At this stage of the litigation, the Company is not able to predict the probability of a favorable or unfavorable outcome.


Other

From time to time the Company may become involved in legal proceedings or may be subject to claims arising in the ordinary course of its business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on its business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.

NOTE 7 — LONG-TERM DEBT:

On September 3, 2019, Chembio entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings II, LP (the “Lender”). The Credit Agreement provides for a $20,000,000 senior secured term loan credit facility, which was drawn in full on September 4, 2019. Under the terms of the Credit Agreement, Chembio may use the proceeds (i) for general working capital purposes and other permitted corporate purposes, (ii) to refinance certain of Chembio’s existing indebtedness and (iii) to pay fees, costs and expenses incurred in connection with the Credit Agreement, including the Lender’s closing cost amount of $550,000, which was netted from the proceeds, and a financing fee of $600,000 (3.0% of gross proceeds) payable to Craig-Hallum Capital Group LLC, Chembio’s financial advisor for the financing.

Principal outstanding under the Credit Agreement bears interest at a rate per annum equal to the sum of (a) the greater of the one-month London Interbank Offered Rate and 2.5% plus (b) 8.75%. At any time at which an event of default has occurred and is continuing, the interest rate will increase by 4.0%. Accrued interest is payable on a monthly basis. On March 31, 2022 the interest rate was 11.25%.

23
No principal repayments are due under the Credit Agreement prior to September 30, 2022, unless Chembio elects to prepay principal or principal is accelerated pursuant to an event of default identified in the Credit Agreement. Principal installments in the amount of $300,000 are payable on the last day of each of the eleven months from September 2022 through July 2023, and all remaining principal is payable at maturity on September 3, 2023. The Company may prepay outstanding principal from time to time, subject to payment of a premium on the prepaid principal amount equal to 10% through September 3, 2020, 8% from September 4, 2020 through September 3, 2021, and 4% from September 4, 2021 through September 3, 2022. No premium will be due with respect to any prepayment made on or after September 4, 2022.

Chembio’s obligations under the Credit Agreement are secured by a first priority, perfected lien on substantially all of its property and assets, including its equity interests in subsidiaries.

As of  March 31, 2022, the loan balance, net of unamortized discounts and debt issuance costs, was $18.9 million, and Chembio was in compliance with its loan covenants.

NOTE 8 — EQUITY INCENTIVE PLAN:


(a)
Equity Plans:

Effective June 19, 2014, Chembio’s stockholders voted to approve the 2014 Stock Incentive Plan (the “2014 Plan”), with 800,000 shares of common stock available to be issued. Under the terms of the 2014 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of Equity Award Units. The awards vest at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through March 31, 2022, there were 732,064 Equity Award Units expired, forfeited or exercised. At March 31, 2022, 46,875 Equity Award Units were outstanding and 21,061 shares were not issued. All shares that expired, forfeited or were not issued rolled over into the 2019 Plan. No Equity Award Units remain available to be issued under the 2014 Plan.

Effective June 18, 2019, Chembio’s stockholders voted to approve the 2019 Omnibus Incentive Plan (the “2019 Plan”), with 2,400,000 shares of common stock available to be issued. At the Annual Stockholder Meeting on June 25, 2021, Chembio’s stockholders voted to approve an increase to the shares of common stock issuable under the SIP by 2,400,000 to 4,800,000. In addition, shares of common stock underlying any outstanding award granted under the 2019 Plan that, following the effective date of the 2019 Plan, expire, or are terminated, surrendered or forfeited for any reason without issuance of such shares, shall be available for the grant of new awards under the 2019 Plan. Under the terms of the 2019 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of options, stock appreciation rights, restricted stock, restricted stock units, performance stock units or other stock-based awards under the 2019 Plan (collectively, “2019 Equity Units”). The 2019 Equity Units become vested at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through March 31, 2022, 866,709 2019 Equity Units have been cancelled or forfeited. At March 31, 2022, 4,915,279 2019 Equity Units were outstanding, and 83,234 2019 Equity Units were available to be awarded.


(b)
Stock Compensation Expense:

Stock-based compensation expense (net of recovery) recognized in the condensed consolidated statements of operations was classified as follows:

 
  
For the three months
ended March 31
  
 
  
2022
    
2021
  
Cost of product sales
  
$
54,250
    
$
28,768
  
Research and development expenses
    
91,189
      
90,920
  
Selling, general and administrative expenses
    
605,464
      
460,101
  
 
  
$
750,903
    
$
579,789
  

24
The weighted-average assumptions made in calculating the fair values of options are as follows:


 
For the three
months ended
March 31,
2021
  
Expected term (in years)
    
6.0
  
Expected volatility
    
91.40
%
Expected dividend yield
    
N/A
  
Risk-free interest rate
    
1.91
%

The following table provides stock option activity for the three months ended March 31, 2022:

 Stock Options
  
Number
of Shares
  
Weighted
Average
Exercise Price
per Share
  
Weighted
Average
Remaining
Contract Term
  
Aggregate
Intrinsic
Value
Outstanding at December 31, 2021
  
1,600,372
  
$
4.18
  
6.59 years
  
$
-
                     
Granted
  
2,358,539
    
1.23
        
-
Exercised
  
-
    
-
        
-
Forfeited
  
14,883
    
2.42
        
-
Expired
  
183,241
    
5.63
          
Outstanding at March 31, 2022
  
3,760,787
  
$
2.27
  
8.65 years
  
$
-
Exercisable at March 31, 2022
  
565,215
  
$
3.68
  
5.89 years
  
$
-

The following table summarizes information about stock options outstanding at March 31, 2022:


 
Stock Options Outstanding
    
Stock Options Exercisable
  
Range of
Exercise Prices
  
Number
of Shares
    
Average
Remaining
Contract Term
(Year)
    
Weighted
Average
Exercise
Price
    
Aggregate
Intrinsic
Value
    
Number
of Shares
    
Weighted
Average
Exercise
Price
    
Aggregate
Intrinsic
Value
  
_1 to 2.79999
    
2,863,910
      
8.83
    
$
1.44
    
$
-
      
317,758
    
$
2.36
    
$
-
  
2.8 to 4.59999
    
30,795
      
9.19
      
3.05
      
-
      
-
      
-
      
-
  
4.6 to 6.39999
    
819,207
      
8.43
      
4.81
      
-
      
209,957
      
4.88
      
-
  
6.4 to 8.19999
    
46,875
      
1.11
      
8.15
      
-
      
37,500
      
8.15
      
-
  
Total
    
3,760,787
      
8.65
    
$
2.27
    
$
-
      
565,215
    
$
3.69
    
$
-
  

As of March 31, 2022, there was $3,073,502 of net unrecognized compensation cost related to stock options that had not vested, which is expected to be recognized over a weighted-average period of approximately 3.32 years. The total fair value of shares vested during the three months ended March 31, 2022 and 2021 was $693,290 and $188,179, respectively.

25
The following table summarizes information about restricted stock, restricted stock units and performance stock units outstanding as of March 31, 2022:


 
Number of
Shares & Units
    
Weighted
Average
Grant Date
Fair Value
  
Outstanding at December 31, 2021
    
705,325
    
$
3.34
  
                 
Granted
    
1,210,448
      
0.76
  
Vested
    
167,782
      
3.60
  
Forfeited
    
8,047
      
2.31
  
Outstanding at March 31, 2022
    
1,739,944
    
$
1.52
  

As of March 31, 2022, there was $2,120,646 of net unrecognized compensation cost related to restricted stock and restricted stock units that had not vested, which is expected to be recognized over a weighted average period of approximately 2.50 years.

NOTE 9 — GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY:

The Company produces only one group of similar products known collectively as “rapid medical tests”, and it operates in a single operating segment. Net product revenue by geographic area were as follows:

 
For the three months ended
March 31
  
   
2022
    
2021
  
Africa
  
$
767,352
    
$
1,344,858
  
Asia
    
15,558
      
216,954
  
Europe & Middle East
    
717,908
      
1,493,734
  
Latin America
    
12,545,054
      
258,019
  
United States
    
4,481,584
      
711,097
  
   
$
18,527,456
    
$
4,024,662
  

Property, plant and equipment by geographic area were as follows at:

 
March 31, 2022
    
December 31, 2021
  
Asia
  
$
85,351
    
$
86,041
  
Europe & Middle East
    
101,231
      
113,883
  
Latin America
    
58,685
      
36,224
  
United States
    
8,169,046
      
8,320,625
  
   
$
8,414,313
    
$
8,556,773
  

NOTE 10 — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES:

Accounts payable and accrued liabilities consisted of:

 
March 31, 2022
    
December 31, 2021
  
Accounts payable – suppliers
  
$
5,622,558
    
$
7,745,592
  
Accrued commissions and royalties
    
1,510,865
      
1,359,691
  
Accrued payroll
    
494,653
      
494,258
  
Accrued vacation
    
657,008
      
421,416
  
Accrued bonuses
    
544,567
      
1,378,706
  
Accrued professional fees
    
893,745
      
522,935
  
Accrued expenses – other
    
819,455
      
1,205,395
  
 TOTAL
  
$
10,542,851
    
$
13,127,993
  

26
NOTE 11 — GOODWILL AND INTANGIBLE ASSETS:

The following table reflects changes in goodwill:

Beginning balance at December 31, 2021
  
$
3,022,787
  
Impairment
     (3,033,565 )
Change in foreign currency exchange rate
    
10,778
  
Balance at March 31, 2022
  
$
-
  

Goodwill represents the excess of the purchase price the Company paid over the fair value of the net tangible and identifiable intangible assets acquired in the Company’s acquisition. Goodwill is not amortized but rather is tested annually as of the first day of the fiscal fourth quarter, or sooner if the Company believes that indicators of impairment exist. The Company makes a qualitative evaluation about the likelihood of goodwill impairment, which is based on a number of applicable factors. If the Company concludes that it is more likely than not that the carrying value of the applicable reporting unit is greater than its fair value, then it would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The quantitative goodwill impairment test is performed using a one-step process. The process is to compare the fair value of a reporting unit with its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit is impaired, and an impairment loss is recognized in an amount equal to that excess.

The Company operates as a single operating segment and has one reporting unit. As of March 31, 2022, the Company determined indicators of impairment existed. As a result, the Company recognized an impairment loss of its goodwill totaling $3.0 million.

NOTE 12 —  OTHER MATTERS:

On March 28, 2022, Chembio Diagnostics GmbH, Chembio’s German subsidiary formed under the laws of the Federal Republic of Germany, successfully withdrew its petition for insolvency filed in February 2022 in the Charlottenburg District Court  (“Amtsgericht Charlottenburg“) in Berlin, Germany. The subsidiary has taken various measures to improve profitability, including a viable business plan, and the Company has provided liquidity and other support to continue the operations.

ITEM 2.
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis should be read in conjunction with our unaudited condensed consolidated financial statements and related notes, or the accompanying financial statements, included elsewhere in this report. In addition to historical information, the following discussion contains forward-looking statements that involves risks, uncertainties and assumptions. See "Forward-Looking Statements" above. Please read Part II, Item 1A. “Risk Factors" of this report for a discussion of factors that could cause our actual results to differ materially from our expectations.

We develop and commercialize point-of-care diagnostic tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment.

Our product portfolio is based upon our proprietary DPP technology, a diagnostic platform that provides high-quality, cost-effective results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases, cardiac markers, cholesterol and lipids, pregnancy and fertility, and drugs of abuse. Compared with traditional lateral flow technology, the DPP technology platform can provide enhanced sensitivity and specificity, advanced multiplexing capabilities and, with the DPP Micro Reader, quantitative results.

27
We target the market for rapid diagnostic test solutions for infectious diseases, which is driven by the high prevalence of infectious diseases globally, an increase in the geriatric population, growing demand for rapid test results, and advancements in multiplexing. We have a broad portfolio of infectious disease products, which prior to 2020 were focused principally on sexually transmitted disease and fever and tropical disease. In February 2020 we began the process of shifting substantially all of our resources to seek to leverage the DPP technology platform to address the acute and escalating need for diagnostic testing for COVID-19. We are continuing to pursue:

•
an emergency use authorization, or EUA, from the U.S. Food and Drug Administration, or FDA, as well as 510(k) clearance   from the FDA, for the DPP SARS-CoV-2 Antigen test system;

•
an EUA from the FDA for the DPP Respiratory Panel; and

•
a Clinical Laboratory Improvement Amendment, or CLIA, waiver from the FDA for the DPP HIV-Syphilis test system.

Our products are sold globally, directly and through distributors, to medical laboratories and hospitals, governmental and public health entities, nongovernmental organizations, medical professionals, and retail establishments. We continue to seek to expand our commercial distribution channels.

Going Concern Considerations

We continued to experience market, clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of COVID-19 test systems during the continuing, but evolving, uncertainty COVID‑19. For the three months ended March 31, 2022, we continued to incur significant expenses in connection with pending legal matters (see Note 6 – Commitments, Contingencies, and Concentrations: Litigation).
 
We performed an assessment to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about our ability to continue as a going concern within one year after the filing date of this report, when the accompanying financial statements are being issued. Initially, this assessment did not consider the potential mitigating effect of management’s plans that had not been fully implemented. Because, as described below, substantial doubt was determined to exist as the result of this initial assessment, management then assessed the mitigating effect of our plans to determine if it is probable that the plans (1) would be effectively implemented within one year after the filing date of this report and (2) when implemented, would mitigate the relevant conditions or events that raise substantial doubt about our ability to continue as a going concern
 
We achieved significant revenue growth in recent years although profitability has not been at our targeted levels. We have taken steps, including investments in automation, to mitigate headwinds such as labor availability, volatile capacity planning and implementation of operational efficiency targets to proactively monitor production with the overarching goal for profitable growth. During the three months ended March 31, 2022, we undertook measures to increase its total revenues and improve its liquidity position by implementing a Global Competitiveness Program. The main pillars of the Global Competitiveness Program include the following:

•
Focus on higher margin business in growth markets

•
Lower manufacturing costs

28
•
Reduce infrastructure costs

•
Strategic review of non-core businesses and assets:

In addition, we will continue to focus on regulatory approvals for its DPP SARS-CoV-2 Antigen test system, DPP Respiratory Antigen Panel, and DPP HIV-Syphilis test system. These measures and other plans and initiatives have been designed to provide us with adequate liquidity to meet our obligations for at least the twelve-month period following the filing date of this report. Our execution of those measures and our other plans and initiative continue to depend, however, on factors and uncertainties that are beyond our control, or that may not be addressable on terms acceptable to us or at all. We considered in particular how:

•
The ongoing healthcare and economic impacts of COVID-19 on the global customer base for our non‑COVID-19 products continue to negatively affect the timing and rate of recovery of our revenues from those products by, for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect our liquidity.

•
Although we entered into agreements to distribute third-party COVID-19 products in the United States, our ability to sell those products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products

We further considered how these factors and uncertainties could impact our ability over the next year to meet the obligations specified in the Credit Agreement with the Lender (as defined in Note 7 – Long-Term Debt). Those obligations include covenants requiring: i) minimum cash balance of $3.0 million and ii) minimum total revenue amounts for the twelve months preceding each quarter end. For the next year, the minimum total revenue requirements range from $43.8 million for the twelve months ending June 30, 2022, and $ 48.8 million for the twelve months ending March 31, 2023.   Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that we would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement or that, if such liquidity were not available, we would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern. Our inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for its operations, could have a material adverse effect on its business, prospects, results of operations, liquidity and financial condition.
 
Accordingly, management determined we could not be certain that our plans and initiatives would be effectively implemented within one year after the filing date of this report. Without giving effect to the prospect of raising additional capital pursuant to our At the Market Offering Agreement dated July 19, 2021 with Craig-Hallum Capital Group LLC or the ATM Agreement, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond our control, it is unlikely that we will be able to generate sufficient cash flows to meet our required financial obligations, including our debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about our ability to continue as a going concern for the twelve-month period following the filing date of this report.
 
The accompanying financial statements have been prepared assuming we will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of this report. As such, the accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should we be unable to continue as a going concern.
 
29
Consolidated Results of Operations

Three Months Ended March 31, 2022 versus Three Months Ended March 31, 2021

The results of operations for the three months ended were as follows (dollars in thousands):

   
March 31, 2022
    
March 31, 2021
  
TOTAL REVENUES
  
$
18,817
      
100
%
  
$
8,724
      
100
%
                                 
OPERATING COSTS AND EXPENSES:
                                
Cost of product sales
    
15,224
      
81
%
    
3,548
      
41
%
Research and development expenses
    
1,654
      
9
%
    
2,863
      
33
%
Selling, general and administrative expenses
    
6,946
      
37
%
    
6,086
      
70
%
Severance and other related costs
    
3,043
      
16
%
    
83
      
1
%
TOTAL OPERATING COSTS AND EXPENSES
    
26,867
              
12,580
          
                                 
LOSS FROM OPERATIONS
    
(8,050
)
            
(3,856
)
        
                                 
OTHER (EXPENSE) INCOME, NET
    
(734
)
            
(712
)
        
                                 
LOSS BEFORE INCOME TAXES
    
(8,784
)
    
(47
)%
    
(4,568
)
    
(52
)%
                                 
Income tax (expense) benefit
    
(6
)
            
68
          
                                 
NET LOSS
  
$
(8,790
)
          
$
(4,500
)
        

Percentages in the table reflect the percent of total revenues.

Total Revenues

Total revenues during the quarter ended March 31, 2022 were $18.8 million, an increase of $10.1 million, or 116%, compared to the quarter ended March 31, 2021. The increase in total revenues is primarily due to higher sales in Latin America, primarily to Bio-Manguinhos for DPP SARS-CoV-2 Antigen tests, and in the United States, partially offset by lower sales volume in our other regions.

Gross Product Margin

Cost of product sales is primarily composed of material, labor, manufacturing overhead, depreciation and amortization, and freight and distribution costs. Gross product margin is net product revenue less cost of product revenue, and gross product margin percentage is gross product margin as a percentage of net product revenue.

Gross product margin increased by $2.8 million, or 592% compared to the quarter ended March 31, 2021. The following schedule calculates gross product margin (dollars in thousands):

   
For the three months
ended March 31
    
Favorable/(unfavorable)
  
   
2022
    
2021
    
$ Change
    
% Change
  
Net product sales
  
$
18,527
    
$
4,025
    
$
14,502
      
360
%
Less: Cost of product sales
    
(15,224
)
    
(3,548
)
    
(11,676
)
    
329
%
Gross product margin
  
$
3,303
    
$
477
    
$
2,826
      
592
%
Gross product margin percentage
    
18
%
    
12
%
                

The $2.8 million increase in gross product margin was comprised of (a) $1.1  million from favorable product margins  and the impact of fixed manufacturing overhead, and (b) $1.7 million from favorable product sales volume as described under “Total Revenues” above.

30
Research and Development

This category includes costs incurred for clinical and regulatory affairs and other research and development, as follows (dollars in thousands):

   
For the three months
ended March 31
    
Favorable/(unfavorable)
  
   
2022
    
2021
    
$ Change
    
% Change
  
Clinical and regulatory affairs
  
$
295
    
$
765
    
$
(470
)
  
$
(61
)%
Other research and development
    
1,359
      
2,098
      
(739
)
    
(35
)%
Total research and development
  
$
1,654
    
$
2,863
    
$
(1,209
)
    
(42
)%

The decrease in research and development costs for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 was primarily associated with work related to pursuing an EUA and 510(k) from the FDA for the DPP SARS-CoV-2 Antigen test system, and an EUA for the DPP Respiratory Panel, each pursuant to awards from the Biomedical Advanced Research and Development Authority, or BARDA (part of the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response).

Selling, General and Administrative Expense

Selling, general and administrative expense includes administrative expenses, sales and marketing costs (including commissions), and other corporate items.

The $0.9 million, or 14%, increase in selling, general and administrative expense for the three months ended March 31, 2022 compared to the three months ended March 31, 2021 principally due to increased costs associated with insurance, commissions and professional fees.

Impairment, restructuring, severance and related costs

Impairment, restructuring, severance and related costs include an impairment loss of $3.0 million during the first quarter of 2022 as a result of an impairment of goodwill due to the substantial decrease in our share price at March 31, 2022. The low price per share value at March 31, 2022 caused our book value to exceed our fair value. In the first quarter of 2021, severance charges of $0.1 million were recorded attributable to the elimination of positions.

Other Income (Expense), net

Other income (expense), net consists principally of interest expense, net of interest income earned on our deposits on long-term debt incurred under the Credit Agreement on September 3, 2019, of which $20 million (carrying value of $18.9 million) was outstanding at March 31, 2022. For a description of Credit Agreement, please see “Liquidity and Capital Resources—Sources of Funds—Credit Agreement” below

Liquidity and Capital Resources

Our cash and cash equivalents totaled $24.4 million at March 31, 2022. We are obligated to maintain aggregate unrestricted cash of not less than $3,000,000 at all times under a covenant in the Credit Agreement.

During the three months ended March 31, 2022, we funded our business operations, including capital expenditures and working capital requirements, principally from cash and cash equivalents and our operations used $4.4 million of cash.

Factors and considerations with respect to our liquidity raised substantial doubt as to our ability to continue as a going concern through one year after the date that the accompanying financial statements are being issued. See “Going Concern Considerations” above.

31
We have considered how the uncertainties around the delivery of the full number of tests covered by customer orders may be affected by limitations of our staffing, supply chain and liquidity and other matters outside our control. We further considered how those uncertainties could impact our ability to meet the obligations specified in the Credit Agreement over the next twelve months, which include (a) a covenant requiring minimum total revenues for the twelve months preceding each quarter end, which requirements range from $43.8 million for the twelve months ending June 30, 2022 to $48.8 million for the twelve months ending March 31, 2023 and (b) an obligation requiring the payment of principal installments, commencing with the payment of $300,000 on September 30, 2022. Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that we would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement or that, if such liquidity were not available, we would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern. Our inability to raise additional capital on acceptable terms or to otherwise generate cash in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for our operations, could have a material adverse effect on our business, prospects, results of operations, liquidity and financial condition.

We cannot be certain that our plans and initiatives would be effectively implemented within one year after the filing date of this report, when the accompanying financial statements are being issued. Without giving effect to the prospect of raising additional capital pursuant to our at-the-market offerings, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond our control, it is unlikely that we will be able to generate sufficient cash flows to meet our required financial obligations, including our debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about our ability to continue as a going concern for the twelve-month period following the filing date of this report, when the accompanying financial statements are being issued.
 
Please see note 2 to the accompanying financial statements for additional information regarding our going concern assessment in connection with the accompanying financial statements. You are urged to read carefully the information provided in “Because of our liquidity limitations, we have concluded there is a substantial doubt about our ability to continue as a going concern and we may require additional capital to fund our operations, which capital may not be available to us on acceptable terms or at all” under Part II, Item 1A, “Risk Factors” of this report and “The failure to comply with the terms of the Credit Agreement could result in a default under its terms and, if uncured, could result in action against our pledged assets and dilution of our stockholders” under Part I, Item 1A, “Risk Factors” of our 2021 Form 10-K.
 
On April 5, 2022, we received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying us that, because the bid price for shares of our common stock had closed below the $1.00 per share minimum bid price requirement for thirty consecutive business days or the Bid Price Requirement, our common stock may be subject to delisting by as early as October 3, 2022 if we have been unable to regain compliance with the Bid Price Requirements or to qualify for an additional period to regain compliance by such date, all as described in more detail in the Current Report on Form 8-K we filed with the SEC on April 7, 2022. There can be no assurance that we will be able to regain compliance with the Bid Price Requirement. Our inability to regain compliance with the Bid Price Requirement would, and the existence of the pending deficiency letter could, materially impair our ability to raise capital.

We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends. We have not entered into, and do not expect to enter into, investments for trading or speculative purposes. Our accounts receivable, accounts payable and inventory balances fluctuate from period to period, which affects our cash flow from operating activities. The amounts of these fluctuations vary depending on cash collections, client mix, raw material lead times, the mix of vendor terms, the timing of shipment of our products and the invoicing of our research and development activities. As of March 31, 2022, we did not have any off-balance sheet arrangements, as defined in Item 303(a)(4)(ii) of Regulation S-K under the Securities Exchange Act of 1934.

We continually evaluate our liquidity requirements, capital needs and availability of capital resources based on our operating needs and our planned growth initiatives. Our future working capital needs will depend on many factors, including the rate of our business and revenue growth, the availability and cost of human, material and other resources required to build and deliver products in accordance with our existing or future product orders, the timing of our continuing automation of U.S. manufacturing, and the timing of our investment in research and development as well as sales and marketing. If we are unable to increase our revenues and manage our expenses in accordance with our operating plan, we may need to reduce the level or slow the timing of the growth plans contemplated by our operating plan, which would likely curtail or delay the growth in our business contemplated by our operating plan and could impair or defer our ability to achieve profitability and generate cash flow, or to seek to raise additional funds through debt or equity financing, strategic relationships, or other arrangements. There can be no assurance that we would be able to complete any proposed financing on terms acceptable to us, or at all, or that we otherwise will be successful in any of our other endeavors to continue to be financially viable and continue as a going concern. Our inability to raise additional capital on acceptable terms could have a material adverse effect on our business, prospects, results of operations, liquidity and financial condition. If we were to raise additional funds through the issuance of equity or convertible securities, the issuance could result in substantial dilution to existing stockholders, and the holders of those new securities may have rights, preferences and privileges senior to those of the holders of common stock. Furthermore, any decline in the market price of our common stock could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.

32
Sources of Funds

Credit Agreement. The following description summarizes certain key provisions of the Credit Agreement:

•
Principal Amount. The Credit Agreement provides for a $20,000,000 senior secured term loan credit facility, which was drawn in full on September 4, 2019. Under the terms of the Credit Agreement, we may use the proceeds (i) for general working capital purposes and other permitted corporate purposes, (ii) to refinance certain of our existing indebtedness and (iii) to pay fees, costs and expenses incurred in connection with the Credit Agreement, including the Lender’s closing cost amount of $550,000, which was netted from the proceeds, and a financing fee of $600,000 (3.0% of gross proceeds) payable to Craig-Hallum Capital Group LLC, our financial advisor for the financing.

•
Interest Rate. Principal outstanding under the Credit Agreement bears interest at a rate per annum equal to the sum of (a) the greater of the one-month London Interbank Offered Rate and 2.5% plus (b) 8.75%. At any time at which an event of default (as described under “—Default Provisions” below) has occurred and is continuing, the interest rate will increase by 4.0%. Accrued interest is payable on a monthly basis. On March 31, 2022, the interest rate was 11.25%.

•
Scheduled Repayment. No principal repayments are due prior to September 30, 2022, unless we elect to prepay principal as described under “—Optional Prepayment” below or principal is accelerated pursuant to an event of default as described under “—Default Provisions” below. Principal installments in the amount of $300,000 are payable on the last day of each of the eleven months from September 2022 through July 2023, and all remaining principal is payable at maturity on September 3, 2023.

•
Optional Prepayment. We may prepay outstanding principal from time to time, subject to payment of a premium on the prepaid principal amount equal to 10% through September 3, 2020, 8% from September 4, 2020 through September 3, 2021, and 4% from September 4, 2021 through September 3, 2022. No premium will be due with respect to any prepayment made on or after September 4, 2022.

•
Guarantees. Our subsidiaries Chembio Diagnostic Systems Inc. and Chembio Diagnostics Malaysia Sdn Bhd. have guaranteed, and the Lender from time to time may require our other subsidiaries to guarantee, our obligations under the Credit Agreement.

•
Security. Our obligations under the Credit Agreement are secured by a first priority, perfected lien on substantially all of our property and assets, including our equity interests in our subsidiaries. Our subsidiary Chembio Diagnostic Systems Inc. has secured its guarantee of our Credit Agreement obligations with a lien on substantially all of its assets, and the Lender from time to time may require Chembio Diagnostics Malaysia Sdn Bhd. and any of our other subsidiaries that has guaranteed our Credit Agreement obligations to do the same.

33
•
Representations and Warranties; Financial and Other Covenants. In the Credit Agreement we made customary representations and warranties as well as customary affirmative and negative covenants, including covenants limiting additional indebtedness, liens, guarantees, mergers and acquisitions, substantial asset sales, investments and loans, sale and leasebacks, transactions with affiliates, and fundamental changes. The Credit Agreement also contains financial covenants requiring that (i) we maintain aggregate unrestricted cash of not less than $3,000,000 at all times and (ii) we achieve specified minimum rolling four-quarter (“last twelve month”) total revenue amounts as of September 30, 2019 and the last day of each calendar quarter thereafter. For the next year, the minimum total revenue requirements range from $43.8 million for the twelve months ending June 30, 2022, and $ 48.8 million for the twelve months ending March 31, 2023. The minimum total revenue amounts were developed for purposes of the Credit Agreement and do not reflect the internal estimates and plans used by our management and board of directors to understand and evaluate our operating performance, to establish budgets, and to establish operational goals for managing our business. We therefore do not believe that the covenant requirements provide useful information to investors or others in enhancing an understanding of our future prospects.

•
Default Provisions. The Credit Agreement provides for customary events of default, including events of default based on non-payment of amounts due under the Credit Agreement, defaults on other debt, misrepresentations, covenant breaches, changes of control, insolvency, bankruptcy and the occurrence of a material adverse effect on our company. Upon an event of default resulting from a voluntary or involuntary proceeding for bankruptcy, insolvency or receivership, the amounts outstanding under the Credit Agreement will become immediately due and payable and the Lender’s commitments will be automatically terminated. Upon the occurrence and continuation of any other event of default, the Lender may accelerate payment of all obligations and terminate its commitments under the Credit Agreement.

Equity and Equity-Related Securities. On July 19, 2021, we and Craig‑Hallum Capital Group LLC, or Craig-Hallum, entered into the ATM Agreement, pursuant to which we may sell from time to time, at our option, up to an aggregate of $60,000,000 of shares of common stock through Craig‑Hallum, as sales agent. Any sales of shares made pursuant to the ATM Agreement will be made pursuant to our shelf registration statement on Form S‑3 (File No. 333‑254261) and the related prospectus previously declared effective by the SEC on May 5, 2021, as supplemented by a prospectus supplement dated July 19, 2021 that we filed with the SEC, pursuant to Rule 424(b)(5) under the Securities Act, on July 19, 2021, as such prospectus supplement may be amended or supplemented from time to time.

Prior to any sale of shares of common stock under the ATM Agreement, we may deliver a sales notice to Craig-Hallum that will set the parameters for such sale, including the number of shares to be issued and sold, the time period during which such sale is requested to be made, any limitation on the number of shares that may be sold in any one trading day and any minimum price below which sales may not be made. Under the ATM Agreement, Craig-Hallum is required to use commercially reasonable efforts consistent with its normal trading and sales practices to sell shares in accordance with the terms of the ATM Agreement and any applicable sales notice.

Subject to the terms and conditions of the ATM Agreement, Craig-Hallum may sell any shares of common stock only by methods deemed to be an “at the market” offering as defined in Rule 415 under the Securities Act, including sales made directly through the Nasdaq Capital Market, by means of ordinary brokers’ transactions, in negotiated transactions, to or through a market maker other than on an exchange or otherwise, at market prices prevailing at the time of sale, at prices related to such prevailing market prices, or at negotiated prices and/or any other method permitted by law. If any sale of shares pursuant to the ATM Agreement is not made directly on the Nasdaq Capital Market or any other existing trading market for common stock at market prices at the time of sale, including a sale to Craig-Hallum acting as principal or a sale in a privately negotiated transaction, we must file a prospectus supplement describing the terms of such sale, the number of shares sold, the price of the shares, the applicable compensation, and such other information as may be required pursuant to Rules 424 and 430B under the Securities Act, as applicable, within the time required by Rule 424 under the Securities Act.

Under the terms of the ATM Agreement, we are to pay Craig-Hallum a placement fee of 3.5% of the gross sales price of shares of common stock sold, unless Craig-Hallum acts as principal, in which case we may sell the shares to Craig-Hallum as principal at a price we agree upon with Craig-Hallum. We are obligated to reimburse Craig-Hallum for certain expenses incurred in connection with the ATM Agreement, and we have provided Craig-Hallum with customary indemnification and contribution rights with respect to certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934.

We are currently subject to General Instruction I.B.6 to Form S-3, or the Baby Shelf Rule, and the amount of funds we can raise through primary public offerings of securities in any twelve-month period using our existing registration statement on Form S-3 is limited to one-third of the aggregate market value of the voting and non-voting common equity held by non-affiliates. We will be limited by the Baby Shelf Rule until such time as our public float exceeds $75 million.
 
34
The offering of shares of common stock pursuant to the ATM Agreement will terminate upon the earliest of (a) the sale of all of the shares registered for purposes of the offering pursuant to the ATM Agreement, (b) our mutual written agreement with Craig-Hallum, (c) written notice from Craig-Hallum, in its sole discretion, to us, and (d) five business days’ prior written notice from us, in our sole discretion, to Craig-Hallum.

As of the filing date of this report, we have issued and sold pursuant to the ATM Agreement a total of 9,709,328 shares of common stock at a volume-weighted average price of $4.20 per share for gross proceeds of $40.8 million and net proceeds, after giving effect to placement fees and other transaction costs, of $38.8 million. Additional shares of common stock may be issued and sold pursuant to the ATM Agreement, but we cannot provide any assurance that will be able to issue any additional shares under the ATM Agreement at an acceptable price or at all.

Research and Development Awards. Under a contract we entered into with BARDA on December 2, 2020, a total of up to $12.7 million of awards were available from BARDA to assist us in (a) developing, and pursuing an EUA from the FDA for, the DPP Respiratory Antigen Panel and (b) performing the clinical trials for and submitting the DPP SARS-CoV-2 Antigen test system to the FDA for 510(k) clearance. Of the total awards available under this contract, no government grant income was recognized during the three months ended March 31, 2022. The completion of milestones to earn the remaining awards are outside our control, and contingent to the EUA approval by the FDA.

Working Capital. The following table sets forth selected working capital information:

   
March 31,
2022
  
   
(in thousands)
  
Cash and cash equivalents
  
$
24,399
  
Accounts receivable, net of allowance for doubtful amounts
    
9,880
  
Inventories, net
    
11,844
  
Prepaid expenses and other current assets
    
2,097
  
Total current assets
    
48,220
  
Less: Total current liabilities
    
(13,632
)
Working capital
  
$
34,588
  

Our cash and cash equivalents at March 31, 2022, were held for working capital purposes. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends. We have not entered into, and do not expect to enter into, investments for trading or speculative purposes. Our accounts receivable and inventory balances fluctuate from period to period, which affects our cash flow from operating activities. Fluctuations vary depending on cash collections, client mix, raw material lead times, the mix of vendor terms, and the timing of shipment of our products and the invoicing of our research and development activities.

Uses of Funds

Cash Flow Used in Operating Activities. Our operations used $4.4 million of cash during the three months ended March 31, 2022, primarily due to a $2.6 million decrease in accounts payable and other accrued liabilities, and a $1.1 million increase in inventory.  Those uses of cash were partially offset by a $1.6 million increase in accounts receivable.

Capital Expenditures. Our capital expenditures totaled $0.3 million in the three months ended March 31, 2022 compared to $1.2 million in prior year period, which were primarily attributable to investments in automated manufacturing equipment, facilities, and other fixed assets.

35
We have capital purchase obligations of $1.5 million related to additional automated manufacturing equipment with payments expected to come due during 2022 based on vendor performance milestones.

Significant Accounting Policies and Critical Accounting Estimates
There were no significant changes in our accounting policies or critical accounting estimates during the three months ended March 31, 2022 to augment the significant accounting policies or critical accounting estimates disclosed under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2021 Form 10-K, other than those described in the notes to the condensed consolidated financial statements included elsewhere in this report.

Recently Issued Accounting Pronouncements

A discussion of recent accounting pronouncements was included in our 2021 Form 10-K and is updated in Note 2 to the condensed consolidated financial statements included elsewhere in this report.

ITEM 3.
CONTROLS AND PROCEDURES

(a)
Disclosure Controls and Procedures. Under the supervision and with the participation of our senior management, consisting of our principal executive officer and our principal financial officer, we conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of the end of the period covered by this report. Based on this evaluation, our management, including our principal executive officer and principal financial officer, concluded that as of March 31, 2022 our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Our disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in our Exchange Act reports is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

(b)
Changes in Internal Control over Financial Reporting. There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 under the Exchange Act that occurred during the three months ended March 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II.
OTHER INFORMATION

ITEM 1.
LEGAL PROCEEDINGS

This information is set forth under “Note 6 – Commitments, Contingencies And Concentrations – Litigation” to the Consolidated Financial Statements of this report is incorporated herein by reference.

ITEM 1A.
RISK FACTORS

Except as set forth below, there have been no material changes to the risk factors described in the section captioned Part I, Item 1A, “Risk Factors,” in our 2021 Form 10-K. In addition to the other information set forth in this report, you should carefully consider the factors discussed in the section captioned Part I, Item 1A, “Risk Factors” in our 2021 Form 10‑K, which could materially affect our business, financial condition, or future results. Moreover, you should interpret many of the risks identified in our 2021 Form 10-K as being heightened as a result of the ongoing and numerous adverse impacts of COVID-19. The risks described in our 2021 Form 10-K and in this report are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may have a material adverse effect on our business, financial condition, and/or operating results.
 
36
Risks Related to Our Business and Our Industry

Our near term success is highly dependent on the success of the our DPP platform, and we cannot be certain that we will succeed in developing one or more of those systems or that, if we do, they will attain market acceptance or be successfully commercialized in the United States or elsewhere.

We do not currently have an Emergency Use Authorization, or EUA, from the U.S. Food and Drug Administration, or FDA, for any of the COVID-19 Diagnostic Test Systems or for our DPP Respiratory Panel. We also do not have a CLIA waiver from the FDA for our DPP HIV-Syphilis test system. Market and regulatory requirements continue to change at a rapid pace. There can be no assurance that, if we make a submission of any future EUA or CLIA waiver application, we will meet the requirements of the prioritization guidance in effect at the time of the submission or otherwise be successful in obtaining either (1) an EUA that would permit us to offer and sell the DPP SARS-CoV-2 Antigen test system or DPP Respiratory Panel in the United States or (2) a CLIA waiver for our DPP HIV-Syphilis test.

Even if we are able to obtain any such EUA or CLIA waiver, our product may not gain broad market acceptance among physicians, healthcare payers, patients, and the medical community. We cannot guarantee market acceptance of our product, and have somewhat limited information on which to estimate our anticipated level of sales. Our products will require healthcare providers and doctors to accept and adopt our technology. Our industry is susceptible to rapid technological developments and there can be no assurance that we will be able to match any new technological advances. Acceptance and use of any products we market will depend upon a number of factors including:

•
perceptions by members of the health care community, including physicians, about the safety and effectiveness of our products;

•
limitation on use or warnings required by the FDA or other global regulators in our product labeling;

•
the cost of our products relative to competing products;

•
convenience and ease of administration;

•
potential advantages of alternative diagnostic and treatment methods;

•
availability of reimbursement for our products from government or other healthcare payers;

•
effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any; and

•
the ability of our diagnostic solutions to address different variants.

In addition, with respect to any EUA we obtain, the FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, even if we obtain an EUA, we cannot predict how long such EUA would remain in place. Such revocation could materially adversely impact our business in a variety of ways, including if the relevant product is not yet approved by the FDA under a traditional approval pathway and if we have invested in the supply chain to provide any of our products under an EUA, and would require us to obtain a 510(k) or other marketing authorization from the FDA. If the FDA revokes a previously issued EUA prior to us having received regulatory approval to commercialize our DPP SARS-CoV-2 Antigen test system or DPP Respiratory Panel through a traditional approval pathway, we would be required to cease our commercialization efforts, which would substantially and negatively impact our business.

37
The failure of these products to find market acceptance would substantially harm our business and would adversely affect our revenue. If the DPP SARS-CoV-2 Antigen test system, DPP Respiratory Panel or DPP HIV-Syphilis test are not as successfully commercialized as expected, we may not be able to generate sufficient revenue to become profitable. Any failure of one of these products to be successfully commercialized in the United States may have a material adverse effect on our business, operating result financial condition and cash flows, and could result in a substantial decline in the price of our common stock. In addition, the production and widely administered use of efficacious vaccines for COVID-19 may reduce the demand for diagnostic tests and, as a result, the COVID-19 diagnostic testing market may not develop or substantially grow. Our future success is substantially dependent on the manner in which the market for diagnostic testing develops and grows. If the market develops in a manner that does not facilitate demand for our products, or fails to develop or grow in the manner in which we expect or at all, our business, financial condition, results of operations and cash flows may be negatively affected.

Clinical trials necessary to support a future test kit submission will be expensive and may require the enrollment of large numbers of subjects, and suitable subjects may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new test kits and will adversely affect our business, operating results and prospects.

We expect competition with respect to testing solutions for COVID-19 to continue to increase and our success will depend on market acceptance of our products.

We expect competition to continue to increase as other established and emerging companies enter the market, as customer requirements evolve, and as new products, services and technologies are introduced. The entrance of new competitors is being encouraged by governmental authorities, which are offering funding to support development of testing solutions for COVID-19. Some of our existing or new competitors may have strong relationships with current and potential customers, including governmental authorities that may help fund those competing entities through grant awards or other funding. As a result, those competitors may be able to respond more quickly to new or changing regulatory requirements, new or emerging technologies, and changes in customer requirements. We do not currently have an EUA from the FDA for any of the COVID-19 Diagnostic Test Systems. Even if we succeed in obtaining approvals for commercialization for one or more of the COVID-19 Diagnostic Test Systems, those products may not compete favorably, and we may not be successful in the face of existing and new products and technologies offered by our existing competitors or new companies entering our markets. Any failure to compete effectively could materially and adversely affect our business, financial condition and operating results.

Some of our programs are supported by government grant awards, and our inability to obtain additional grant awards in the future or to derive all of the funding potentially available under those awards could delay our development and introduction of products.

We have received funding under grant award programs funded by governmental agencies such as BARDA. To fund a portion of our future research and development programs, we may apply for additional grant funding from these or similar governmental agencies. Funding by these governmental agencies may, however, be significantly reduced or eliminated in the future for a number of reasons. For example, some programs are subject to a yearly appropriations process in Congress. We may not receive full funding under current or future grants because of budgeting constraints of the agency administering the program or unsatisfactory progress on the study being funded.

There can be no assurance that we will receive any future grant awards from any government agencies or that, if a grant award is obtained, we will receive the full amount potentially available under the grant award. Our inability to obtain future grant awards, or to earn the full amount available under those awards, could delay the development of our product candidates and the introduction of new products.

38
Risks Related to Our Products

Industry adoption of alternative technology to our COVID-19 Diagnostic Test Systems could negatively impact our ability to compete successfully.

Of the manufacturers and commercial laboratories to receive an EUA for COVID-19 diagnostics as of September 21, 2021, 88 were for serology tests, 235 were for molecular tests, and 34 were for antigen tests. Customers or the industry as a whole could adopt alternative technologies for testing, including molecular point of care testing, which could result in lower demand for our antigen test. Various advances in the treatment and monitoring of patients could cause lower demand for the COVID-19 Diagnostic Test Systems, including our revised DPP SARS CoV 2 Antigen System or for antigen testing for COVID-19 as a whole.

Risks Related to Regulations

COVID‑19 diagnostic tests, including the COVID-19 Diagnostic Test Systems, are subject to changes in CLIA, FDA, ANVISA and other regulatory requirements.

Our COVID-19 Diagnostic Test Systems are subject to regulations of the FDA and other regulatory requirements, including ANVISA, Brazil’s health regulatory agency. The regulations regarding the manufacture and sale of COVID-19 Diagnostic Test Systems may be unclear and are subject to recurring change. Newly promulgated regulations could require changes to COVID-19 Diagnostic Test Systems, necessitate additional procedures, or make it impractical or impossible for us to market COVID-19 Diagnostic Test Systems for certain uses, in certain markets, or at all. The FDA and other regulatory authorities also have the ability to impose new or additional requirements relating to the COVID-19 Diagnostic Test Systems. The implementation of such changes or new or additional requirements may result in a substantial additional costs and could delay or make it more difficult or complicated to sell our products.

On February 4, 2020, the U.S. Department of Health and Human Services issued a declaration that the threat to public health posed by COVID-19 justify the emergency use of unapproved in vitro diagnostics for the detection or diagnosis of SARS-CoV-2. Under Section 564 of the Food, Drug, and Cosmetic Act, because the U.S. Department of Health and Human Services has issued this declaration, the Commissioner of the FDA is authorized to issue EUAs to permit certain developers of SARS-CoV-2 diagnostics to begin offering the tests for detection and diagnosis of COVID-19 without having completed the normally applicable FDA review and clearance or approval process for marketing authorization. We received an EUA for the DPP COVID-19 IgM/IgG System on April 14, 2020, which was subsequent revoked by the FDA on June 16, 2020. Such revocation precludes the sale of DPP COVID-19 IgM/IgG Systems in the United States unless and until a further regulatory approval or authorization is obtained. We have not received a subsequent EUA for any of the COVID-19 Diagnostic Test Systems. Moreover, market and regulatory requirements continue to change at a rapid pace. The FDA has announced, for example, that it intends to update its EUA templates with additional considerations related to the impact of genetic variants on test performance as the FDA learns more about the COVID-19 disease and its knowledge in this area progresses. The time required to obtain marketing authorizations and other approvals from regulatory authorities is unpredictable. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can change, and do often change, during development, which makes it difficult to predict with any certainty how they will be applied. If we make future submissions to the FDA, we may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA policy during the period of FDA regulatory review. There can be no assurance that if we are to make a submission of any future EUA application, we will be successful in obtaining an EUA that would permit us to offer and sell any COVID-19 Diagnostic Test System in the United States.

Because we may not be able to obtain or maintain the necessary regulatory approvals for some of our products, we may not generate revenues in the amounts we expect, or in the amounts necessary to continue our business. Our existing products as well as our manufacturing facility must meet quality standards and are subject to inspection by a number of domestic regulatory and other governmental and non‑governmental agencies.

All of our proposed and existing products are subject to regulation in the United States by the FDA, the U.S. Department of Agriculture, and/or other domestic and international governmental, public health agencies, regulatory bodies or non-governmental organizations. In particular, we are subject to strict governmental controls on the development, manufacture, labeling, distribution and marketing of our products. The process of obtaining required approvals or clearances varies according to the nature of, and uses for, a specific product. These processes can involve lengthy and detailed laboratory testing, human or animal clinical trials, sampling activities, and other costly, time consuming procedures. The submission of an application to a regulatory authority does not guarantee that the authority will grant an approval or clearance for that product. Each authority may impose its own requirements and can delay or refuse to grant approval or clearance, even though a product has been approved in another country.

39
The time taken to obtain approval or clearance varies depending on the nature of the application and may result in the passage of a significant period of time from the date of submission of the application. As an example, the time required to obtain an EUA from the FDA for COVID‑19 tests has lengthened markedly over the past months due to, among other things, application volume. Delays in the approval or clearance processes increase the risk that we will not succeed in introducing or selling the subject products, and we may determine to devote our resources to different products.

Changes or developments in government regulations, policies or interpretations could increase our costs and could require us to undergo additional trials or procedures, or could make it impractical or impossible for us to market our products for certain uses, in certain markets, or at all. For example, on June 16, 2020, the FDA revoked the EUA it had granted for the DPP COVID-19 IgM/IgG System based in part on performance criteria identified after the EUA was granted on April 14, 2020. We do not currently have an EUA from the FDA for any of the COVID-19 Diagnostic Test Systems. Moreover, FDA regulations, policies and procedures with respect to COVID-19 tests may be significantly impacted by the availability of vaccines for COVID-19 and changes in the FDA’s prioritization guidance. Similarly, the regulatory pathway to 510(k) clearance by the FDA for COVID-19 tests is unclear in light of limited FDA feedback resulting in part from the FDA’s constrained resources.

Changes in government regulations may adversely affect our financial condition and results of operations because we may have to incur additional expenses if we are required to change or implement new testing, manufacturing and control procedures. If we are required to devote resources to develop such new procedures, we may not have sufficient resources to devote to research and development, marketing, or other activities that are critical to our business. We are, for example, expending resources to modify the design of the COVID-19 Diagnostic Test System to achieve performance targets consistent with the FDA’s performance criteria issued subsequent to the granting of our original EUA.

If we do not comply with FDA or other regulatory requirements, we may be required to suspend production or sale of our products or institute a recall, which could result in higher costs and a loss of revenues.

Regulations of the FDA and other federal, state and foreign regulatory agencies have significant effects on many aspects of our operations and the operations of our suppliers and distributors, including packaging, labeling, manufacturing, adverse event reporting, recalls, distribution, storage, advertising, promotion and record keeping. We are subject to routine inspection by the FDA and other agencies to determine compliance with FDA regulatory requirements, including QSRs, in the United States and other applicable regulations worldwide, including ISO standards. We believe that our facilities and procedures are in material compliance with the FDA requirements and ISO standards, but the regulations may be unclear and are subject to change, and we cannot be sure that the FDA or other regulators will agree with our compliance with these requirements. The FDA and foreign regulatory agencies may require post marketing testing and surveillance to monitor the performance of approved or cleared products or impose conditions on any product clearances or approvals that could restrict the distribution or commercial applications of those products. Regulatory agencies may impose restrictions on our or our distributors’ advertising and promotional activities or preclude these activities altogether if a noncompliance is believed to exist. In addition, the subsequent discovery of previously unknown problems with a product may result in restrictions on the product or additional regulatory actions, including withdrawal of the product from the market.

Our inability to comply with the applicable requirements of the FDA can result in, among other things, 483 notices, warning letters, administrative or judicially imposed sanctions such as injunctions, recall or seizure of products, civil penalties, withdrawal of product registrations, total or partial suspension of production, refusal to grant premarket clearance for devices, a determination that a device is not approvable, marketing clearances or approvals, or criminal prosecution. For example, in February 2020, we received a “not approvable” letter from the FDA with respect to our premarket approval submission on our DPP HIV Syphilis multiplex test for commercial use in the United States, in June 2020 we received notice from the FDA that the EUA for the DPP COVID-19 IgM/IgG System had been revoked, and in January 2021 we received notice from the FDA that it was declining to review the DPP SARS CoV 2 Antigen System based on its updated prioritization guidance, under which review of the system was not a priority. The ability of our suppliers to supply critical components or materials and of our distributors to sell our products could also be adversely affected if their operations are determined to be out of compliance. Such actions by the FDA and other regulatory bodies could adversely affect our revenues, costs and results of operations.

40
We must frequently make judgment decisions with respect to compliance with applicable laws and regulations. If regulators subsequently disagree with how we have sought to comply with these regulations, we could be subjected to substantial civil and criminal penalties, as well as product recall, seizure or injunction with respect to the sale of our products. Our reputation could be substantially impaired if we are assessed any civil and criminal penalties and limit our ability to manufacture and market our products which could have a material adverse effect on our business.

Our inability to respond to changes in regulatory requirements could adversely affect our business.

We believe that our existing products and procedures are in material compliance with all applicable FDA regulations, ISO requirements, and other applicable regulatory requirements, but the regulations regarding the manufacture and sale of our products and QSR, ISO and other requirements may be unclear and are subject to change. Newly promulgated regulations could require changes to our products, necessitate additional clinical trials or procedures, or make it impractical or impossible for us to market our products for certain uses, in certain markets, or at all. The FDA and other regulatory authorities also have the ability to change the requirements for obtaining product approval and/or impose new or additional requirements as part of the approval process. These changes or new or additional requirements may occur after the completion of substantial clinical work and other costly development activities. The implementation of such changes or new or additional requirements may result in additional clinical trials and substantial additional costs and could delay or make it more difficult or complicated to obtain approvals and sell our products. In addition, the FDA may revoke an Emergency Use Authorization under which our products are sold, where it is determined that the underlying health emergency no longer exists or warrants such authorization. Such revocation would preclude the sale of our affected products unless and until a further regulatory approval or authorization is obtained. For example, For example, on June 16, 2020, the FDA revoked the EUA it had granted for the DPP COVID‑19 IgM/IgG System based in part on performance criteria identified after the Emergency Use Authorization was granted on April 14, 2020, and since that time we expended resources to design the new COVID-19 Diagnostic Test Systems, including the DPP Respiratory Antigen Panel. We do not currently have an EUA from the FDA for any of the COVID-19 Diagnostic Test Systems. We cannot anticipate or predict the effect, if any, that these types of changes might have on our business, financial condition or results of operations.

Ongoing changes in healthcare regulation could negatively affect our revenues, business and financial condition.

There have been several proposed changes in the United States at the federal and state level for comprehensive reforms regarding the payment for, the availability of and reimbursement for healthcare services. These proposals have ranged from fundamentally changing federal and state healthcare reimbursement programs, including providing comprehensive healthcare coverage to the public under government‑funded programs, to minor modifications to existing programs. One example is the Patient Protection and Affordable Care or the Affordable Care Act, the Federal healthcare reform law enacted in 2010.

Healthcare reform initiatives will continue to be proposed, and may reduce healthcare related funding in an effort. It is impossible to predict the ultimate content and timing of any healthcare reform legislation and its resulting impact on us. If significant reforms are made to the healthcare system in the United States, or in other jurisdictions, those reforms may increase our costs or otherwise negatively effect on our financial condition and results of operations.

41
The EU landscape concerning medical devices recently evolved. On May 25, 2017, the E.U. In-Vitro Diagnostic Regulation entered into force, which repeals and replaces the Council Directive 98/79/EC, or E.U. In-Vitro Diagnostic Directive. Unlike directives, which must be implemented into the national laws of the EU member states, regulations are directly applicable (i.e., without the need for adoption of E.U. member state laws implementing them) in all E.U. member states and are intended to eliminate current differences in the regulation of medical devices among E.U. member states. Devices lawfully placed on the market pursuant to the E.U. In-Vitro Diagnostic Directive prior to May 26, 2022 may generally continue to be made available on the market or put into service until May 26, 2027, provided that the requirements of the transitional provisions are fulfilled. In particular, the certificate in question must still be valid. However, even in this case, manufacturers must comply with a number of new or reinforced requirements set forth in the E.U. In-Vitro Diagnostic Regulation with regard to registration of economic operators and of devices, post-market surveillance, market surveillance and vigilance requirements.

Subject to the transitional provisions, in order to sell our products in E.U. member states, our products must comply with the general safety and performance requirements of the E.U. In-Vitro Device Regulation, which repeals and replaces EU In-Vitro Diagnostic Directive. Compliance with these requirements is a prerequisite to be able to affix the CE mark to our products, without which they cannot be sold or marketed in the EU. To demonstrate compliance with the general safety and performance requirements, we must undergo a conformity assessment procedure, which varies according to the type of medical device and its (risk) classification. Except for low risk medical devices (Class I), where the manufacturer can self-assess the conformity of its products with the general safety and performance requirements (except for any parts which relate to sterility, metrology or reuse aspects), a conformity assessment procedure requires the intervention of a notified body. The notified body would typically audit and examine the technical file and the quality system for the manufacture, design and final inspection of our devices. If satisfied that the relevant product conforms to the relevant general safety and performance requirements, the notified body issues a certificate of conformity, which the manufacturer uses as a basis for its own declaration of conformity. The manufacturer may then apply the CE mark to the device, which allows the device to be placed on the market throughout the E.U. If we fail to comply with applicable laws and regulations, we would be unable to affix the CE mark to our products, which would prevent us from selling them within the E.U.

We must inform the notified body that carried out the conformity assessment of the medical devices that we market or sell in the E.U. and the EEA of any planned substantial changes to our quality system or substantial changes to our medical devices that could affect compliance with the general safety and performance requirements laid down in Annex I to the E.U. In-Vitro Diagnostic Regulation or cause a substantial change to the intended use for which the device has been CE marked. The notified body will then assess the planned changes and verify whether they affect the products’ ongoing conformity with the E.U. In-Vitro Diagnostic Regulation. If the assessment is favorable, the notified body will issue a new certificate of conformity or an addendum to the existing certificate attesting compliance with the general safety and performance requirements and quality system requirements laid down in the Annexes to the E.U. In-Vitro Diagnostic Regulation.

Financial, Economic and Financing Risks
 
Because of our liquidity limitations, we have concluded there is a substantial doubt about our ability to continue as a going concern and we may require additional capital to fund our operations, which capital may not be available to us on acceptable terms or at all.
 
As described under “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations─Going Concern Considerations” and “─Liquidity and Capital Resources,” management has determined we could not be certain that our plans and initiatives to increase our total revenues and improve our liquidity position would be effectively implemented within one year after the filing date of this report, when the accompanying financial statements are being issued. Without giving effect to the prospect of raising additional capital pursuant to our at-the-market offerings under the ATM Agreement, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond our control, it is unlikely that we will be able to generate sufficient cash flows to meet our required financial obligations, including our debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about our ability to continue as a going concern for the twelve-month period following the filing date of this report, when the accompanying financial statements are being issued.
 
Our diagnostic test products require ongoing funding to continue our current development and operational plans, and we have a history of net losses. We may encounter challenges in fulfilling our obligations, and therefore receiving revenue, under those purchase orders. We will also incur costs associated with research and development activity, corporate administration, business development, debt service, marketing and selling of our products, and litigation. In addition, other unanticipated costs may arise.
 
As of March 31, 2022, our loan balance, net of unamortized discounts and debt issuance costs, of $18.9 million under the Credit Agreement. We may face further liquidity challenges if we are unable to meet obligations set forth in the Credit Agreement, including a financial covenant requiring that we achieve specified minimum total revenue amounts measured as of the end of each quarter. A breach of the minimum total revenue covenant or any other covenant in the Credit Agreement would result in a default under the Credit Agreement, which could enable the Lender to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. We cannot assure you that, in such an event, we would have sufficient assets to pay amounts due under the Credit Agreement.
 
As a result, we may need to raise capital in one or more debt or equity offerings to fund our operations and obligations. There can be no assurance, however, that we will be successful in raising the necessary capital or that any such offering will be available to us on terms acceptable to us, or at all. If we are unable to raise additional capital that may be needed on terms in sufficient amounts or on terms acceptable to us, it could have a material adverse effect on our company. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue our deliveries under our outstanding customer purchase orders or the development or commercialization of one or more of our products or one or more of our other research and development initiatives. The effects of COVID-19 have significantly disrupted world financial markets and negatively impacted U.S. market conditions, and they may reduce opportunities for us to seek out additional funding. A decline in the market price of our common stock, whether or not coupled with the suspension of trading of our common stock on the Nasdaq Capital Market, could make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate, or at all. Moreover, on April 5, 2022, we received a deficiency letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying us that, because the bid price for shares of our common stock had closed below the $1.00 per share minimum Bid Price Requirement for thirty consecutive business days, our common stock may be subject to delisting by as early as October 3, 2022 if we have been unable to regain compliance with the Bid Price Requirements or to qualify for an additional period to regain compliance by such date, all as described in more detail in the Current Report on Form 8-K we filed with the SEC on April 7, 2022. There can be no assurance that we will be able to regain compliance with the Bid Price Requirement. Our inability to regain compliance with the Bid Price Requirement would, and the existence of the pending deficiency letter could, materially impair our ability to raise capital.
 
Continuing doubt about our ability to continue as a going concern may materially and adversely affect the price of our common stock, and it may be more difficult for us to obtain financing. Any uncertainty about our ability to continue as a going concern may also adversely affect our relationships with current and future employees, suppliers, vendors, customers, grantors, creditors, regulators and investors, who may become concerned about our ability to meet our ongoing financial obligations. There is risk that, among other things:
 
•
third parties lose confidence in our ability to continue to operate in the ordinary course, which could impact our ability to execute on our business strategy;
 
•
it may become more difficult for us to attract, retain or replace employees;
 
•
employees could be distracted from performance of their duties;
 
•
we could lose some or a significant portion of our liquidity, either due to stricter credit terms from vendors, or, in the event we undertake a Chapter 11 proceeding and conclude that we need to procure debtor-in-possession financing, an inability to obtain any needed debtor-in-possession financing or to provide adequate protection to certain secured lenders to permit us to access some or all of our cash; and
 
•
our vendors and service providers could seek to renegotiate the terms of our arrangements, terminate their relationships with us or require financial assurances from us.
 
The accompanying financial statements have been prepared assuming we will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date of this report. As such, the accompanying financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should we be unable to continue as a going concern.
 
Additionally, we are currently subject to the Baby Shelf Rule and the amount of funds we can raise through primary public offerings of securities in any 12-month period using our registration statement on Form S-3 is limited to one-third of the aggregate market value of the voting and non-voting common equity held by non-affiliates. We will be limited by the Baby Shelf Rule until such time, if any, as our public float exceeds $75 million.
 
42
ITEM 6.
EXHIBITS

Number
  
Description
 
Employment Agreement, dated as of December 30, 2021 and effective as of January 5, 2022, between Chembio Diagnostics, Inc. and Lawrence J. Steenvoorden (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on January 6, 2022)
     
 
Amendment No. 1 dated February 9, 2022 between Chembio Diagnostics, Inc. and Richard L. Eberly, amending the Employment Agreement dated March 4, 2020 (incorporated by reference to Exhibit 10.1 to Current Report on Form 8-K filed on February 14, 2022)
     
 
Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
 
Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
 
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS
  
XBRL Instance Document
101.SCH
  
XBRL Taxonomy Extension Schema Document
101.CAL
  
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
  
XBRL Taxonomy Definition Linkbase Document
101.LAB
  
XBRL Taxonomy Label Linkbase Document
101.PRE
  
XBRL Taxonomy Presentation Linkbase Document

†
Indicates management contract or compensatory plan or arrangement.

*
Certain sensitive personally identifiable information in this exhibit was omitted by means of redacting a portion of the text and replacing it with [***]. ç The certifications attached as Exhibit 32.1 accompany the Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed “filed” by the registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

43
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
Chembio Diagnostics, Inc.
   
Date: May 5, 2022
By: /s/ Richard Eberly
 
Richard Eberly
 
Chief Executive Officer and President
   
Date: May 5, 2022
By: /s / Lawrence J. Steenvoorden
 
Lawrence J. Steenvoorden
 
Chief Financial Officer and Executive Vice President


44
EX-31.1 2 brhc10037126_ex31-1.htm EXHIBIT 31.1
Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Richard L. Eberly, certify that:

1.
I have reviewed this Quarterly Report on Form 10-Q of Chembio Diagnostics, Inc.

2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


(a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


(a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

Date: May 5, 2022
 /s/ Richard L. Eberly
 
Richard L. Eberly
 
Chief Executive Officer and President

EX-31.2 3 brhc10037126_ex31-2.htm EXHIBIT 31.2
Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Lawrence J. Steenvoorden, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Chembio Diagnostics, Inc.

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


 (a)
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;


(b)
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;


(c)
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and


(d)
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):


 (a)
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and


(b)
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal controls.

Date: May 5, 2022
/s/ Lawrence J. Steenvoorden
 
Lawrence J. Steenvoorden
 
Chief Financial Officer and Executive Vice President

EX-32.1 4 brhc10037126_ex32-1.htm EXHIBIT 32.1
Exhibit 32.1


CERTIFICATION PURSUANT TO 18 U.S.C. 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Chembio Diagnostics, Inc. for the quarterly period ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to his knowledge on the date hereof:


 1.
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Chembio Diagnostics, Inc. for the period presented therein.

Date: May 5, 2022
/s/ Richard L. Eberly
 
Richard L. Eberly
 
Chief Executive Officer and President

Date: May 5, 2022
/s/ Lawrence J. Steenvoorden
 
Lawrence J. Steenvoorden
 
Chief Financial Officer and Executive Vice President

The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.

 EX-101.SCH 5 cemi-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 050000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 050100 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Calc 3 link:presentationLink link:calculationLink link:definitionLink 060100 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 060200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 060300 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 060400 - Disclosure - INVENTORY link:presentationLink link:calculationLink link:definitionLink 060500 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 060600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS link:presentationLink link:calculationLink link:definitionLink 060700 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 060800 - Disclosure - EQUITY INCENTIVE PLAN link:presentationLink link:calculationLink link:definitionLink 060900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY link:presentationLink link:calculationLink link:definitionLink 061000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 061100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 061200 - Disclosure - OTHER MATTERS link:presentationLink link:calculationLink link:definitionLink 070200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 080300 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 080400 - Disclosure - INVENTORY (Tables) link:presentationLink link:calculationLink link:definitionLink 080600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 080800 - Disclosure - EQUITY INCENTIVE PLAN (Tables) link:presentationLink link:calculationLink link:definitionLink 080900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Tables) link:presentationLink link:calculationLink link:definitionLink 081000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 081100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 090200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Going Concern Considerations (Details) link:presentationLink link:calculationLink link:definitionLink 090202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Fair Value of Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 090204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 090206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 090300 - Disclosure - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 090400 - Disclosure - INVENTORY (Details) link:presentationLink link:calculationLink link:definitionLink 090500 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 090600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details) link:presentationLink link:calculationLink link:definitionLink 090604 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details) Calc 3 link:presentationLink link:calculationLink link:definitionLink 090700 - Disclosure - LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 090800 - Disclosure - EQUITY INCENTIVE PLAN, Summary (Details) link:presentationLink link:calculationLink link:definitionLink 090802 - Disclosure - EQUITY INCENTIVE PLAN, Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 090804 - Disclosure - EQUITY INCENTIVE PLAN, Restricted Stock and Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 090900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Details) link:presentationLink link:calculationLink link:definitionLink 091000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 091100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 cemi-20220331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 cemi-20220331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 cemi-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Award Type [Axis] SIGNIFICANT ACCOUNTING POLICIES [Abstract] ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Accounts payable and accrued liabilities TOTAL Accounts Payable and Accrued Liabilities, Current Accounts payable - suppliers Accounts Payable, Trade, Current Accounts Payable Accounts Payable, Current Accounts receivable, net of allowance for doubtful accounts of $242,981 and $243,042 at March 31, 2022 and December 31, 2021, respectively Accounts Receivable Accrued vacation Accrued Vacation, Current Accrued bonuses Accrued Bonuses, Current Accrued professional fees Accrued payroll Accrued Salaries, Current Accumulated other comprehensive (loss) AOCL [Member] Additional paid-in capital Additional Paid-in-Capital [Member] Additional Paid-in Capital [Member] Adjustments: Restricted stock compensation, net Shares tendered for withholding taxes Share-based Payment Arrangement, Decrease for Tax Withholding Obligation Stock option compensation APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition Allocated share-based compensation expense Accounts receivable, allowance for doubtful accounts Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from calculation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities, Name [Domain] TOTAL ASSETS Assets ASSETS Assets [Abstract] TOTAL CURRENT ASSETS Assets, Current CURRENT ASSETS: OTHER ASSETS: SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation DECREASE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents - end of the period Cash and cash equivalents - beginning of the period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Cash and Cash Equivalents [Axis] INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS: Cash and cash equivalents COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS [Abstract] COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS Commitments and Contingencies Disclosure [Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Common Stock [Abstract] Common Stock: Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Common Stock [Member] Common stock, shares issued (in shares) Common stock, par value (in dollars per share) Common stock - $0.01 par value; 100,000,000 shares authorized; 30,269,916 shares and 30,104,986 shares issued at March 31, 2022 and December 31, 2021, respectively Common stock, shares authorized (in shares) COMPREHENSIVE LOSS Comprehensive Income (Loss), Net of Tax, Attributable to Parent Concentration Risk [Table] Concentration Risk Type [Domain] Percentage of product sales Concentration Risk Benchmark [Domain] Concentration Risk Type [Axis] Concentration Risk [Line Items] Concentration Risk Benchmark [Axis] Purchases Cost of Goods and Services Sold Purchases [Member] Cost of product revenue Cost of Revenue Cost of Product Sales [Member] TOTAL COSTS AND EXPENSES Costs and Expenses Customer Concentration Risk [Member] Disaggregation of Revenue Disaggregation of Revenue [Abstract] September 4, 2019 to September 3, 2020 [Member] Basis spread on variable rate Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Axis] September 4, 2021 to September 3, 2022 [Member] September 4, 2020 to September 3, 2021 [Member] LONG-TERM DEBT [Abstract] Fair value of total debt Debt Instrument [Axis] Financing fee Debt instrument, face amount Schedule of Long-term Debt Instruments [Table] Debt Instrument [Line Items] Interest rate Debt instrument maturity date Debt Instrument, Name [Domain] Principal installment payable Benefit from deferred tax liability Deferred Income Tax Expense (Benefit) Benefit Plan [Abstract] Defined Contribution Plan [Table] Defined Contribution Plan Disclosure [Line Items] Employer matching contribution Expenses related to matching contribution Deposits and other assets Deposits Assets, Noncurrent Depreciation and amortization EQUITY INCENTIVE PLAN [Abstract] EQUITY INCENTIVE PLAN Loss Per Share Earnings Per Share, Policy [Policy Text Block] Basic loss per share (in dollars per share) Loss Per Share [Abstract] Earnings Per Share [Abstract] Diluted loss per share (in dollars per share) Effect of exchange rate changes on cash Effective tax rate Income Taxes [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Weighted average period for recognition of net unrecognized compensation cost Options [Member] Stock Options [Member] Net unrecognized compensation cost Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Stock Compensation Expense [Abstract] Net unrecognized compensation cost Equity Component [Domain] Exchange Transactions [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value of Financial Instruments Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, by Balance Sheet Grouping [Table] Level 1 [Member] Level 2 [Member] 2023 Finance Lease, Liability, to be Paid, Year One Total lease payments Finance Lease, Liability, Payment, Due Finance leases Finance leases Finance Lease, Weighted Average Discount Rate, Percent 2022 Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Total Finance Lease, Liability Financing cash flows for finance leases Payments on finance lease Less: imputed interest Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Maturities of Finance Lease Liabilities [Abstract] 2024 Finance Lease, Liability, to be Paid, Year Two Amortization of right-of-use assets 2025 Finance Lease, Liability, to be Paid, Year Three Finance lease liabilities Finance Lease, Liability, Current Interest on lease liabilities 2026 Finance Lease, Liability, to be Paid, Year Four Finance lease right-of-use assets, net Finance lease right-of-use asset, net Fair Value of Financial Instruments [Abstract] Government Grant Revenue [Member] Government Grant Income [Member] Geographic Areas, Long-Lived Assets [Abstract] Geographic Areas, Revenues from External Customers [Abstract] GOODWILL AND INTANGIBLE ASSETS Goodwill Goodwill, Ending balance Goodwill, Beginning balance Impairment Goodwill, Impairment Loss Goodwill [Roll Forward] GOODWILL AND INTANGIBLE ASSETS [Abstract] Changes in foreign currency exchange rate Impairment LOSS BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income Statement Location [Domain] Income Statement Location [Axis] CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract] Income tax (expense)/benefit Income Tax Expense (Benefit) Income Taxes Deferred revenue Increase (Decrease) in Contract with Customer, Liability Accounts receivable Increase (Decrease) in Accounts Receivable Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Deposits and other assets Increase (Decrease) in Deposit Assets Inventories Increase (Decrease) in Inventories Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Stockholders' Equity [Roll Forward] Interest expense, net INVENTORY [Abstract] INVENTORY Inventory Disclosure [Text Block] Work in process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Inventories, net Inventories Inventory, Net Raw materials Inventory, Raw Materials, Net of Reserves LIBOR [Member] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Total lease payments Lessee, Operating Lease, Liability, to be Paid Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four 2022 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Leases [Abstract] Lessee, Operating Lease, Description [Abstract] Components of Lease Expense [Abstract] Components of Lease Expense TOTAL LIABILITIES Liabilities LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES AND STOCKHOLDERS' EQUITY TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity OTHER LIABILITIES: TOTAL CURRENT LIABILITIES Liabilities, Current CURRENT LIABILITIES: License and Royalty Revenue [Member] License and Royalty Revenue [Member] Long-lived Assets by Geographic Area Carrying value Outstanding loan balance, net Long-term Debt LONG-TERM DEBT Long-term Debt [Text Block] Current portion of long-term debt Long-term debt, net Employee Litigation [Abstract] Loss Contingency [Abstract] Number of filed complaints Loss contingency, claims entitlement to recover damages amount Number of class action lawsuits Money Market Funds [Member] DESCRIPTION OF BUSINESS Nature of Operations [Text Block] RECONCILIATION OF NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities CASH FLOWS FROM FINANCING ACTIVITIES: Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM INVESTING ACTIVITIES: CASH FLOWS FROM OPERATING ACTIVITIES: Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities NET LOSS Net loss Net loss Recently Issued Accounting Standards Affecting the Company New Accounting Pronouncements, Policy [Policy Text Block] Number of operating segments Number of operating segment Number of reporting unit Number of Reporting Units Non-Exchange Transactions [Member] Operating lease liabilities Operating Lease, Liability, Current Operating leases Operating Lease, Weighted Average Discount Rate, Percent Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Maturities of Operating Lease Liabilities [Abstract] Cash paid for operating leases Operating cash flows for operating leases Operating lease right-of-use assets, net Operating Lease, Right-of-Use Asset Operating lease expense Operating Lease, Cost Operating leases Operating Lease, Weighted Average Remaining Lease Term Total Operating Lease, Liability COSTS AND EXPENSES: LOSS FROM OPERATIONS Operating Income (Loss) DESCRIPTION OF BUSINESS [Abstract] Future minimum salary commitments [Abstract] 2023 2024 Other Commitment, to be Paid, Year Two 2022 Other Commitment, to be Paid, Remainder of Fiscal Year Foreign currency translation adjustments, net of tax Comprehensive income (loss) Other comprehensive income (loss): OTHER EXPENSE: Accrued expenses - other ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract] Payments of tax withholdings on stock award Payment, Tax Withholding, Share-based Payment Arrangement Patent application costs Payments to Acquire Intangible Assets Cash paid to suppliers and employees Payments to Suppliers and Employees Plan Name [Domain] Plan Name [Axis] Preferred stock - 10,000,000 shares authorized, none outstanding Preferred stock, shares authorized (in shares) Preferred stock - shares authorized (in shares) Preferred stock, shares outstanding (in shares) Preferred stock - shares outstanding (in shares) Preferred Stock [Abstract] Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Cash received from customers and grants Net Product Revenue [Member] Product Revenue [Member] Property, plant and equipment, net Provision of (recovery of) doubtful accounts Finance leases Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Research and development expenses Research and Development Expenses [Member] Cash and Cash Equivalents [Domain] Restricted Stock [Member] Impairment, restructuring, severance and related costs Restructuring Costs and Asset Impairment Charges Accumulated Deficit [Member] Retained Earnings [Member] Accumulated deficit REVENUE [Abstract] REVENUES Revenues Net product revenue REVENUE REVENUES: Revenues from External Customers and Long-Lived Assets [Line Items] Expected term Average remaining contract term Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Term to exercise stock options Outstanding, weighted average remaining contract term Aggregate intrinsic value Exercisable, aggregate intrinsic value, end of period Total fair value of stock options vested during period Exercise price of stock options Exercisable, weighted average remaining contract term Weighted average exercise price (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price Weighted average exercise price (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Sales [Member] Revenue Benchmark [Member] Assumptions Made in Calculating Fair Values of Options Stock Option Activity Inventories Schedule of Inventory, Current [Table Text Block] Product Revenue by Geographic Area Schedule of Revenues from External Customers and Long-Lived Assets [Table] Summary of Restricted Stock and Restricted Stock Units Outstanding Accounts Payable and Accrued Liabilities Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Stock-Based Compensation Expense (Net of Recovery) Recognized Changes in Goodwill Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Stock Options Outstanding Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table] Customer and Purchase Concentration Risks GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY [Abstract] GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY Selling, General and Administrative Expenses [Member] Selling, general and administrative expenses Stock Options, Weighted Average Exercise Price per Share [Roll Forward] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Arrangements with Employees and Nonemployees [Abstract] Forfeited (in dollars per share) Weighted Average Grant Date Fair Value [Abstract] Increase in number of shares authorized (in shares) Share based compensation Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Expired (in dollars per share) Exercised (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Expected dividend yield Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Forfeited (in shares) Number of Shares & Units [Abstract] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Assumptions Made in Calculating Fair Values of Options [Abstract] Granted (in shares) Vested (in shares) Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Number of shares authorized under the plan (in shares) Expired (in shares) Options still available to be issued (in shares) Exercisable, end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Exercisable, end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Exercised, aggregate intrinsic value Stock Options, Additional Disclosure [Abstract] Outstanding, beginning of period (in shares) Outstanding, end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, beginning of period (in dollars per share) Outstanding, end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Aggregate intrinsic value Outstanding, aggregate intrinsic value, beginning of period Outstanding, aggregate intrinsic value, end of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Vested shares exercisable (in shares) Stock Options, Number of Shares [Roll forward] Number of stock options exercised under the plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Shares outstanding (in shares) Award Type [Domain] Exercise Price Range [Axis] Range of exercise prices, minimum (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain] Shares exercisable (in shares) Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Range of exercise prices, maximum (in dollars per share) Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Shares tendered for withholding taxes (in shares) Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Balance (in shares) Balance (in shares) Shares, Outstanding CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract] CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract] Statement [Table] Statement [Line Items] CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract] Statement, Equity Components [Axis] CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY [Abstract] Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Restricted stock issued (in shares) Restricted stock issued TOTAL STOCKHOLDERS' EQUITY Balance Balance Stockholders' Equity Attributable to Parent STOCKHOLDERS' EQUITY STOCKHOLDERS' EQUITY: STOCKHOLDERS' EQUITY [Abstract] Supplier Concentration Risk [Member] Transaction [Domain] Transaction Type [Axis] Treasury Stock, 48,057 shares at cost, at March 31, 2022 and December 31, 2021 Treasury Stock, Value Treasury Stock [Abstract] Treasury stock, shares (in shares) Treasury Stock, Shares Treasury Stock [Member] Variable Rate [Axis] Variable Rate [Domain] Weighted average number of shares outstanding, diluted (in shares) Weighted average number of shares outstanding, basic (in shares) Asia [Member] Africa [Member] Major Suppliers [Axis] Future Minimum Salary Commitment Contractual Obligation, Fiscal Year Maturity [Table Text Block] Latin America [Member] Major Customers [Axis] Maximum [Member] Name of Major Customer [Domain] Products and Services [Domain] Products and Services [Axis] Statistical Measurement [Domain] Statistical Measurement [Axis] Name of Major Supplier [Domain] Forecast [Member] Scenario [Domain] Geographical [Domain] Scenario [Axis] Geographical [Axis] United States [Member] Cover [Abstract] Document Type Document Quarterly Report Document Transition Report Entity Interactive Data Current Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Options [Abstract] Options: Shares of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement. APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition, Shares Restricted stock compensation, net (in shares) The Credit Agreement contains financial covenants requiring that the Company maintain revenue amounts for four rolling quarters. Line Of Credit Facility Covenant Amount, Revenue Covenant amount, revenue Credit Agreement [Abstract] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Discloses pertinent information about significant accounting policies. Significant Accounting Policies [Table] Significant Accounting Policies [Table] Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fourth fiscal year following latest fiscal year. Finance Lease, Liability, Payments, Due after Year Four Thereafter Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fourth fiscal year following latest fiscal year. Lessee, Operating Lease, Liability, Payments, Due after Year Four Thereafter Lease Weighted Average Discount Rate Percent [Abstract] Weighted Average Discount Rate [Abstract] Leases Weighted Average Remaining Lease Term [Abstract] Weighted Average Remaining Lease Term [Abstract] Amount of accumulated depreciation expense attributable to right-of-use asset from finance lease. Finance Lease Right of Use Asset Accumulated depreciation Accumulated depreciation Amount of lessee's right to use underlying asset before accumulated depreciation under finance lease. Finance Lease, Right-of-Use Asset before Amortization Finance lease right-of-use asset Finance Leases [Abstract] Finance Leases [Abstract] Supplemental Balance Sheet Information Related to Leases [Abstract] Supplemental Balance Sheet Information Related to Leases [Abstract] Right of Use Assets Obtained in Exchange for Lease Obligations [Abstract] Right-of-use assets obtained in exchange for lease obligations [Abstract] Cash Paid for Amounts Included in Measurement of Lease Liabilities [Abstract] Cash paid for amounts included in the measurement of lease liabilities [Abstract] Supplemental Cash Flow Information Related to Leases [Abstract] Supplemental Cash Flow Information Related to Leases [Abstract] Amount of financial lease cost recognized by lessee for lease contract. Finance Lease Cost Total finance lease expense Financial Lease Cost [Abstract] Finance lease cost [Abstract] Period within which lead plaintiffs can replead their claims. Period within which lead plaintiffs can replead their claims The excess value (monetary amount) of the award the plaintiff seeks in the legal matter. Loss Contingency, Damages Sought, Claims Excess Value Loss contingency, asserting damages excess amount The number of complaint purport to allege claims for breach of each of the separate stock option agreements. Number of Complaint Purpote to Allege Claims for Breach of Each Separate Stock Option Agreements Number of complaint purport to allege claims for breach of each of separate stock option agreements Percentage of prejudgment interest rate. Percentage of Prejudgment Interest Rate Prejudgment interest rate The value (monetary amount) of the award the plaintiff seeks in the legal matter. Loss Contingency, Asserting Damages Amount Loss contingency, asserting damages amount Concentrations [Abstract] Concentrations [Abstract] Percentage of employees' salary deferral contribution for which the employer contributes a matching contribution to a defined contribution plan. Defined Contribution Plan, Employer Matching Contribution Percentage of Employees' Contribution Percentage of employer's matching contribution The number of motions were withdrawn or otherwise abandoned during the period. Number of Motions Abandoned Number of motions abandoned The number of key employees with whom the Company has employment contracts. Number of key employees with whom Company has employment contracts Number of key employees with whom Company has employment contracts Aggregate amount of annual salaries called for by the employment contracts. Aggregate annual salaries of employment contracts Aggregate annual salaries of employment contracts Refers to the expiration date of contract two. Contract Two Expiration Date Contract two expiration date A party from whom the goods or services were or are to be received. Supplier 1 [Member] Vendor 1 [Member] Refers to the expiration date of contract one. Contract One Expiration Date Contract one, expiration date Employment Contracts [Abstract] A party from whom the goods or services were or are to be received. Supplier 2 [Member] Vendor 2 [Member] Employee contribution as a percentage of employee gross pay per pay period that is subject to the employer matching contribution. Defined Contribution Plan, Employee Contribution Subject To Match Employee contribution subject to employer matching contribution The number of motions for appointment as lead plaintiff by the court during the period. Number of Motions for Appointment as Lead Plaintiff Number of motions for appointment as lead plaintiff The number of motions filed by special situations funds during the period. Number of Motions Filed by Special Situations Funds Number of motions filed by special situations funds The number of remaining motions for appointment as lead plaintiff by the court during the period. Number of Remaining Motions for Appointment as Lead Plaintiff Number of remaining motions for appointment as lead plaintiff The number of motions filed by municipal employees retirement system during the period. Number of Motions Filed by Municipal Employees Retirement System Number of motions filed by municipal employees retirement system Stockholder Litigation [Abstract] Stockholder Litigation [Abstract] A customer that accounts for 10 percent or more of the entity's revenues. Customer 1 [Member] Tabular disclosure of supplemental cash flow information related to operating leases. Lessee Operating Lease Cash Flow Information [Table Text Block] Supplemental Cash Flow Information Related to Leases Tabular disclosure of undiscounted cash flows of lessee's operating and financing lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and financing lease liability recognized in statement of financial position. Lessee Operating and Financing Lease Liability Maturity [Table Text Block] Maturities of Lease Liabilities Tabular disclosure of lessee's right of use assets and lease liabilities. Lessee Operating Lease Balance Sheet Information [Table Text Block] Supplemental Balance Sheet Information Related to Leases Continent of Europe and Region of Middle East. Europe & Middle East [Member] Europe & Middle East [Member] Revenue earned during the period from research and development. Research and Development Revenue [Member] R&D Revenue [Member] Amount of cash out flows from finance lease, associated with operating activities. Operating Cash Flows from Finance Leases Operating cash flows for finance leases Cash paid for finance leases The amount of interest and tax expenses, net. Interest and Tax Expense, Net Interest and taxes, net The net cash outflow or inflow from acquisition of and deposits on long-lived, physical assets that are used in the normal conduct of business to produce goods and services. Payments for (Proceeds from) Acquisition of and Deposits on Fixed Assets Acquisition of and deposits on fixed assets Fixed Asset [Abstract] FIXED ASSETS: Summary information about stock options outstanding [Abstract] Summary information about stock options outstanding [Abstract] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Abstract] Range of Exercise Prices [Abstract] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Stock Options Exercisable [Abstract] Stock Options Exercisable [Abstract] Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options [Abstract] Stock Options Outstanding [Abstract] Information relating to stock options which are exercisable in the range of $1 per share to $2.79999 per share. Range One [Member] 1 to 2.79999 [Member] Information relating to stock options which are exercisable in the range of $2.8 per share to $4.59999 per share. Range Two [Member] 2.8 to 4.59999 [Member] Information relating to stock options which are exercisable in the range of $4.6 per share to $6.39999 per share. Range Three [Member] 4.6 to 6.39999 [Member] Information relating to stock options which are exercisable in the range of $6.4 per share to $8.19999 per share. Range Four [Member] 6.4 to 8.19999 [Member] Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Restricted Stock Restricted Stock Units And Performance Stock Units [Member] Restricted Stock, Restricted Stock Units, and Performance Stock Units [Member] The percentage of gross proceeds from borrowing considered as financing fee under the credit agreement. Percentage of Gross Proceeds from Borrowing Considered for Financing Fee Percentage of gross proceeds considered as financing fee Term of interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Debt Instrument Term of Variable Rate Term of variable rate Percentage of prepaid principal amount of debt paid as a premium as per credit agreement. Debt Instrument Percentage of Prepaid Principal as Premium Percentage of prepaid principal as premium A Credit facility provided under this Agreement, including any guarantees, collateral documents, instruments and agreements executed in connection therewith, and any amendments, supplements, modifications, extensions, replacements, renewals, restatements, refundings or refinancings thereof and any indentures or credit facilities or commercial paper facilities with banks or other institutional lenders or investors that extend, replace, refund, refinance, renew or defease any part of the loans, notes, other credit facilities or commitments thereunder, including any such replacement, refunding or refinancing facility or indenture that increases the amount borrowable thereunder or alters the maturity thereof (provided that such increase in borrowings is permitted under Section 6.01). Senior Secured Term Loan Credit Facility [Member] The interest rate percentage in event of default in excess of standard rate as per credit agreement. Debt Instrument, Percentage Increase in Interest Rate in Event of Default Increase in interest rate in event of default Amount of expenses incurred associated with the Lender's closing cost. Lenders Closing Cost Lender's closing cost Number of groups of similar products. Number of groups of similar products Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions and royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Sales Commission and Royalties Current Accrued commissions and royalties OTHER MATTERS [Abstract] The entire disclosure for the nature of an entity's other matters which are not reported separately. Other Matters [Text Block] OTHER MATTERS Number of share options (or share units) expired, forfeited or exercised during the current period. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired, Forfeited or Exercised in Period Number of stock options expired, forfeited or exercised under the plan (in shares) Stock incentive plans. Under the terms of the SIP, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to covered by each grant. Awards can be incentive stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee. Stock Incentive Plan 2014 & 2019 [Member] 2014 & 2019 Stock Incentive Plan [Member] A Omnibus Incentive Plan ("2019 Plan") established on June 18, 2019 by the Company. Under the terms of the plan, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to covered by each grant. Awards can be incentive stock options, restricted stock. The awards become vested at such times and under such conditions as determined by the Compensation Committee. Omnibus Incentive Plan 2019 [Member] 2019 Omnibus Incentive Plan [Member] Amount of presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that forfeited. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures, Intrinsic Value Forfeited, aggregate intrinsic value The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Intrinsic Value Granted, aggregate intrinsic value A stock incentive plan ("SIP14") established on June 19, 2014 by the Company. Under the terms of the SIP14, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to covered by each grant. Awards can be incentive stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee. 2014 Stock Incentive Plan [Member] EX-101.PRE 9 cemi-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 10 image00005.jpg begin 644 image00005.jpg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end XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Document and Entity Information - shares
 3 Months Ended
Mar. 31, 2022
Apr. 29, 2022
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2022  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2022  
Document Fiscal Period Focus Q1  
Document Transition Report false  
Entity File Number 000-30379  
Entity Registrant Name Chembio Diagnostics, Inc.  
Entity Central Index Key 0001092662  
Entity Incorporation, State or Country Code NV  
Entity Tax Identification Number 88-0425691  
Entity Address, Address Line One 555 Wireless Blvd.  
Entity Address, City or Town Hauppauge  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 11788  
City Area Code 631  
Local Phone Number 924-1135  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, $0.01 par value  
Trading Symbol CEMI  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   30,221,859

XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Mar. 31, 2022
Dec. 31, 2021
CURRENT ASSETS:    
Cash and cash equivalents $ 24,399,388 $ 28,772,892
Accounts receivable, net of allowance for doubtful accounts of $242,981 and $243,042 at March 31, 2022 and December 31, 2021, respectively 9,879,954 11,441,107
Inventories, net 11,844,121 12,920,451
Prepaid expenses and other current assets 2,097,491 2,096,399
TOTAL CURRENT ASSETS 48,220,954 55,230,849
FIXED ASSETS:    
Property, plant and equipment, net 8,414,313 8,556,773
Finance lease right-of-use assets, net 190,526 191,870
OTHER ASSETS:    
Operating lease right-of-use assets, net 5,693,482 5,891,906
Goodwill 0 3,022,787
Deposits and other assets 370,940 358,010
TOTAL ASSETS 62,890,215 73,252,195
CURRENT LIABILITIES:    
Accounts payable and accrued liabilities 10,542,851 13,127,993
Current portion of long-term debt 2,100,000 1,200,000
Operating lease liabilities 916,524 886,294
Finance lease liabilities 72,203 68,176
TOTAL CURRENT LIABILITIES 13,631,578 15,282,463
OTHER LIABILITIES:    
Long-term operating lease liabilities 5,733,214 5,976,151
Long-term finance lease liabilities 134,955 139,678
Long-term debt, net 16,855,322 17,589,003
TOTAL LIABILITIES 36,355,069 38,987,295
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:    
Preferred stock - 10,000,000 shares authorized, none outstanding 0 0
Common stock - $0.01 par value; 100,000,000 shares authorized; 30,269,916 shares and 30,104,986 shares issued at March 31, 2022 and December 31, 2021, respectively 302,699 301,050
Additional paid-in capital 166,483,376 165,772,636
Accumulated deficit (139,800,154) (131,009,860)
Treasury Stock, 48,057 shares at cost, at March 31, 2022 and December 31, 2021 (206,554) (206,554)
Accumulated other comprehensive (loss) (244,221) (592,372)
TOTAL STOCKHOLDERS' EQUITY 26,535,146 34,264,900
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 62,890,215 $ 73,252,195
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
CURRENT ASSETS:    
Accounts receivable, allowance for doubtful accounts $ 242,981 $ 243,042
STOCKHOLDERS' EQUITY:    
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 30,269,916 30,104,986
Treasury stock, shares (in shares) 48,057 48,057
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
REVENUES:    
REVENUES $ 18,816,611 $ 8,724,359
COSTS AND EXPENSES:    
Cost of product revenue 15,223,861 3,548,441
Research and development expenses 1,653,706 2,863,338
Selling, general and administrative expenses 6,946,271 6,085,067
Impairment, restructuring, severance and related costs 3,043,179 83,087
TOTAL COSTS AND EXPENSES 26,867,017 12,579,933
LOSS FROM OPERATIONS (8,050,406) (3,855,574)
OTHER EXPENSE:    
Interest expense, net (733,561) (712,477)
LOSS BEFORE INCOME TAXES (8,783,967) (4,568,051)
Income tax (expense)/benefit (6,327) 67,888
NET LOSS $ (8,790,294) $ (4,500,163)
Basic loss per share (in dollars per share) $ (0.29) $ (0.22)
Diluted loss per share (in dollars per share) $ (0.29) $ (0.22)
Weighted average number of shares outstanding, basic (in shares) 30,090,045 20,163,386
Weighted average number of shares outstanding, diluted (in shares) 30,090,045 20,163,386
Product Revenue [Member]    
REVENUES:    
REVENUES $ 18,527,456 $ 4,024,662
R&D Revenue [Member]    
REVENUES:    
REVENUES 18,173 1,106,639
Government Grant Income [Member]    
REVENUES:    
REVENUES 0 3,350,000
License and Royalty Revenue [Member]    
REVENUES:    
REVENUES $ 270,982 $ 243,058
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]    
Net loss $ (8,790,294) $ (4,500,163)
Other comprehensive income (loss):    
Foreign currency translation adjustments, net of tax 348,151 (455,722)
COMPREHENSIVE LOSS $ (8,442,143) $ (4,955,885)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
Common Stock [Member]
Additional Paid-in-Capital [Member]
Treasury Stock [Member]
Accumulated Deficit [Member]
AOCL [Member]
Total
Balance at Dec. 31, 2020 $ 202,235 $ 124,961,514 $ (190,093) $ (97,106,331) $ (90,916) $ 27,776,409
Balance (in shares) at Dec. 31, 2020 20,223,498   (41,141)      
Common Stock:            
Restricted stock issued $ 622 58,909 $ 0 0 0 59,531
Restricted stock issued (in shares) 62,197   0      
Restricted stock compensation, net $ 0 309,010 $ 0 0 0 309,010
Restricted stock compensation, net (in shares) 0   0      
Shares tendered for withholding taxes $ 0 (115,059) $ 0 0 0 (115,059)
Shares tendered for withholding taxes (in shares) 0   0      
Options:            
Stock option compensation $ 0 211,140 $ 0 0 0 211,140
Comprehensive income (loss) 0 0 0 0 (455,722) (455,722)
Net loss 0 0 0 (4,500,163) 0 (4,500,163)
Balance at Mar. 31, 2021 $ 202,857 125,425,514 $ (190,093) (101,606,494) (546,638) 23,285,146
Balance (in shares) at Mar. 31, 2021 20,285,695   (41,141)      
Balance at Dec. 31, 2021 $ 301,050 165,772,636 $ (206,554) (131,009,860) (592,372) 34,264,900
Balance (in shares) at Dec. 31, 2021 30,104,986   (48,057)      
Common Stock:            
Restricted stock issued $ 1,649 264,437 $ 0 0 0 266,086
Restricted stock issued (in shares) 164,930   0      
Restricted stock compensation, net $ 0 229,563 $ 0 0 0 229,563
Restricted stock compensation, net (in shares) 0   0      
Shares tendered for withholding taxes $ 0 (38,514) $ 0 0 0 (38,514)
Shares tendered for withholding taxes (in shares) 0   0      
Options:            
Stock option compensation $ 0 255,254 $ 0 0 0 255,254
Comprehensive income (loss) 0 0 0 0 348,151 348,151
Net loss 0 0 0 (8,790,294) 0 (8,790,294)
Balance at Mar. 31, 2022 $ 302,699 $ 166,483,376 $ (206,554) $ (139,800,154) $ (244,221) $ 26,535,146
Balance (in shares) at Mar. 31, 2022 30,269,916   (48,057)      
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:    
Cash received from customers and grants $ 20,377,703 $ 8,485,683
Cash paid to suppliers and employees (23,810,426) (14,830,243)
Cash paid for operating leases (360,878) (347,871)
Cash paid for finance leases (4,686) (4,944)
Interest and taxes, net (570,672) (563,885)
Net cash used in operating activities (4,368,959) (7,261,260)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Patent application costs 0 (4,130)
Acquisition of and deposits on fixed assets (286,544) (1,235,038)
Net cash used in investing activities (286,544) (1,239,168)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Payments of tax withholdings on stock award (38,514) (115,059)
Payments on finance lease (16,930) (14,282)
Net cash used in financing activities (55,444) (129,341)
Effect of exchange rate changes on cash 337,443 (85,579)
DECREASE IN CASH AND CASH EQUIVALENTS (4,373,504) (8,715,348)
Cash and cash equivalents - beginning of the period 28,772,892 23,066,301
Cash and cash equivalents - end of the period 24,399,388 14,350,953
RECONCILIATION OF NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:    
Net loss (8,790,294) (4,500,163)
Adjustments:    
Depreciation and amortization 598,548 687,227
Share based compensation 750,903 579,789
Benefit from deferred tax liability 0 (69,941)
Provision of (recovery of) doubtful accounts (61) 57,735
Impairment 3,033,565 0
Changes in assets and liabilities:    
Accounts receivable 1,561,214 906,100
Inventories 1,076,330 (2,174,225)
Prepaid expenses and other current assets (387,297) (33,955)
Deposits and other assets 373,275 134,480
Accounts payable and accrued liabilities (2,585,142) (1,645,796)
Deferred revenue 0 (1,202,511)
Net cash used in operating activities $ (4,368,959) $ (7,261,260)
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.1
DESCRIPTION OF BUSINESS
 3 Months Ended
Mar. 31, 2022
DESCRIPTION OF BUSINESS [Abstract]  
DESCRIPTION OF BUSINESS
NOTE 1 — DESCRIPTION OF BUSINESS:

Chembio Diagnostics, Inc. (“Chembio”) and its subsidiaries (collectively with Chembio, the “Company”) develop and commercialize point-of-care diagnostic tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment.

The Company’s product portfolio is based upon our proprietary DPP technology, a diagnostic platform that provides high-quality, cost-effective results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as STIs and HIV, Gastroenterology and Women’s Health. Compared with traditional lateral flow technology, the DPP technology platform can provide:
 

 
•
Enhanced sensitivity and specificity: This is achieved via the Company’s proprietary approach to separating the sample path from the buffer path, together with patent and other proprietary strategies, which differ significantly from traditional lateral flow test.
 
•
Advanced multiplexing capabilities: Through advanced multiplexing, the DPP platform can detect and differentiate up to eight distinct test results from a single patient sample, which can deliver greater clinical value than other rapid tests currently on the market.
 
•
Objective results: For some diagnostic applications, the Company’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzers can report accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still onsite. Objective results produced by the DPP Micro Reader can reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.

The Company targets the market for rapid diagnostic test solutions for infectious diseases, which is driven by the high prevalence of infectious diseases globally, an increase in the geriatric population, growing demand for rapid test results, and advancements in multiplexing. The Company has a broad portfolio of infectious disease products, which prior to 2020 were focused principally on sexually transmitted disease and fever and tropical disease. In February 2020 the Company began the process of shifting substantially all of its resources to seek to leverage the DPP technology platform to address the acute and escalating need for diagnostic testing for COVID-19. The Company is continuing to pursue:
 
•
an emergency use authorization (“EUA”), from the U.S. Food and Drug Administration (the “FDA”), as well as 510(k) clearance from the FDA, for the DPP SARS-CoV-2 Antigen test system;
 
•
an EUA from the FDA for the DPP Respiratory Antigen Panel; and
 
•
a Clinical Laboratory Improvement Amendment (“CLIA”), waiver from the FDA for the DPP HIV-Syphilis test system.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Mar. 31, 2022
SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES
NOTE 2 — SIGNIFICANT ACCOUNTING POLICIES:

(a)
Basis of presentation:

The accompanying unaudited condensed consolidated financial statements include the accounts of Chembio and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Certain reclassifications have been made to the unaudited condensed consolidated balance sheet of the prior year to conform to the current year presentation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Chembio’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC.

Going Concern Considerations

The Company continued to experience market, clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of COVID-19 test systems during the continuing, but evolving, uncertainty resulting from COVID‑19. For the three months ended March 31, 2022, the Company continued to incur significant expenses in connection with pending legal matters (see Note 6 – Commitments, Contingencies, and Concentrations: Litigation).
 
The Company performed an assessment to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are being issued. Initially, this assessment did not consider the potential mitigating effect of management’s plans that had not been fully implemented. Because, as described below, substantial doubt was determined to exist as the result of this initial assessment, management then assessed the mitigating effect of its plans to determine if it is probable that the plans (1) would be effectively implemented within one year after the date the accompanying unaudited condensed consolidated financial statements are issued and (2) when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern.
 
The Company achieved significant revenue growth in recent years while profitability has not been at levels as expected. It has taken steps including investments in automation to mitigate headwinds such as labor availability, volatile capacity planning and implementation of operational efficiency targets to proactively monitor production with the overarching goal for profitable growth. During the three months ended March 31, 2022, the Company undertook measures to increase its total revenues and improve its liquidity position by implementing the Global Competitiveness Program. The main pillars of the Global Competitiveness Program include the following:

•
Focus on higher margin business in growth markets

•
Lower manufacturing costs

•
Reduce infrastructure costs

•
Strategic review of non-core businesses and assets:

In addition, the Company will continue to focus on regulatory approvals for its DPP SARS-CoV-2 Antigen test system, DPP Respiratory Antigen Panel, and DPP HIV-Syphilis test system. These measures and other plans and initiatives have been designed to provide the Company with adequate liquidity to meet its obligations for at least the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are being issued. The Company’s execution of those measures and its other plans and initiative continue to depend, however, on factors and uncertainties that are beyond the Company’s control, or that may not be addressable on terms acceptable to the Company or at all. The Company considered in particular how:

•
The ongoing healthcare and economic impacts of COVID-19 on the global customer base for the Company’s non‑COVID-19 products continue to negatively affect the timing and rate of recovery of the Company’s revenues from those products by, for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect the Company’s liquidity.

•
Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products.

The Company further considered how these factors and uncertainties could impact its ability over the next year to meet the obligations specified in the Credit Agreement with the Lender (both as defined in Note 7 – Long-Term Debt). Those obligations include covenants requiring: i) minimum cash balance of $3.0 million and ii) minimum total revenue amounts for the twelve months preceding each quarter end. For the next year, the minimum total revenue requirements range from $43.8 million for the twelve months ending June 30, 2022 to $48.8 million for the twelve months ending March 31, 2023. Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that the Company would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement or that, if such liquidity were not available, the Company would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern. The Company’s inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for its operations, could have a material adverse effect on its business, prospects, results of operations, liquidity and financial condition.

Accordingly, management determined the Company could not be certain that the Company’s plans and initiatives would be effectively implemented within one year after the date on which the accompanying unaudited condensed consolidated financial statements are being issued. Without giving effect to the prospect of raising additional capital pursuant to the Company’s At the Market Offering Agreement dated July 19, 2021 with Chembio Diagnostics, Inc. and Craig-Hallum Capital Group LLC, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond the Company’s control, it is unlikely that the Company will be able to generate sufficient cash flows to meet its required financial obligations, including its debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited condensed consolidated financial statements are being issued.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are issued. As such, the accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.


 (b)
Significant Accounting Policies:

During the three months ended March 31, 2022, there has been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.


 (c)
Fair Value of Financial Instruments:

The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate fair value due to the immediate or short-term maturity of these financial instruments. Included in cash and cash equivalents were $ 17.1 million and $25.0 million as of March 31, 2022 and December 31, 2021, respectively, of money market funds that are Level 1 fair value measurements under the hierarchy. The fair value of the Company’s total debt of $20.0 million (carrying value of $18.9 million) and $20.0 million (carrying value of $18.8 million) as of March 31, 2022 and December 31, 2021 respectively, is a Level 2 fair value measurement under the hierarchy and the Company’s debt face value approximates the recorded value, as the rate is based upon the current rates available to the Company for similar financial instruments.
Fair value measurements of all financial assets and liabilities that are measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1:
Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;


Level 2:
Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,


Level 3:
Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).


(d)
Cash and Cash Equivalents:

Cash and cash equivalents are defined as short-term, highly liquid investments, such as money market funds, with original maturities of three months or less at date of purchase.

(e)
Loss Per Share:

Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period excluding unvested restricted stock. Diluted loss per share for the three months ended March 31, 2022 and 2021 reflects the potential dilution from the exercise or conversion of other securities into common stock, if dilutive.

There were 3,760,787 and 1,848,286 options outstanding as of March 31, 2022 and 2021, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.
There were 1,739,944 and 847,795 shares of restricted stock outstanding as of March 31, 2022 and 2020, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.

(f)
Income Taxes:

At the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis, and may change in subsequent interim periods. Accordingly, the Company’s effective tax rate for the three months ended March 31, 2022 was (0.1)%, compared to the effective tax rate of 1.6% for the three months ended March 31, 2021. The Company’s effective tax rates for both periods were affected primarily by a full valuation allowance on domestic net deferred tax assets.


 (g)
Recently Issued Accounting Standards Affecting the Company:

Recently Adopted
ASU 2021-10 - Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which creates Accounting Standards Codification (“ASC”) 832 and aims to provide increased transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. The disclosure requirements in ASC 832 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model (for example, in ASC 958-605, Not-for-Profit Entities – Revenue Recognition). The FASB broadly defined “government assistance” in ASC 832 to ensure that assistance received from most types of governmental entities or other related organizations would be disclosed.  Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The Company adopted the standard effective January 1, 2022 and has determined that the adoption did not have a material impact on the Company’s consolidated financial statements.
Not Yet Adopted
ASU 2020-06 - Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
On August 5, 2020, the FASB issued ASU 2020-06, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. ASU 2020-06 simplifies the guidance in GAAP on the issuer’s accounting for convertible debt instruments, requires entities to provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance. The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.

ASU 2021-08—Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
  
On October 28, 2021, the FASB issued ASU 2021-08,1 which amends ASC 805 to “require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination.” Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. ASU 2021-08 amends ASC 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to “require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606.” While primarily related to contract assets and contract liabilities that were accounted for by the acquiree in accordance with ASC 606, “the amendments also apply to contract assets and contract liabilities from other contracts to which the provisions of Topic 606 apply, such as contract liabilities from the sale of nonfinancial assets within the scope of Subtopic 610-20.” The ASU’s amendments are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE
 3 Months Ended
Mar. 31, 2022
REVENUE [Abstract]  
REVENUE
NOTE 3 — REVENUE:

Disaggregation of Revenue

The following table disaggregates Total Revenues by revenue type:

 
March 31, 2022
    
March 31, 2021
  
   
Exchange
Transactions
    
Non-Exchange
Transactions
    
Total
    
Exchange
Transactions
    
Non-Exchange
Transactions
    
Total
  
Net product revenue
  
$
18,527,456
    
$
-
    
$
18,527,456
    
$
4,024,662
    
$
-
    
$
4,024,662
  
R&D Revenue
    
18,173
      
-
      
18,173
      
1,106,639
      
-
      
1,106,639
  
Government grant revenue
    
–
      
–
      
–
      
–
      
3,350,000
      
3,350,000
  
License and royalty revenue
    
270,982
      
-
      
270,982
      
243,058
      
-
      
243,058
  
   
$
18,816,611
    
$
-
    
$
18,816,611
    
$
5,374,359
    
$
3,350,000
    
$
8,724,359
  

Exchange transactions are recognized in accordance with ASC 606, while non-exchange transactions are recognized in accordance with ASU No. 2018-08.

The following table disaggregates Total Revenues by geographic location:

 
For the three months ended
  
   
March 31, 2022
    
March 31, 2021
  
Africa
  
$
767,352
    
$
1,344,858
  
Asia
    
15,558
      
216,954
  
Europe & Middle East
    
723,745
      
2,600,274
  
Latin America
    
12,557,390
      
258,019
  
United States
    
4,752,566
      
4,304,254
  
   
$
18,816,611
    
$
8,724,359
  
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.1
INVENTORY
 3 Months Ended
Mar. 31, 2022
INVENTORY [Abstract]  
INVENTORY
NOTE 4 — INVENTORY:

Inventories are presented net of reserves and consist of the following at:

 
March 31,
2022
    
December 31,
2021
  
Raw materials
  
$
7,197,257
    
$
7,306,095
  
Work in process
    
1,932,069
      
3,556,878
  
Finished goods
    
2,714,795
      
2,057,478
  
   
$
11,844,121
    
$
12,920,451
  
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY
 3 Months Ended
Mar. 31, 2022
STOCKHOLDERS' EQUITY [Abstract]  
STOCKHOLDERS' EQUITY
NOTE 5 — STOCKHOLDERS’ EQUITY:

(a)
Common Stock

During the first three months of 2022 and 2021, there were no options exercised.

(b)
Preferred Stock

Chembio has 10,000,000 shares of preferred stock authorized and none outstanding. These shares can become issuable upon an approved resolution by the board of directors of Chembio (the “Board”) and the filing of a Certificate of Designation with the state of Nevada.

(c)
Treasury Stock

Chembio has 48,057 shares of treasury stock acquired upon the vesting of restricted stock awards related to the tax withholding requirements paid on behalf of the employees.

(d)
Options, Restricted Stock, and Restricted Stock Units

The Board or its Compensation Committee may issue options, restricted stock, and restricted stock units pursuant to equity incentive plans that have been approved by Chembio’s stockholders.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS
 3 Months Ended
Mar. 31, 2022
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS [Abstract]  
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS
NOTE 6 — COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS:

a)
Concentrations:

The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company’s net product sales for the periods indicated:

   
For the three months ended
    
Accounts Receivable as of
  
   
March 31, 2022
   
March 31, 2021
   
March 31,
2022
    
December
31, 2021
  
   
Product
Sales
    
% of
Product
Sales
    
Product
Sales
    
% of
Product
Sales
              
Customer 1
   $ 11,856,024       64 %  
$
 *      
*
     $ 5,930,162    
$
7,672,845
  

Revenue includes product sales only, while accounts receivable reflects the total due from the customer, including freight.

The following table discloses purchases the Company had to each vendor that purchased in excess of 10% of the Company’s net purchases for the periods indicated:

 
For the three months ended
    
Accounts Payable as of
  
   
March 31, 2022
   
March 31, 2021
   
March 31,
2022
    
December
31, 2021
  
   
Purchases
    
% of
Purchases
    
Purchases
    
% of
Purchases
              
Vendor 1
  
$
2,323,605
      
34
%
  
$
*
      
*
    
$
224,500
     $ *
  
Vendor 2
    
1,088,251
      
16
%
    
469,635
      
11
%
    
164,983
      
353,097
  


In the tables above, an asterisk (*) indicates that indicates that sales, accounts receivable, purchases or accounts payable, as applicable to the tabular column, did not exceed 10% for the period indicated.

The Company purchases materials pursuant to intellectual property rights agreements that are important components in its products.  Management believes that other suppliers could provide similar materials on comparable terms.  A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which could adversely affect operating results.

b)
Employment Contracts:

The Company has multi-year contracts with three key employees. The contracts call for salaries presently aggregating $1,178,000 per year. The contracts expire in December 2022 and December 31, 2024. The following table is a schedule of future minimum salary commitments:

2022
  
$
883,500
  
2023
    
383,000
  
2024
     383,000  

c)
Benefit Plan:

Chembio has a 401(k) plan established for the Company’s employees whereby it matches 40% of the first 5% of salary (or up to 2% of salary) that an employee contributes to the plan. Matching contribution expenses totaled approximately $67,135 and $35,456 for the three months ended March 31, 2022 and 2021, respectively.

d)
Leases:

The Company leases facilities in New York, Germany, Malaysia, and Brazil, and certain equipment.

The Company’s facility leases generally include optional renewal periods. Upon entering into a new facility lease, the Company evaluates the leasehold improvements and regulatory requirements related to its operations in that location. To the extent that the initial lease term of the related facility lease is less than the useful life of the leasehold improvements and potential regulatory costs associated with moving the facility, the Company concludes that it is reasonably certain that a renewal option will be exercised, and thus that renewal period is included in the lease term and the related payments are reflected in the right-of-use asset and lease liability.

The Company’s leases generally include fixed rental payments with defined annual increases. While certain of the Company’s leases are gross leases, the majority of the Company’s leases are net leases in which the Company makes separate payments to the lessor based on the lessor’s property and casualty insurance costs, the property taxes assessed on the property, and a portion of the common area maintenance where applicable. The Company has elected the practical expedient not to separate lease and non-lease components for all of the Company’s facility leases.

The components of lease expense were as follows:

 
Three Months Ended
March 31
  
   
2022
    
2021
  
Operating lease expense
  
$
403,385
    
$
408,466
  
                 
Finance lease cost
                
Amortization of right-of-use assets
  
$
17,579
    
$
15,758
  
Interest on lease liabilities
    
4,686
      
4,944
  
Total finance lease expense
  
$
22,265
    
$
20,702
  

Supplemental cash flow information related to leases was as follows.

 
  
Three Months Ended
March 31
  
 
  
2022
    
2021
  
Cash paid for amounts included in the measurement of lease liabilities:
            
Operating cash flows for operating leases
  
$
360,878
    
$
347,871
  
Operating cash flows for finance leases
    
4,686
      
4,944
  
Financing cash flows for finance leases
    
16,930
      
14,282
  
Right-of-use assets obtained in exchange for lease obligations:
                
Finance leases
    
16,234
      
-
  

Supplemental balance sheet information related to leases was as follows:

 
  
March 31, 2022
    
March 31, 2021
  
Finance Leases
            
Finance lease right of use asset
  
$
356,997
    
$
315,153
  
Accumulated depreciation
    
(166,471
)
    
(97,777
)
Finance lease right of use asset, net
  
$
190,526
    
$
217,376
  
 
                
Weighted Average Remaining Lease Term
                
Operating leases
  
7.4 years
    
8.6 years
  
Finance leases
  
2.8 years
    
3.5 years
  
 
                
Weighted Average Discount Rate
                
Operating leases
    
9.32
%
    
9.30
%
Finance leases
    
8.56
%
    
8.18
%

Maturities of lease liabilities were as follows.

 
  
March 31, 2022
    
March 31, 2021
  
 
  
Operating
Leases
    
Finance
Leases
    
Operating
Leases
    
Finance
Leases
  
2022
  
$
1,086,370
    
$
65,913
    
$
861,916
    
$
57,678
  
2023
    
1,221,017
      
87,884
      
1,057,757
      
76,904
  
2024
    
1,018,875
      
60,116
      
1,026,272
      
76,904
  
2025
    
1,049,442
      
16,731
      
1,018,875
      
49,136
  
2026
    
1,080,925
      
5,940
      
1,049,442
      
5,751
  
Thereafter
    
3,643,521
      
355
      
4,724,446
      
-
  
Total lease payments
  
$
9,100,150
    
$
236,939
    
$
9,738,708
    
$
266,373
  
Less: imputed interest
    
2,450,412
      
29,781
      
2,968,703
      
36,544
  
Total
  
$
6,649,738
    
$
207,158
    
$
6,770,005
    
$
229,829
  

e)
Litigation:

SEC Investigation

The SEC is conducting a non-public, fact-finding investigation relating to the public offering of common stock that Chembio completed in May 2020 (the “May 2020 Offering”) and to the FDA’s revocation in June 2020 of an emergency use authorization for the DPP COVID-19 IgM/IgG system that was issued by the FDA in April 2020. Chembio received subpoenas from the SEC in July 2020 and April 2021 seeking the production of documents in connection with this investigation. In addition, the SEC delivered subpoenas in April 2021 to five of Chembio’s employees (including its three executive officers, who consist of its Chief Executive Officer and President, its former Executive Vice President and Chief Financial Officer, and its Executive Vice President and Chief Scientific and Technology Officer). An additional subpoena was issued in June 2021 to Chembio’s former Interim Chief Executive Officer and Executive Chair. Each subpoena requested the production of documents relating to the same matters as are the subject of the subpoenas Chembio received. Chembio and the six individuals are cooperating fully in the SEC’s investigation and expect to continue to do so.

The SEC’s letters transmitting the subpoenas expressly provide that the inquiry does not mean that the SEC or its staff have concluded that anyone has violated the federal securities laws or have a negative opinion of any person, entity or security. The Company cannot predict the scope, duration or outcome of the investigation or the impact, if any, of the investigation on its results of operations.

Legal Proceedings


Stockholder Litigation

Putative Stockholder Securities Class-Action Litigation

In 2020 four purported securities class-action lawsuits were filed in the United States District Court for the Eastern District of New York by alleged stockholders of Chembio:

•
Sergey Chernysh v. Chembio Diagnostics, Inc., Richard L. Eberly, and Gail S. Page, filed on June 18, 2020;

•
James Gowen v. Chembio Diagnostics, Inc., Richard L. Eberly, and Gail S. Page, filed on June 22, 2020;

•
Anthony Bailey v. Chembio Diagnostics, Inc. Richard J. Eberly, Gail S. Page, and Neil A. Goldman, filed on July 3, 2020; and;

•
Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P., and Special Situations Private Equity Fund, L.P. v. Chembio Diagnostics, Inc., Richard Eberly, Gail S. Page, Robert W. Baird & Co. Inc. and Dougherty & Company LLC, filed August 17, 2020.

The plaintiffs in each of the above cases alleged claims under Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), Rule 10b-5 thereunder and Section 20(a) of the Exchange Act. Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P. and Special Situations Private Equity Fund, L.P. (collectively, the “Special Situations Funds”) also asserted claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “Securities Act”) relating to the May 2020 Offering.

Chembio and the plaintiffs entered into Court-approved stipulations relieving Chembio and the other defendants of the obligation to respond to the complaints in these cases pending the designation of a lead plaintiff pursuant to the Private Securities Litigation Reform Act of 1995. Eight motions for appointment as lead plaintiff were filed by various prospective lead plaintiffs. However, all but two of these motions were withdrawn or otherwise abandoned, leaving before the Court two motions for appointment as lead plaintiff - one filed by the Special Situations Funds and one by Municipal Employees’ Retirement System of Michigan. By order entered December 29, 2020, Magistrate Judge Lindsay consolidated the cases and appointed the Special Situations Funds and Municipal Employees’ Retirement System of Michigan (together, the “Lead Plaintiffs”), as co-lead plaintiffs and their respective counsel as co-lead counsel. The consolidated cases are now pending under the caption “In re Chembio Diagnostics, Inc. Securities Litigation.”

The Lead Plaintiffs filed their Consolidated Amended Complaint (the “CAC”) on February 12, 2021. In summary, the CAC purported to allege claims based on assertedly false and misleading statements and omissions concerning the performance of the DPP COVID-19 IgM/IgG System, as well as an asserted failure to timely disclose that the emergency use authorization that had been granted by the FDA with respect to the DPP COVID-19 IgM/IgG System “was - or was at an increased risk of - being revoked.” The CAC named as defendants Chembio, Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan, John Potthoff (together, the “Chembio Defendants”) and the underwriters for the May 2020 Offering, Robert W. Baird & Co., Inc. and Dougherty & Company LLC (the “Underwriter Defendants”).

The CAC purported to assert five counts under the Securities Act and the Exchange Act. Counts I through III were brought under the Securities Act, allegedly on behalf of a purported class consisting of all persons who purchased Chembio common stock directly in or traceable to the May 2020 Offering pursuant to Chembio’s shelf registration statement on Form S 3 (File No. 333-227398) and the related prospectus, as supplemented by a prospectus supplement dated May 7, 2020 (the “Securities Act Class”). Count I purported to allege a claim for violation of Section 11 of the Securities Act against all defendants other than Messrs. Eberly and Esfandiari. Count II purported to allege a claim for violation of Section 12 of the Securities Act against all defendants other than Messrs. Eberly and Esfandiari. Count III purported to allege a claim under Section 15 of the Securities Act against Ms. Davis, Dr. Polan, Dr. Potthoff, Ms. Page and Mr. Goldman.

Counts IV and V alleged claims under the Exchange Act on behalf of a purported class consisting of all persons who purchased Chembio common stock on the open market from March 12, 2020 through June 16, 2020 (the “Exchange Act Class”). Count IV purported to allege a claim for violation of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder against Chembio, Mr. Eberly, Ms. Page, Mr. Goldman and Mr. Esfandiari. Count V purported to allege a claim under Section 20(a) of the Exchange Act against Mr. Eberly, Ms. Page, Mr. Goldman and Mr. Esfandiari.

In their CAC, the Lead Plaintiffs sought, on behalf of the Securities Act Class and the Exchange Act Class, among other things, an award of damages in an amount to be proven at trial, as well as an award of reasonable costs, including attorneys’ fees and expenses, expert fees, pre-judgment and post-judgment interest, and such other relief as the Court deems just and proper. The Lead Plaintiffs also sought rescission “or a rescissory measure of damages” on behalf of the Securities Act Class as to Count II.

Pursuant to an order entered by the Court on January 29, 2021, any defendant wishing to move against the amended complaint was required to file, by February 18, 2021, a letter requesting a pre-motion conference. On that date, the defendants submitted letters to the Court requesting a pre-motion conference regarding anticipated motions to dismiss the CAC, and the Lead Plaintiffs responded on February 24, 2021. In its January 29, 2021 order, the Court indicated that it would consider a briefing schedule on motions to dismiss after it had received and reviewed the parties’ correspondence.

On March 5, 2021, the Court entered an order in which it advised the parties that it had determined a pre motion conference was not necessary and established a briefing schedule on the defendants’ anticipated motions to dismiss. However, the defendants subsequently agreed with the Lead Plaintiffs’ counsel to a modification of the schedule, which was then approved by the Court. Pursuant to that schedule, defendants’ motions and supporting papers were filed on March 26, 2021, the Lead Plaintiffs’ opposition papers were filed on April 16, 2021, and the defendants’ reply papers were filed on April 30, 2021.

The Court issued its Opinion and Order (the “Order”) on the defendants’ motions to dismiss on February 23, 2022.  In its Order, the Court: (i) dismissed Counts I and II without prejudice as to all defendants named in those Counts except the Underwriter Defendants as to which Counts I and II were not dismissed; (ii) dismissed Count III without prejudice as to all defendants named in that Count; and (iii) dismissed Counts IV and V with prejudice as to all defendants named in those Counts.  The Court gave Lead Plaintiffs fourteen days within which to attempt to replead their claims under the Securities Act against Chembio, Ms. Page, Mr. Goldman, Ms. Davis, Ms. Polan and Mr. Potthoff.

On March 4, 2022, Lead Plaintiffs filed a letter motion in which they advised the Court that they intended to file an amended complaint, but that they wished to first seek reconsideration of the Court’s February 23 order.  They accordingly requested, and the Court granted, an adjournment of the deadline for filing an amended complaint until three business days after the Court’s ruling on Lead Plaintiffs’ anticipated motion for reconsideration.  The Court also granted a request by the Underwriter Defendants to extend the time for them to file their answer to the CAC, and set May 2, 2022 as the date for the filing of that answer.

On March 7, 2022, Magistrate Judge John Wicks entered an order requiring that the parties meet and confer regarding the scheduling of discovery in the case, requiring that the parties submit a Proposed Scheduling Order by March 23, and setting a hearing (via zoom) on March 30.  The Chembio Defendants filed a letter motion requesting that the Court adjourn the initial conference and suspend the other requirements in the March 7, 2022 order.  Magistrate Judge Wicks granted the letter motion on March 14, and further ordered that the initial conference would be rescheduled “following the resolution of all preliminary dispositive issues.”

On March 9, 2022, Lead Plaintiffs filed a motion for partial reconsideration of the Court’s February 23 Order.  In their motion, Lead Plaintiffs requested that the Court reconsider and reverse its dismissal of Counts IV and V with prejudice, and its dismissal of Counts I, II and III without prejudice.  The Chembio Defendants filed their memorandum in opposition to this motion on March 23, 2022; Lead Plaintiffs filed their reply memorandum in support of the motion on March 30, 2022.  The Court has not yet ruled upon the motion for partial reconsideration.

On April 26, 2022, the Court entered an order canceling the previously-set May 2 date by which the Underwriter Defendants were required to file their answer to the CAC, and providing that the Underwriter Defendants’ answer to an amended complaint shall be due within three weeks after such amended complaint has been served.

Putative Stockholder Derivative Litigation

On September 11, 2020, a putative stockholder derivative action captioned Karen Wong, derivatively on behalf of Chembio Diagnostics, Inc., Plaintiff v. Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan and John G. Potthoff, Defendants, and Chembio Diagnostics, Inc., Nominal Defendant (the “Wong complaint”) was filed purportedly on Chembio’s behalf in the United States District Court for the Eastern District of New York. The Wong complaint purports to assert a claim for violation of Section 14(a) of the Exchange Act and Rule 14a-9 thereunder based on ostensibly false and misleading statements and omissions concerning the Company’s rapid COVID-19 antibody test in the proxy statement disseminated in advance of Chembio’s Annual Meeting of Stockholders held on July 28, 2020. The Wong complaint also asserts claims against the individual defendants for purported breaches of fiduciary duties owed to Chembio, as well as unjust enrichment.

The Wong complaint requests a declaration that the individual defendants have breached or aided and abetted the breach of their fiduciary duties to Chembio, an award of damages to us, restitution, and an award of the plaintiff’s costs and disbursements in the action, including reasonable attorneys’ and experts’ fees, costs and expenses, and improvements to Chembio’s corporate governance and internal procedures regarding compliance with laws. Pursuant to a stipulation by which the individual defendants named in the Wong complaint agreed to waive service of process, the Court ordered that the time for defendants to answer or otherwise respond to the complaint be extended to November 19, 2020. The parties subsequently entered into a stipulation for a stay of proceedings in the action relating to the Wong complaint pending final disposition of motions to dismiss the pending putative class-action litigation, subject to certain conditions. The Court entered an order granting the requested stay on November 3, 2020. At this stage of the litigation, the Company is not able to predict the probability of a favorable or unfavorable outcome.

On March 31, 2022, a second putative stockholder derivative action captioned Michelle Chen, derivatively on behalf of Chembio Diagnostics, Inc., Plaintiff v. Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan and John G. Potthoff, Defendants, and Chembio Diagnostics, Inc., Nominal Defendant (the “Chen complaint”) was filed purportedly on behalf of Chembio in the Supreme Court for the State of New York, County of Suffolk.  The Chen complaint purports to assert a claim for breach of fiduciary duty against the defendants based on ostensibly false and misleading statements and omissions concerning the Company’s rapid COVID-19 antibody test.  The Chen complaint goes on to allege that the misconduct asserted in the complaint gave rise to the filing of the consolidated securities litigation described above.

Counsel for the defendants in the Chen action are engaged in discussions with counsel for Chen concerning a possible stay of the Chen action.


Employee Litigation

On March 19, 2021, John J. Sperzel III, Chembio’s former chief executive officer, filed a fifteen-count complaint in the United States District Court for the Eastern District of New York. The complaint was filed following the dismissal of an action previously filed by Mr. Sperzel in the United States District Court in Maine, which was dismissed for lack of personal jurisdiction over Chembio. In summary, the complaint filed in the Eastern District of New York alleges that Chembio wrongfully refused to allow Mr. Sperzel to exercise certain options to purchase, for an aggregate exercise price of $943,126, a total of 266,666 shares of common stock that were allegedly vested as of the date of his separation from Chembio, on January 3, 2020. The complaint alleges that under the terms of the applicable stock incentive plans, Mr. Sperzel had thirty days after the date on which he ceased to qualify as an “Eligible Person” under the plans within which to exercise the options, and asserts that by reason of his alleged continued service to us, he remained an “Eligible Person” and ostensibly retained the right to exercise the options. The Compensation Committee of the Board determined that the options expired on February 3, 2020, thirty days after Mr. Sperzel’s separation from Chembio, and that a purported attempt by Mr. Sperzel to exercise the options after that date was not valid.

Count I of the complaint purports to allege that Chembio breached Mr. Sperzel’s separation agreement by refusing to allow him to exercise the stock options. Counts II through XI of the complaint purport to allege claims for breach of each of ten separate stock option agreements, collectively asserting damages of “at least” $3,190,198. Count XII of the complaint alleges a breach of Mr. Sperzel’s separation agreement based on Chembio’s purported failure to pay Mr. Sperzel consulting fees to which he claims to be entitled for consulting services allegedly performed following his separation. Count XIII of the complaint alleges a claim for breach of an implied covenant of good faith and fair dealing under Nevada common law based on the allegation that Chembio prevented Mr. Sperzel from obtaining the benefits of the stock option agreements and separation agreement. Mr. Sperzel alleges that he suffered damages in excess of $3 million as a result of the purported breach of the covenant of good faith and fair dealing. Count XIV of the complaint purports to assert a claim for quantum meruit, alleging that “it is reasonable for Sperzel to expect payment in exchange for ... services” he allegedly provided to us and, based on allegations that upon his separation Mr. Sperzel was not informed as to the pending expiration of the stock options he later sought to exercise, that Chembio has been unjustly enriched. Finally, Count XV of the complaint seeks a declaratory judgment that Mr. Sperzel is relieved from performance under his separation agreement due to asserted material breaches of the agreement based on the allegations summarized above. The complaint seeks compensatory damages in an unspecified amount, a declaration, as described above, and an award of Mr. Sperzel’s costs and expenses in the litigation, including reasonable attorneys’ fees, expert costs and disbursements. The complaint requests a trial by jury. In his initial disclosures served in discovery, Mr. Sperzel claims entitlement to recover damages in a total amount not less than $10 million, together with prejudgment interest at the rate of 9% per annum.

On May 20, 2021, Chembio filed its answer and affirmative defenses denying the material allegations of Mr. Sperzel’s complaint. Chembio and Mr. Sperzel are presently engaged in discovery. Under the present case schedule, all fact discovery was completed on April 28, 2022, and the parties are currently in the midst of an additional period of expert witness discovery, concluding on June 28, 2022. At this stage of the litigation, the Company is not able to predict the probability of a favorable or unfavorable outcome.


Other

From time to time the Company may become involved in legal proceedings or may be subject to claims arising in the ordinary course of its business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on its business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.1
LONG-TERM DEBT
 3 Months Ended
Mar. 31, 2022
LONG-TERM DEBT [Abstract]  
LONG-TERM DEBT
NOTE 7 — LONG-TERM DEBT:

On September 3, 2019, Chembio entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings II, LP (the “Lender”). The Credit Agreement provides for a $20,000,000 senior secured term loan credit facility, which was drawn in full on September 4, 2019. Under the terms of the Credit Agreement, Chembio may use the proceeds (i) for general working capital purposes and other permitted corporate purposes, (ii) to refinance certain of Chembio’s existing indebtedness and (iii) to pay fees, costs and expenses incurred in connection with the Credit Agreement, including the Lender’s closing cost amount of $550,000, which was netted from the proceeds, and a financing fee of $600,000 (3.0% of gross proceeds) payable to Craig-Hallum Capital Group LLC, Chembio’s financial advisor for the financing.

Principal outstanding under the Credit Agreement bears interest at a rate per annum equal to the sum of (a) the greater of the one-month London Interbank Offered Rate and 2.5% plus (b) 8.75%. At any time at which an event of default has occurred and is continuing, the interest rate will increase by 4.0%. Accrued interest is payable on a monthly basis. On March 31, 2022 the interest rate was 11.25%.

No principal repayments are due under the Credit Agreement prior to September 30, 2022, unless Chembio elects to prepay principal or principal is accelerated pursuant to an event of default identified in the Credit Agreement. Principal installments in the amount of $300,000 are payable on the last day of each of the eleven months from September 2022 through July 2023, and all remaining principal is payable at maturity on September 3, 2023. The Company may prepay outstanding principal from time to time, subject to payment of a premium on the prepaid principal amount equal to 10% through September 3, 2020, 8% from September 4, 2020 through September 3, 2021, and 4% from September 4, 2021 through September 3, 2022. No premium will be due with respect to any prepayment made on or after September 4, 2022.

Chembio’s obligations under the Credit Agreement are secured by a first priority, perfected lien on substantially all of its property and assets, including its equity interests in subsidiaries.

As of  March 31, 2022, the loan balance, net of unamortized discounts and debt issuance costs, was $18.9 million, and Chembio was in compliance with its loan covenants.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY INCENTIVE PLAN
 3 Months Ended
Mar. 31, 2022
EQUITY INCENTIVE PLAN [Abstract]  
EQUITY INCENTIVE PLAN
NOTE 8 — EQUITY INCENTIVE PLAN:


 (a)
Equity Plans:

Effective June 19, 2014, Chembio’s stockholders voted to approve the 2014 Stock Incentive Plan (the “2014 Plan”), with 800,000 shares of common stock available to be issued. Under the terms of the 2014 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of Equity Award Units. The awards vest at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through March 31, 2022, there were 732,064 Equity Award Units expired, forfeited or exercised. At March 31, 2022, 46,875 Equity Award Units were outstanding and 21,061 shares were not issued. All shares that expired, forfeited or were not issued rolled over into the 2019 Plan. No Equity Award Units remain available to be issued under the 2014 Plan.

Effective June 18, 2019, Chembio’s stockholders voted to approve the 2019 Omnibus Incentive Plan (the “2019 Plan”), with 2,400,000 shares of common stock available to be issued. At the Annual Stockholder Meeting on June 25, 2021, Chembio’s stockholders voted to approve an increase to the shares of common stock issuable under the SIP by 2,400,000 to 4,800,000. In addition, shares of common stock underlying any outstanding award granted under the 2019 Plan that, following the effective date of the 2019 Plan, expire, or are terminated, surrendered or forfeited for any reason without issuance of such shares, shall be available for the grant of new awards under the 2019 Plan. Under the terms of the 2019 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of options, stock appreciation rights, restricted stock, restricted stock units, performance stock units or other stock-based awards under the 2019 Plan (collectively, “2019 Equity Units”). The 2019 Equity Units become vested at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through March 31, 2022, 866,709 2019 Equity Units have been cancelled or forfeited. At March 31, 2022, 4,915,279 2019 Equity Units were outstanding, and 83,234 2019 Equity Units were available to be awarded.


 (b)
Stock Compensation Expense:

Stock-based compensation expense (net of recovery) recognized in the condensed consolidated statements of operations was classified as follows:

 
  
For the three months
ended March 31
  
 
  
2022
    
2021
  
Cost of product sales
  
$
54,250
    
$
28,768
  
Research and development expenses
    
91,189
      
90,920
  
Selling, general and administrative expenses
    
605,464
      
460,101
  
 
  
$
750,903
    
$
579,789
  

The weighted-average assumptions made in calculating the fair values of options are as follows:


  
For the three
months ended
March 31,
2021
  
Expected term (in years)
    
6.0
  
Expected volatility
    
91.40
%
Expected dividend yield
    
N/A
  
Risk-free interest rate
    
1.91
%

The following table provides stock option activity for the three months ended March 31, 2022:

 Stock Options
  
Number
of Shares
  
Weighted
Average
Exercise Price
per Share
  
Weighted
Average
Remaining
Contract Term
  
Aggregate
Intrinsic
Value
Outstanding at December 31, 2021
  
1,600,372
  
$
4.18
  
6.59 years
  
$
-
                     
Granted
  
2,358,539
    
1.23
        
-
Exercised
  
-
    
-
        
-
Forfeited
  
14,883
    
2.42
        
-
Expired
  
183,241
    
5.63
          
Outstanding at March 31, 2022
  
3,760,787
  
$
2.27
  
8.65 years
  
$
-
Exercisable at March 31, 2022
  
565,215
  
$
3.68
  
5.89 years
  
$
-

The following table summarizes information about stock options outstanding at March 31, 2022:


  
Stock Options Outstanding
    
Stock Options Exercisable
  
Range of
Exercise Prices
  
Number
of Shares
    
Average
Remaining
Contract Term
(Year)
    
Weighted
Average
Exercise
Price
    
Aggregate
Intrinsic
Value
    
Number
of Shares
    
Weighted
Average
Exercise
Price
    
Aggregate
Intrinsic
Value
  
_1 to 2.79999
    
2,863,910
      
8.83
    
$
1.44
    
$
-
      
317,758
    
$
2.36
    
$
-
  
2.8 to 4.59999
    
30,795
      
9.19
      
3.05
      
-
      
-
      
-
      
-
  
4.6 to 6.39999
    
819,207
      
8.43
      
4.81
      
-
      
209,957
      
4.88
      
-
  
6.4 to 8.19999
    
46,875
      
1.11
      
8.15
      
-
      
37,500
      
8.15
      
-
  
Total
    
3,760,787
      
8.65
    
$
2.27
    
$
-
      
565,215
    
$
3.69
    
$
-
  

As of March 31, 2022, there was $3,073,502 of net unrecognized compensation cost related to stock options that had not vested, which is expected to be recognized over a weighted-average period of approximately 3.32 years. The total fair value of shares vested during the three months ended March 31, 2022 and 2021 was $693,290 and $188,179, respectively.

The following table summarizes information about restricted stock, restricted stock units and performance stock units outstanding as of March 31, 2022:


  
Number of
Shares & Units
    
Weighted
Average
Grant Date
Fair Value
  
Outstanding at December 31, 2021
    
705,325
    
$
3.34
  
                 
Granted
    
1,210,448
      
0.76
  
Vested
    
167,782
      
3.60
  
Forfeited
    
8,047
      
2.31
  
Outstanding at March 31, 2022
    
1,739,944
    
$
1.52
  

As of March 31, 2022, there was $2,120,646 of net unrecognized compensation cost related to restricted stock and restricted stock units that had not vested, which is expected to be recognized over a weighted average period of approximately 2.50 years.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.1
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY
 3 Months Ended
Mar. 31, 2022
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY [Abstract]  
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY
NOTE 9 — GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY:

The Company produces only one group of similar products known collectively as “rapid medical tests”, and it operates in a single operating segment. Net product revenue by geographic area were as follows:

 
For the three months ended
March 31
  
   
2022
    
2021
  
Africa
  
$
767,352
    
$
1,344,858
  
Asia
    
15,558
      
216,954
  
Europe & Middle East
    
717,908
      
1,493,734
  
Latin America
    
12,545,054
      
258,019
  
United States
    
4,481,584
      
711,097
  
   
$
18,527,456
    
$
4,024,662
  

Property, plant and equipment by geographic area were as follows at:

 
March 31, 2022
    
December 31, 2021
  
Asia
  
$
85,351
    
$
86,041
  
Europe & Middle East
    
101,231
      
113,883
  
Latin America
    
58,685
      
36,224
  
United States
    
8,169,046
      
8,320,625
  
   
$
8,414,313
    
$
8,556,773
  
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
 3 Months Ended
Mar. 31, 2022
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract]  
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES
NOTE 10 — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES:

Accounts payable and accrued liabilities consisted of:

 
March 31, 2022
    
December 31, 2021
  
Accounts payable – suppliers
  
$
5,622,558
    
$
7,745,592
  
Accrued commissions and royalties
    
1,510,865
      
1,359,691
  
Accrued payroll
    
494,653
      
494,258
  
Accrued vacation
    
657,008
      
421,416
  
Accrued bonuses
    
544,567
      
1,378,706
  
Accrued professional fees
    
893,745
      
522,935
  
Accrued expenses – other
    
819,455
      
1,205,395
  
 TOTAL
  
$
10,542,851
    
$
13,127,993
  
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS
 3 Months Ended
Mar. 31, 2022
GOODWILL AND INTANGIBLE ASSETS [Abstract]  
GOODWILL AND INTANGIBLE ASSETS
NOTE 11 — GOODWILL AND INTANGIBLE ASSETS:

The following table reflects changes in goodwill:

Beginning balance at December 31, 2021
  
$
3,022,787
  
Impairment
     (3,033,565 )
Change in foreign currency exchange rate
    
10,778
  
Balance at March 31, 2022
  
$
-
  

Goodwill represents the excess of the purchase price the Company paid over the fair value of the net tangible and identifiable intangible assets acquired in the Company’s acquisition. Goodwill is not amortized but rather is tested annually as of the first day of the fiscal fourth quarter, or sooner if the Company believes that indicators of impairment exist. The Company makes a qualitative evaluation about the likelihood of goodwill impairment, which is based on a number of applicable factors. If the Company concludes that it is more likely than not that the carrying value of the applicable reporting unit is greater than its fair value, then it would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.

The quantitative goodwill impairment test is performed using a one-step process. The process is to compare the fair value of a reporting unit with its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit is impaired, and an impairment loss is recognized in an amount equal to that excess.

The Company operates as a single operating segment and has one reporting unit. As of March 31, 2022, the Company determined indicators of impairment existed. As a result, the Company recognized an impairment loss of its goodwill totaling $3.0 million.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.1
OTHER MATTERS
 3 Months Ended
Mar. 31, 2022
OTHER MATTERS [Abstract]  
OTHER MATTERS
NOTE 12 —  OTHER MATTERS:

On March 28, 2022, Chembio Diagnostics GmbH, Chembio’s German subsidiary formed under the laws of the Federal Republic of Germany, successfully withdrew its petition for insolvency filed in February 2022 in the Charlottenburg District Court  (“Amtsgericht Charlottenburg“) in Berlin, Germany. The subsidiary has taken various measures to improve profitability, including a viable business plan, and the Company has provided liquidity and other support to continue the operations.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Mar. 31, 2022
SIGNIFICANT ACCOUNTING POLICIES [Abstract]  
Basis of Presentation

(a)
Basis of presentation:

The accompanying unaudited condensed consolidated financial statements include the accounts of Chembio and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Certain reclassifications have been made to the unaudited condensed consolidated balance sheet of the prior year to conform to the current year presentation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Chembio’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC.

Going Concern Considerations

The Company continued to experience market, clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of COVID-19 test systems during the continuing, but evolving, uncertainty resulting from COVID‑19. For the three months ended March 31, 2022, the Company continued to incur significant expenses in connection with pending legal matters (see Note 6 – Commitments, Contingencies, and Concentrations: Litigation).
 
The Company performed an assessment to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are being issued. Initially, this assessment did not consider the potential mitigating effect of management’s plans that had not been fully implemented. Because, as described below, substantial doubt was determined to exist as the result of this initial assessment, management then assessed the mitigating effect of its plans to determine if it is probable that the plans (1) would be effectively implemented within one year after the date the accompanying unaudited condensed consolidated financial statements are issued and (2) when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern.
 
The Company achieved significant revenue growth in recent years while profitability has not been at levels as expected. It has taken steps including investments in automation to mitigate headwinds such as labor availability, volatile capacity planning and implementation of operational efficiency targets to proactively monitor production with the overarching goal for profitable growth. During the three months ended March 31, 2022, the Company undertook measures to increase its total revenues and improve its liquidity position by implementing the Global Competitiveness Program. The main pillars of the Global Competitiveness Program include the following:

•
Focus on higher margin business in growth markets

•
Lower manufacturing costs

•
Reduce infrastructure costs

•
Strategic review of non-core businesses and assets:

In addition, the Company will continue to focus on regulatory approvals for its DPP SARS-CoV-2 Antigen test system, DPP Respiratory Antigen Panel, and DPP HIV-Syphilis test system. These measures and other plans and initiatives have been designed to provide the Company with adequate liquidity to meet its obligations for at least the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are being issued. The Company’s execution of those measures and its other plans and initiative continue to depend, however, on factors and uncertainties that are beyond the Company’s control, or that may not be addressable on terms acceptable to the Company or at all. The Company considered in particular how:

•
The ongoing healthcare and economic impacts of COVID-19 on the global customer base for the Company’s non‑COVID-19 products continue to negatively affect the timing and rate of recovery of the Company’s revenues from those products by, for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect the Company’s liquidity.

•
Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products.

The Company further considered how these factors and uncertainties could impact its ability over the next year to meet the obligations specified in the Credit Agreement with the Lender (both as defined in Note 7 – Long-Term Debt). Those obligations include covenants requiring: i) minimum cash balance of $3.0 million and ii) minimum total revenue amounts for the twelve months preceding each quarter end. For the next year, the minimum total revenue requirements range from $43.8 million for the twelve months ending June 30, 2022 to $48.8 million for the twelve months ending March 31, 2023. Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that the Company would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement or that, if such liquidity were not available, the Company would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern. The Company’s inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for its operations, could have a material adverse effect on its business, prospects, results of operations, liquidity and financial condition.

Accordingly, management determined the Company could not be certain that the Company’s plans and initiatives would be effectively implemented within one year after the date on which the accompanying unaudited condensed consolidated financial statements are being issued. Without giving effect to the prospect of raising additional capital pursuant to the Company’s At the Market Offering Agreement dated July 19, 2021 with Chembio Diagnostics, Inc. and Craig-Hallum Capital Group LLC, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond the Company’s control, it is unlikely that the Company will be able to generate sufficient cash flows to meet its required financial obligations, including its debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited condensed consolidated financial statements are being issued.

The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are issued. As such, the accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.
Fair Value of Financial Instruments

(c)
Fair Value of Financial Instruments:

The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate fair value due to the immediate or short-term maturity of these financial instruments. Included in cash and cash equivalents were $ 17.1 million and $25.0 million as of March 31, 2022 and December 31, 2021, respectively, of money market funds that are Level 1 fair value measurements under the hierarchy. The fair value of the Company’s total debt of $20.0 million (carrying value of $18.9 million) and $20.0 million (carrying value of $18.8 million) as of March 31, 2022 and December 31, 2021 respectively, is a Level 2 fair value measurement under the hierarchy and the Company’s debt face value approximates the recorded value, as the rate is based upon the current rates available to the Company for similar financial instruments.
Fair value measurements of all financial assets and liabilities that are measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:

Level 1:
Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;


Level 2:
Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,


Level 3:
Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).
Cash and Cash Equivalents

(d)
Cash and Cash Equivalents:

Cash and cash equivalents are defined as short-term, highly liquid investments, such as money market funds, with original maturities of three months or less at date of purchase.
Loss Per Share

(e)
Loss Per Share:

Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period excluding unvested restricted stock. Diluted loss per share for the three months ended March 31, 2022 and 2021 reflects the potential dilution from the exercise or conversion of other securities into common stock, if dilutive.

There were 3,760,787 and 1,848,286 options outstanding as of March 31, 2022 and 2021, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.
There were 1,739,944 and 847,795 shares of restricted stock outstanding as of March 31, 2022 and 2020, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.
Income Taxes

(f)
Income Taxes:

At the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis, and may change in subsequent interim periods. Accordingly, the Company’s effective tax rate for the three months ended March 31, 2022 was (0.1)%, compared to the effective tax rate of 1.6% for the three months ended March 31, 2021. The Company’s effective tax rates for both periods were affected primarily by a full valuation allowance on domestic net deferred tax assets.
Recently Issued Accounting Standards Affecting the Company

(g)
Recently Issued Accounting Standards Affecting the Company:

Recently Adopted
ASU 2021-10 - Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance
In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which creates Accounting Standards Codification (“ASC”) 832 and aims to provide increased transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. The disclosure requirements in ASC 832 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model (for example, in ASC 958-605, Not-for-Profit Entities – Revenue Recognition). The FASB broadly defined “government assistance” in ASC 832 to ensure that assistance received from most types of governmental entities or other related organizations would be disclosed.  Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The Company adopted the standard effective January 1, 2022 and has determined that the adoption did not have a material impact on the Company’s consolidated financial statements.
Not Yet Adopted
ASU 2020-06 - Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity
On August 5, 2020, the FASB issued ASU 2020-06, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. ASU 2020-06 simplifies the guidance in GAAP on the issuer’s accounting for convertible debt instruments, requires entities to provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance. The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.

ASU 2021-08—Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers
  
On October 28, 2021, the FASB issued ASU 2021-08,1 which amends ASC 805 to “require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination.” Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. ASU 2021-08 amends ASC 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to “require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606.” While primarily related to contract assets and contract liabilities that were accounted for by the acquiree in accordance with ASC 606, “the amendments also apply to contract assets and contract liabilities from other contracts to which the provisions of Topic 606 apply, such as contract liabilities from the sale of nonfinancial assets within the scope of Subtopic 610-20.” The ASU’s amendments are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE (Tables)
 3 Months Ended
Mar. 31, 2022
REVENUE [Abstract]  
Disaggregation of Revenue
The following table disaggregates Total Revenues by revenue type:

 
March 31, 2022
    
March 31, 2021
  
   
Exchange
Transactions
    
Non-Exchange
Transactions
    
Total
    
Exchange
Transactions
    
Non-Exchange
Transactions
    
Total
  
Net product revenue
  
$
18,527,456
    
$
-
    
$
18,527,456
    
$
4,024,662
    
$
-
    
$
4,024,662
  
R&D Revenue
    
18,173
      
-
      
18,173
      
1,106,639
      
-
      
1,106,639
  
Government grant revenue
    
–
      
–
      
–
      
–
      
3,350,000
      
3,350,000
  
License and royalty revenue
    
270,982
      
-
      
270,982
      
243,058
      
-
      
243,058
  
   
$
18,816,611
    
$
-
    
$
18,816,611
    
$
5,374,359
    
$
3,350,000
    
$
8,724,359
  

The following table disaggregates Total Revenues by geographic location:

 
For the three months ended
  
   
March 31, 2022
    
March 31, 2021
  
Africa
  
$
767,352
    
$
1,344,858
  
Asia
    
15,558
      
216,954
  
Europe & Middle East
    
723,745
      
2,600,274
  
Latin America
    
12,557,390
      
258,019
  
United States
    
4,752,566
      
4,304,254
  
   
$
18,816,611
    
$
8,724,359
  
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.1
INVENTORY (Tables)
 3 Months Ended
Mar. 31, 2022
INVENTORY [Abstract]  
Inventories
Inventories are presented net of reserves and consist of the following at:

 
March 31,
2022
    
December 31,
2021
  
Raw materials
  
$
7,197,257
    
$
7,306,095
  
Work in process
    
1,932,069
      
3,556,878
  
Finished goods
    
2,714,795
      
2,057,478
  
   
$
11,844,121
    
$
12,920,451
  
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables)
 3 Months Ended
Mar. 31, 2022
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS [Abstract]  
Customer and Purchase Concentration Risks
The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company’s net product sales for the periods indicated:

   
For the three months ended
    
Accounts Receivable as of
  
   
March 31, 2022
   
March 31, 2021
   
March 31,
2022
    
December
31, 2021
  
   
Product
Sales
    
% of
Product
Sales
    
Product
Sales
    
% of
Product
Sales
              
Customer 1
   $ 11,856,024       64 %  
$
 *      
*
     $ 5,930,162    
$
7,672,845
  

Revenue includes product sales only, while accounts receivable reflects the total due from the customer, including freight.

The following table discloses purchases the Company had to each vendor that purchased in excess of 10% of the Company’s net purchases for the periods indicated:

 
For the three months ended
    
Accounts Payable as of
  
   
March 31, 2022
   
March 31, 2021
   
March 31,
2022
    
December
31, 2021
  
   
Purchases
    
% of
Purchases
    
Purchases
    
% of
Purchases
              
Vendor 1
  
$
2,323,605
      
34
%
  
$
*
      
*
    
$
224,500
     $ *
  
Vendor 2
    
1,088,251
      
16
%
    
469,635
      
11
%
    
164,983
      
353,097
  


In the tables above, an asterisk (*) indicates that indicates that sales, accounts receivable, purchases or accounts payable, as applicable to the tabular column, did not exceed 10% for the period indicated.
Future Minimum Salary Commitment The following table is a schedule of future minimum salary commitments:

2022
  
$
883,500
  
2023
    
383,000
  
2024
     383,000  
Components of Lease Expense
The components of lease expense were as follows:

 
Three Months Ended
March 31
  
   
2022
    
2021
  
Operating lease expense
  
$
403,385
    
$
408,466
  
                 
Finance lease cost
                
Amortization of right-of-use assets
  
$
17,579
    
$
15,758
  
Interest on lease liabilities
    
4,686
      
4,944
  
Total finance lease expense
  
$
22,265
    
$
20,702
  
Supplemental Cash Flow Information Related to Leases
Supplemental cash flow information related to leases was as follows.

 
  
Three Months Ended
March 31
  
 
  
2022
    
2021
  
Cash paid for amounts included in the measurement of lease liabilities:
            
Operating cash flows for operating leases
  
$
360,878
    
$
347,871
  
Operating cash flows for finance leases
    
4,686
      
4,944
  
Financing cash flows for finance leases
    
16,930
      
14,282
  
Right-of-use assets obtained in exchange for lease obligations:
                
Finance leases
    
16,234
      
-
  
Supplemental Balance Sheet Information Related to Leases
Supplemental balance sheet information related to leases was as follows:

 
  
March 31, 2022
    
March 31, 2021
  
Finance Leases
            
Finance lease right of use asset
  
$
356,997
    
$
315,153
  
Accumulated depreciation
    
(166,471
)
    
(97,777
)
Finance lease right of use asset, net
  
$
190,526
    
$
217,376
  
 
                
Weighted Average Remaining Lease Term
                
Operating leases
  
7.4 years
    
8.6 years
  
Finance leases
  
2.8 years
    
3.5 years
  
 
                
Weighted Average Discount Rate
                
Operating leases
    
9.32
%
    
9.30
%
Finance leases
    
8.56
%
    
8.18
%
Maturities of Lease Liabilities
Maturities of lease liabilities were as follows.

 
  
March 31, 2022
    
March 31, 2021
  
 
  
Operating
Leases
    
Finance
Leases
    
Operating
Leases
    
Finance
Leases
  
2022
  
$
1,086,370
    
$
65,913
    
$
861,916
    
$
57,678
  
2023
    
1,221,017
      
87,884
      
1,057,757
      
76,904
  
2024
    
1,018,875
      
60,116
      
1,026,272
      
76,904
  
2025
    
1,049,442
      
16,731
      
1,018,875
      
49,136
  
2026
    
1,080,925
      
5,940
      
1,049,442
      
5,751
  
Thereafter
    
3,643,521
      
355
      
4,724,446
      
-
  
Total lease payments
  
$
9,100,150
    
$
236,939
    
$
9,738,708
    
$
266,373
  
Less: imputed interest
    
2,450,412
      
29,781
      
2,968,703
      
36,544
  
Total
  
$
6,649,738
    
$
207,158
    
$
6,770,005
    
$
229,829
  
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY INCENTIVE PLAN (Tables)
 3 Months Ended
Mar. 31, 2022
EQUITY INCENTIVE PLAN [Abstract]  
Stock-Based Compensation Expense (Net of Recovery) Recognized
Stock-based compensation expense (net of recovery) recognized in the condensed consolidated statements of operations was classified as follows:

 
  
For the three months
ended March 31
  
 
  
2022
    
2021
  
Cost of product sales
  
$
54,250
    
$
28,768
  
Research and development expenses
    
91,189
      
90,920
  
Selling, general and administrative expenses
    
605,464
      
460,101
  
 
  
$
750,903
    
$
579,789
  
Assumptions Made in Calculating Fair Values of Options
The weighted-average assumptions made in calculating the fair values of options are as follows:


  
For the three
months ended
March 31,
2021
  
Expected term (in years)
    
6.0
  
Expected volatility
    
91.40
%
Expected dividend yield
    
N/A
  
Risk-free interest rate
    
1.91
%
Stock Option Activity
The following table provides stock option activity for the three months ended March 31, 2022:

 Stock Options
  
Number
of Shares
  
Weighted
Average
Exercise Price
per Share
  
Weighted
Average
Remaining
Contract Term
  
Aggregate
Intrinsic
Value
Outstanding at December 31, 2021
  
1,600,372
  
$
4.18
  
6.59 years
  
$
-
                     
Granted
  
2,358,539
    
1.23
        
-
Exercised
  
-
    
-
        
-
Forfeited
  
14,883
    
2.42
        
-
Expired
  
183,241
    
5.63
          
Outstanding at March 31, 2022
  
3,760,787
  
$
2.27
  
8.65 years
  
$
-
Exercisable at March 31, 2022
  
565,215
  
$
3.68
  
5.89 years
  
$
-
Stock Options Outstanding
The following table summarizes information about stock options outstanding at March 31, 2022:


  
Stock Options Outstanding
    
Stock Options Exercisable
  
Range of
Exercise Prices
  
Number
of Shares
    
Average
Remaining
Contract Term
(Year)
    
Weighted
Average
Exercise
Price
    
Aggregate
Intrinsic
Value
    
Number
of Shares
    
Weighted
Average
Exercise
Price
    
Aggregate
Intrinsic
Value
  
_1 to 2.79999
    
2,863,910
      
8.83
    
$
1.44
    
$
-
      
317,758
    
$
2.36
    
$
-
  
2.8 to 4.59999
    
30,795
      
9.19
      
3.05
      
-
      
-
      
-
      
-
  
4.6 to 6.39999
    
819,207
      
8.43
      
4.81
      
-
      
209,957
      
4.88
      
-
  
6.4 to 8.19999
    
46,875
      
1.11
      
8.15
      
-
      
37,500
      
8.15
      
-
  
Total
    
3,760,787
      
8.65
    
$
2.27
    
$
-
      
565,215
    
$
3.69
    
$
-
  
Summary of Restricted Stock and Restricted Stock Units Outstanding
The following table summarizes information about restricted stock, restricted stock units and performance stock units outstanding as of March 31, 2022:


  
Number of
Shares & Units
    
Weighted
Average
Grant Date
Fair Value
  
Outstanding at December 31, 2021
    
705,325
    
$
3.34
  
                 
Granted
    
1,210,448
      
0.76
  
Vested
    
167,782
      
3.60
  
Forfeited
    
8,047
      
2.31
  
Outstanding at March 31, 2022
    
1,739,944
    
$
1.52
  
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.1
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Tables)
 3 Months Ended
Mar. 31, 2022
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY [Abstract]  
Product Revenue by Geographic Area
The Company produces only one group of similar products known collectively as “rapid medical tests”, and it operates in a single operating segment. Net product revenue by geographic area were as follows:

 
For the three months ended
March 31
  
   
2022
    
2021
  
Africa
  
$
767,352
    
$
1,344,858
  
Asia
    
15,558
      
216,954
  
Europe & Middle East
    
717,908
      
1,493,734
  
Latin America
    
12,545,054
      
258,019
  
United States
    
4,481,584
      
711,097
  
   
$
18,527,456
    
$
4,024,662
  
Long-lived Assets by Geographic Area
Property, plant and equipment by geographic area were as follows at:

 
March 31, 2022
    
December 31, 2021
  
Asia
  
$
85,351
    
$
86,041
  
Europe & Middle East
    
101,231
      
113,883
  
Latin America
    
58,685
      
36,224
  
United States
    
8,169,046
      
8,320,625
  
   
$
8,414,313
    
$
8,556,773
  
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)
 3 Months Ended
Mar. 31, 2022
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract]  
Accounts Payable and Accrued Liabilities
Accounts payable and accrued liabilities consisted of:

 
March 31, 2022
    
December 31, 2021
  
Accounts payable – suppliers
  
$
5,622,558
    
$
7,745,592
  
Accrued commissions and royalties
    
1,510,865
      
1,359,691
  
Accrued payroll
    
494,653
      
494,258
  
Accrued vacation
    
657,008
      
421,416
  
Accrued bonuses
    
544,567
      
1,378,706
  
Accrued professional fees
    
893,745
      
522,935
  
Accrued expenses – other
    
819,455
      
1,205,395
  
 TOTAL
  
$
10,542,851
    
$
13,127,993
  
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS (Tables)
 3 Months Ended
Mar. 31, 2022
GOODWILL AND INTANGIBLE ASSETS [Abstract]  
Changes in Goodwill
The following table reflects changes in goodwill:

Beginning balance at December 31, 2021
  
$
3,022,787
  
Impairment
     (3,033,565 )
Change in foreign currency exchange rate
    
10,778
  
Balance at March 31, 2022
  
$
-
  
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES, Going Concern Considerations (Details) - USD ($)
$ in Millions
 12 Months Ended
Mar. 31, 2023
Jun. 30, 2022
Forecast [Member]    
Credit Agreement [Abstract]    
Covenant amount, revenue $ 48.8 $ 43.8
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES, Fair Value of Financial Instruments (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
Fair Value of Financial Instruments [Abstract]    
Cash and cash equivalents $ 24,399,388 $ 28,772,892
Level 2 [Member]    
Fair Value of Financial Instruments [Abstract]    
Fair value of total debt 20,000,000.0 20,000,000.0
Carrying value 18,900,000 18,800,000
Money Market Funds [Member] | Level 1 [Member]    
Fair Value of Financial Instruments [Abstract]    
Cash and cash equivalents $ 17,100,000 $ 25,000,000.0
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES, Loss Per Share (Details) - shares
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Options [Member]    
Loss Per Share [Abstract]    
Antidilutive securities excluded from calculation of diluted earnings per share (in shares) 3,760,787 1,848,286
Restricted Stock [Member]    
Loss Per Share [Abstract]    
Antidilutive securities excluded from calculation of diluted earnings per share (in shares) 1,739,944 847,795
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.1
SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Taxes [Abstract]    
Effective tax rate 0.10% 1.60%
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUE (Details) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Disaggregation of Revenue [Abstract]    
Revenues $ 18,816,611 $ 8,724,359
Africa [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 767,352 1,344,858
Asia [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 15,558 216,954
Europe & Middle East [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 723,745 2,600,274
Latin America [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 12,557,390 258,019
United States [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 4,752,566 4,304,254
Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 18,816,611 5,374,359
Non-Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 0 3,350,000
Net Product Revenue [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 18,527,456 4,024,662
Net Product Revenue [Member] | Africa [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 767,352 1,344,858
Net Product Revenue [Member] | Asia [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 15,558 216,954
Net Product Revenue [Member] | Europe & Middle East [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 717,908 1,493,734
Net Product Revenue [Member] | Latin America [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 12,545,054 258,019
Net Product Revenue [Member] | United States [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 4,481,584 711,097
Net Product Revenue [Member] | Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 18,527,456 4,024,662
Net Product Revenue [Member] | Non-Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 0 0
R&D Revenue [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 18,173 1,106,639
R&D Revenue [Member] | Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 18,173 1,106,639
R&D Revenue [Member] | Non-Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 0 0
Government Grant Revenue [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 0 3,350,000
Government Grant Revenue [Member] | Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 0 0
Government Grant Revenue [Member] | Non-Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 0 3,350,000
License and Royalty Revenue [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 270,982 243,058
License and Royalty Revenue [Member] | Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues 270,982 243,058
License and Royalty Revenue [Member] | Non-Exchange Transactions [Member]    
Disaggregation of Revenue [Abstract]    
Revenues $ 0 $ 0
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.1
INVENTORY (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
INVENTORY [Abstract]    
Raw materials $ 7,197,257 $ 7,306,095
Work in process 1,932,069 3,556,878
Finished goods 2,714,795 2,057,478
Inventories $ 11,844,121 $ 12,920,451
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.1
STOCKHOLDERS' EQUITY (Details) - shares
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Common Stock [Abstract]      
Number of stock options exercised under the plan (in shares) 0 0  
Preferred Stock [Abstract]      
Preferred stock - shares authorized (in shares) 10,000,000   10,000,000
Preferred stock - shares outstanding (in shares) 0   0
Treasury Stock [Abstract]      
Treasury stock, shares (in shares) 48,057   48,057
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.1
COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details)
 3 Months Ended 12 Months Ended
Mar. 19, 2021
Claim
Jan. 03, 2020
USD ($)
shares
Mar. 31, 2022
USD ($)
Applicants
Claim
KeyEmployee
Mar. 31, 2021
USD ($)
Dec. 31, 2020
Lawsuit
Dec. 31, 2021
USD ($)
Concentrations [Abstract]            
Net product revenue     $ 18,816,611 $ 8,724,359    
Accounts Receivable     $ 9,879,954     $ 11,441,107
Employment Contracts [Abstract]            
Number of key employees with whom Company has employment contracts | KeyEmployee     3      
Aggregate annual salaries of employment contracts     $ 1,178,000      
Contract one, expiration date     Dec. 31, 2022      
Contract two expiration date     Dec. 31, 2024      
Future minimum salary commitments [Abstract]            
2022     $ 883,500      
2023     383,000      
2024     $ 383,000      
Benefit Plan [Abstract]            
Percentage of employer's matching contribution     40.00%      
Expenses related to matching contribution     $ 67,135 35,456    
Components of Lease Expense [Abstract]            
Operating lease expense     403,385 408,466    
Finance lease cost [Abstract]            
Amortization of right-of-use assets     17,579 15,758    
Interest on lease liabilities     4,686 4,944    
Total finance lease expense     22,265 20,702    
Cash paid for amounts included in the measurement of lease liabilities [Abstract]            
Operating cash flows for operating leases     360,878 347,871    
Operating cash flows for finance leases     4,686 4,944    
Financing cash flows for finance leases     16,930 14,282    
Right-of-use assets obtained in exchange for lease obligations [Abstract]            
Finance leases     16,234 0    
Finance Leases [Abstract]            
Finance lease right-of-use asset     356,997 315,153    
Accumulated depreciation     (166,471) (97,777)    
Finance lease right-of-use asset, net     $ 190,526 $ 217,376   191,870
Weighted Average Remaining Lease Term [Abstract]            
Operating leases     7 years 4 months 24 days 8 years 7 months 6 days    
Finance leases     2 years 9 months 18 days 3 years 6 months    
Weighted Average Discount Rate [Abstract]            
Operating leases     9.32% 9.30%    
Finance leases     8.56% 8.18%    
Maturities of Operating Lease Liabilities [Abstract]            
2022     $ 1,086,370 $ 861,916    
2023     1,221,017 1,057,757    
2024     1,018,875 1,026,272    
2025     1,049,442 1,018,875    
2026     1,080,925 1,049,442    
Thereafter     3,643,521 4,724,446    
Total lease payments     9,100,150 9,738,708    
Less: imputed interest     2,450,412 2,968,703    
Total     6,649,738 6,770,005    
Maturities of Finance Lease Liabilities [Abstract]            
2022     65,913 57,678    
2023     87,884 76,904    
2024     60,116 76,904    
2025     16,731 49,136    
2026     5,940 5,751    
Thereafter     355 0    
Total lease payments     236,939 266,373    
Less: imputed interest     29,781 36,544    
Total     $ 207,158 229,829    
Stockholder Litigation [Abstract]            
Number of class action lawsuits | Lawsuit         4  
Number of motions for appointment as lead plaintiff | Applicants     8      
Number of motions abandoned | Applicants     2      
Number of remaining motions for appointment as lead plaintiff | Applicants     2      
Number of motions filed by special situations funds | Applicants     1      
Number of motions filed by municipal employees retirement system | Applicants     1      
Period within which lead plaintiffs can replead their claims     14 days      
Employee Litigation [Abstract]            
Number of filed complaints | Claim 15          
Exercise price of stock options   $ 943,126        
Vested shares exercisable (in shares) | shares   266,666        
Term to exercise stock options     30 days      
Number of complaint purport to allege claims for breach of each of separate stock option agreements | Claim     10      
Loss contingency, asserting damages amount     $ 3,190,198      
Loss contingency, asserting damages excess amount     3,000,000      
Loss contingency, claims entitlement to recover damages amount     $ 10,000,000      
Prejudgment interest rate     9.00%      
Customer Concentration Risk [Member] | Customer 1 [Member]            
Concentrations [Abstract]            
Accounts Receivable     $ 5,930,162     7,672,845
Supplier Concentration Risk [Member] | Vendor 1 [Member]            
Concentrations [Abstract]            
Accounts Payable     224,500     [1]
Supplier Concentration Risk [Member] | Vendor 2 [Member]            
Concentrations [Abstract]            
Accounts Payable     $ 164,983     $ 353,097
Maximum [Member]            
Benefit Plan [Abstract]            
Employee contribution subject to employer matching contribution     5.00%      
Employer matching contribution     2.00%      
Sales [Member] | Customer Concentration Risk [Member] | Customer 1 [Member]            
Concentrations [Abstract]            
Net product revenue     $ 11,856,024 [1]    
Percentage of product sales     64.00% [1]    
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 1 [Member]            
Concentrations [Abstract]            
Percentage of product sales     34.00% [1]    
Purchases     $ 2,323,605 [1]    
Purchases [Member] | Supplier Concentration Risk [Member] | Vendor 2 [Member]            
Concentrations [Abstract]            
Percentage of product sales     16.00% 11.00%    
Purchases     $ 1,088,251 $ 469,635    
[1] In the tables above, an asterisk (*) indicates that indicates that sales, accounts receivable, purchases or accounts payable, as applicable to the tabular column, did not exceed 10% for the period indicated.
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.1
LONG-TERM DEBT (Details) - Senior Secured Term Loan Credit Facility [Member] - USD ($)
 3 Months Ended
Sep. 03, 2019
Mar. 31, 2022
Credit Agreement [Abstract]    
Debt instrument, face amount $ 20,000,000  
Lender's closing cost 550,000  
Financing fee $ 600,000  
Percentage of gross proceeds considered as financing fee 3.00%  
Interest rate 8.75% 11.25%
Increase in interest rate in event of default 4.00%  
Principal installment payable $ 300,000  
Debt instrument maturity date   Sep. 03, 2023
Outstanding loan balance, net   $ 18,900,000
September 4, 2019 to September 3, 2020 [Member]    
Credit Agreement [Abstract]    
Percentage of prepaid principal as premium 10.00%  
September 4, 2020 to September 3, 2021 [Member]    
Credit Agreement [Abstract]    
Percentage of prepaid principal as premium 8.00%  
September 4, 2021 to September 3, 2022 [Member]    
Credit Agreement [Abstract]    
Percentage of prepaid principal as premium 4.00%  
LIBOR [Member]    
Credit Agreement [Abstract]    
Term of variable rate   1 month
Basis spread on variable rate 2.50%  
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY INCENTIVE PLAN, Summary (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jun. 25, 2021
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Jun. 18, 2019
Jun. 19, 2014
Stock Compensation Expense [Abstract]            
Allocated share-based compensation expense   $ 750,903 $ 579,789      
Stock Options, Additional Disclosure [Abstract]            
Outstanding, aggregate intrinsic value, end of period   0        
Exercisable, aggregate intrinsic value, end of period   0        
Cost of Product Sales [Member]            
Stock Compensation Expense [Abstract]            
Allocated share-based compensation expense   54,250 28,768      
Research and Development Expenses [Member]            
Stock Compensation Expense [Abstract]            
Allocated share-based compensation expense   91,189 90,920      
Selling, General and Administrative Expenses [Member]            
Stock Compensation Expense [Abstract]            
Allocated share-based compensation expense   $ 605,464 $ 460,101      
Stock Options [Member]            
Assumptions Made in Calculating Fair Values of Options [Abstract]            
Expected term   6 years        
Expected volatility   91.40%        
Expected dividend yield          
Risk-free interest rate   1.91%        
Stock Options, Number of Shares [Roll forward]            
Outstanding, beginning of period (in shares)   1,600,372        
Granted (in shares)   2,358,539        
Exercised (in shares)   0        
Forfeited (in shares)   14,883        
Expired (in shares)   183,241        
Outstanding, end of period (in shares)   3,760,787   1,600,372    
Exercisable, end of period (in shares)   565,215        
Stock Options, Weighted Average Exercise Price per Share [Roll Forward]            
Outstanding, beginning of period (in dollars per share)   $ 4.18        
Granted (in dollars per share)   1.23        
Exercised (in dollars per share)   0        
Forfeited (in dollars per share)   2.42        
Expired (in dollars per share)   5.63        
Outstanding, end of period (in dollars per share)   2.27   $ 4.18    
Exercisable, end of period (in dollars per share)   $ 3.68        
Stock Options, Additional Disclosure [Abstract]            
Outstanding, weighted average remaining contract term   8 years 7 months 24 days   6 years 7 months 2 days    
Exercisable, weighted average remaining contract term   5 years 10 months 20 days        
Outstanding, aggregate intrinsic value, beginning of period   $ 0        
Granted, aggregate intrinsic value   0        
Exercised, aggregate intrinsic value   0        
Forfeited, aggregate intrinsic value   0        
Outstanding, aggregate intrinsic value, end of period   0   $ 0    
Exercisable, aggregate intrinsic value, end of period   $ 0        
2014 Stock Incentive Plan [Member] | Stock Options [Member]            
Share-based Arrangements with Employees and Nonemployees [Abstract]            
Number of shares authorized under the plan (in shares)           800,000
Number of stock options expired, forfeited or exercised under the plan (in shares)   732,064        
Options still available to be issued (in shares)   0        
Stock Options, Number of Shares [Roll forward]            
Outstanding, end of period (in shares)   46,875        
2019 Omnibus Incentive Plan [Member] | Stock Options [Member]            
Share-based Arrangements with Employees and Nonemployees [Abstract]            
Number of shares authorized under the plan (in shares) 4,800,000       2,400,000  
Increase in number of shares authorized (in shares) 2,400,000          
Number of stock options expired, forfeited or exercised under the plan (in shares)   866,709        
Options still available to be issued (in shares)   83,234        
Stock Options, Number of Shares [Roll forward]            
Outstanding, end of period (in shares)   4,915,279        
2014 & 2019 Stock Incentive Plan [Member] | Stock Options [Member]            
Stock Options, Number of Shares [Roll forward]            
Outstanding, end of period (in shares)   21,061        
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY INCENTIVE PLAN, Stock Options (Details) - USD ($)
 3 Months Ended
Jan. 03, 2020
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Stock Options Outstanding [Abstract]        
Shares outstanding (in shares)   3,760,787    
Average remaining contract term   8 years 7 months 24 days    
Weighted average exercise price (in dollars per share)   $ 2.27    
Aggregate intrinsic value   $ 0    
Stock Options Exercisable [Abstract]        
Shares exercisable (in shares)   565,215    
Weighted average exercise price (in dollars per share)   $ 3.69    
Aggregate intrinsic value   $ 0    
Total fair value of stock options vested during period $ 943,126      
Stock Options [Member]        
Stock Options Outstanding [Abstract]        
Aggregate intrinsic value   0   $ 0
Stock Options Exercisable [Abstract]        
Aggregate intrinsic value   0    
Net unrecognized compensation cost   $ 3,073,502    
Weighted average period for recognition of net unrecognized compensation cost   3 years 3 months 25 days    
Total fair value of stock options vested during period   $ 693,290 $ 188,179  
1 to 2.79999 [Member]        
Range of Exercise Prices [Abstract]        
Range of exercise prices, minimum (in dollars per share)   $ 1    
Range of exercise prices, maximum (in dollars per share)   $ 2.79999    
Stock Options Outstanding [Abstract]        
Shares outstanding (in shares)   2,863,910    
Average remaining contract term   8 years 9 months 29 days    
Weighted average exercise price (in dollars per share)   $ 1.44    
Aggregate intrinsic value   $ 0    
Stock Options Exercisable [Abstract]        
Shares exercisable (in shares)   317,758    
Weighted average exercise price (in dollars per share)   $ 2.36    
Aggregate intrinsic value   $ 0    
2.8 to 4.59999 [Member]        
Range of Exercise Prices [Abstract]        
Range of exercise prices, minimum (in dollars per share)   $ 2.8    
Range of exercise prices, maximum (in dollars per share)   $ 4.59999    
Stock Options Outstanding [Abstract]        
Shares outstanding (in shares)   30,795    
Average remaining contract term   9 years 2 months 8 days    
Weighted average exercise price (in dollars per share)   $ 3.05    
Aggregate intrinsic value   $ 0    
Stock Options Exercisable [Abstract]        
Shares exercisable (in shares)   0    
Weighted average exercise price (in dollars per share)   $ 0    
Aggregate intrinsic value   $ 0    
4.6 to 6.39999 [Member]        
Range of Exercise Prices [Abstract]        
Range of exercise prices, minimum (in dollars per share)   $ 4.6    
Range of exercise prices, maximum (in dollars per share)   $ 6.39999    
Stock Options Outstanding [Abstract]        
Shares outstanding (in shares)   819,207    
Average remaining contract term   8 years 5 months 4 days    
Weighted average exercise price (in dollars per share)   $ 4.81    
Aggregate intrinsic value   $ 0    
Stock Options Exercisable [Abstract]        
Shares exercisable (in shares)   209,957    
Weighted average exercise price (in dollars per share)   $ 4.88    
Aggregate intrinsic value   $ 0    
6.4 to 8.19999 [Member]        
Range of Exercise Prices [Abstract]        
Range of exercise prices, minimum (in dollars per share)   $ 6.4    
Range of exercise prices, maximum (in dollars per share)   $ 8.19999    
Stock Options Outstanding [Abstract]        
Shares outstanding (in shares)   46,875    
Average remaining contract term   1 year 1 month 9 days    
Weighted average exercise price (in dollars per share)   $ 8.15    
Aggregate intrinsic value   $ 0    
Stock Options Exercisable [Abstract]        
Shares exercisable (in shares)   37,500    
Weighted average exercise price (in dollars per share)   $ 8.15    
Aggregate intrinsic value   $ 0    
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.1
EQUITY INCENTIVE PLAN, Restricted Stock and Restricted Stock Units (Details) - Restricted Stock, Restricted Stock Units, and Performance Stock Units [Member]
 3 Months Ended
Mar. 31, 2022
USD ($)
$ / shares
shares
Number of Shares & Units [Abstract]  
Outstanding, beginning of period (in shares) | shares 705,325
Granted (in shares) | shares 1,210,448
Vested (in shares) | shares 167,782
Forfeited (in shares) | shares 8,047
Outstanding, end of period (in shares) | shares 1,739,944
Weighted Average Grant Date Fair Value [Abstract]  
Outstanding, beginning of period (in dollars per share) | $ / shares $ 3.34
Granted (in dollars per share) | $ / shares 0.76
Vested (in dollars per share) | $ / shares 3.60
Forfeited (in dollars per share) | $ / shares 2.31
Outstanding, end of period (in dollars per share) | $ / shares $ 1.52
Net unrecognized compensation cost | $ $ 2,120,646
Weighted average period for recognition of net unrecognized compensation cost 2 years 6 months
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.1
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Details)
 3 Months Ended
Mar. 31, 2022
USD ($)
Segment
Group
Mar. 31, 2021
USD ($)
Dec. 31, 2021
USD ($)
GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY [Abstract]      
Number of groups of similar products | Group 1    
Number of operating segments | Segment 1    
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue $ 18,816,611 $ 8,724,359  
Geographic Areas, Long-Lived Assets [Abstract]      
Property, plant and equipment, net 8,414,313   $ 8,556,773
Net Product Revenue [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 18,527,456 4,024,662  
Africa [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 767,352 1,344,858  
Africa [Member] | Net Product Revenue [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 767,352 1,344,858  
Asia [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 15,558 216,954  
Geographic Areas, Long-Lived Assets [Abstract]      
Property, plant and equipment, net 85,351   86,041
Asia [Member] | Net Product Revenue [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 15,558 216,954  
Europe & Middle East [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 723,745 2,600,274  
Geographic Areas, Long-Lived Assets [Abstract]      
Property, plant and equipment, net 101,231   113,883
Europe & Middle East [Member] | Net Product Revenue [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 717,908 1,493,734  
Latin America [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 12,557,390 258,019  
Geographic Areas, Long-Lived Assets [Abstract]      
Property, plant and equipment, net 58,685   36,224
Latin America [Member] | Net Product Revenue [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 12,545,054 258,019  
United States [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue 4,752,566 4,304,254  
Geographic Areas, Long-Lived Assets [Abstract]      
Property, plant and equipment, net 8,169,046   $ 8,320,625
United States [Member] | Net Product Revenue [Member]      
Geographic Areas, Revenues from External Customers [Abstract]      
Net product revenue $ 4,481,584 $ 711,097  
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.1
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) - USD ($)
Mar. 31, 2022
Dec. 31, 2021
ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract]    
Accounts payable - suppliers $ 5,622,558 $ 7,745,592
Accrued commissions and royalties 1,510,865 1,359,691
Accrued payroll 494,653 494,258
Accrued vacation 657,008 421,416
Accrued bonuses 544,567 1,378,706
Accrued professional fees 893,745 522,935
Accrued expenses - other 819,455 1,205,395
TOTAL $ 10,542,851 $ 13,127,993
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.22.1
GOODWILL AND INTANGIBLE ASSETS (Details)
 3 Months Ended
Mar. 31, 2022
USD ($)
Segment
Unit
Goodwill [Roll Forward]  
Goodwill, Beginning balance $ 3,022,787
Impairment (3,033,565)
Changes in foreign currency exchange rate 10,778
Goodwill, Ending balance $ 0
Number of operating segment | Segment 1
Number of reporting unit | Unit 1
XML 53 brhc10037126_10q_htm.xml IDEA: XBRL DOCUMENT 0001092662 2022-01-01 2022-03-31 0001092662 2022-04-29 0001092662 2022-03-31 0001092662 2021-12-31 0001092662 cemi:ResearchAndDevelopmentRevenueMember 2021-01-01 2021-03-31 0001092662 us-gaap:LicenseMember 2021-01-01 2021-03-31 0001092662 us-gaap:ProductMember 2021-01-01 2021-03-31 0001092662 us-gaap:GrantMember 2022-01-01 2022-03-31 0001092662 us-gaap:GrantMember 2021-01-01 2021-03-31 0001092662 us-gaap:ProductMember 2022-01-01 2022-03-31 0001092662 2021-01-01 2021-03-31 0001092662 us-gaap:LicenseMember 2022-01-01 2022-03-31 0001092662 cemi:ResearchAndDevelopmentRevenueMember 2022-01-01 2022-03-31 0001092662 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001092662 2020-12-31 0001092662 us-gaap:RetainedEarningsMember 2021-12-31 0001092662 us-gaap:CommonStockMember 2021-12-31 0001092662 us-gaap:TreasuryStockMember 2020-12-31 0001092662 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001092662 us-gaap:RetainedEarningsMember 2020-12-31 0001092662 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001092662 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001092662 us-gaap:TreasuryStockMember 2021-12-31 0001092662 us-gaap:CommonStockMember 2020-12-31 0001092662 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001092662 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001092662 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001092662 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001092662 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001092662 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001092662 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001092662 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001092662 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001092662 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0001092662 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001092662 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001092662 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001092662 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001092662 us-gaap:RetainedEarningsMember 2021-03-31 0001092662 us-gaap:TreasuryStockMember 2022-03-31 0001092662 2021-03-31 0001092662 us-gaap:RetainedEarningsMember 2022-03-31 0001092662 us-gaap:CommonStockMember 2021-03-31 0001092662 us-gaap:CommonStockMember 2022-03-31 0001092662 us-gaap:TreasuryStockMember 2021-03-31 0001092662 srt:ScenarioForecastMember 2022-04-01 2023-03-31 0001092662 srt:ScenarioForecastMember 2021-07-01 2022-06-30 0001092662 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001092662 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2022-03-31 0001092662 us-gaap:FairValueInputsLevel2Member 2022-03-31 0001092662 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001092662 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001092662 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001092662 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001092662 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001092662 srt:LatinAmericaMember 2022-01-01 2022-03-31 0001092662 srt:AfricaMember 2021-01-01 2021-03-31 0001092662 cemi:EuropeMiddleEastMember 2021-01-01 2021-03-31 0001092662 us-gaap:GrantMember us-gaap:ExchangeTradedMember 2022-01-01 2022-03-31 0001092662 us-gaap:ProductMember us-gaap:OverTheCounterMember 2021-01-01 2021-03-31 0001092662 us-gaap:ProductMember us-gaap:ExchangeTradedMember 2022-01-01 2022-03-31 0001092662 us-gaap:ExchangeTradedMember 2022-01-01 2022-03-31 0001092662 cemi:EuropeMiddleEastMember 2022-01-01 2022-03-31 0001092662 us-gaap:GrantMember us-gaap:OverTheCounterMember 2021-01-01 2021-03-31 0001092662 us-gaap:LicenseMember us-gaap:OverTheCounterMember 2022-01-01 2022-03-31 0001092662 country:US 2021-01-01 2021-03-31 0001092662 cemi:ResearchAndDevelopmentRevenueMember us-gaap:OverTheCounterMember 2021-01-01 2021-03-31 0001092662 cemi:ResearchAndDevelopmentRevenueMember us-gaap:ExchangeTradedMember 2021-01-01 2021-03-31 0001092662 us-gaap:ProductMember us-gaap:OverTheCounterMember 2022-01-01 2022-03-31 0001092662 us-gaap:ProductMember us-gaap:ExchangeTradedMember 2021-01-01 2021-03-31 0001092662 srt:AsiaMember 2022-01-01 2022-03-31 0001092662 us-gaap:ExchangeTradedMember 2021-01-01 2021-03-31 0001092662 us-gaap:GrantMember us-gaap:OverTheCounterMember 2022-01-01 2022-03-31 0001092662 us-gaap:OverTheCounterMember 2022-01-01 2022-03-31 0001092662 cemi:ResearchAndDevelopmentRevenueMember us-gaap:OverTheCounterMember 2022-01-01 2022-03-31 0001092662 srt:LatinAmericaMember 2021-01-01 2021-03-31 0001092662 us-gaap:LicenseMember us-gaap:ExchangeTradedMember 2022-01-01 2022-03-31 0001092662 us-gaap:LicenseMember us-gaap:OverTheCounterMember 2021-01-01 2021-03-31 0001092662 srt:AfricaMember 2022-01-01 2022-03-31 0001092662 us-gaap:OverTheCounterMember 2021-01-01 2021-03-31 0001092662 srt:AsiaMember 2021-01-01 2021-03-31 0001092662 us-gaap:LicenseMember us-gaap:ExchangeTradedMember 2021-01-01 2021-03-31 0001092662 us-gaap:GrantMember us-gaap:ExchangeTradedMember 2021-01-01 2021-03-31 0001092662 cemi:ResearchAndDevelopmentRevenueMember us-gaap:ExchangeTradedMember 2022-01-01 2022-03-31 0001092662 country:US 2022-01-01 2022-03-31 0001092662 cemi:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001092662 cemi:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-03-31 0001092662 cemi:Supplier1Member us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001092662 cemi:Supplier2Member us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2022-01-01 2022-03-31 0001092662 cemi:Supplier2Member us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-03-31 0001092662 cemi:Supplier1Member us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-03-31 0001092662 cemi:Customer1Member us-gaap:CustomerConcentrationRiskMember 2021-12-31 0001092662 cemi:Customer1Member us-gaap:CustomerConcentrationRiskMember 2022-03-31 0001092662 cemi:Supplier2Member us-gaap:SupplierConcentrationRiskMember 2021-12-31 0001092662 cemi:Supplier1Member us-gaap:SupplierConcentrationRiskMember 2022-03-31 0001092662 cemi:Supplier1Member us-gaap:SupplierConcentrationRiskMember 2021-12-31 0001092662 cemi:Supplier2Member us-gaap:SupplierConcentrationRiskMember 2022-03-31 0001092662 srt:MaximumMember 2022-01-01 2022-03-31 0001092662 2020-01-01 2020-12-31 0001092662 2021-03-19 2021-03-19 0001092662 2020-01-03 2020-01-03 0001092662 2020-01-03 0001092662 cemi:TermLoanCreditFacilityMember 2019-09-03 0001092662 cemi:TermLoanCreditFacilityMember 2019-09-03 2019-09-03 0001092662 cemi:TermLoanCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0001092662 cemi:TermLoanCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2019-09-03 2019-09-03 0001092662 cemi:TermLoanCreditFacilityMember 2022-03-31 0001092662 cemi:TermLoanCreditFacilityMember 2022-01-01 2022-03-31 0001092662 cemi:TermLoanCreditFacilityMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2019-09-03 2019-09-03 0001092662 cemi:TermLoanCreditFacilityMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2019-09-03 2019-09-03 0001092662 cemi:TermLoanCreditFacilityMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2019-09-03 2019-09-03 0001092662 us-gaap:EmployeeStockOptionMember cemi:OmnibusIncentivePlan2019Member 2021-06-25 0001092662 us-gaap:EmployeeStockOptionMember cemi:StockIncentivePlan2014Member 2014-06-19 0001092662 us-gaap:EmployeeStockOptionMember cemi:OmnibusIncentivePlan2019Member 2019-06-18 0001092662 us-gaap:EmployeeStockOptionMember cemi:OmnibusIncentivePlan2019Member 2021-06-25 2021-06-25 0001092662 us-gaap:EmployeeStockOptionMember cemi:StockIncentivePlan2014Member 2022-01-01 2022-03-31 0001092662 us-gaap:EmployeeStockOptionMember cemi:OmnibusIncentivePlan2019Member 2022-01-01 2022-03-31 0001092662 us-gaap:EmployeeStockOptionMember cemi:StockIncentivePlan2014Member 2022-03-31 0001092662 us-gaap:EmployeeStockOptionMember cemi:OmnibusIncentivePlan2019Member 2022-03-31 0001092662 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2021-01-01 2021-03-31 0001092662 us-gaap:CostOfSalesMember 2022-01-01 2022-03-31 0001092662 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001092662 us-gaap:CostOfSalesMember 2021-01-01 2021-03-31 0001092662 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001092662 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-03-31 0001092662 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001092662 us-gaap:EmployeeStockOptionMember 2021-12-31 0001092662 us-gaap:EmployeeStockOptionMember 2022-03-31 0001092662 us-gaap:EmployeeStockOptionMember cemi:StockIncentivePlan20142019Member 2022-03-31 0001092662 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001092662 cemi:RangeTwoMember 2022-01-01 2022-03-31 0001092662 cemi:RangeOneMember 2022-01-01 2022-03-31 0001092662 cemi:RangeThreeMember 2022-01-01 2022-03-31 0001092662 cemi:RangeFourMember 2022-01-01 2022-03-31 0001092662 cemi:RangeThreeMember 2022-03-31 0001092662 cemi:RangeTwoMember 2022-03-31 0001092662 cemi:RangeFourMember 2022-03-31 0001092662 cemi:RangeOneMember 2022-03-31 0001092662 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001092662 cemi:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember 2021-12-31 0001092662 cemi:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember 2022-01-01 2022-03-31 0001092662 cemi:RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember 2022-03-31 0001092662 us-gaap:ProductMember country:US 2022-01-01 2022-03-31 0001092662 us-gaap:ProductMember srt:AsiaMember 2021-01-01 2021-03-31 0001092662 us-gaap:ProductMember srt:LatinAmericaMember 2021-01-01 2021-03-31 0001092662 us-gaap:ProductMember cemi:EuropeMiddleEastMember 2022-01-01 2022-03-31 0001092662 us-gaap:ProductMember country:US 2021-01-01 2021-03-31 0001092662 us-gaap:ProductMember srt:AfricaMember 2022-01-01 2022-03-31 0001092662 us-gaap:ProductMember srt:AsiaMember 2022-01-01 2022-03-31 0001092662 us-gaap:ProductMember cemi:EuropeMiddleEastMember 2021-01-01 2021-03-31 0001092662 us-gaap:ProductMember srt:LatinAmericaMember 2022-01-01 2022-03-31 0001092662 us-gaap:ProductMember srt:AfricaMember 2021-01-01 2021-03-31 0001092662 country:US 2021-12-31 0001092662 srt:LatinAmericaMember 2022-03-31 0001092662 cemi:EuropeMiddleEastMember 2021-12-31 0001092662 cemi:EuropeMiddleEastMember 2022-03-31 0001092662 srt:LatinAmericaMember 2021-12-31 0001092662 srt:AsiaMember 2021-12-31 0001092662 srt:AsiaMember 2022-03-31 0001092662 country:US 2022-03-31 shares iso4217:USD iso4217:USD shares pure cemi:KeyEmployee cemi:Lawsuit cemi:Applicants cemi:Claim cemi:Group cemi:Segment cemi:Unit false --12-31 2022 Q1 0001092662 1 1 2022-12-31 10-Q true 2022-03-31 false 000-30379 Chembio Diagnostics, Inc. NV 88-0425691 555 Wireless Blvd. Hauppauge NY 11788 631 924-1135 Yes Yes Accelerated Filer true false false Common Stock, $0.01 par value CEMI NASDAQ 30221859 24399388 28772892 242981 243042 9879954 11441107 11844121 12920451 2097491 2096399 48220954 55230849 8414313 8556773 190526 191870 5693482 5891906 0 3022787 370940 358010 62890215 73252195 10542851 13127993 2100000 1200000 916524 886294 72203 68176 13631578 15282463 5733214 5976151 134955 139678 16855322 17589003 36355069 38987295 10000000 10000000 0 0 0 0 0.01 0.01 100000000 100000000 30269916 30104986 302699 301050 166483376 165772636 -139800154 -131009860 48057 48057 206554 206554 -244221 -592372 26535146 34264900 62890215 73252195 18527456 4024662 18173 1106639 0 3350000 270982 243058 18816611 8724359 15223861 3548441 1653706 2863338 6946271 6085067 3043179 83087 26867017 12579933 -8050406 -3855574 -733561 -712477 -8783967 -4568051 6327 -67888 -8790294 -4500163 -0.29 -0.29 -0.22 -0.22 30090045 30090045 20163386 20163386 -8790294 -4500163 348151 -455722 -8442143 -4955885 30104986 301050 165772636 -48057 -206554 -131009860 -592372 34264900 164930 1649 264437 0 0 0 0 266086 0 0 229563 0 0 0 0 229563 0 0 38514 0 0 0 0 38514 0 255254 0 0 0 255254 0 0 0 0 348151 348151 0 0 0 -8790294 0 -8790294 30269916 302699 166483376 -48057 -206554 -139800154 -244221 26535146 20223498 202235 124961514 -41141 -190093 -97106331 -90916 27776409 62197 622 58909 0 0 0 0 59531 0 0 309010 0 0 0 0 309010 0 0 115059 0 0 0 0 115059 0 211140 0 0 0 211140 0 0 0 0 -455722 -455722 0 0 0 -4500163 0 -4500163 20285695 202857 125425514 -41141 -190093 -101606494 -546638 23285146 20377703 8485683 23810426 14830243 360878 347871 4686 4944 -570672 -563885 -4368959 -7261260 0 4130 286544 1235038 -286544 -1239168 38514 115059 16930 14282 -55444 -129341 337443 -85579 -4373504 -8715348 28772892 23066301 24399388 14350953 -8790294 -4500163 598548 687227 750903 579789 0 -69941 -61 57735 3033565 0 -1561214 -906100 -1076330 2174225 387297 33955 -373275 -134480 -2585142 -1645796 0 -1202511 -4368959 -7261260 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 1 — DESCRIPTION OF BUSINESS:</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Chembio Diagnostics, Inc. (“Chembio”) and its subsidiaries (collectively with Chembio, the “Company”) develop and commercialize point-of-care diagnostic tests used for the rapid detection and diagnosis of infectious diseases, including sexually transmitted disease, insect vector and tropical disease, COVID-19 and other viral and bacterial infections, enabling expedited treatment.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">The Company’s product portfolio is based upon our proprietary DPP technology, a diagnostic platform that provides high-quality, cost-effective results in 15 to 20 minutes using fingertip blood, nasal swabs and other sample types. The DPP technology platform addresses the rapid diagnostic test market, which includes infectious diseases such as STIs and HIV, Gastroenterology and Women’s Health. Compared with traditional lateral flow technology, the DPP technology platform can provide:</div> <div> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div><span style="font-weight: normal;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="vertical-align: top; width: 18pt;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Enhanced sensitivity and specificity: This is achieved via the Company’s proprietary approach to separating the sample path from the buffer path, together with patent and other proprietary strategies, which differ significantly from traditional lateral flow test.</div> <span style="font-weight: normal;"> </span></td> </tr> </table> <div><span style="font-weight: normal;"> </span></div> <div><span style="font-weight: normal;"> </span></div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="vertical-align: top; width: 18pt;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Advanced multiplexing capabilities: Through advanced multiplexing, the DPP platform can detect and differentiate up to eight distinct test results from a single patient sample, which can deliver greater clinical value than other rapid tests currently on the market.</div> </td> </tr> </table> </div> <div><span style="font-weight: normal;"> </span></div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="vertical-align: top; width: 18pt;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">Objective results: For some diagnostic applications, the Company’s easy-to-use, highly portable, battery-operated DPP Micro Reader optical analyzers can report accurate results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still onsite. Objective results produced by the DPP Micro Reader can reduce the possibility of the types of human error that can be experienced in the visual interpretations required by many rapid tests.</div> </td> </tr> </table> </div> <div><span style="font-weight: normal;"> </span></div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company targets the market for rapid diagnostic test solutions for infectious diseases, which is driven by the high prevalence of infectious diseases globally, an increase in the geriatric population, growing demand for rapid test results, and advancements in multiplexing. The Company has a broad portfolio of infectious disease products, which prior to 2020 were focused principally on sexually transmitted disease and fever and tropical disease. In February 2020 the Company began the process of shifting substantially all of its resources to seek to leverage the DPP technology platform to address the acute and escalating need for diagnostic testing for COVID-19. The Company is continuing to pursue:</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-weight: normal; font-style: italic;"><br/> </span> </div> <div><span style="font-weight: normal; font-style: italic;"> </span></div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="vertical-align: top; width: 18pt;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: italic;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman';">an emergency use authorization (“EUA”), from the U.S. Food and Drug Administration (the “FDA”), as well as 510(k) clearance from the FDA, for the DPP SARS-CoV-2 Antigen test system;</span></div> </td> </tr> </table> </div> <div><span style="font-weight: normal; font-style: italic;"> </span></div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="vertical-align: top; width: 18pt;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: italic;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman';">an EUA from the FDA for the DPP Respiratory Antigen Panel; and</span></div> </td> </tr> </table> </div> <div><span style="font-weight: normal; font-style: italic;"> </span></div> <div><span style="font-weight: normal; font-style: italic;"> </span> <span style="font-weight: normal; font-style: italic;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt;"> </td> <td style="vertical-align: top; width: 18pt;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; font-style: italic;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"><span style="font-weight: normal; font-style: italic;"> </span> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; font-style: normal;"><span style="font-size: 10pt; font-family: 'Times New Roman';">a Clinical Laboratory Improvement Amendment (“CLIA”), waiver from the FDA for the DPP HIV-Syphilis test system.</span></div> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">N<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">OTE 2 — SIGNIFICANT ACCOUNTING POLICIES:</span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(a)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Basis of presentation:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements include the accounts of Chembio and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Certain reclassifications have been made to the unaudited condensed consolidated balance sheet of the prior year to conform to the current year presentation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Chembio’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <br/></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;">Going Concern Considerations</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">The Company continued to experience market, clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of COVID-19 test systems during the continuing, but evolving, uncertainty <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">resulting from </span>COVID‑19. For the three months ended March 31, 2022, the Company continued to incur significant expenses in connection with pending legal matters (see Note 6 – Commitments, Contingencies, and Concentrations: Litigation).</div> <div> </div> <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">The Company performed an assessment to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are being issued. Initially, this assessment did not consider the potential mitigating effect of management’s plans that had not been fully implemented. Because, as described below, substantial doubt was determined to exist as the result of this initial assessment, management then assessed the mitigating effect of its plans to determine if it is probable that the plans (1) would be effectively implemented within one year after the date the accompanying unaudited condensed consolidated financial statements are issued and (2) when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">Company’s </span>ability to continue as a going concern.</div> <div> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company achieved significant revenue growth in recent years while profitability has not been at levels as expected. It has taken steps including investments in automation to mitigate headwinds such as labor availability, volatile capacity planning and implementation of operational efficiency targets to proactively monitor production with the overarching goal for profitable growth. During the three months ended March 31, 2022, the Company undertook measures to increase its total revenues and improve its liquidity position by implementing the Global Competitiveness Program. The main pillars of the Global Competitiveness Program include the following:</div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Focus on higher margin business in growth markets</div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Lower manufacturing costs</div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Reduce infrastructure costs</div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Strategic review of non-core businesses and assets:</div> </td> </tr> </table> </div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In addition, the Company will continue to focus on regulatory approvals for its DPP SARS-CoV-2 Antigen test system, DPP Respiratory Antigen Panel, and DPP HIV-Syphilis test system. These measures and other plans and initiatives have been designed to provide the Company with adequate liquidity to meet its obligations for at least the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are being issued. The Company’s execution of those measures and its other plans and initiative continue to depend, however, on factors and uncertainties that are beyond the Company’s control, or that may not be addressable on terms acceptable to the Company or at all. The Company considered in particular how:</div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <div>The ongoing healthcare and economic impacts of COVID-19 on the global customer base for the Company’s non‑COVID-19 products continue to negatively affect the timing and rate of recovery of the Company’s revenues from those products by, for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect the Company’s liquidity. <br/> </div> </div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products.</div> </td> </tr> </table> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company further considered how these factors and uncertainties could impact its ability over the next year to meet the obligations specified in the Credit Agreement with the Lender (both as defined in Note 7 – Long-Term Debt). Those obligations include covenants requiring: i) minimum cash balance of $3.0 million and ii) minimum total revenue amounts for the twelve months preceding each quarter end. For the next year, the minimum total revenue requirements range from $43.8 million for the twelve months ending June 30, 2022 to $48.8 million for the twelve months ending March 31, 2023. Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that the Company would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement or that, if such liquidity were not available, the Company would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern. The Company’s inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for its operations, could have a material adverse effect on its business, prospects, results of operations, liquidity and financial condition.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Accordingly, management determined the Company could not be certain that the Company’s plans and initiatives would be effectively implemented within one year after the date on which the accompanying unaudited condensed consolidated financial statements are being issued. Without giving effect to the prospect of raising additional capital pursuant to the Company’s At the Market Offering Agreement dated July 19, 2021 with Chembio Diagnostics, Inc. and Craig-Hallum Capital Group LLC, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond the Company’s control, it is unlikely that the Company will be able to generate sufficient cash flows to meet its required financial obligations, including its debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited condensed consolidated financial statements are being issued.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are issued. As such, the accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(b)</td> <td style="width: auto; vertical-align: top; text-align: left;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Significant Accounting Policies:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">During the three months ended March 31, 2022, there has been no significant changes to the Company’s summary of significant accounting policies contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(c)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Fair Value of Financial Instruments:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate fair value due to the immediate or short-term maturity of these financial instruments. Included in cash and cash equivalents were $ 17.1 million and $25.0 million as of March 31, 2022 and December 31, 2021, respectively, of money market funds that are Level 1 fair value measurements under the hierarchy. The fair value of the Company’s total debt of $20.0 million (carrying value of $18.9 million) and $20.0 million (carrying value of $18.8 million) as of March 31, 2022 and December 31, 2021 respectively, is a Level 2 fair value measurement under the hierarchy and the Company’s debt face value approximates the recorded value, as the rate is based upon the current rates available to the Company for similar financial instruments.</span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Fair value measurements of all financial assets and liabilities that are measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.2pt;"><br/> </td> <td style="width: 51.85pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Level 1:</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"><br/> </td> <td style="width: 51.75pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Level 2:</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"><br/> </td> <td style="width: 51.75pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Level 3:</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(d)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Cash and Cash Equivalents:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents are defined as short-term, highly liquid investments, such as money market funds, with original maturities of three months or less at date of purchase.</span></div> <div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(e)</td> <td style="width: auto; vertical-align: top; text-align: left;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Loss Per Share:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period excluding unvested restricted stock. Diluted loss per share for the three months ended March 31, 2022 and 2021 reflects the potential dilution from the exercise or conversion of other securities into common stock, if dilutive.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">There were 3,760,787 and 1,848,286 options outstanding as of March 31, 2022 and 2021, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">There were 1,739,944 and 847,795 shares of restricted stock outstanding as of March 31, 2022 and 2020, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(f)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Income</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: bold;">Taxes:</span></span></div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">At the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis, and may change in subsequent interim periods. Accordingly, the Company’s effective tax rate for the three months ended March 31, 2022 was (0.1)%, compared to the effective tax rate of 1.6% for the three months ended March 31, 2021. The Company’s effective tax rates for both periods were affected primarily by a full valuation allowance on domestic net deferred tax assets.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(g)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Recently Issued Accounting Standards Affecting the Company:</span></div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Recently Adopted</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ASU 2021-10 - Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which creates Accounting Standards Codification (“ASC”) 832 and aims to provide increased transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. The disclosure requirements in ASC 832 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model (for example, in ASC 958-605, Not-for-Profit Entities – Revenue Recognition). The FASB broadly defined “government assistance” in ASC 832 to ensure that assistance received from most types of governmental entities or other related organizations would be disclosed.  Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The Company adopted the standard effective January 1, 2022 and has determined that the adoption did not have a material impact on the Company’s consolidated financial statements.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Not Yet Adopted</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ASU 2020-06 - Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity<br/> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On August 5, 2020, the FASB issued ASU 2020-06, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. ASU 2020-06 simplifies the guidance in GAAP on the issuer’s accounting for convertible debt instruments, requires entities to provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance. The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ASU 2021-08—Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">  </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On October 28, 2021, the FASB issued ASU 2021-08,1 which amends ASC 805 to “require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination.” Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. ASU 2021-08 amends ASC 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to “require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606.” While primarily related to contract assets and contract liabilities that were accounted for by the acquiree in accordance with ASC 606, “the amendments also apply to contract assets and contract liabilities from other contracts to which the provisions of Topic 606 apply, such as contract liabilities from the sale of nonfinancial assets within the scope of Subtopic 610-20.” The ASU’s amendments are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"><br/> </span> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(a)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Basis of presentation:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The accompanying unaudited condensed consolidated financial statements include the accounts of Chembio and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Certain reclassifications have been made to the unaudited condensed consolidated balance sheet of the prior year to conform to the current year presentation. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in Chembio’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as filed with the SEC.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <br/></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: italic; font-variant: normal; text-transform: none;">Going Concern Considerations</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">The Company continued to experience market, clinical trial and regulatory complications in seeking to develop and commercialize a portfolio of COVID-19 test systems during the continuing, but evolving, uncertainty <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">resulting from </span>COVID‑19. For the three months ended March 31, 2022, the Company continued to incur significant expenses in connection with pending legal matters (see Note 6 – Commitments, Contingencies, and Concentrations: Litigation).</div> <div> </div> <div style="text-align: justify; font-family: 'Times New Roman', serif; font-size: 10pt;">The Company performed an assessment to determine whether there were conditions or events that, considered in the aggregate, raised substantial doubt about the Company’s ability to continue as a going concern within one year after the date the accompanying unaudited condensed consolidated financial statements are being issued. Initially, this assessment did not consider the potential mitigating effect of management’s plans that had not been fully implemented. Because, as described below, substantial doubt was determined to exist as the result of this initial assessment, management then assessed the mitigating effect of its plans to determine if it is probable that the plans (1) would be effectively implemented within one year after the date the accompanying unaudited condensed consolidated financial statements are issued and (2) when implemented, would mitigate the relevant conditions or events that raise substantial doubt about the <span style="font-family: 'Times New Roman', serif; font-size: 10pt;">Company’s </span>ability to continue as a going concern.</div> <div> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company achieved significant revenue growth in recent years while profitability has not been at levels as expected. It has taken steps including investments in automation to mitigate headwinds such as labor availability, volatile capacity planning and implementation of operational efficiency targets to proactively monitor production with the overarching goal for profitable growth. During the three months ended March 31, 2022, the Company undertook measures to increase its total revenues and improve its liquidity position by implementing the Global Competitiveness Program. The main pillars of the Global Competitiveness Program include the following:</div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Focus on higher margin business in growth markets</div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Lower manufacturing costs</div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Reduce infrastructure costs</div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Strategic review of non-core businesses and assets:</div> </td> </tr> </table> </div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In addition, the Company will continue to focus on regulatory approvals for its DPP SARS-CoV-2 Antigen test system, DPP Respiratory Antigen Panel, and DPP HIV-Syphilis test system. These measures and other plans and initiatives have been designed to provide the Company with adequate liquidity to meet its obligations for at least the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are being issued. The Company’s execution of those measures and its other plans and initiative continue to depend, however, on factors and uncertainties that are beyond the Company’s control, or that may not be addressable on terms acceptable to the Company or at all. The Company considered in particular how:</div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <div>The ongoing healthcare and economic impacts of COVID-19 on the global customer base for the Company’s non‑COVID-19 products continue to negatively affect the timing and rate of recovery of the Company’s revenues from those products by, for example, decreasing the allocation of funding for HIV testing, thereby continuing to adversely affect the Company’s liquidity. <br/> </div> </div> </td> </tr> </table> </div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="width: 18pt; vertical-align: top;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">•</div> </td> <td style="width: auto; vertical-align: top; align: left;"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Although the Company has entered into agreements to distribute third-party COVID-19 products in the United States, its ability to sell those products could be constrained because of staffing and supply chain limitations affecting the suppliers of those products.</div> </td> </tr> </table> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company further considered how these factors and uncertainties could impact its ability over the next year to meet the obligations specified in the Credit Agreement with the Lender (both as defined in Note 7 – Long-Term Debt). Those obligations include covenants requiring: i) minimum cash balance of $3.0 million and ii) minimum total revenue amounts for the twelve months preceding each quarter end. For the next year, the minimum total revenue requirements range from $43.8 million for the twelve months ending June 30, 2022 to $48.8 million for the twelve months ending March 31, 2023. Upon an event of default under the Credit Agreement, the Lender could elect to declare all amounts outstanding thereunder, together with accrued interest, to be immediately due and payable. In such an event, there can be no assurance that the Company would have sufficient liquidity to fund payment of the amounts that would be due under the Credit Agreement or that, if such liquidity were not available, the Company would be successful in raising additional capital on acceptable terms, or at all, or in completing any other endeavor to continue to be financially viable and continue as a going concern. The Company’s inability to raise additional capital on acceptable terms in the near future, whether for purposes of funding payments required under the Credit Agreement or providing additional liquidity needed for its operations, could have a material adverse effect on its business, prospects, results of operations, liquidity and financial condition.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Accordingly, management determined the Company could not be certain that the Company’s plans and initiatives would be effectively implemented within one year after the date on which the accompanying unaudited condensed consolidated financial statements are being issued. Without giving effect to the prospect of raising additional capital pursuant to the Company’s At the Market Offering Agreement dated July 19, 2021 with Chembio Diagnostics, Inc. and Craig-Hallum Capital Group LLC, increasing product revenue in the near future or executing other mitigating plans, many of which are beyond the Company’s control, it is unlikely that the Company will be able to generate sufficient cash flows to meet its required financial obligations, including its debt service and other obligations due to third parties. The existence of these conditions raises substantial doubt about the Company’s ability to continue as a going concern for the twelve-month period following the date on which the accompanying unaudited condensed consolidated financial statements are being issued.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates continuity of operations, realization of assets and the satisfaction of liabilities in the normal course of business for the twelve-month period following the date the accompanying unaudited condensed consolidated financial statements are issued. As such, the accompanying unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amount and classification of liabilities that may result should the Company be unable to continue as a going concern.</div> 43800000 48800000 <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(c)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Fair Value of Financial Instruments:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The carrying values for cash and cash equivalents, accounts receivable, accounts payable and accrued expenses and other current liabilities approximate fair value due to the immediate or short-term maturity of these financial instruments. Included in cash and cash equivalents were $ 17.1 million and $25.0 million as of March 31, 2022 and December 31, 2021, respectively, of money market funds that are Level 1 fair value measurements under the hierarchy. The fair value of the Company’s total debt of $20.0 million (carrying value of $18.9 million) and $20.0 million (carrying value of $18.8 million) as of March 31, 2022 and December 31, 2021 respectively, is a Level 2 fair value measurement under the hierarchy and the Company’s debt face value approximates the recorded value, as the rate is based upon the current rates available to the Company for similar financial instruments.</span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Fair value measurements of all financial assets and liabilities that are measured and reported on a fair value basis are required to be classified and disclosed in one of the following three categories:</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.2pt;"><br/> </td> <td style="width: 51.85pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Level 1:</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"><br/> </td> <td style="width: 51.75pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Level 2:</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and,</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"><br/> </td> <td style="width: 51.75pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Level 3:</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</div> </td> </tr> </table> 17100000 25000000.0 20000000.0 18900000 20000000.0 18800000 <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(d)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Cash and Cash Equivalents:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Cash and cash equivalents are defined as short-term, highly liquid investments, such as money market funds, with original maturities of three months or less at date of purchase.</span></div> <div> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 18pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(e)</td> <td style="width: auto; vertical-align: top; text-align: left;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Loss Per Share:</div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Basic loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period excluding unvested restricted stock. Diluted loss per share for the three months ended March 31, 2022 and 2021 reflects the potential dilution from the exercise or conversion of other securities into common stock, if dilutive.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">There were 3,760,787 and 1,848,286 options outstanding as of March 31, 2022 and 2021, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">There were 1,739,944 and 847,795 shares of restricted stock outstanding as of March 31, 2022 and 2020, respectively, that were not included in the calculation of diluted per common share equivalents for the three months ended March 31, 2022 and 2021, respectively, because the effect would have been anti-dilutive.</div> 3760787 1848286 1739944 847795 <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(f)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"><span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Income</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> <span style="font-weight: bold;">Taxes:</span></span></div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">At the end of each interim reporting period, the Company estimates its effective tax rate expected to be applied for the full year. This estimate is used to determine the income tax provision or benefit on a year-to-date basis, and may change in subsequent interim periods. Accordingly, the Company’s effective tax rate for the three months ended March 31, 2022 was (0.1)%, compared to the effective tax rate of 1.6% for the three months ended March 31, 2021. The Company’s effective tax rates for both periods were affected primarily by a full valuation allowance on domestic net deferred tax assets.</div> 0.001 0.016 <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt; font-style: italic;"><br/> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">(g)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Recently Issued Accounting Standards Affecting the Company:</span></div> </td> </tr> </table> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Recently Adopted</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ASU 2021-10 - Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance</span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">In November 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance, which creates Accounting Standards Codification (“ASC”) 832 and aims to provide increased transparency by requiring business entities to disclose information about certain types of government assistance they receive in the notes to the financial statements. The disclosure requirements in ASC 832 only apply to transactions with a government that are accounted for by analogizing to either a grant model (for example, in International Accounting Standard 20, Accounting for Government Grants and Disclosure of Government Assistance), or a contribution model (for example, in ASC 958-605, Not-for-Profit Entities – Revenue Recognition). The FASB broadly defined “government assistance” in ASC 832 to ensure that assistance received from most types of governmental entities or other related organizations would be disclosed.  Entities are required to provide the new disclosures prospectively for all transactions with a government entity that are accounted for under either a grant or a contribution accounting model and are reflected in the financial statements at the date of initially applying the new amendments, and to new transactions entered into after that date. Retrospective application of the guidance is permitted. The Company adopted the standard effective January 1, 2022 and has determined that the adoption did not have a material impact on the Company’s consolidated financial statements.</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Not Yet Adopted</div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ASU 2020-06 - Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity<br/> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/> </span> </div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On August 5, 2020, the FASB issued ASU 2020-06, which simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU is part of the FASB’s simplification initiative, which aims to reduce unnecessary complexity in GAAP. ASU 2020-06 simplifies the guidance in GAAP on the issuer’s accounting for convertible debt instruments, requires entities to provide expanded disclosures about “the terms and features of convertible instruments” and how the instruments have been reported in the entity’s financial statements. It also removes from ASC 815-40-25-10 certain conditions for equity classification and amends certain guidance in ASC 260 on the computation of EPS for convertible instruments and contracts on an entity’s own equity. An entity can use either a full or modified retrospective approach to adopt the ASU’s guidance. The ASU’s amendments are effective for smaller public business entities fiscal years beginning after December 15, 2023. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">ASU 2021-08—Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span></div> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">  </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On October 28, 2021, the FASB issued ASU 2021-08,1 which amends ASC 805 to “require acquiring entities to apply Topic 606 to recognize and measure contract assets and contract liabilities in a business combination.” Under current GAAP, an acquirer generally recognizes such items at fair value on the acquisition date. ASU 2021-08 amends ASC 805 to add contract assets and contract liabilities to the list of exceptions to the recognition and measurement principles that apply to business combinations and to “require that an entity (acquirer) recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Topic 606.” While primarily related to contract assets and contract liabilities that were accounted for by the acquiree in accordance with ASC 606, “the amendments also apply to contract assets and contract liabilities from other contracts to which the provisions of Topic 606 apply, such as contract liabilities from the sale of nonfinancial assets within the scope of Subtopic 610-20.” The ASU’s amendments are effective for public business entities for the fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The amendments should be applied prospectively to business combinations occurring on or after the effective date of the amendments. The Company continues to assess the potential impact of the standard and will disclose the nature and reason for any elections that the Company makes.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 3 — REVENUE:</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Disaggregation of Revenue</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The following table disaggregates Total Revenues by revenue type:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">March 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exchange</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Transactions</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Non-Exchange</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Transactions</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Exchange</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Transactions</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Non-Exchange</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Transactions</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Net product revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,527,456</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,527,456</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,024,662</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,024,662</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">R&amp;D Revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,173</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,173</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,106,639</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,106,639</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Government grant revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,350,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,350,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">License and royalty revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">270,982</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">270,982</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">243,058</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">243,058</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,816,611</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,816,611</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,374,359</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,350,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,724,359</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Exchange transactions are recognized in accordance with ASC 606, while non-exchange transactions are recognized in accordance with ASU No. 2018-08.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table disaggregates Total Revenues by geographic location:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three months ended</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">March 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Africa</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">767,352</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,344,858</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Asia</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">15,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">216,954</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Europe &amp; Middle East</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">723,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,600,274</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Latin America</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">12,557,390</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">258,019</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">United States</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4,752,566</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,304,254</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">18,816,611</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,724,359</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The following table disaggregates Total Revenues by revenue type:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">March 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exchange</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Transactions</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Non-Exchange</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Transactions</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Exchange</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Transactions</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Non-Exchange</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Transactions</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Net product revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,527,456</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,527,456</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,024,662</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,024,662</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">R&amp;D Revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,173</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,173</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,106,639</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,106,639</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Government grant revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">–</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,350,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,350,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">License and royalty revenue</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">270,982</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">270,982</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">243,058</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">243,058</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,816,611</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">18,816,611</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,374,359</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,350,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,724,359</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table disaggregates Total Revenues by geographic location:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three months ended</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">March 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Africa</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">767,352</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,344,858</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Asia</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">15,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">216,954</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Europe &amp; Middle East</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">723,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,600,274</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Latin America</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">12,557,390</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">258,019</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">United States</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4,752,566</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,304,254</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">18,816,611</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,724,359</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 18527456 0 18527456 4024662 0 4024662 18173 0 18173 1106639 0 1106639 0 0 0 0 3350000 3350000 270982 0 270982 243058 0 243058 18816611 0 18816611 5374359 3350000 8724359 767352 1344858 15558 216954 723745 2600274 12557390 258019 4752566 4304254 18816611 8724359 <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 4 — INVENTORY:</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Inventories are presented net of reserves and consist of the following at:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31,<br/> 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">December 31,</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Raw materials</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">7,197,257</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,306,095</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Work in process</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1,932,069</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,556,878</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finished goods</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2,714,795</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,057,478</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">11,844,121</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">12,920,451</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Inventories are presented net of reserves and consist of the following at:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31,<br/> 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">December 31,</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Raw materials</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">7,197,257</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,306,095</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Work in process</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1,932,069</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,556,878</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finished goods</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2,714,795</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,057,478</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">11,844,121</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">12,920,451</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 7197257 7306095 1932069 3556878 2714795 2057478 11844121 12920451 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 5 — STOCKHOLDERS’ EQUITY:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"/> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(a)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Common Stock</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">During the </span>first three months of 2022 and 2021, there were no options exercised. </div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"/> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(b)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Preferred Stock</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Chembio has </span>10,000,000<span style="font-size: 10pt; font-family: 'Times New Roman';"> shares of preferred stock authorized and </span>none<span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>outstanding. These shares can become issuable upon an approved resolution by the board of directors of Chembio (the “Board”) and the filing of a Certificate of Designation with the state of Nevada.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"> </td> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(c)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Treasury Stock</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Chembio has 48,057 shares of treasury stock acquired upon the vesting of restricted stock awards related to the tax withholding requirements paid on behalf of the employees.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"/> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(d)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Options, Restricted Stock, and Restricted Stock Units<br/> </div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The </span>Board or its Compensation Committee may issue options, restricted stock, and restricted stock units pursuant to equity incentive plans that have been approved by Chembio’s<span style="font-size: 10pt; font-family: 'Times New Roman';"> stockholders.</span></div> 0 0 10000000 0 48057 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 6 — COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"/> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">a)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Concentrations:</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company’s net product sales for the periods indicated:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; text-indent: -27pt; margin-left: 27pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="14" rowspan="1" style="vertical-align: top; text-align: center; text-indent: -27pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; text-align: center;">For the three months ended</div> </td> <td colspan="1" rowspan="1" style="text-indent: -27pt; margin-left: 27pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: top; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="font-weight: bold;"> Accounts Receivable as of<br/> </div> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2021 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December<br/> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">31, 2021</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); text-align: center;">Product </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); text-align: center;">Sales</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">% of </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Product </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Sales</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); text-align: center;">Product </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); text-align: center;">Sales</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">% of </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Product </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Sales</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Customer 1</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">11,856,024</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">64</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"><span style="-sec-ix-hidden:Fact_0226cc4d972f48848e9057ed3e7eb738">*</span></td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_05d719468636475dbc07007117b94ff5">*</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">5,930,162</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,672,845</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Revenue includes product sales only, while accounts receivable reflects the total due from the customer, including freight.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table discloses purchases the Company had to each vendor that purchased in excess of 10% of the Company’s net purchases for the periods indicated:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three months ended</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Accounts Payable as of</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2021 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December <br/> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">31, 2021</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">% of </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">% of </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Vendor 1</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,323,605</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">34</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_1a9e8f49619e486c8c21ad677e5efd36">*</span><br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><span style="-sec-ix-hidden:Fact_2c75ac3484f5434da6384ab955c8c4d1">*</span><br/> </div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">224,500</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><span style="-sec-ix-hidden:Fact_5985b6b8f25443aab6ef761d2dd0ed82">*</span><br/> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Vendor 2</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,088,251<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">16</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">469,635<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">11</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">164,983<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">353,097<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In the tables above, an asterisk (*) indicates that indicates that sales, accounts receivable, purchases or accounts payable, as applicable to the tabular column, did not exceed 10% for the period indicated.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company purchases materials pursuant to intellectual property rights agreements that are important components in its products.  Management believes that other suppliers could provide similar materials on comparable terms.  A change in suppliers, however, could cause a delay in manufacturing and a possible loss of sales, which could adversely affect operating results.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"> <br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt;"/> <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">b)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Employment Contracts:</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company has multi-year contracts with three key employees. The contracts call for salaries presently aggregating $1,178,000 per year. The contracts expire in <span style="-sec-ix-hidden:Fact_3339d534b71d45f994239fecaa409c2e">December 2022</span> and December 31, 2024. <span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table is a schedule of future minimum salary commitments:</span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; margin-left: 0px; margin-right: auto; width: 100%;"> <tr> <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">2022</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">883,500</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 88%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">2023</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">383,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">2024</div> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">383,000</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 22.5pt;"/> <td style="width: 22.5pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">c)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Benefit Plan:</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Chembio has a 401(k) plan established for the Company’s employees whereby it matches 40% of the first 5% of salary (or up to 2% of salary) that an employee contributes to the plan. Matching contribution expenses totaled approximately $67,135 and $35,456 for the three months ended March 31, 2022 and 2021, respectively.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 20.25pt;"/> <td style="width: 27pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">d)</td> <td style="width: auto; vertical-align: top; text-align: justify;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Leases:</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The </span>Company leases facilities in New York, Germany, Malaysia, and Brazil, and certain equipment.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company’s facility leases generally include optional renewal periods. Upon entering into a new facility lease, the Company evaluates the leasehold improvements and regulatory requirements related to its operations in that location. To the extent that the initial lease term of the related facility lease is less than the useful life of the leasehold improvements and potential regulatory costs associated with moving the facility, the Company concludes that it is reasonably certain that a renewal option will be exercised, and thus that renewal period is included in the lease term and the related payments are reflected in the right-of-use asset and lease liability.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company’s leases generally include fixed rental payments with defined annual increases. While certain of the Company’s leases are gross leases, the majority of the Company’s leases are net leases in which the Company makes separate payments to the lessor based on the lessor’s property and casualty insurance costs, the property taxes assessed on the property, and a portion of the common area maintenance where applicable. The Company has elected the practical expedient not to separate lease and non-lease components for all of the Company’s facility leases.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The components of lease expense were as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Three Months Ended</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating lease expense</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">403,385</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">408,466</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance lease cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Amortization of right-of-use assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">17,579</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">15,758</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Interest on lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,944</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Total finance lease expense</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">22,265</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">20,702</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Supplemental cash flow information related to leases was as follows.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Three Months Ended</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for amounts included in the measurement of lease liabilities:</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating cash flows for operating leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">360,878</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">347,871</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating cash flows for finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,944</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Financing cash flows for finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">16,930</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">14,282</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Right-of-use assets obtained in exchange for lease obligations:</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">16,234</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Supplemental balance sheet information related to leases was as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; text-indent: -7pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">March 31, 2021</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Finance Leases</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance lease right of use asset</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">356,997</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">315,153</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accumulated depreciation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">(166,471</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">(97,777</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance lease right of use asset, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">190,526</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">217,376</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted Average Remaining Lease Term</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating leases</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">7.4 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">8.6</span> years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2.8 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: right; text-indent: -7pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">3.5</span> years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted Average Discount Rate</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9.32</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9.30</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.56</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.18</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Maturities of lease liabilities were as follows.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Operating</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Finance</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Operating</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Finance</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2022</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,086,370</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">65,913</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">861,916</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">57,678</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2023</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,221,017</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">87,884</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,057,757</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">76,904</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2024</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,018,875</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">60,116</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,026,272</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">76,904</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2025</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,049,442</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">16,731</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,018,875</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">49,136</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2026</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,080,925</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,940</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,049,442</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,751</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Thereafter</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,643,521</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">355</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,724,446</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Total lease payments</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,100,150</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">236,939</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,738,708</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">266,373</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Less: imputed interest</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,450,412</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">29,781</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,968,703</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">36,544</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">6,649,738</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">207,158</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">6,770,005</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">229,829</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 27pt;"/> <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">e)</td> <td style="width: auto; vertical-align: top; text-align: left;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Litigation:</div> </td> </tr> </table> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;">SEC Investigation</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: left;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The SEC is conducting a non-public, fact-finding investigation relating to the public offering of common stock that Chembio completed in May 2020 (the “May 2020 Offering”) and to the FDA’s revocation in June 2020 of an emergency use authorization for the DPP COVID-19 IgM/IgG system that was issued by the FDA in April 2020. Chembio received subpoenas from the SEC in July 2020 and April 2021 seeking the production of documents in connection with this investigation. In addition, the SEC delivered subpoenas in April 2021 to five of Chembio’s employees (including its three executive officers, who consist of its Chief Executive Officer and President, its former Executive Vice President and Chief Financial Officer, and its Executive Vice President and Chief Scientific and Technology Officer). An additional subpoena was issued in June 2021 to Chembio’s former Interim Chief Executive Officer and Executive Chair. Each subpoena requested the production of documents relating to the same matters as are the subject of the subpoenas Chembio received. Chembio and the six individuals are cooperating fully in the SEC’s investigation and expect to continue to do so.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The SEC’s letters transmitting the subpoenas expressly provide that the inquiry does not mean that the SEC or its staff have concluded that anyone has violated the federal securities laws or have a negative opinion of any person, entity or security. The Company cannot predict the scope, duration or outcome of the investigation or the impact, if any, of the investigation on its results of operations.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; text-align: justify;">Legal Proceedings</div> <div><br/> </div> <div style="display:none;"><br/></div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify; text-indent: 36pt;"><span style="text-decoration: underline;">Stockholder Litigation</span></div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic; text-align: left;">Putative Stockholder Securities Class-Action Litigation</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In 2020 four purported securities class-action lawsuits were filed in the United States District Court for the Eastern District of New York by alleged stockholders of Chembio:</div> <div><br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 18pt;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Sergey Chernysh v. Chembio Diagnostics, Inc., Richard L. Eberly, and Gail S. Page, filed on June 18, 2020;</div> </td> </tr> </table> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 18pt;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">James Gowen v. Chembio Diagnostics, Inc., Richard L. Eberly, and Gail S. Page, filed on June 22, 2020;</div> </td> </tr> </table> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 18pt;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Anthony Bailey v. Chembio Diagnostics, Inc. Richard J. Eberly, Gail S. Page, and Neil A. Goldman, filed on July 3, 2020; and;</div> </td> </tr> </table> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"> <tr style="vertical-align: top;"> <td style="vertical-align: top; width: 18pt;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">•</div> </td> <td style="align: left; vertical-align: top; width: auto;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P., and Special Situations Private Equity Fund, L.P. v. Chembio Diagnostics, Inc., Richard Eberly, Gail S. Page, Robert W. Baird &amp; Co. Inc. and Dougherty &amp; Company LLC, filed August 17, 2020.</div> </td> </tr> </table> </div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The plaintiffs in each of the above cases alleged claims under Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”), Rule 10b-5 thereunder and Section 20(a) of the Exchange Act. Special Situations Fund III QP, L.P., Special Situations Cayman Fund, L.P. and Special Situations Private Equity Fund, L.P. (collectively, the “Special Situations Funds”) also asserted claims under Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 (the “Securities Act”) relating to the May 2020 Offering.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Chembio and the plaintiffs entered into Court-approved stipulations relieving Chembio and the other defendants of the obligation to respond to the complaints in these cases pending the designation of a lead plaintiff pursuant to the Private Securities Litigation Reform Act of 1995. Eight motions for appointment as lead plaintiff were filed by various prospective lead plaintiffs. However, all but two of these motions were withdrawn or otherwise abandoned, leaving before the Court two motions for appointment as lead plaintiff - one filed by the Special Situations Funds and one by Municipal Employees’ Retirement System of Michigan. By order entered December 29, 2020, Magistrate Judge Lindsay consolidated the cases and appointed the Special Situations Funds and Municipal Employees’ Retirement System of Michigan (together, the “Lead Plaintiffs”), as co-lead plaintiffs and their respective counsel as co-lead counsel. The consolidated cases are now pending under the caption “In re Chembio Diagnostics, Inc. Securities Litigation.”</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Lead Plaintiffs filed their Consolidated Amended Complaint (the “CAC”) on February 12, 2021. In summary, the CAC purported to allege claims based on assertedly false and misleading statements and omissions concerning the performance of the DPP COVID-19 IgM/IgG System, as well as an asserted failure to timely disclose that the emergency use authorization that had been granted by the FDA with respect to the DPP COVID-19 IgM/IgG System “was - or was at an increased risk of - being revoked.” The CAC named as defendants Chembio, Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan, John Potthoff (together, the “Chembio Defendants”) and the underwriters for the May 2020 Offering, Robert W. Baird &amp; Co., Inc. and Dougherty &amp; Company LLC (the “Underwriter Defendants”).</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The CAC purported to assert five counts under the Securities Act and the Exchange Act. Counts I through III were brought under the Securities Act, allegedly on behalf of a purported class consisting of all persons who purchased Chembio common stock directly in or traceable to the May 2020 Offering pursuant to Chembio’s shelf registration statement on Form S 3 (File No. 333-227398) and the related prospectus, as supplemented by a prospectus supplement dated May 7, 2020 (the “Securities Act Class”). Count I purported to allege a claim for violation of Section 11 of the Securities Act against all defendants other than Messrs. Eberly and Esfandiari. Count II purported to allege a claim for violation of Section 12 of the Securities Act against all defendants other than Messrs. Eberly and Esfandiari. Count III purported to allege a claim under Section 15 of the Securities Act against Ms. Davis, Dr. Polan, Dr. Potthoff, Ms. Page and Mr. Goldman.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Counts IV and V alleged claims under the Exchange Act on behalf of a purported class consisting of all persons who purchased Chembio common stock on the open market from March 12, 2020 through June 16, 2020 (the “Exchange Act Class”). Count IV purported to allege a claim for violation of Section 10(b) of the Exchange Act and Rule 10b-5 thereunder against Chembio, Mr. Eberly, Ms. Page, Mr. Goldman and Mr. Esfandiari. Count V purported to allege a claim under Section 20(a) of the Exchange Act against Mr. Eberly, Ms. Page, Mr. Goldman and Mr. Esfandiari.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">In their CAC, the Lead Plaintiffs sought, on behalf of the Securities Act Class and the Exchange Act Class, among other things, an award of damages in an amount to be proven at trial, as well as an award of reasonable costs, including attorneys’ fees and expenses, expert fees, pre-judgment and post-judgment interest, and such other relief as the Court deems just and proper. The Lead Plaintiffs also sought rescission “or a rescissory measure of damages” on behalf of the Securities Act Class as to Count II.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Pursuant to an order entered by the Court on January 29, 2021, any defendant wishing to move against the amended complaint was required to file, by February 18, 2021, a letter requesting a pre-motion conference. On that date, the defendants submitted letters to the Court requesting a pre-motion conference regarding anticipated motions to dismiss the CAC, and the Lead Plaintiffs responded on February 24, 2021. In its January 29, 2021 order, the Court indicated that it would consider a briefing schedule on motions to dismiss after it had received and reviewed the parties’ correspondence.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On March 5, 2021, the Court entered an order in which it advised the parties that it had determined a pre motion conference was not necessary and established a briefing schedule on the defendants’ anticipated motions to dismiss. However, the defendants subsequently agreed with the Lead Plaintiffs’ counsel to a modification of the schedule, which was then approved by the Court. Pursuant to that schedule, defendants’ motions and supporting papers were filed on March 26, 2021, the Lead Plaintiffs’ opposition papers were filed on April 16, 2021, and the defendants’ reply papers were filed on April 30, 2021.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Court issued its Opinion and Order (the “Order”) on the defendants’ motions to dismiss on February 23, 2022.  In its Order, the Court: (i) dismissed Counts I and II without prejudice as to all defendants named in those Counts except the Underwriter Defendants as to which Counts I and II were not dismissed; (ii) dismissed Count III without prejudice as to all defendants named in that Count; and (iii) dismissed Counts IV and V with prejudice as to all defendants named in those Counts.  The Court gave Lead Plaintiffs fourteen days within which to attempt to replead their claims under the Securities Act against Chembio, Ms. Page, Mr. Goldman, Ms. Davis, Ms. Polan and Mr. Potthoff.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On March 4, 2022, Lead Plaintiffs filed a letter motion in which they advised the Court that they intended to file an amended complaint, but that they wished to first seek reconsideration of the Court’s February 23 order.  They accordingly requested, and the Court granted, an adjournment of the deadline for filing an amended complaint until three business days after the Court’s ruling on Lead Plaintiffs’ anticipated motion for reconsideration.  The Court also granted a request by the Underwriter Defendants to extend the time for them to file their answer to the CAC, and set May 2, 2022 as the date for the filing of that answer.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On March 7, 2022, Magistrate Judge John Wicks entered an order requiring that the parties meet and confer regarding the scheduling of discovery in the case, requiring that the parties submit a Proposed Scheduling Order by March 23, and setting a hearing (via zoom) on March 30.  The Chembio Defendants filed a letter motion requesting that the Court adjourn the initial conference and suspend the other requirements in the March 7, 2022 order.  Magistrate Judge Wicks granted the letter motion on March 14, and further ordered that the initial conference would be rescheduled “following the resolution of all preliminary dispositive issues.”</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On March 9, 2022, Lead Plaintiffs filed a motion for partial reconsideration of the Court’s February 23 Order.  In their motion, Lead Plaintiffs requested that the Court reconsider and reverse its dismissal of Counts IV and V with prejudice, and its dismissal of Counts I, II and III without prejudice.  The Chembio Defendants filed their memorandum in opposition to this motion on March 23, 2022; Lead Plaintiffs filed their reply memorandum in support of the motion on March 30, 2022.  The Court has not yet ruled upon the motion for partial reconsideration.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On April 26, 2022, the Court entered an order canceling the previously-set May 2 date by which the Underwriter Defendants were required to file their answer to the CAC, and providing that the Underwriter Defendants’ answer to an amended complaint shall be due within three weeks after such amended complaint has been served.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Putative Stockholder Derivative Litigation</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;"> <br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On September 11, 2020, a putative stockholder derivative action captioned Karen Wong, derivatively on behalf of Chembio Diagnostics, Inc., Plaintiff v. Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan and John G. Potthoff, Defendants, and Chembio Diagnostics, Inc., Nominal Defendant (the “Wong complaint”) was filed purportedly on Chembio’s behalf in the United States District Court for the Eastern District of New York. The Wong complaint purports to assert a claim for violation of Section 14(a) of the Exchange Act and Rule 14a-9 thereunder based on ostensibly false and misleading statements and omissions concerning the Company’s rapid COVID-19 antibody test in the proxy statement disseminated in advance of Chembio’s Annual Meeting of Stockholders held on July 28, 2020. The Wong complaint also asserts claims against the individual defendants for purported breaches of fiduciary duties owed to Chembio, as well as unjust enrichment.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">The Wong complaint requests a declaration that the individual defendants have breached or aided and abetted the breach of their fiduciary duties to Chembio, an award of damages to us, restitution, and an award of the plaintiff’s costs and disbursements in the action, including reasonable attorneys’ and experts’ fees, costs and expenses, and improvements to Chembio’s corporate governance and internal procedures regarding compliance with laws. Pursuant to a stipulation by which the individual defendants named in the Wong complaint agreed to waive service of process, the Court ordered that the time for defendants to answer or otherwise respond to the complaint be extended to November 19, 2020. The parties subsequently entered into a stipulation for a stay of proceedings in the action relating to the Wong complaint pending final disposition of motions to dismiss the pending putative class-action litigation, subject to certain conditions. The Court entered an order granting the requested stay on November 3, 2020. At this stage of the litigation, the Company is not able to predict the probability of a favorable or unfavorable outcome.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On March 31, 2022, a second putative stockholder derivative action captioned Michelle Chen, derivatively on behalf of Chembio Diagnostics, Inc., Plaintiff v. Richard L. Eberly, Gail S. Page, Neil A. Goldman, Javan Esfandiari, Katherine L. Davis, Mary Lake Polan and John G. Potthoff, Defendants, and Chembio Diagnostics, Inc., Nominal Defendant (the “Chen complaint”) was filed purportedly on behalf of Chembio in the Supreme Court for the State of New York, County of Suffolk.  The Chen complaint purports to assert a claim for breach of fiduciary duty against the defendants based on ostensibly false and misleading statements and omissions concerning the Company’s rapid COVID-19 antibody test.  The Chen complaint goes on to allege that the misconduct asserted in the complaint gave rise to the filing of the consolidated securities litigation described above.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Counsel for the defendants in the Chen action are engaged in discussions with counsel for Chen concerning a possible stay of the Chen action.</div> <div><br/> </div> <div style="display:none;"><br/></div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><span style="text-decoration: underline;">Employee Litigation</span></div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On March 19, 2021, John J. Sperzel III, Chembio’s former chief executive officer, filed a fifteen-count complaint in the United States District Court for the Eastern District of New York. The complaint was filed following the dismissal of an action previously filed by Mr. Sperzel in the United States District Court in Maine, which was dismissed for lack of personal jurisdiction over Chembio. In summary, the complaint filed in the Eastern District of New York alleges that Chembio wrongfully refused to allow Mr. Sperzel to exercise certain options to purchase, for an aggregate exercise price of $943,126, a total of 266,666 shares of common stock that were allegedly vested as of the date of his separation from Chembio, on January 3, 2020. The complaint alleges that under the terms of the applicable stock incentive plans, Mr. Sperzel had thirty days after the date on which he ceased to qualify as an “Eligible Person” under the plans within which to exercise the options, and asserts that by reason of his alleged continued service to us, he remained an “Eligible Person” and ostensibly retained the right to exercise the options. The Compensation Committee of the Board determined that the options expired on February 3, 2020, thirty days after Mr. Sperzel’s separation from Chembio, and that a purported attempt by Mr. Sperzel to exercise the options after that date was not valid.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Count I of the complaint purports to allege that Chembio breached Mr. Sperzel’s separation agreement by refusing to allow him to exercise the stock options. Counts II through XI of the complaint purport to allege claims for breach of each of ten separate stock option agreements, collectively asserting damages of “at least” $3,190,198. Count XII of the complaint alleges a breach of Mr. Sperzel’s separation agreement based on Chembio’s purported failure to pay Mr. Sperzel consulting fees to which he claims to be entitled for consulting services allegedly performed following his separation. Count XIII of the complaint alleges a claim for breach of an implied covenant of good faith and fair dealing under Nevada common law based on the allegation that Chembio prevented Mr. Sperzel from obtaining the benefits of the stock option agreements and separation agreement. Mr. Sperzel alleges that he suffered damages in excess of $3 million as a result of the purported breach of the covenant of good faith and fair dealing. Count XIV of the complaint purports to assert a claim for quantum meruit, alleging that “it is reasonable for Sperzel to expect payment in exchange for ... services” he allegedly provided to us and, based on allegations that upon his separation Mr. Sperzel was not informed as to the pending expiration of the stock options he later sought to exercise, that Chembio has been unjustly enriched. Finally, Count XV of the complaint seeks a declaratory judgment that Mr. Sperzel is relieved from performance under his separation agreement due to asserted material breaches of the agreement based on the allegations summarized above. The complaint seeks compensatory damages in an unspecified amount, a declaration, as described above, and an award of Mr. Sperzel’s costs and expenses in the litigation, including reasonable attorneys’ fees, expert costs and disbursements. The complaint requests a trial by jury. In his initial disclosures served in discovery, Mr. Sperzel claims entitlement to recover damages in a total amount not less than $10 million, together with prejudgment interest at the rate of 9% per annum. </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">On May 20, 2021, Chembio filed its answer and affirmative defenses denying the material allegations of Mr. Sperzel’s complaint. Chembio and Mr. Sperzel are presently engaged in discovery. Under the present case schedule, all fact discovery was completed on April 28, 2022, and the parties are currently in the midst of an additional period of expert witness discovery, concluding on June 28, 2022. At this stage of the litigation, the Company is not able to predict the probability of a favorable or unfavorable outcome. </div> <div><br/> </div> <div style="display:none;"><br/></div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left; text-indent: 36pt;"><span style="text-decoration: underline;">Other</span></div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">From time to time the Company may become involved in legal proceedings or may be subject to claims arising in the ordinary course of its business. Although the results of litigation and claims cannot be predicted with certainty, the Company currently believes that the final outcome of these ordinary course matters will not have a material adverse effect on its business, operating results, financial condition or cash flows. Regardless of the outcome, litigation can have an adverse impact on the Company because of defense and settlement costs, diversion of management resources, and other factors.</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table discloses product sales the Company had to each customer that purchased in excess of 10% of the Company’s net product sales for the periods indicated:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td rowspan="1" style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; text-indent: -27pt; margin-left: 27pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="14" rowspan="1" style="vertical-align: top; text-align: center; text-indent: -27pt; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-indent: -9pt; text-align: center;">For the three months ended</div> </td> <td colspan="1" rowspan="1" style="text-indent: -27pt; margin-left: 27pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" rowspan="1" style="vertical-align: top; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="font-weight: bold;"> Accounts Receivable as of<br/> </div> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2021 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December<br/> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">31, 2021</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); text-align: center;">Product </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); text-align: center;">Sales</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">% of </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Product </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Sales</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); text-align: center;">Product </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold; color: rgb(0, 0, 0); text-align: center;">Sales</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">% of </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Product </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Sales</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Customer 1</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">11,856,024</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">64</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">%</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"><span style="-sec-ix-hidden:Fact_0226cc4d972f48848e9057ed3e7eb738">*</span></td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_05d719468636475dbc07007117b94ff5">*</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">5,930,162</td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,672,845</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Revenue includes product sales only, while accounts receivable reflects the total due from the customer, including freight.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table discloses purchases the Company had to each vendor that purchased in excess of 10% of the Company’s net purchases for the periods indicated:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"/> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three months ended</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Accounts Payable as of</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2021 </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">December <br/> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">31, 2021</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">% of </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">% of </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Purchases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Vendor 1</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,323,605</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">34</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">$</div> </div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="-sec-ix-hidden:Fact_1a9e8f49619e486c8c21ad677e5efd36">*</span><br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;"> <div style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><span style="-sec-ix-hidden:Fact_2c75ac3484f5434da6384ab955c8c4d1">*</span><br/> </div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">224,500</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"><span style="-sec-ix-hidden:Fact_5985b6b8f25443aab6ef761d2dd0ed82">*</span><br/> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 28%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Vendor 2</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,088,251<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">16</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">469,635<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">11</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">164,983<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">353,097<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In the tables above, an asterisk (*) indicates that indicates that sales, accounts receivable, purchases or accounts payable, as applicable to the tabular column, did not exceed 10% for the period indicated.</div> 11856024 0.64 5930162 7672845 2323605 0.34 224500 1088251 0.16 469635 0.11 164983 353097 3 1178000 2024-12-31 <span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The following table is a schedule of future minimum salary commitments:</span> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; margin-left: 0px; margin-right: auto; width: 100%;"> <tr> <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">2022</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">883,500</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: top; width: 88%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">2023</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">383,000</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255); white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: left;">2024</div> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">383,000</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> 883500 383000 383000 0.40 0.05 0.02 67135 35456 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The components of lease expense were as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Three Months Ended</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating lease expense</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">403,385</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">408,466</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance lease cost</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Amortization of right-of-use assets</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">17,579</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">15,758</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Interest on lease liabilities</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,944</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Total finance lease expense</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">22,265</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">20,702</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 403385 408466 17579 15758 4686 4944 22265 20702 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Supplemental cash flow information related to leases was as follows.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Three Months Ended</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Cash paid for amounts included in the measurement of lease liabilities:</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating cash flows for operating leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">360,878</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">347,871</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating cash flows for finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4,686</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,944</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Financing cash flows for finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">16,930</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">14,282</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Right-of-use assets obtained in exchange for lease obligations:</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">16,234</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> 360878 347871 4686 4944 16930 14282 16234 0 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Supplemental balance sheet information related to leases was as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; text-indent: -7pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="text-indent: 0pt;">March 31, 2021</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Finance Leases</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance lease right of use asset</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">356,997</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">315,153</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accumulated depreciation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">(166,471</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">(97,777</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance lease right of use asset, net</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">190,526</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">217,376</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted Average Remaining Lease Term</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating leases</div> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">7.4 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; white-space: nowrap;" valign="bottom"> <div style="text-align: right; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">8.6</span> years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2.8 years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: right; text-indent: -7pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">3.5</span> years</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted Average Discount Rate</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Operating leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9.32</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9.30</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Finance leases</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.56</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.18</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">%</div> </td> </tr> </table> 356997 315153 166471 97777 190526 217376 P7Y4M24D P8Y7M6D P2Y9M18D P3Y6M 0.0932 0.0930 0.0856 0.0818 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Maturities of lease liabilities were as follows.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Operating</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Finance</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Operating</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Finance</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Leases</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2022</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,086,370</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">65,913</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">861,916</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">57,678</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2023</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,221,017</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">87,884</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,057,757</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">76,904</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2024</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,018,875</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">60,116</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,026,272</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">76,904</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2025</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,049,442</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">16,731</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,018,875</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">49,136</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">2026</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,080,925</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,940</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,049,442</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,751</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Thereafter</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,643,521</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">355</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,724,446</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Total lease payments</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,100,150</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">236,939</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,738,708</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">266,373</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Less: imputed interest</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,450,412</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">29,781</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,968,703</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">36,544</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 52%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">6,649,738</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">207,158</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">6,770,005</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">229,829</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 1086370 65913 861916 57678 1221017 87884 1057757 76904 1018875 60116 1026272 76904 1049442 16731 1018875 49136 1080925 5940 1049442 5751 3643521 355 4724446 0 9100150 236939 9738708 266373 2450412 29781 2968703 36544 6649738 207158 6770005 229829 4 8 2 2 1 1 P14D 15 943126 266666 P30D 10 3190198 3000000 10000000 0.09 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 7 — LONG-TERM DEBT:</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">O<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">n September 3, 2019, Chembio entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Holdings II, LP (the “Lender”)</span>. The Credit Agreement provides for a $20,000,000 senior secured term loan credit facility, which was drawn in full on September 4, 2019. Under the terms of the Credit Agreement, Chembio may use the proceeds (i) for general working capital purposes and other permitted corporate purposes, (ii) to refinance certain of Chembio’s existing indebtedness and (iii) to pay fees, costs and expenses incurred in connection with the Credit Agreement, including the Lender’s closing cost amount of $550,000, which was netted from the proceeds, and a financing fee of $600,000 (3.0% of gross proceeds) payable to Craig-Hallum <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Capital Group LLC, Chembio’s</span></span> financial advisor for the financing.</div> <div><br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Principal outstanding under the Credit Agreement bears interest at a rate per annum equal to the sum of (a) the greater of the one-month London Interbank Offered Rate and 2.5% plus (b) 8.75%. At any time at which an event of default has occurred and is continuing, the interest rate will increase by 4.0%. Accrued interest is payable on a monthly basis. On March 31, 2022 the interest rate was 11.25%.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">No principal repayments are due under the Credit Agreement prior to September 30, 2022, unless Chembio elects to prepay principal or principal is accelerated pursuant to an event of default identified in the Credit Agreement. Principal installments in the amount of $300,000 are payable on the last day of each of the eleven months from September 2022 through July 2023, and all remaining principal is payable at maturity on September 3, 2023. The Company may prepay outstanding principal from time to time, subject to payment of a premium on the prepaid principal amount equal to 10% through September 3, 2020, 8% from September 4, 2020 through September 3, 2021, and 4% from September 4, 2021 through September 3, 2022. No premium will be due with respect to any prepayment made on or after September 4, 2022.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">Chembio’s obligations under the Credit Agreement are secured by a first priority, perfected lien on substantially all of its property and assets, including its equity interests in subsidiaries.</div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;"> <br/> </div> <div style="font-size: 10pt; font-family: 'Times New Roman'; text-align: justify;">As of  March 31, 2022, the loan balance, net of unamortized discounts and debt issuance costs, was $18.9 million, and Chembio was in compliance with its loan covenants.</div> 20000000 550000 600000 0.030 P1M 0.025 0.0875 0.040 0.1125 300000 2023-09-03 0.10 0.08 0.04 18900000 <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 8 — EQUITY INCENTIVE PLAN:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt;"><br/> </td> <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(a)</td> <td style="width: auto; vertical-align: top; text-align: left;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Equity Plans:</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Effective June 19, 2014, Chembio’s stockholders voted to approve the 2014 Stock Incentive Plan (the “2014 Plan”), with 800,000 shares of common stock available to be issued. Under the terms of the 2014 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of Equity Award Units. The awards vest at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through March 31, 2022, there were 732,064 Equity Award Units<span style="font-size: 10pt; font-family: 'Times New Roman';"> expired, forfeited or exercised. At March 31, </span>2022, 46,875 Equity Award Units were outstanding and 21,061 shares were not issued. All shares that expired, forfeited or were not issued rolled over into the 2019 Plan. No Equity Award <span style="font-size: 10pt; font-family: 'Times New Roman';">Units remain available to be issued under the 2014 Plan.</span></div> <div><br/></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">Effective </span>June 18, 2019, Chembio’s stockholders voted to approve the 2019 Omnibus Incentive Plan (the “2019 Plan”), with<span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>2,400,000<span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>shares of common stock available to be issued. At the Annual Stockholder Meeting on June 25, 2021, Chembio’s stockholders voted to approve an increase to the shares of common stock issuable under the SIP by 2,400,000 to 4,800,000. In addition, shares of common stock underlying any outstanding award granted under the 2019 Plan that, following the effective date of the 2019 Plan, expire, or are terminated, surrendered or forfeited for any reason without issuance of such shares, shall be available for the grant of new awards under the 2019 Plan. Under the terms of the 2019 Plan, the Board or its Compensation Committee has the discretion to select the persons to whom awards are to be granted. Awards can be in the form of options, stock appreciation rights, restricted stock, restricted stock units, performance stock units or other stock-based awards under the 2019 Plan (collectively, “2019 Equity Units”). The 2019 Equity Units become vested at such times and under such conditions as determined by the Board or its Compensation Committee. Cumulatively through March 31, 2022<span style="font-size: 10pt; font-family: 'Times New Roman';">, </span>866,709<span style="font-size: 10pt; font-family: 'Times New Roman';"> 2019 </span>Equity Units have been cancelled or forfeited. At March 31, 2022<span style="font-size: 10pt; font-family: 'Times New Roman';">, </span>4,915,279<span style="font-size: 10pt; font-family: 'Times New Roman';"> 2019 </span>Equity Units were outstanding, and<span style="font-size: 10pt; font-family: 'Times New Roman';"> </span>83,234<span style="font-size: 10pt; font-family: 'Times New Roman';"> 2019 </span>Equity Units were available to be awarded.</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;"> <tr> <td style="width: 36pt;"><br/> </td> <td style="width: 18pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">(b)</td> <td style="width: auto; vertical-align: top; text-align: left;"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Stock Compensation Expense:</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation expense (net of recovery) recognized in the condensed consolidated statements of operations was classified as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three months </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ended March 31</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Cost of product sales</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">54,250</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">28,768</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Research and development expenses</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">91,189</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">90,920</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Selling, general and administrative expenses</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">605,464</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">460,101</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(255, 255, 255);" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">750,903</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">579,789</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The weighted-average assumptions made in calculating the fair values of options are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> months ended</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31,</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2021</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Expected term (in years)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">6.0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Expected volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">91.40</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Expected dividend yield</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_db420d4ea83c495182a14a16eb528e06">N/A</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Risk-free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1.91</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">%</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides stock option activity for the three months ended March 31, 2022:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"> <tr> <td style="width: 50.38%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Stock Options</span></div> </td> <td style="width: 1.36%; vertical-align: bottom;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of Shares</div> </td> <td style="width: 0.95%; vertical-align: bottom;"> </td> <td colspan="2" style="width: 11.79%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise Price</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">per Share</div> </td> <td style="width: 0.87%; vertical-align: bottom;"> </td> <td style="width: 10.88%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contract Term</div> </td> <td style="width: 1.09%; vertical-align: bottom;"> </td> <td colspan="2" style="width: 12.08%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1,600,372</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4.18</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">6.59 years</div> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #FFFFFF;"> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Granted</div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2,358,539</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">1.23</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Exercised</div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Forfeited</div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">14,883</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2.42</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Expired</div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">183,241</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">5.63</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">3,760,787</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.6%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2.27</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">8.65 years</div> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.62%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercisable at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">565,215</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">3.68</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">5.89 years</div> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.62%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes information about stock options outstanding at March 31, 2022:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Stock Options Outstanding</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Stock Options Exercisable</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Range of</div> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise Prices</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contract Term</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Year)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 1pt;">_</span><span style="text-indent: 0pt;">1</span> to <span style="text-indent: 0pt;">2.79999</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,863,910</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.83</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1.44</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">317,758</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2.36</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2.8</span> to <span style="text-indent: 0pt;">4.59999</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">30,795</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9.19</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3.05</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">4.6</span> to <span style="text-indent: 0pt;">6.39999</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">819,207</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.43</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.81</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">209,957</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.88</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">6.4</span> to <span style="text-indent: 0pt;">8.19999</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">46,875</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1.11</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.15</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">37,500</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.15</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">3,760,787</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">8.65</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">2.27</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">565,215</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">3.69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of March 31, 2022, there was $3,073,502 of net unrecognized compensation cost related to stock options that had not vested, which is expected to be recognized over a weighted-average period of approximately 3.32 years. The total fair value of shares vested during the three months ended March 31, 2022 and 2021 was $693,290 and $188,179, respectively.</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The </span>following table summarizes information about restricted stock, restricted stock units and performance stock units outstanding as of March 31, 2022<span style="font-size: 10pt; font-family: 'Times New Roman';">:</span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number of</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Shares &amp; Units</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Grant Date</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Fair Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">705,325</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3.34</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Granted</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,210,448</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">0.76</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Vested</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">167,782</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3.60</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Forfeited</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,047</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2.31</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding at March 31, 2022</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1,739,944</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1.52</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">As of March 31, 2022, there was $2,120,646 of net unrecognized compensation cost related to restricted stock and restricted stock units that had not vested, which is expected to be recognized over a weighted average period of approximately 2.50 years.</div> 800000 732064 46875 21061 0 2400000 2400000 4800000 866709 4915279 83234 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Stock-based compensation expense (net of recovery) recognized in the condensed consolidated statements of operations was classified as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three months </div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ended March 31</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Cost of product sales</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">54,250</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">28,768</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Research and development expenses</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">91,189</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">90,920</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Selling, general and administrative expenses</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">605,464</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">460,101</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(255, 255, 255);" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> </div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">750,903</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255); white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255);" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">579,789</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255); white-space: nowrap;" valign="bottom"> </td> </tr> </table> 54250 28768 91189 90920 605464 460101 750903 579789 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The weighted-average assumptions made in calculating the fair values of options are as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> months ended</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31,</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2021</div> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Expected term (in years)</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">6.0</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Expected volatility</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">91.40</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">%</div> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Expected dividend yield</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="-sec-ix-hidden:Fact_db420d4ea83c495182a14a16eb528e06">N/A</span></div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #FFFFFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Risk-free interest rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #FFFFFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1.91</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #FFFFFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">%</div> </td> </tr> </table> P6Y 0.9140 0.0191 <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The following table provides stock option activity for the three months ended March 31, 2022:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;"> <tr> <td style="width: 50.38%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">Stock Options</span></div> </td> <td style="width: 1.36%; vertical-align: bottom;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of Shares</div> </td> <td style="width: 0.95%; vertical-align: bottom;"> </td> <td colspan="2" style="width: 11.79%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise Price</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">per Share</div> </td> <td style="width: 0.87%; vertical-align: bottom;"> </td> <td style="width: 10.88%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contract Term</div> </td> <td style="width: 1.09%; vertical-align: bottom;"> </td> <td colspan="2" style="width: 12.08%; vertical-align: bottom; border-bottom: #000000 2px solid;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; border-top: #000000 2px solid; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1,600,372</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4.18</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">6.59 years</div> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #FFFFFF;"> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Granted</div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2,358,539</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">1.23</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Exercised</div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Forfeited</div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">14,883</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">2.42</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Expired</div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">183,241</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt;">5.63</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> </td> <td style="width: 10.62%; vertical-align: bottom; border-bottom: #000000 2px solid; background-color: #FFFFFF;"> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">3,760,787</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.6%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2.27</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #CCEEFF;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">8.65 years</div> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #CCEEFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.62%; vertical-align: bottom; border-top: #000000 2px solid; border-bottom: #000000 4px double; background-color: #CCEEFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> </tr> <tr> <td style="width: 50.38%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercisable at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div> </td> <td style="width: 1.36%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">565,215</div> </td> <td style="width: 0.95%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.2%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.6%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">3.68</div> </td> <td style="width: 0.87%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 10.88%; vertical-align: bottom; background-color: #FFFFFF;"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">5.89 years</div> </td> <td style="width: 1.09%; vertical-align: bottom; background-color: #FFFFFF;"> </td> <td style="width: 1.46%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td style="width: 10.62%; vertical-align: bottom; border-bottom: #000000 4px double; background-color: #FFFFFF;"> <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> </tr> </table> 1600372 4.18 P6Y7M2D 0 2358539 1.23 0 0 0 0 14883 2.42 0 183241 5.63 3760787 2.27 P8Y7M24D 0 565215 3.68 P5Y10M20D 0 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The following table summarizes information about stock options outstanding at March 31, 2022:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"><br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="14" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Stock Options Outstanding</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Stock Options Exercisable</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Range of</div> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise Prices</div> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Remaining</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Contract Term</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">(Year)</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">of Shares</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Exercise</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Price</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Aggregate</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Intrinsic</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 1pt;">_</span><span style="text-indent: 0pt;">1</span> to <span style="text-indent: 0pt;">2.79999</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,863,910</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.83</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1.44</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">317,758</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2.36</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">2.8</span> to <span style="text-indent: 0pt;">4.59999</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">30,795</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">9.19</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3.05</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">4.6</span> to <span style="text-indent: 0pt;">6.39999</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">819,207</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.43</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.81</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">209,957</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4.88</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-indent: 0pt;">6.4</span> to <span style="text-indent: 0pt;">8.19999</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">46,875</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1.11</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.15</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">37,500</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8.15</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 16%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Total</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">3,760,787</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">8.65</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">2.27</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">565,215</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal;">3.69</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 1 2.79999 2863910 P8Y9M29D 1.44 0 317758 2.36 0 2.8 4.59999 30795 P9Y2M8D 3.05 0 0 0 0 4.6 6.39999 819207 P8Y5M4D 4.81 0 209957 4.88 0 6.4 8.19999 46875 P1Y1M9D 8.15 0 37500 8.15 0 3760787 P8Y7M24D 2.27 0 565215 3.69 0 3073502 P3Y3M25D 693290 188179 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The </span>following table summarizes information about restricted stock, restricted stock units and performance stock units outstanding as of March 31, 2022<span style="font-size: 10pt; font-family: 'Times New Roman';">:</span></div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> <br/> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Number of</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Shares &amp; Units</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Weighted</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Average</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Grant Date</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Fair Value</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">705,325</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3.34</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Granted</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,210,448</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">0.76</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Vested</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">167,782</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3.60</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Forfeited</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,047</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">2.31</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Outstanding at March 31, 2022</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1,739,944</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1.52</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 705325 3.34 1210448 0.76 167782 3.60 8047 2.31 1739944 1.52 2120646 P2Y6M <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 9 — GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY:</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The </span>Company produces only one group of similar products known collectively as “rapid medical tests”, and it operates in a <span style="-sec-ix-hidden:Fact_3c7629f5cbf64334ad117ce9f2df23d9">single</span> operating segment. Net product revenue by geographic area were as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three months ended</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Africa</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">767,352</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,344,858</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Asia</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">15,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">216,954</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Europe &amp; Middle East</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">717,908</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,493,734</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Latin America</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">12,545,054</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">258,019</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">United States</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4,481,584</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">711,097</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">18,527,456</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,024,662</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Property, plant and equipment by geographic area were as follows at:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Asia</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">85,351</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">86,041</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Europe &amp; Middle East</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">101,231</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">113,883</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Latin America</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">58,685</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">36,224</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">United States</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">8,169,046</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,320,625</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">8,414,313</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,556,773</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt; font-family: 'Times New Roman';">The </span>Company produces only one group of similar products known collectively as “rapid medical tests”, and it operates in a <span style="-sec-ix-hidden:Fact_3c7629f5cbf64334ad117ce9f2df23d9">single</span> operating segment. Net product revenue by geographic area were as follows:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="6" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">For the three months ended</div> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31<br/> </div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Africa</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">767,352</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,344,858</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Asia</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">15,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">216,954</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Europe &amp; Middle East</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">717,908</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,493,734</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Latin America</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">12,545,054</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">258,019</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">United States</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">4,481,584</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">711,097</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">18,527,456</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,024,662</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 1 767352 1344858 15558 216954 717908 1493734 12545054 258019 4481584 711097 18527456 4024662 <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Property, plant and equipment by geographic area were as follows at:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Asia</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">85,351</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">86,041</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Europe &amp; Middle East</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">101,231</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">113,883</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Latin America</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">58,685</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">36,224</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">United States</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">8,169,046</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,320,625</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">8,414,313</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,556,773</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 85351 86041 101231 113883 58685 36224 8169046 8320625 8414313 8556773 <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 10 — ACCOUNTS PAYABLE AND ACCRUED LIABILITIES:</div> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Accounts payable and accrued liabilities consisted of:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accounts payable – suppliers</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">5,622,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,745,592</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued commissions and royalties</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1,510,865</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,359,691</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued payroll</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">494,653</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">494,258</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued vacation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">657,008</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">421,416</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued bonuses</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">544,567</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,378,706</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued professional fees</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">893,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">522,935</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses – other</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">819,455</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,205,395</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> TOTAL</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">10,542,851</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">13,127,993</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Accounts payable and accrued liabilities consisted of:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">March 31, 2022</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"> <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">December 31, 2021</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accounts payable – suppliers</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">5,622,558</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,745,592</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued commissions and royalties</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">1,510,865</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,359,691</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued payroll</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">494,653</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">494,258</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued vacation</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">657,008</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">421,416</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued bonuses</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">544,567</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,378,706</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued professional fees</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">893,745</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">522,935</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Accrued expenses – other</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">819,455</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,205,395</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 76%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> TOTAL</div> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">10,542,851</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">13,127,993</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 5622558 7745592 1510865 1359691 494653 494258 657008 421416 544567 1378706 893745 522935 819455 1205395 10542851 13127993 <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 11 — GOODWILL AND INTANGIBLE ASSETS:</div> <div><br/> </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The following table reflects changes in goodwill:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Beginning balance at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,022,787</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom">Impairment<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(3,033,565</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Change in foreign currency exchange rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">10,778</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> <div><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Goodwill represents the excess of the purchase price the Company paid over the fair value of the net tangible and identifiable intangible assets acquired in the Company’s acquisition. Goodwill is not amortized but rather is tested annually as of the first day of the fiscal fourth quarter, or sooner if the Company believes that indicators of impairment exist. The Company makes a qualitative evaluation about the likelihood of goodwill impairment, which is based on a number of applicable factors. If the Company concludes that it is more likely than not that the carrying value of the applicable reporting unit is greater than its fair value, then it would recognize an impairment charge for the amount by which the carrying value exceeds the reporting unit’s fair value, provided the impairment charge does not exceed the total amount of goodwill allocated to the reporting unit.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The quantitative goodwill impairment test is performed using a one-step process. The process is to compare the fair value of a reporting unit with its carrying amount. If the fair value of a reporting unit exceeds its carrying amount, goodwill of the reporting unit is not impaired. If the carrying amount of a reporting unit exceeds its fair value, goodwill of the reporting unit is impaired, and an impairment loss is recognized in an amount equal to that excess.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Company operates as a <span style="-sec-ix-hidden:Fact_c3eb8caaf3514d1d9d0012244b0f53f4">single</span> operating segment and has one reporting unit. As of March 31, 2022, the Company determined indicators of impairment existed. As a result, the Company recognized an impairment loss of its goodwill totaling $3.0 million. </div> <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">The following table reflects changes in goodwill:</div> <div><br/> </div> <table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%;"> <tr> <td style="vertical-align: bottom; width: 88%; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Beginning balance at December 31, <span style="text-indent: 0pt;">2021</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,022,787</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td rowspan="1" style="vertical-align: bottom; width: 88%;" valign="bottom">Impairment<br/> </td> <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"> </td> <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(3,033,565</td> <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Change in foreign currency exchange rate</div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">10,778</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"> </td> </tr> <tr> <td style="vertical-align: bottom; width: 88%; padding-bottom: 4px;" valign="bottom"> <div style="text-align: left; text-indent: -7.2pt; margin-left: 7.2pt; font-family: 'Times New Roman'; font-size: 10pt;">Balance at <span style="text-indent: 0pt;">March 31</span>, <span style="text-indent: 0pt;">2022</span></div> </td> <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div> </td> <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"> <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div> </td> <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"> </td> </tr> </table> 3022787 3033565 10778 0 1 3000000.0 <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTE 12 —  OTHER MATTERS:</div> <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/> </div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On March 28, 2022, Chembio Diagnostics GmbH, Chembio’s German subsidiary formed under the laws of the Federal Republic of Germany, successfully withdrew its petition for insolvency filed in February 2022 in the Charlottenburg District Court  (“Amtsgericht Charlottenburg“) in Berlin, Germany. The subsidiary has taken various measures to improve profitability, including a viable business plan, and the Company has provided liquidity and other support to continue the operations.</div> In the tables above, an asterisk (*) indicates that indicates that sales, accounts receivable, purchases or accounts payable, as applicable to the tabular column, did not exceed 10% for the period indicated. EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 160 288 1 true 47 0 false 11 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://chembio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://chembio.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://chembio.com/role/CondensedConsolidatedStatementsOfOperations CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Statements 5 false false R6.htm 040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Sheet http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY Statements 6 false false R7.htm 050000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 060100 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://chembio.com/role/DescriptionOfBusiness DESCRIPTION OF BUSINESS Notes 8 false false R9.htm 060200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://chembio.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 9 false false R10.htm 060300 - Disclosure - REVENUE Sheet http://chembio.com/role/Revenue REVENUE Notes 10 false false R11.htm 060400 - Disclosure - INVENTORY Sheet http://chembio.com/role/Inventory INVENTORY Notes 11 false false R12.htm 060500 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://chembio.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 12 false false R13.htm 060600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS Sheet http://chembio.com/role/CommitmentsContingenciesAndConcentrations COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS Notes 13 false false R14.htm 060700 - Disclosure - LONG-TERM DEBT Sheet http://chembio.com/role/LongtermDebt LONG-TERM DEBT Notes 14 false false R15.htm 060800 - Disclosure - EQUITY INCENTIVE PLAN Sheet http://chembio.com/role/EquityIncentivePlan EQUITY INCENTIVE PLAN Notes 15 false false R16.htm 060900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY Sheet http://chembio.com/role/GeographicInformationAndEconomicDependency GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY Notes 16 false false R17.htm 061000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Sheet http://chembio.com/role/AccountsPayableAndAccruedLiabilities ACCOUNTS PAYABLE AND ACCRUED LIABILITIES Notes 17 false false R18.htm 061100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS Sheet http://chembio.com/role/GoodwillAndIntangibleAssets GOODWILL AND INTANGIBLE ASSETS Notes 18 false false R19.htm 061200 - Disclosure - OTHER MATTERS Sheet http://chembio.com/role/OtherMatters OTHER MATTERS Notes 19 false false R20.htm 070200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://chembio.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 20 false false R21.htm 080300 - Disclosure - REVENUE (Tables) Sheet http://chembio.com/role/RevenueTables REVENUE (Tables) Tables http://chembio.com/role/Revenue 21 false false R22.htm 080400 - Disclosure - INVENTORY (Tables) Sheet http://chembio.com/role/InventoryTables INVENTORY (Tables) Tables http://chembio.com/role/Inventory 22 false false R23.htm 080600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables) Sheet http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables) Tables http://chembio.com/role/CommitmentsContingenciesAndConcentrations 23 false false R24.htm 080800 - Disclosure - EQUITY INCENTIVE PLAN (Tables) Sheet http://chembio.com/role/EquityIncentivePlanTables EQUITY INCENTIVE PLAN (Tables) Tables http://chembio.com/role/EquityIncentivePlan 24 false false R25.htm 080900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Tables) Sheet http://chembio.com/role/GeographicInformationAndEconomicDependencyTables GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Tables) Tables http://chembio.com/role/GeographicInformationAndEconomicDependency 25 false false R26.htm 081000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Sheet http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesTables ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables) Tables http://chembio.com/role/AccountsPayableAndAccruedLiabilities 26 false false R27.htm 081100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) Sheet http://chembio.com/role/GoodwillAndIntangibleAssetsTables GOODWILL AND INTANGIBLE ASSETS (Tables) Tables http://chembio.com/role/GoodwillAndIntangibleAssets 27 false false R28.htm 090200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Going Concern Considerations (Details) Sheet http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails SIGNIFICANT ACCOUNTING POLICIES, Going Concern Considerations (Details) Details 28 false false R29.htm 090202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Fair Value of Financial Instruments (Details) Sheet http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails SIGNIFICANT ACCOUNTING POLICIES, Fair Value of Financial Instruments (Details) Details 29 false false R30.htm 090204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Loss Per Share (Details) Sheet http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails SIGNIFICANT ACCOUNTING POLICIES, Loss Per Share (Details) Details 30 false false R31.htm 090206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details) Sheet http://chembio.com/role/SignificantAccountingPoliciesIncomeTaxesDetails SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details) Details 31 false false R32.htm 090300 - Disclosure - REVENUE (Details) Sheet http://chembio.com/role/RevenueDetails REVENUE (Details) Details http://chembio.com/role/RevenueTables 32 false false R33.htm 090400 - Disclosure - INVENTORY (Details) Sheet http://chembio.com/role/InventoryDetails INVENTORY (Details) Details http://chembio.com/role/InventoryTables 33 false false R34.htm 090500 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://chembio.com/role/StockholdersEquityDetails STOCKHOLDERS' EQUITY (Details) Details http://chembio.com/role/StockholdersEquity 34 false false R35.htm 090600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details) Sheet http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details) Details http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables 35 false false R36.htm 090700 - Disclosure - LONG-TERM DEBT (Details) Sheet http://chembio.com/role/LongtermDebtDetails LONG-TERM DEBT (Details) Details http://chembio.com/role/LongtermDebt 36 false false R37.htm 090800 - Disclosure - EQUITY INCENTIVE PLAN, Summary (Details) Sheet http://chembio.com/role/EquityIncentivePlanSummaryDetails EQUITY INCENTIVE PLAN, Summary (Details) Details 37 false false R38.htm 090802 - Disclosure - EQUITY INCENTIVE PLAN, Stock Options (Details) Sheet http://chembio.com/role/EquityIncentivePlanStockOptionsDetails EQUITY INCENTIVE PLAN, Stock Options (Details) Details 38 false false R39.htm 090804 - Disclosure - EQUITY INCENTIVE PLAN, Restricted Stock and Restricted Stock Units (Details) Sheet http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails EQUITY INCENTIVE PLAN, Restricted Stock and Restricted Stock Units (Details) Details 39 false false R40.htm 090900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Details) Sheet http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Details) Details http://chembio.com/role/GeographicInformationAndEconomicDependencyTables 40 false false R41.htm 091000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Sheet http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details) Details http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesTables 41 false false R42.htm 091100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details) Sheet http://chembio.com/role/GoodwillAndIntangibleAssetsDetails GOODWILL AND INTANGIBLE ASSETS (Details) Details http://chembio.com/role/GoodwillAndIntangibleAssetsTables 42 false false All Reports Book All Reports brhc10037126_10q.htm brhc10037126_ex31-1.htm brhc10037126_ex31-2.htm brhc10037126_ex32-1.htm cemi-20220331.xsd cemi-20220331_cal.xml cemi-20220331_def.xml cemi-20220331_lab.xml cemi-20220331_pre.xml image00005.jpg http://fasb.org/srt/2021-01-31 http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "brhc10037126_10q.htm": { "axisCustom": 0, "axisStandard": 20, "contextCount": 160, "dts": { "calculationLink": { "local": [ "cemi-20220331_cal.xml" ] }, "definitionLink": { "local": [ "cemi-20220331_def.xml" ] }, "inline": { "local": [ "brhc10037126_10q.htm" ] }, "labelLink": { "local": [ "cemi-20220331_lab.xml" ] }, "presentationLink": { "local": [ "cemi-20220331_pre.xml" ] }, "schema": { "local": [ "cemi-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 474, "entityCount": 1, "hidden": { "http://chembio.com/20220331": 1, "http://fasb.org/us-gaap/2021-01-31": 8, "http://xbrl.sec.gov/dei/2021q4": 5, "total": 14 }, "keyCustom": 40, "keyStandard": 248, "memberCustom": 14, "memberStandard": 32, "nsprefix": "cemi", "nsuri": "http://chembio.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000100 - Document - Document and Entity Information", "role": "http://chembio.com/role/DocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060300 - Disclosure - REVENUE", "role": "http://chembio.com/role/Revenue", "shortName": "REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060400 - Disclosure - INVENTORY", "role": "http://chembio.com/role/Inventory", "shortName": "INVENTORY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060500 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://chembio.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS", "role": "http://chembio.com/role/CommitmentsContingenciesAndConcentrations", "shortName": "COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060700 - Disclosure - LONG-TERM DEBT", "role": "http://chembio.com/role/LongtermDebt", "shortName": "LONG-TERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060800 - Disclosure - EQUITY INCENTIVE PLAN", "role": "http://chembio.com/role/EquityIncentivePlan", "shortName": "EQUITY INCENTIVE PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY", "role": "http://chembio.com/role/GeographicInformationAndEconomicDependency", "shortName": "GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "role": "http://chembio.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "role": "http://chembio.com/role/GoodwillAndIntangibleAssets", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "cemi:OtherMattersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "061200 - Disclosure - OTHER MATTERS", "role": "http://chembio.com/role/OtherMatters", "shortName": "OTHER MATTERS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "cemi:OtherMattersTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "role": "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "070200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://chembio.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080300 - Disclosure - REVENUE (Tables)", "role": "http://chembio.com/role/RevenueTables", "shortName": "REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080400 - Disclosure - INVENTORY (Tables)", "role": "http://chembio.com/role/InventoryTables", "shortName": "INVENTORY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables)", "role": "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables", "shortName": "COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080800 - Disclosure - EQUITY INCENTIVE PLAN (Tables)", "role": "http://chembio.com/role/EquityIncentivePlanTables", "shortName": "EQUITY INCENTIVE PLAN (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "080900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Tables)", "role": "http://chembio.com/role/GeographicInformationAndEconomicDependencyTables", "shortName": "GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "role": "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "081100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "role": "http://chembio.com/role/GoodwillAndIntangibleAssetsTables", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220401to20230331_StatementScenarioAxis_ScenarioForecastMember", "decimals": "-5", "first": true, "lang": null, "name": "cemi:LineOfCreditFacilityCovenantAmountRevenue", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Going Concern Considerations (Details)", "role": "http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Going Concern Considerations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220401to20230331_StatementScenarioAxis_ScenarioForecastMember", "decimals": "-5", "first": true, "lang": null, "name": "cemi:LineOfCreditFacilityCovenantAmountRevenue", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Fair Value of Financial Instruments (Details)", "role": "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Fair Value of Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member", "decimals": "-5", "lang": null, "name": "us-gaap:DebtInstrumentFairValue", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "010100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "role": "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Loss Per Share (Details)", "role": "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U004", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)", "role": "http://chembio.com/role/SignificantAccountingPoliciesIncomeTaxesDetails", "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U004", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090300 - Disclosure - REVENUE (Details)", "role": "http://chembio.com/role/RevenueDetails", "shortName": "REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331_TransactionTypeAxis_ExchangeTradedMember", "decimals": "0", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090400 - Disclosure - INVENTORY (Details)", "role": "http://chembio.com/role/InventoryDetails", "shortName": "INVENTORY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090500 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "role": "http://chembio.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS' EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090600 - Disclosure - COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details)", "role": "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails", "shortName": "COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "INF", "lang": null, "name": "cemi:NumberOfKeyEmployeesWithWhomCompanyHasEmploymentContracts", "reportCount": 1, "unique": true, "unitRef": "U005", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20190903_DebtInstrumentAxis_TermLoanCreditFacilityMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090700 - Disclosure - LONG-TERM DEBT (Details)", "role": "http://chembio.com/role/LongtermDebtDetails", "shortName": "LONG-TERM DEBT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20190903_DebtInstrumentAxis_TermLoanCreditFacilityMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090800 - Disclosure - EQUITY INCENTIVE PLAN, Summary (Details)", "role": "http://chembio.com/role/EquityIncentivePlanSummaryDetails", "shortName": "EQUITY INCENTIVE PLAN, Summary (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090802 - Disclosure - EQUITY INCENTIVE PLAN, Stock Options (Details)", "role": "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails", "shortName": "EQUITY INCENTIVE PLAN, Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20211231_AwardTypeAxis_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090804 - Disclosure - EQUITY INCENTIVE PLAN, Restricted Stock and Restricted Stock Units (Details)", "role": "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails", "shortName": "EQUITY INCENTIVE PLAN, Restricted Stock and Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20211231_AwardTypeAxis_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "U001", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "020000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "role": "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "INF", "first": true, "lang": null, "name": "cemi:NumberOfGroupsOfSimilarProducts", "reportCount": 1, "unique": true, "unitRef": "U009", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "090900 - Disclosure - GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Details)", "role": "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "shortName": "GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "INF", "first": true, "lang": null, "name": "cemi:NumberOfGroupsOfSimilarProducts", "reportCount": 1, "unique": true, "unitRef": "U009", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091000 - Disclosure - ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "role": "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "shortName": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableTradeCurrent", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20211231", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "091100 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Details)", "role": "http://chembio.com/role/GoodwillAndIntangibleAssetsDetails", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "lang": null, "name": "us-gaap:GoodwillImpairmentLoss", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "030000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "role": "http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20201231_StatementEquityComponentsAxis_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "040000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "role": "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20201231_StatementEquityComponentsAxis_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "050000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "role": "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromCustomers", "reportCount": 1, "unique": true, "unitRef": "U002", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060100 - Disclosure - DESCRIPTION OF BUSINESS", "role": "http://chembio.com/role/DescriptionOfBusiness", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "060200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://chembio.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "brhc10037126_10q.htm", "contextRef": "c20220101to20220331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 47, "tag": { "cemi_APICShareBasedPaymentArrangementRestrictedStockUnitIncreaseForCostRecognitionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition, Shares", "negatedLabel": "Restricted stock compensation, net (in shares)" } } }, "localname": "APICShareBasedPaymentArrangementRestrictedStockUnitIncreaseForCostRecognitionShares", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "cemi_AccruedSalesCommissionAndRoyaltiesCurrent": { "auth_ref": [], "calculation": { "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions and royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Sales Commission and Royalties Current", "verboseLabel": "Accrued commissions and royalties" } } }, "localname": "AccruedSalesCommissionAndRoyaltiesCurrent", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "cemi_AggregateAnnualSalariesOfEmploymentContracts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate amount of annual salaries called for by the employment contracts.", "label": "Aggregate annual salaries of employment contracts", "terseLabel": "Aggregate annual salaries of employment contracts" } } }, "localname": "AggregateAnnualSalariesOfEmploymentContracts", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Paid for Amounts Included in Measurement of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities [Abstract]" } } }, "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_ConcentrationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentrations [Abstract]", "terseLabel": "Concentrations [Abstract]" } } }, "localname": "ConcentrationsAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_ContractOneExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the expiration date of contract one.", "label": "Contract One Expiration Date", "terseLabel": "Contract one, expiration date" } } }, "localname": "ContractOneExpirationDate", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "dateItemType" }, "cemi_ContractTwoExpirationDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refers to the expiration date of contract two.", "label": "Contract Two Expiration Date", "terseLabel": "Contract two expiration date" } } }, "localname": "ContractTwoExpirationDate", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "dateItemType" }, "cemi_CreditAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Credit Agreement [Abstract]" } } }, "localname": "CreditAgreementAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/LongtermDebtDetails", "http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails" ], "xbrltype": "stringItemType" }, "cemi_Customer1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A customer that accounts for 10 percent or more of the entity's revenues.", "label": "Customer 1 [Member]" } } }, "localname": "Customer1Member", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "cemi_DebtInstrumentPercentageIncreaseInInterestRateInEventOfDefault": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The interest rate percentage in event of default in excess of standard rate as per credit agreement.", "label": "Debt Instrument, Percentage Increase in Interest Rate in Event of Default", "terseLabel": "Increase in interest rate in event of default" } } }, "localname": "DebtInstrumentPercentageIncreaseInInterestRateInEventOfDefault", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "percentItemType" }, "cemi_DebtInstrumentPercentageOfPrepaidPrincipalAsPremium": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of prepaid principal amount of debt paid as a premium as per credit agreement.", "label": "Debt Instrument Percentage of Prepaid Principal as Premium", "terseLabel": "Percentage of prepaid principal as premium" } } }, "localname": "DebtInstrumentPercentageOfPrepaidPrincipalAsPremium", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "percentItemType" }, "cemi_DebtInstrumentTermOfVariableRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term of interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument Term of Variable Rate", "terseLabel": "Term of variable rate" } } }, "localname": "DebtInstrumentTermOfVariableRate", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "durationItemType" }, "cemi_DefinedContributionPlanEmployeeContributionSubjectToMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee contribution as a percentage of employee gross pay per pay period that is subject to the employer matching contribution.", "label": "Defined Contribution Plan, Employee Contribution Subject To Match", "verboseLabel": "Employee contribution subject to employer matching contribution" } } }, "localname": "DefinedContributionPlanEmployeeContributionSubjectToMatch", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "percentItemType" }, "cemi_DefinedContributionPlanEmployerMatchingContributionPercentageOfEmployeesContribution": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' salary deferral contribution for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution Percentage of Employees' Contribution", "terseLabel": "Percentage of employer's matching contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentageOfEmployeesContribution", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "percentItemType" }, "cemi_EmploymentContractsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employment Contracts [Abstract]" } } }, "localname": "EmploymentContractsAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_EuropeMiddleEastMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Europe and Region of Middle East.", "label": "Europe & Middle East [Member]", "terseLabel": "Europe & Middle East [Member]" } } }, "localname": "EuropeMiddleEastMember", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "cemi_FinanceLeaseCost": { "auth_ref": [], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of financial lease cost recognized by lessee for lease contract.", "label": "Finance Lease Cost", "totalLabel": "Total finance lease expense" } } }, "localname": "FinanceLeaseCost", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_FinanceLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Four", "verboseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_FinanceLeaseRightOfUseAssetAccumulatedDepreciation": { "auth_ref": [], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease Right of Use Asset Accumulated depreciation", "negatedLabel": "Accumulated depreciation" } } }, "localname": "FinanceLeaseRightOfUseAssetAccumulatedDepreciation", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_FinanceLeaseRightOfUseAssetBeforeAmortization": { "auth_ref": [], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseRightOfUseAsset", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset before accumulated depreciation under finance lease.", "label": "Finance Lease, Right-of-Use Asset before Amortization", "terseLabel": "Finance lease right-of-use asset" } } }, "localname": "FinanceLeaseRightOfUseAssetBeforeAmortization", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_FinanceLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Finance Leases [Abstract]", "terseLabel": "Finance Leases [Abstract]" } } }, "localname": "FinanceLeasesAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_FinancialLeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial Lease Cost [Abstract]", "terseLabel": "Finance lease cost [Abstract]" } } }, "localname": "FinancialLeaseCostAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_FixedAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fixed Asset [Abstract]", "terseLabel": "FIXED ASSETS:" } } }, "localname": "FixedAssetAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "cemi_InterestAndTaxExpenseNet": { "auth_ref": [], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of interest and tax expenses, net.", "label": "Interest and Tax Expense, Net", "terseLabel": "Interest and taxes, net" } } }, "localname": "InterestAndTaxExpenseNet", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cemi_LeaseWeightedAverageDiscountRatePercentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease Weighted Average Discount Rate Percent [Abstract]", "terseLabel": "Weighted Average Discount Rate [Abstract]" } } }, "localname": "LeaseWeightedAverageDiscountRatePercentAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_LeasesWeightedAverageRemainingLeaseTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases Weighted Average Remaining Lease Term [Abstract]", "terseLabel": "Weighted Average Remaining Lease Term [Abstract]" } } }, "localname": "LeasesWeightedAverageRemainingLeaseTermAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_LendersClosingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred associated with the Lender's closing cost.", "label": "Lenders Closing Cost", "terseLabel": "Lender's closing cost" } } }, "localname": "LendersClosingCost", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "cemi_LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating and financing lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating and financing lease liability recognized in statement of financial position.", "label": "Lessee Operating and Financing Lease Liability Maturity [Table Text Block]", "terseLabel": "Maturities of Lease Liabilities" } } }, "localname": "LesseeOperatingAndFinancingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "cemi_LesseeOperatingLeaseBalanceSheetInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's right of use assets and lease liabilities.", "label": "Lessee Operating Lease Balance Sheet Information [Table Text Block]", "terseLabel": "Supplemental Balance Sheet Information Related to Leases" } } }, "localname": "LesseeOperatingLeaseBalanceSheetInformationTableTextBlock", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "cemi_LesseeOperatingLeaseCashFlowInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information related to operating leases.", "label": "Lessee Operating Lease Cash Flow Information [Table Text Block]", "terseLabel": "Supplemental Cash Flow Information Related to Leases" } } }, "localname": "LesseeOperatingLeaseCashFlowInformationTableTextBlock", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "cemi_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_LineOfCreditFacilityCovenantAmountRevenue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The Credit Agreement contains financial covenants requiring that the Company maintain revenue amounts for four rolling quarters.", "label": "Line Of Credit Facility Covenant Amount, Revenue", "terseLabel": "Covenant amount, revenue" } } }, "localname": "LineOfCreditFacilityCovenantAmountRevenue", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_LossContingencyAssertingDamagesAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Asserting Damages Amount", "terseLabel": "Loss contingency, asserting damages amount" } } }, "localname": "LossContingencyAssertingDamagesAmount", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_LossContingencyDamagesSoughtClaimsExcessValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The excess value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Claims Excess Value", "terseLabel": "Loss contingency, asserting damages excess amount" } } }, "localname": "LossContingencyDamagesSoughtClaimsExcessValue", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "cemi_NumberOfComplaintPurpoteToAllegeClaimsForBreachOfEachSeparateStockOptionAgreements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of complaint purport to allege claims for breach of each of the separate stock option agreements.", "label": "Number of Complaint Purpote to Allege Claims for Breach of Each Separate Stock Option Agreements", "terseLabel": "Number of complaint purport to allege claims for breach of each of separate stock option agreements" } } }, "localname": "NumberOfComplaintPurpoteToAllegeClaimsForBreachOfEachSeparateStockOptionAgreements", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "cemi_NumberOfGroupsOfSimilarProducts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of groups of similar products.", "label": "Number of groups of similar products" } } }, "localname": "NumberOfGroupsOfSimilarProducts", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails" ], "xbrltype": "integerItemType" }, "cemi_NumberOfKeyEmployeesWithWhomCompanyHasEmploymentContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of key employees with whom the Company has employment contracts.", "label": "Number of key employees with whom Company has employment contracts", "terseLabel": "Number of key employees with whom Company has employment contracts" } } }, "localname": "NumberOfKeyEmployeesWithWhomCompanyHasEmploymentContracts", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "cemi_NumberOfMotionsAbandoned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of motions were withdrawn or otherwise abandoned during the period.", "label": "Number of Motions Abandoned", "terseLabel": "Number of motions abandoned" } } }, "localname": "NumberOfMotionsAbandoned", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "cemi_NumberOfMotionsFiledByMunicipalEmployeesRetirementSystem": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of motions filed by municipal employees retirement system during the period.", "label": "Number of Motions Filed by Municipal Employees Retirement System", "terseLabel": "Number of motions filed by municipal employees retirement system" } } }, "localname": "NumberOfMotionsFiledByMunicipalEmployeesRetirementSystem", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "cemi_NumberOfMotionsFiledBySpecialSituationsFunds": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of motions filed by special situations funds during the period.", "label": "Number of Motions Filed by Special Situations Funds", "terseLabel": "Number of motions filed by special situations funds" } } }, "localname": "NumberOfMotionsFiledBySpecialSituationsFunds", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "cemi_NumberOfMotionsForAppointmentAsLeadPlaintiff": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of motions for appointment as lead plaintiff by the court during the period.", "label": "Number of Motions for Appointment as Lead Plaintiff", "terseLabel": "Number of motions for appointment as lead plaintiff" } } }, "localname": "NumberOfMotionsForAppointmentAsLeadPlaintiff", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "cemi_NumberOfRemainingMotionsForAppointmentAsLeadPlaintiff": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of remaining motions for appointment as lead plaintiff by the court during the period.", "label": "Number of Remaining Motions for Appointment as Lead Plaintiff", "terseLabel": "Number of remaining motions for appointment as lead plaintiff" } } }, "localname": "NumberOfRemainingMotionsForAppointmentAsLeadPlaintiff", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "cemi_OTHERMATTERSAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER MATTERS [Abstract]" } } }, "localname": "OTHERMATTERSAbstract", "nsuri": "http://chembio.com/20220331", "xbrltype": "stringItemType" }, "cemi_OmnibusIncentivePlan2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A Omnibus Incentive Plan (\"2019 Plan\") established on June 18, 2019 by the Company. Under the terms of the plan, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to covered by each grant. Awards can be incentive stock options, restricted stock. The awards become vested at such times and under such conditions as determined by the Compensation Committee.", "label": "Omnibus Incentive Plan 2019 [Member]", "terseLabel": "2019 Omnibus Incentive Plan [Member]" } } }, "localname": "OmnibusIncentivePlan2019Member", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "cemi_OperatingCashFlowsFromFinanceLeases": { "auth_ref": [], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash out flows from finance lease, associated with operating activities.", "label": "Operating Cash Flows from Finance Leases", "negatedLabel": "Cash paid for finance leases", "verboseLabel": "Operating cash flows for finance leases" } } }, "localname": "OperatingCashFlowsFromFinanceLeases", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails", "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cemi_OptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options [Abstract]", "terseLabel": "Options:" } } }, "localname": "OptionsAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "cemi_OtherMattersTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's other matters which are not reported separately.", "label": "Other Matters [Text Block]", "terseLabel": "OTHER MATTERS" } } }, "localname": "OtherMattersTextBlock", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/OtherMatters" ], "xbrltype": "textBlockItemType" }, "cemi_PaymentsForProceedsFromAcquisitionOfAndDepositsOnFixedAssets": { "auth_ref": [], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow from acquisition of and deposits on long-lived, physical assets that are used in the normal conduct of business to produce goods and services.", "label": "Payments for (Proceeds from) Acquisition of and Deposits on Fixed Assets", "negatedLabel": "Acquisition of and deposits on fixed assets" } } }, "localname": "PaymentsForProceedsFromAcquisitionOfAndDepositsOnFixedAssets", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "cemi_PercentageOfGrossProceedsFromBorrowingConsideredForFinancingFee": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of gross proceeds from borrowing considered as financing fee under the credit agreement.", "label": "Percentage of Gross Proceeds from Borrowing Considered for Financing Fee", "terseLabel": "Percentage of gross proceeds considered as financing fee" } } }, "localname": "PercentageOfGrossProceedsFromBorrowingConsideredForFinancingFee", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "percentItemType" }, "cemi_PercentageOfPrejudgmentInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of prejudgment interest rate.", "label": "Percentage of Prejudgment Interest Rate", "terseLabel": "Prejudgment interest rate" } } }, "localname": "PercentageOfPrejudgmentInterestRate", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "percentItemType" }, "cemi_PeriodWithinWhichLeadPlaintiffsCanRepleadTheirClaims": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period within which lead plaintiffs can replead their claims.", "label": "Period within which lead plaintiffs can replead their claims" } } }, "localname": "PeriodWithinWhichLeadPlaintiffsCanRepleadTheirClaims", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "durationItemType" }, "cemi_RangeFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information relating to stock options which are exercisable in the range of $6.4 per share to $8.19999 per share.", "label": "Range Four [Member]", "terseLabel": "6.4 to 8.19999 [Member]" } } }, "localname": "RangeFourMember", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "domainItemType" }, "cemi_RangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information relating to stock options which are exercisable in the range of $1 per share to $2.79999 per share.", "label": "Range One [Member]", "terseLabel": "1 to 2.79999 [Member]" } } }, "localname": "RangeOneMember", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "domainItemType" }, "cemi_RangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information relating to stock options which are exercisable in the range of $4.6 per share to $6.39999 per share.", "label": "Range Three [Member]", "terseLabel": "4.6 to 6.39999 [Member]" } } }, "localname": "RangeThreeMember", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "domainItemType" }, "cemi_RangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information relating to stock options which are exercisable in the range of $2.8 per share to $4.59999 per share.", "label": "Range Two [Member]", "terseLabel": "2.8 to 4.59999 [Member]" } } }, "localname": "RangeTwoMember", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "domainItemType" }, "cemi_ResearchAndDevelopmentRevenueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue earned during the period from research and development.", "label": "Research and Development Revenue [Member]", "terseLabel": "R&D Revenue [Member]" } } }, "localname": "ResearchAndDevelopmentRevenueMember", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "cemi_RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Restricted Stock Units And Performance Stock Units [Member]", "terseLabel": "Restricted Stock, Restricted Stock Units, and Performance Stock Units [Member]" } } }, "localname": "RestrictedStockRestrictedStockUnitsAndPerformanceStockUnitsMember", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "cemi_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Right of Use Assets Obtained in Exchange for Lease Obligations [Abstract]", "terseLabel": "Right-of-use assets obtained in exchange for lease obligations [Abstract]" } } }, "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrExercisedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) expired, forfeited or exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired, Forfeited or Exercised in Period", "terseLabel": "Number of stock options expired, forfeited or exercised under the plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredForfeitedOrExercisedInPeriod", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "cemi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that forfeited.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures, Intrinsic Value", "terseLabel": "Forfeited, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresIntrinsicValue", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cemi_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Intrinsic Value", "terseLabel": "Granted, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedIntrinsicValue", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "monetaryItemType" }, "cemi_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Abstract]", "terseLabel": "Range of Exercise Prices [Abstract]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "stringItemType" }, "cemi_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options [Abstract]", "terseLabel": "Stock Options Outstanding [Abstract]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptionsAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "stringItemType" }, "cemi_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfStockOptionsExercisableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Stock Options Exercisable [Abstract]", "terseLabel": "Stock Options Exercisable [Abstract]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfStockOptionsExercisableAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "stringItemType" }, "cemi_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails" ], "xbrltype": "stringItemType" }, "cemi_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails" ], "xbrltype": "stringItemType" }, "cemi_StockIncentivePlan20142019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock incentive plans. Under the terms of the SIP, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to covered by each grant. Awards can be incentive stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee.", "label": "Stock Incentive Plan 2014 & 2019 [Member]", "terseLabel": "2014 & 2019 Stock Incentive Plan [Member]" } } }, "localname": "StockIncentivePlan20142019Member", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "cemi_StockIncentivePlan2014Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A stock incentive plan (\"SIP14\") established on June 19, 2014 by the Company. Under the terms of the SIP14, the Compensation Committee of the Company's Board has the discretion to select the persons to whom awards are to be granted and the number of shares of common stock to covered by each grant. Awards can be incentive stock options, restricted stock and/or restricted stock units. The awards become vested at such times and under such conditions as determined by the Compensation Committee.", "label": "2014 Stock Incentive Plan [Member]" } } }, "localname": "StockIncentivePlan2014Member", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "cemi_StockholderLitigationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholder Litigation [Abstract]", "terseLabel": "Stockholder Litigation [Abstract]" } } }, "localname": "StockholderLitigationAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_SummaryInformationAboutStockOptionsOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary information about stock options outstanding [Abstract]", "terseLabel": "Summary information about stock options outstanding [Abstract]" } } }, "localname": "SummaryInformationAboutStockOptionsOutstandingAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "stringItemType" }, "cemi_SupplementalBalanceSheetInformationRelatedToLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Information Related to Leases [Abstract]", "terseLabel": "Supplemental Balance Sheet Information Related to Leases [Abstract]" } } }, "localname": "SupplementalBalanceSheetInformationRelatedToLeasesAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_SupplementalCashFlowInformationRelatedToLeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information Related to Leases [Abstract]", "terseLabel": "Supplemental Cash Flow Information Related to Leases [Abstract]" } } }, "localname": "SupplementalCashFlowInformationRelatedToLeasesAbstract", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "cemi_Supplier1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A party from whom the goods or services were or are to be received.", "label": "Supplier 1 [Member]", "terseLabel": "Vendor 1 [Member]" } } }, "localname": "Supplier1Member", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "cemi_Supplier2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A party from whom the goods or services were or are to be received.", "label": "Supplier 2 [Member]", "terseLabel": "Vendor 2 [Member]" } } }, "localname": "Supplier2Member", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "cemi_TermLoanCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A Credit facility provided under this Agreement, including any guarantees, collateral documents, instruments and agreements executed in connection therewith, and any amendments, supplements, modifications, extensions, replacements, renewals, restatements, refundings or refinancings thereof and any indentures or credit facilities or commercial paper facilities with banks or other institutional lenders or investors that extend, replace, refund, refinance, renew or defease any part of the loans, notes, other credit facilities or commitments thereunder, including any such replacement, refunding or refinancing facility or indenture that increases the amount borrowable thereunder or alters the maturity thereof (provided that such increase in borrowings is permitted under Section 6.01).", "label": "Senior Secured Term Loan Credit Facility [Member]" } } }, "localname": "TermLoanCreditFacilityMember", "nsuri": "http://chembio.com/20220331", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United States [Member]" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r466" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://chembio.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_AfricaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Africa.", "label": "Africa [Member]" } } }, "localname": "AfricaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Continent of Asia.", "label": "Asia [Member]" } } }, "localname": "AsiaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation.", "label": "Contractual Obligation, Fiscal Year Maturity [Table Text Block]", "verboseLabel": "Future Minimum Salary Commitment" } } }, "localname": "ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r52", "r54", "r100", "r101", "r215", "r237", "r483" ], "lang": { "en-us": { "role": { "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Major Suppliers [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region of Latin America.", "label": "Latin America [Member]" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r164", "r267", "r271", "r441" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of a single external customer or a group of external customers.", "label": "Major Customers [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r214", "r236", "r284", "r286", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r438", "r442", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Upper limit of the provided range.", "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r164", "r267", "r271", "r441" ], "lang": { "en-us": { "role": { "documentation": "Single external customer or group of external customers.", "label": "Name of Major Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r159", "r267", "r269", "r408", "r437", "r439" ], "lang": { "en-us": { "role": { "documentation": "Information by product and service, or group of similar products and similar services.", "label": "Products and Services [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations", "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r159", "r267", "r269", "r408", "r437", "r439" ], "lang": { "en-us": { "role": { "documentation": "Product or service, or a group of similar products or similar services.", "label": "Products and Services [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations", "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r214", "r236", "r274", "r284", "r286", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r438", "r442", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r214", "r236", "r274", "r284", "r286", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r438", "r442", "r462", "r463" ], "lang": { "en-us": { "role": { "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.", "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r53", "r54", "r100", "r101", "r215", "r237" ], "lang": { "en-us": { "role": { "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.", "label": "Name of Major Supplier [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r112", "r285", "r472" ], "lang": { "en-us": { "role": { "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.", "label": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r112", "r117", "r285" ], "lang": { "en-us": { "role": { "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r160", "r161", "r267", "r270", "r440", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r473", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482" ], "lang": { "en-us": { "role": { "documentation": "Geographical area.", "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r160", "r161", "r267", "r270", "r440", "r450", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r473", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by geographical components.", "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r112", "r117", "r194", "r285", "r395" ], "lang": { "en-us": { "role": { "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.", "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesGoingConcernConsiderationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "totalLabel": "TOTAL", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r37", "r394" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts Payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r8", "r37" ], "calculation": { "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Accounts payable - suppliers" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r19", "r166", "r167" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net of allowance for doubtful accounts of $242,981 and $243,042 at March 31, 2022 and December 31, 2021, respectively", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails", "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r7", "r8", "r41" ], "calculation": { "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonuses" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r7", "r8", "r41" ], "calculation": { "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalariesCurrent": { "auth_ref": [ "r7", "r8", "r41" ], "calculation": { "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Salaries, Current", "terseLabel": "Accrued payroll" } } }, "localname": "AccruedSalariesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedVacationCurrent": { "auth_ref": [ "r7", "r41", "r273" ], "calculation": { "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Vacation, Current", "terseLabel": "Accrued vacation" } } }, "localname": "AccruedVacationCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r22", "r57", "r58", "r59", "r427", "r447", "r448" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r66", "r67", "r68", "r104", "r105", "r106", "r349", "r443", "r444", "r484" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCL [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r20", "r325", "r394" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r104", "r105", "r106", "r322", "r323", "r324", "r352" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in-Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedLabel": "Shares tendered for withholding taxes" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "Restricted stock compensation, net" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition", "verboseLabel": "Stock option compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r288", "r319", "r327" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated share-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r26", "r168", "r172" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts receivable, allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from calculation of diluted earnings per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r96", "r145", "r149", "r155", "r170", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r347", "r350", "r366", "r392", "r394", "r411", "r425" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r51", "r96", "r170", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r347", "r350", "r366", "r392", "r394" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "TOTAL CURRENT ASSETS" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r289", "r321" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails", "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails", "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r103" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r35", "r91" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS:" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r11", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r84", "r91", "r93" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents - end of the period", "periodStartLabel": "Cash and cash equivalents - beginning of the period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r84", "r367" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "DECREASE IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r47", "r193", "r415", "r431" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r190", "r191", "r192", "r197", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS, CONTINGENCIES, AND CONCENTRATIONS" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrations" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r104", "r105", "r352" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Common Stock:", "verboseLabel": "Common Stock [Abstract]" } } }, "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://chembio.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r18", "r394" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock - $0.01 par value; 100,000,000 shares authorized; 30,269,916 shares and 30,104,986 shares issued at March 31, 2022 and December 31, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r72", "r418", "r433" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "COMPREHENSIVE LOSS" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r133", "r134", "r164", "r363", "r364", "r451" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r133", "r134", "r164", "r363", "r364", "r449", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r133", "r134", "r164", "r363", "r364", "r449", "r451" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r133", "r134", "r164", "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Percentage of product sales" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r131", "r133", "r134", "r135", "r363", "r365", "r451" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r133", "r134", "r164", "r363", "r364", "r451" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r77", "r408" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Purchases" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsTotalMember": { "auth_ref": [ "r133" ], "lang": { "en-us": { "role": { "documentation": "Cost of product sold and service rendered, when it serves as benchmark in concentration of risk calculation.", "label": "Purchases [Member]" } } }, "localname": "CostOfGoodsTotalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r78", "r96", "r170", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r366" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of product revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Product Sales [Member]" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r75" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "TOTAL COSTS AND EXPENSES" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r132", "r164" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LONG-TERM DEBT [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r14", "r15", "r16", "r95", "r102", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r376", "r412", "r413", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r211", "r230", "r231", "r375", "r376", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt instrument, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r220", "r230", "r231", "r360" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Fair value of total debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFeeAmount": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.", "label": "Financing fee" } } }, "localname": "DebtInstrumentFeeAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r43", "r212" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r44", "r214", "r357" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt instrument maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r46", "r95", "r102", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r230", "r231", "r232", "r233", "r376" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "auth_ref": [ "r46" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments applied to principal.", "label": "Principal installment payable" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "September 4, 2019 to September 3, 2020 [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "September 4, 2021 to September 3, 2022 [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "September 4, 2020 to September 3, 2021 [Member]" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r46", "r95", "r102", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r230", "r231", "r232", "r233", "r250", "r251", "r252", "r253", "r374", "r375", "r376", "r377", "r423" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r89", "r97", "r337", "r342", "r343", "r344" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Benefit from deferred tax liability" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAdditionalInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Benefit Plan [Abstract]" } } }, "localname": "DefinedBenefitPlanAdditionalInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r283" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Expenses related to matching contribution" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Employer matching contribution" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DepositsAssetsNoncurrent": { "auth_ref": [ "r36" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits Assets, Noncurrent", "verboseLabel": "Deposits and other assets" } } }, "localname": "DepositsAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r89", "r143" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Abstract]" } } }, "localname": "DisaggregationOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r328" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "EQUITY INCENTIVE PLAN" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EQUITY INCENTIVE PLAN [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Loss Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r73", "r109", "r110", "r111", "r112", "r113", "r118", "r120", "r122", "r123", "r124", "r127", "r128", "r353", "r354", "r419", "r434" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic loss per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r73", "r109", "r110", "r111", "r112", "r113", "r120", "r122", "r123", "r124", "r127", "r128", "r353", "r354", "r419", "r434" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Diluted loss per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "verboseLabel": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r367" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Income Taxes [Abstract]" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r98", "r333", "r345" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Compensation Expense [Abstract]" } } }, "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted average period for recognition of net unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails", "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Net unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r320" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Net unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock Options [Member]", "terseLabel": "Options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails", "http://chembio.com/role/EquityIncentivePlanSummaryDetails", "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r66", "r67", "r68", "r104", "r105", "r106", "r108", "r114", "r116", "r129", "r171", "r249", "r254", "r322", "r323", "r324", "r339", "r340", "r352", "r368", "r369", "r370", "r371", "r372", "r373", "r443", "r444", "r445", "r484" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_ExchangeTradedMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Transaction that takes place on an organized exchange.", "label": "Exchange Transactions [Member]" } } }, "localname": "ExchangeTradedMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r355", "r361", "r362" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r220", "r230", "r231", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r356", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r220", "r275", "r276", "r281", "r282", "r356", "r396" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r220", "r230", "r231", "r275", "r276", "r281", "r282", "r356", "r397" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r220", "r230", "r231", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r396", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r380", "r383", "r391" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 1.0, "parentTag": "cemi_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Interest on lease liabilities" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturities of Finance Lease Liabilities [Abstract]" } } }, "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r379", "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Total" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r379" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "verboseLabel": "Finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r379" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Long-term finance lease liabilities" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 0.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Two", "verboseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.", "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r390" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r381", "r385" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Financing cash flows for finance leases", "negatedLabel": "Payments on finance lease" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails", "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r378" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance lease right-of-use assets, net", "totalLabel": "Finance lease right-of-use asset, net" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails", "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r380", "r383", "r391" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 0.0, "parentTag": "cemi_FinanceLeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r388", "r391" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "verboseLabel": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r387", "r391" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance leases" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentsOwnedAtFairValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments [Abstract]" } } }, "localname": "FinancialInstrumentsOwnedAtFairValueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicAreasLongLivedAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographic Areas, Long-Lived Assets [Abstract]" } } }, "localname": "GeographicAreasLongLivedAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeographicAreasRevenuesFromExternalCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographic Areas, Revenues from External Customers [Abstract]" } } }, "localname": "GeographicAreasRevenuesFromExternalCustomersAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r176", "r178", "r394", "r410" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill, Ending balance", "periodStartLabel": "Goodwill, Beginning balance" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/GoodwillAndIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GOODWILL AND INTANGIBLE ASSETS [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "GOODWILL AND INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GoodwillAndIntangibleAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "auth_ref": [ "r180" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Changes in foreign currency exchange rate" } } }, "localname": "GoodwillForeignCurrencyTranslationGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GoodwillAndIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r89", "r177", "r179", "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "negatedTerseLabel": "Impairment" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GoodwillAndIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GoodwillAndIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Government Grant Income [Member]", "terseLabel": "Government Grant Revenue [Member]" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r89", "r185", "r187" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r145", "r148", "r151", "r154", "r157", "r409", "r416", "r420", "r435" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "LOSS BEFORE INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r99", "r115", "r116", "r144", "r332", "r341", "r346", "r436" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax (expense)/benefit" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r65", "r330", "r331", "r334", "r335", "r336", "r338" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r88" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r88" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r88", "r406" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r88" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposits and other assets" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r88" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r88" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest expense, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVENTORY [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r175" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORY" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r27", "r174" ], "calculation": { "http://chembio.com/role/InventoryDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r50", "r394" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://chembio.com/role/InventoryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "totalLabel": "Inventories", "verboseLabel": "Inventories, net" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r29", "r174" ], "calculation": { "http://chembio.com/role/InventoryDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r28", "r174" ], "calculation": { "http://chembio.com/role/InventoryDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/InventoryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Components of Lease Expense [Abstract]" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r389" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Components of Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseDescriptionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Description [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LesseeOperatingLeaseDescriptionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetailsCalc3": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "verboseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "verboseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "verboseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r390" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetailsCalc3": { "order": 0.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r40", "r96", "r150", "r170", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r348", "r350", "r351", "r366", "r392", "r393" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r25", "r96", "r170", "r366", "r394", "r414", "r429" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY", "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r42", "r96", "r170", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r348", "r350", "r351", "r366", "r392", "r393", "r394" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "TOTAL CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER LIABILITIES:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License and Royalty Revenue [Member]", "terseLabel": "License and Royalty Revenue [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LondonInterbankOfferedRateLIBORMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "LIBOR [Member]" } } }, "localname": "LondonInterbankOfferedRateLIBORMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.", "label": "Long-lived Assets by Geographic Area" } } }, "localname": "LongLivedAssetsByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r16", "r219", "r229", "r230", "r231", "r413", "r426" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Carrying value", "verboseLabel": "Outstanding loan balance, net" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails", "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r39" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-term Debt [Text Block]", "verboseLabel": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongTermLineOfCredit": { "auth_ref": [ "r46", "r198", "r199" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the noncurrent portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term debt, net" } } }, "localname": "LongTermLineOfCredit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss Contingency [Abstract]", "terseLabel": "Employee Litigation [Abstract]" } } }, "localname": "LossContingencyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r193", "r195", "r196" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss contingency, claims entitlement to recover damages amount" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r195" ], "lang": { "en-us": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Number of class action lawsuits" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency.", "label": "Number of filed complaints" } } }, "localname": "LossContingencyNumberOfPlaintiffs", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r130", "r136" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "verboseLabel": "DESCRIPTION OF BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/DescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r84" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r84", "r87", "r90" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "verboseLabel": "RECONCILIATION OF NET LOSS TO NET CASH USED IN OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r60", "r62", "r68", "r71", "r90", "r96", "r107", "r109", "r110", "r111", "r112", "r115", "r116", "r121", "r145", "r148", "r151", "r154", "r157", "r170", "r200", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r354", "r366", "r417", "r432" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows", "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss", "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards Affecting the Company" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of operating segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/GoodwillAndIntangibleAssetsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportingUnits": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.", "label": "Number of Reporting Units", "terseLabel": "Number of reporting unit" } } }, "localname": "NumberOfReportingUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GoodwillAndIntangibleAssetsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "COSTS AND EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r145", "r148", "r151", "r154", "r157" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "LOSS FROM OPERATIONS" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r384", "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maturities of Operating Lease Liabilities [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r379" ], "calculation": { "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetailsCalc3": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r379" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "verboseLabel": "Operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r379" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r382", "r385" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating cash flows for operating leases", "negatedLabel": "Cash paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails", "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r378" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r388", "r391" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r387", "r391" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating leases" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DESCRIPTION OF BUSINESS [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r41" ], "calculation": { "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Accrued expenses - other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInNextTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "2023" } } }, "localname": "OtherCommitmentDueInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentDueInSecondYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Other Commitment, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "OtherCommitmentDueInSecondYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Future minimum salary commitments [Abstract]" } } }, "localname": "OtherCommitmentFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of commitment classified as other to be paid in remainder of current fiscal year.", "label": "Other Commitment, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022" } } }, "localname": "OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r55" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustments, net of tax", "terseLabel": "Comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://chembio.com/role/CondensedConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER EXPENSE:" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OverTheCounterMember": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Transaction that does not take place on an organized exchange.", "label": "Non-Exchange Transactions [Member]" } } }, "localname": "OverTheCounterMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACCOUNTS PAYABLE AND ACCRUED LIABILITIES [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r81" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-based Payment Arrangement", "negatedLabel": "Payments of tax withholdings on stock award" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r80" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Patent application costs" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToSuppliersAndEmployees": { "auth_ref": [ "r82", "r83", "r86" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to suppliers for goods and services provided and to employees for services provided.", "label": "Payments to Suppliers and Employees", "negatedLabel": "Cash paid to suppliers and employees" } } }, "localname": "PaymentsToSuppliersAndEmployees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r289", "r321" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]", "terseLabel": "Preferred Stock [Abstract]" } } }, "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)", "verboseLabel": "Preferred stock - shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://chembio.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)", "verboseLabel": "Preferred stock - shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://chembio.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r17", "r394" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock - 10,000,000 shares authorized, none outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r33", "r34" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "verboseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromCustomers": { "auth_ref": [ "r85" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services.", "label": "Cash received from customers and grants" } } }, "localname": "ProceedsFromCustomers", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Net Product Revenue [Member]", "terseLabel": "Product Revenue [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations", "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r12", "r13", "r186", "r394", "r421", "r430" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r74", "r173" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Provision of (recovery of) doubtful accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r329", "r407", "r464" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expenses [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesFairValueOfFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "auth_ref": [ "r89" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation.", "label": "Restructuring Costs and Asset Impairment Charges", "terseLabel": "Impairment, restructuring, severance and related costs" } } }, "localname": "RestructuringCostsAndAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r21", "r254", "r325", "r394", "r428", "r446", "r448" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r104", "r105", "r106", "r108", "r114", "r116", "r171", "r322", "r323", "r324", "r339", "r340", "r352", "r443", "r445" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUE [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r141", "r142", "r147", "r152", "r153", "r159", "r160", "r164", "r266", "r267", "r408" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "REVENUES", "terseLabel": "Net product revenue", "verboseLabel": "Revenues" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails", "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations", "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r268", "r272" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "REVENUES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues from External Customers and Long-Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "auth_ref": [ "r386", "r391" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases" } } }, "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r133", "r164" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Sales [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "verboseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/SignificantAccountingPoliciesLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r288", "r318", "r327" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Stock-Based Compensation Expense (Net of Recovery) Recognized" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r181", "r183" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Changes in Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GoodwillAndIntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r10", "r30", "r31", "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": { "auth_ref": [ "r76", "r163" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Product Revenue by Geographic Area" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r69", "r163" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependencyDetails", "http://chembio.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r289", "r321" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails", "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "Stock Options Outstanding" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r294", "r306", "r308" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r312" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Assumptions Made in Calculating Fair Values of Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Summary of Restricted Stock and Restricted Stock Units Outstanding" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r131", "r133", "r134", "r135", "r363", "r365" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Customer and Purchase Concentration Risks" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r137", "r139", "r140", "r145", "r146", "r151", "r155", "r156", "r157", "r158", "r159", "r163", "r164", "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "GEOGRAPHIC INFORMATION AND ECONOMIC DEPENDENCY" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/GeographicInformationAndEconomicDependency" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r79" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedArrangementsToObtainGoodsAndServicesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Arrangements with Employees and Nonemployees [Abstract]" } } }, "localname": "ShareBasedArrangementsToObtainGoodsAndServicesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r88" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedCalc3": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding, end of period (in shares)", "periodStartLabel": "Outstanding, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Number of Shares & Units [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assumptions Made in Calculating Fair Values of Options [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r314" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails", "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Increase in number of shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r291" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Number of shares authorized under the plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Options still available to be issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options, Additional Disclosure [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Exercisable, end of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "periodEndLabel": "Exercisable, end of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Exercised, aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Expired (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "terseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "verboseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding, aggregate intrinsic value, end of period", "periodStartLabel": "Outstanding, aggregate intrinsic value, beginning of period", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails", "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r296", "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end of period (in shares)", "periodStartLabel": "Outstanding, beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Stock Options, Number of Shares [Roll forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end of period (in dollars per share)", "periodStartLabel": "Outstanding, beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options, Weighted Average Exercise Price per Share [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested shares exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "verboseLabel": "Number of stock options exercised under the plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r287", "r292" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanRestrictedStockAndRestrictedStockUnitsDetails", "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails", "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "terseLabel": "Range of exercise prices, minimum (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "terseLabel": "Shares exercisable (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Shares outstanding (in shares)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "terseLabel": "Range of exercise prices, maximum (in dollars per share)" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r290" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term to exercise stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r313", "r326" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r321" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate intrinsic value", "periodEndLabel": "Exercisable, aggregate intrinsic value, end of period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails", "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r321" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable, weighted average remaining contract term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding, weighted average remaining contract term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r293" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Total fair value of stock options vested during period", "verboseLabel": "Exercise price of stock options" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails", "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "verboseLabel": "Weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (in dollars per share)" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Average remaining contract term" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanStockOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedLabel": "Shares tendered for withholding taxes (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r49", "r66", "r67", "r68", "r104", "r105", "r106", "r108", "r114", "r116", "r129", "r171", "r249", "r254", "r322", "r323", "r324", "r339", "r340", "r352", "r368", "r369", "r370", "r371", "r372", "r373", "r443", "r444", "r445", "r484" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement, Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r104", "r105", "r106", "r129", "r408" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity", "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r17", "r18", "r249", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Restricted stock issued (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r17", "r18", "r249", "r254", "r298" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/EquityIncentivePlanSummaryDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r249", "r254" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Restricted stock issued" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r18", "r23", "r24", "r96", "r169", "r170", "r366", "r394" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets", "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r94", "r235", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r254", "r257" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CommitmentsContingenciesAndConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/RevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/RevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r48", "r255" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfChangesInStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r48", "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "verboseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://chembio.com/role/StockholdersEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Treasury Stock [Abstract]" } } }, "localname": "TreasuryStockSharesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/StockholdersEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r48", "r255", "r256" ], "calculation": { "http://chembio.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury Stock, 48,057 shares at cost, at March 31, 2022 and December 31, 2021" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/LongtermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r119", "r124" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted average number of shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r118", "r124" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://chembio.com/role/CondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r103": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r136": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "b", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1314-112600" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1336-112600" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r234": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r257": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r328": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r465": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r466": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r467": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r468": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r469": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "303", "Subparagraph": "(5)" }, "r471": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r472": { "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "11", "Subsection": "03" }, "r473": { "Footnote": "2", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r474": { "Footnote": "4", "Name": "Regulation S-X (SX)", "Number": "210", "Publisher": "SEC", "Section": "12", "Subsection": "29" }, "r475": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column B", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r476": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column C", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r477": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column D", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r478": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column E", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r479": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column F", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column G", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r481": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column H", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r482": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "Column I", "Publisher": "SEC", "Section": "12", "Subsection": "28" }, "r483": { "Name": "Regulation S-X (SX)", "Number": "210", "Paragraph": "(m)", "Publisher": "SEC", "Section": "4", "Subparagraph": "(1)(iii)", "Subsection": "08" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" } }, "version": "2.1" } ZIP 61 0001140361-22-017906-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-22-017906-xbrl.zip M4$L#!!0 ( ,N)I5290YD[D-8! -=$%@ 4 8G)H8S$P,#,W,3(V7S$P M<2YH=&WLO6MSVSBR/_Q^J\YWX/'NG/],E9P0%^*2R;A*L96):QW;:SM[>=Y, MX4:;&UGTDE02[Z=_ %*R=:%LV=:%DI%*(HE7H-']0W>CT?W^JKCN!C^NN[W\ MW0^9=9/?=JZ*XN;=V[??OW]_XXZ\2;/+MS ,T=NDEQ>BI\S.X/INTOOZP.7N MM!3YW>4_IJ[_CLJK >?\;7GV[M(\J;O0/A:\_>?GHW-U9:[%[F1[W.OU_8VC MK2%OJY/#2Y,\Q1#0ASI;77%WPX]9UP)'&-MX\\\/9T?WEQ?UU]]?^K;(1"^/ MT^Q:%$G:9'^_N4R_/?HJ-)^K\ANZY\[ M.%D^^^Z&?I:9GIIUQ^#LV"T]D:B\_OKRU-C%>:+J+[4GQB\L;K(95]HS8Y>: M'^JJ_E)W9ORI63$])/9@W7 4V6YQ>V/R>DK;TV_=:7=GZ.X%=9$=(/SM-MWK)JW@L.>>E/=6_XY2%7_ MVO2*0&5&%/89_3SI70:=@]_;9W%B.?XR#T[/3NQ7$[ W\$WX)ARY>S^]NFT($KL>[YC_]Y-MO._MIK[ OWKVP9-P)5/7K MMYW"_"C>EA0(WMI[W[\=D,!^E:F^#?+BMFM^VY%"?;W,+ OK795VT^Q=\.>X M_/-K,/P=EG]^=91\KY-O0:)_VSDX/_V8.!G^E&AM>CO#Q^DDO^F*VW=!+^T9 M>\O[Y,<[]V*355_+J\NO]H)C2[$L44%/7+M;3?*N;4FH'1D_=L7E3OFFCT(5 M?TA.&!9$:8(P#C$7C$"%#=>(X"@D:-#O'\69B7_;426'@! 4Z3VO5##SVXZ% MIG\.5%K<[>P!:Z9J[M4.VO&_N1WLD M'VDLYT3%$'$B ,(: \&H1"%0*A+81%0^WM@]]^V9+3JU9U,]V29AH!UP%H>1 MUI@SS&(.M8G"R$2V80XB'FW3W^:G4:=GD>!VW[8I$]W#GC8__FIN1UH#0:@@ M,;& 2F F#),PTH1*' +*(HWG:(V5'Q!R2,@L.GW,[)LLL R:-9C>WIV9;Z;7 M-Q^S]-J)N;OH'TEQM=_/B]3>W_FANGUML:6=Y\;^U1?BQTC#[>N)4EAS"F/, M+!D-#R-J-#+42(K8=,/!7<.!:_@?]J6JI(MKVUF2?_UP^\'.7%?7(OO:_I'D M?YR+KLD'K3PVQ6>+TB:KN\VA4WG'L.U3UPSN_2S^G6;#B_*Q6T!UR4[0[R55 MF[^$(;330)Z\ZR5=BWE9W\KSD,1#FCY"XZF&6)YT!\2E :/$C#0%'!-&+.;0 M2$L5TC"D %#)<1S7"/4&$A.OB)A0T4@HA!F.(VQA1Q!D\5WR*%+,,FR-@#^9 MF/MI7IS$OZ>ISB_20G3GH.9Y_^:FF\RFYK[3]$QV([+B]MAV>^RF9='SKA?M MGCXWV3>KH^16#=$CU 2"&Q9C3@ WF!%+0@B$12AJ(A/;*7);J/EB46^K4EG/ M3\6MD%TSF,I'*!G9N5H2R6(888R$D!;V*0$::AT:S6 -)0&LIU^3Z7!^)3+S MP1JX>C^]OK$Z;]FF=F;-L4OC)N76&*Y0^WO(M,?19+]773[QDXX_>N; M4A7N_+@QRFJ\!\FWQ"IW^FQ<&=(2PU!C(QA2F$> 00&P ,3("#(3UC#GQ.SY M1_GF.W)VKF^ZZ:TQYT6JOIZ435B*Y-D)VC[T)#ZY,6[(>I?GYM+1851/08H2 MR.-(R9A@A+#0=CI0AL=06Y5*\SD4O9$V@W GT$8EUU8?_6WG\/BC5?:6T&B% MC&1*B!A%P$*MYMHJ)Q!B+,,X0O$CG[[MU0JSGI&EG^?=55:^Q39^=_C\-S]R"\?5:6?,_K:3)Y9+2YX;?T;UNM%WE#_S MM)^5OTH_UKM!=TH*U'9G<)TI%=?A+R=\11);T C*]YE:[\O^X5_'U=')F_>& MA\:??E,JZL-?>6'1R@U31=G0&?W#^^[/W353CUR*RD$8/S/\/7S)VS$ZS"8+ MAKP!Q*B<><6@?W@7\KL'#H?&(+$0OHWH62= M9JGN6ZC+!FI<.9V=F=P:Y>K*:G<'5O/OIC<.KP=&P&!B6S*)!F);S1353VU? M]L,J("H96"&!3NS9W(*S!;>L>%?7EYV]$M+GZ-'[M[4ON2/L75N>"D5@?B@" MBX2BN89ZX%[ILL>QX]-T?^&J"6;PYC>\6NP8P]UPAZ*VP;ACHL??'GA5LO MMXWM_*?OUG73ZYNTYWR@Y4BWE>I?][LN1..DN')>^>N;S%PYJGXSASV57C=T MO.]\]P]U[UZHY^[G(KE@Q),2+M*3$C;/4[30_H$Y&/?,%"+I&=T16<]%$VT% ME]9W:DDLN5CGWAQ#9G]>I[URH6HK1FNJ/YLP4/-,"A>9$7D_N]V>H:KIT28 M_3Q2U=8Z<:N$HGLJ$GW8VQ@G_G6-O,UPFLXN?+H^:$9_-"42!!OS"S!F-G MD?:3]Z:-[]-F>B_)KV8.]T;OJY1P/^ZO4]Z]CV3[9=MK9YLFPT\;7R_#FSG& M?E9>]1+$8O?H>9=8@Q8'5SVP7C*;.X!^\:(YDKERR/6^JHV31:_ -DF^FA5, MOG)F]/C1/);T#H[M 'H_4!LB47Y&;HQ4X8$G$(T/V[DR/6&?5*7$&_SXF&9& MB;S!^\AKV[^S5YZJ[<0R_7YX3K\?6NSZ#+WS[1(4^A%=Y&H,G=^32W91N* 1 MK?)X=FGZV@'3[661?3?&QW],#[>N/NXR1'V[OOGZRX^#V M)M\>N9W)Y=UWYPY[-_TB+T^ 9O+#$&SGZ]D].#_0Q9G<,G=C9@_,?0/J1VAI M$\1"0W:19S[/?.M1)2OF>P$KP>UG);@YPUE-9'XXUS><2TVRV;9MT(FKTO+- MG!O5SY(B,7E5*,'HJI#"M>UHF6CX)![ZBDY-5F6\OJU_P".IIQO*"TLDQCT# MS:3*,G7@1D0D>5[;?EYK2G34,GGMS.1%EK@<_AO@"EL)G]529.MX;)5SI^>Q M]?)84^;,.T_:[R:]S,3-5:)$I6L?N8(5[;(J@V@F>XQY B?;7WD#ISNQ]:@Q M>T3;\4:/Y6CSMTXNYQ_%3C]+;\SG1.NNZ6R&EWYZ/,NJE3/?9FE'^K*58.RY^R4U\PQOU_VG&K_B,E0TY'GNSR;D>:[*=#_>)KO M6MXZ^6:RBRLS*'RVP;Q5UY%E\I8OX# '=VT"'$MF0T$CZUDPTTP;1K/ABLUJQJM(7DGW]*T M[U=59] [^;;2R=<4['I@;3I/-GAE^J[Q6X\/FRK\7B87NASMM8D&^_*:L@#@ M&6?;1M1[8IIF K\*-IS?C>N#5K=("7E\V>=U:IX+4$/F6VG:%KSPBXK;N*C8 M%.SR ??;@!&;"@!>+I^Q$<8[&S=B!+=8*VS6O/TJ')\+"6+NKH6V=]FT.SUX ]2=&,*MGW6]X*R*8YHO&"O!ATV=<9XL./MI M7IS$OZ>ISB_2NZI,#TK.>?_&$FNVY Q<43>VR[?'XGK\IH;*SM.YNIYP+\/[ M.LH-Y'>"?BL2GT>&VHO/JL6GX1E1E\I4VR/$2TCZV@CQ>;*]X\5GD6RS 0*R M$;-/4[S8C1.?ABIO6Z4ZK5^(-U9\JKHIWN9?I]1DY:0@F, MUZ;/-F.B7)\QMCY"I9POG) M$HZ#X4L]>0CPH2V"=56G;2GT]ZA4WREZ'T]B6-C[W.GCPX_G)PUFRS.R,V>> M;KU7PIXFP94RZ6)]8N"YN+E,_ Q]?!4PWV#_CQ\O/"W;PP?OV9 MT>:ZK%]\6K:BO/_A2RZN,F->$Z<\\[5UI+V?/^:F\;;-(>MGX)/>1K'O2_CH MKJM;II6_7N:]^)YN$O-N(O8.*;QMS M!2&#T1_N[R/3]+OOKFVYZ:TQ9^_ND M),. 54^[HG>WTGARW4MD/S\LU\R2;\:==,UK-B^.=75D4_RL/K^<#4>)-N#[ MATFWM-7KD.S":#'.3QP2P)_'-^7IR:YCSS6/0M'KPR87IG*M;3-$A-[LVU7 MTFMSE];N*%5EE'4%+J;;37J7OYN>R42WW=-M?9WTDKR,Q/YF.C]N7/;7O-E\ M\T '1R+-G]+396K6CGP-UP/Q;,-IS M]&_K9/LIX^]E>[/&]BFX[65[^[#]*>/O=;G5ZG)-X8DY+<2FCOBK]PU5F]O] M*"YFI7WA^\3]P#3.P[%P;ZKWC;W A[NQWC&/N^NRD!:X?WVJW,B5R,P'D1N] MGUX[/;#4'\NC>;M?7*59\E^CO_2TR4:(XW@Y_W#;^6$RE>3F-$N4N4_D4'YK M?*SG$GH^K)PSUO^M4\!6QD*-CW5?,@L]'@#O6>@Q%&K^?I]EX]#R=^-L/QM] M3/L-KR2[9"ZZ)\ 6,I%'H$U$H.5:RUXOWB2]>$-YP4\K2YE6-I0;O+FS0;/$ M9!2!]XMM=N1 G7?SS.2%Y=;"Z++_$S^_])(B;_?TJ67.LU2W5?%279NLF]6-2F'?7!P ML")ZOF$EV>NZ=#^GC_7M^>N>OO;[4/5[$0>U\T0T$RF:PDGN]#V5MD_Q7"0W M'5F+K->^M@U0#>:J1P9[NA,OXZU%,/&F;83<6DQ7*45].;H:9O MQ0RW.8I4$SCK.1J;GP:]->C5].5ZKAJN9"U"]]D8CEKOLNFFV7(K-[&6N^7. MSP -7&=Z3#(V1P=6QHFNTT68LO8UU(YH=B98#U MV%!XE7BAY._WDHKV7RQ-[BA[;43>S\S>H%UEB/+P <-SP]_N"75/@U-/2_(4 M0T M)0Z>^K#[*M Z^68':_2:X[Y%?E&DV3/?-W6_.WA@>NEUTJM[[+Q$&7O$ MV_'6/])=/&,D;NS7IY(NFGI6J=+\U=P.PY.?^D12_\0C\3WO)\53GT;KG]:^ M<3)B&?G)C,?J'[C?%Y;V;Y[X+!#6/^N\DOJG/FU:6,NGN7#" MAQ^5_'B7F6ZY]R"_2FZ"--,F^VT'O EW I&I+.V.(Z>[]TV:7;Z%5@S?#JYX M&PM5[,9I6O32PNP$<99>GYDX_VWGHSWQ1\19)(ED,8PP1D)(8F)*@(9:AT8S MN!,4Z>!R^X@_0*@H#2$1D,98("HE0)#'(4<4AIR!G:";]+Z>/=RRLEGN.DN8 MMQ.=7$VOPTA3P#%A!!%,(RU52"U_ T EQW$<;6>OH:*14 @S'$<882T(8EA( M'D6**:S!=O8:"&Y8C#D!W&!&;%5$;K4JNQDN_<_?_J?/P6!^_?>_@SRXM:] M++9*T&XLKI/N[;O@_UU872X/CLWWX"R]%KW_]VM0GL^3_YIW 0AOBE\#IS+M MBFYRV7L7=$ULCZBTFV;O@C^'Y9]?@YT]]Y+QUXS>Y=(8F6SPZ#E?C=VKRP/? M37)Y5;P+9-K5OPY?95]VE0W?)=A,= MR*Y07^_.%^G-NP!/GKP:O,QV_<=]1^/RC[W57G-IY[^>WIT\5=??:Y%=)KU= M1[1W@>@7Z=VAK'I+>6PG>#LV8"NBXY?CPXO.07!^T;[HG ?GG?TO9X<7A_9K M^_@@Z/QS_U/[^/=.L'_R^?/A^?GAR?'RF@AG-?$?PC)Z[[)(>ZW@X,W^FP"& M$>;3#=E[+S-+Q,&!I;63S6KGQY.SSX$#(8R8I@K+",C:$@8 W@G&)@K%E1J5WAW]D"X^[=2 M[._?6\-)#U&G<%7>+3&ZW?Q&*$OKWW8L9+K?-T+KX>_G(L?W1!=7[D?XTQPP M8M_;%;G%SX/STX]'25Y^R"Q?=6_/S$V:%2/#'0,NXQ!'RB"%,55"2T$D MB77(HM#.%(\/=U#NG2E^VTDL(:U-_TZF:5>*;C:( M0L]%J@JA:DDU.GC_[N=%$M^.0/$ D%\PR5C26@;LC4FJ-BK-RNGN7=!W.X/M M1&CLE7_[TCZ[Z)P=_2LXZYR>G%T$IU_.SK^TCR^"BQ.'8Q<6K * @I.S $0_ MZU^"DX_!Q:?.*,3=P5M[_\*=!ASA-^_?NB;<"=!(Q\8)6'+?VQ'VJS[_YT_V MH./8O94#4T7!CVD6%%')9@N%&>W!6:+.R8GV=Y&X=(W =#JH>_[+(T7*4OKX, M\DQ9.+D6E\9!7.X'H6HP9K)?4FX"KX1(XTT*<'RL>X:E_O9$ M1ERACC%PH%C%HBMN&\"AG^?! MZ71=>.M*<60W \DJEU/WJX73_52/B0O2V$*PP#B2&*A(Z%@;K,)08APC+9^A MW.3N;3=9^LVUR:GBQ^:;T&(60,^/&'C#T>P!FW"6AJ-YL,/>'/PCR4S7/C[XT/VF:]2YAA)EWWX]R2[2 M[[T1DJ!84\2@B0DA&#$@%".800FY57DY,'.0Y)/HW]R(_J69I$1KMFMOK&$E M_IQDIW:RMU@SJE=HC3@62''*# :2L\A *%40H0AXWJ.UAW_:[)9 R"8JVFG M5G$7W?\ON9E0> 36/()<2T)#3"VEE%5X-",1B)D&(9]GC010QAIA;P[ZZK#^ M)K,CD-R(;F!^&-5W-5[L80LH]LGV3+?O%/;@O\F-[9\V"S5)%R,*/\\<5\?^ M[N8(VH>(<83&'7VZ/H"E%XI?9K._JV75/K]+> MM"=#0LVTI""R<(0M>TDJ#)!Q%"/+[B&:9^6-0[P+ (H:P5CWYO7__9E!0'_- MK1W6-3>N\T&O['UKA*V$'9U9?+7\UMXMWZ_13Q^,2D\E036^@?6V\?AM>T6M MFL%5'ZVE:'6=X])ID06#GP,0L_P4!_M7+O>N#L[==!(5]=!?E5ZCPY0_]P M<26*R;9_%V.MK+KOVED]8="17UJ!Z.G@9UAU5%I+W9Z7_[;=<%TK+[4WN:8, M'N:62?*R)65+W=CP,-#B-G\S3?4Z;AHN/RQR_:::\_?[669;5[&*;;+32_KY MJ/YHN*(P=F ,<*RQI#B4-!*48 D00G/@\[]<>'*M/C(J@/62,+NOSKKA%)-? M!Y(9'*?!(AZ(?YWIG'S&1/^"D7N:W#E6M%QXG12%95X[XZ@B2WO.9NO>!L;: M;[=6D"W_VS%U"LZ!*$3E:9\0R_MGW/2SO.\>;4^<]>V5.(R=?&)NS4G\FLK,?8=V1 1[2!?6YKN629&EE.&T0AK_.:&9Y%OS:&E[VZ 6SFSFXLIRC!A'+,5S&I+7YCP\OO$EA_739E>>L]GS<4O)PE=[SA5N=P)/EM M!^Y,=(*O2XH[]=K@DIEU^-;?RY?N5^\<]4DK%'-K8KD -@P!9R0D=A+#(2/" M8@Y=9JQH$V(@7V(MQ:-VR<2P.F=SK3&5Q'4NA-)Q8*&]EY9V?S^OC!G;T"IP MO2;0TII%[EW=6_?R[XE]M>.FGFURZC#Q6Y(;/229-8E$3R6BZ[1 %U;C[G%I M K3(=!ZXV)=$3_@>[OV#/XM?YC1/%DQA:\8O=IKS%KL(\BMK$=ZAS\^6^4J3 MN8J]>]@@_64CAORQZ=OU?QH(*8XT51$&$C&LH> <&*&$8=*B%Y/+!\*AK"Z( M1:?T^;E9]-'EJ1<,[\C*0L67)IL%._!G>0<[EO?>U2T![8TO8DU=LG$ND5&G M2+UR-EL]0WR&9O/T^+QE+/M=)$6W#/VU8G55;<"9GOMKE+H'@KSFU.16IY$^ MJ?EPEN'4D/'*1+E8<'Y[+=/NZQZJAHO6\2"HOI0L,YRP+8A^OTK*!=0ATLY% MAAHK<6%0M IJS)S_!Y//K=5O2C :"_4U6#$D><@,1A$2")J8V[]"(:/Y'+/_ MGMM*X];F7%&_5O"7\$T(@AN1!=]$MS\5K_:ZQ6DF\JV5/0: 5^'=:-RB) S+ M2,B8"(P$YD8SJSUP90CCD9DG;G&_\_G0L\#F(,30Z)G8JN5&&X144!U9N' . M$JY":C2@BAHNY@C*F';\VS<-MYU<6$WWN'U^T/Y;A2+!9VO+F2(X.MI_%O/, MDS7;L>URL;9]DR7= /)J"WQKVE%RMX/_8QE!8.%V*K"F1.&2?%5E M]9-^43HZK&2/RC13%!&AB8AC+"ED(5$L9H@8*G#,:S=R8LAW I=#K3Q6YDNT MIK-*KD4W_VWG\/BCM20L,YO2IAC=[=_K7^NT&%RZLX?"%H2@Q:*[+:##WMP- M5)5<,$COVU[NCG ;XZI9)A_,,F.3S/*M\^#I3/%9,<325Q6@TQ=%4 M_J/&I3A272,R%UI<7-W=736]-#4'1^[R.94T&LUB<"HNS8?,B*\N[K@^PO3& M7K(KW36[(K8-?R>ZW\5M/N,YHS@\,@950RIRE[2K,X('Q\)[.L-1,@]39M60 M>7AJE!PUA!O_];^[NZ=G)VY5S+6^"G4^,[DI?K+??X(__?33[N[>V$TE,HZ0 MYLFF_]/R@8T-QRA=%S&S342EU\3UCCM%EO/:NZ0_@_!79WVX<-F@RL^TBB:X MI 1N"KUO2I7-)>@X%_IJVC"9Q*7NG7OK&:'WHIS^RE0G:;SOIK=>D=OC5GS: M/7659E9*WK\5>^45;KX97M.H;CRPU_VYK9S/2R@'"16;YC <=QG.LM0?"&N8 MJ8@/%?TII7[VP]A"GP;F]9#=N5N"[%+^'+8"]_>7&EOB<9X<4'KL.<]B5#<7 MU:GI,\VD*9_+*QG+VIPA,]_P;$K5A 3,9W].*&K/X _'#'9*/'P3?#P\;A_O M'[:/ FLOG)Q];KL$0N_F9I-M(.\F\LYZI&P9C'A8&*N364:\BPBX*UV0;P4? M>D!<+*5JK#3'U\)@C?3L\ZGSO'Y MX=]GJP?CR. "#C-SY6J&?3/!49IO!T+4LR29=+K-;)B79B_-:Y;F\XN3_;]^ M.CDZZ)S-.\U723]OKU\;XI\[[?/ M/\TKUR*_"CYVT^_;/#ES+[Q>>#=%>(]/+CKG;@=T8:\ITF"&&-=YLT=%N,GR M"$(OD%X@-T4@/[>/V[]W/G>.+\X/#L_WOY1E\=K'!^W!TA)\8^?$GK@L9? N M%>-!DJM^56;"39'MGNC>YDDYY]Z+KI/M:HNKN^;,Y/WNI%>MR7(,J9=8+['- MD]C]D^.+LY.C:I ]T_'[=[#NOT_N?Q]2\8F;VI:T:W?R-77= MGGQ,M>VU>LYT_K"98]\*RB.M(#=9$H_M66-3A8]Z;E-[=[Q8RN#8C/;L[,$9 M%5PF^_C\W/7C"6^G_FA8/]JA/7 M.&=KGMCNB\R"6G;MTN'%+F%C&LS5.6 N%_Z'!V9O"_S1"=?Y0=.+?32;#_J;/_5U>$*W!T',D$6&16 M$%P*R[RJ]F,O_/SA\*3\_OEP_^PD..NT#SIG=_?>W_#&[3=WM/EF>HGIJ8H[ MR*[ZV*+@Z9\N%M(SUMU(;LCR=G_VB?'>P>G9S\]?#X]W*XJP7" MH'U\4/X\/+\XW&\?!1W[^=F>/5\CC_Z[R/1N-TV_ M#M+M#MXQ+ #BF*UD15,RSB#+B_MYFB7?7%;7D7291_;CLEP%'>77,^.:<5^< MBT=O7 X$R_6S7U_*SJ7IF:PL4I0,"KDZZ;NR<]WE5=F$LE9>/JC+6T%L6>5' MY'?%4NQMKH!C8>Z*GPS.2---S+>IPR607]]T:^Y0:;^K)P]:(4FN:RXV/V[L M"$T>M1TV2N13QQ,WTTT]^UK<3AY*RUIBR72[[=@[*@X/C])_<(7M4V_RKIO4 MB7W/C?DZ=>RJCBXN'5)A+JF# MLD3RW/E$=Z8].:MH>[Z4UU]1!<*QZH:@,-V;!"W%19F0D&JE_8^]65>DK*X/BF[ TMN _VN^D5R61LB]JC=+2\MI@ M%AIP4CEN%40-*']/2#MM6.Y?JSI0B[A#V;8]&>N%;7%5&ER[2FGV&S==:TUBO'#VNM.?[:B9=G;5109[<%HUY_9F0&= M[NZ.$Z?BWI/-TCK3+G&9$ZC6R+A>&Y?/O%M>.IBB@IN^[ [*C-MK+]-OEB.< M/%6O'6U';D==6=TW.!F\Q6ICEFKE..NTU,7N>>!.X7:4']Q9$F),'RP3J):L M4;[-?58T6Y]$U5M]\_@.YGQ#G3/@@2JI#P'> .J3O/3XW$N]'7(GDB7X);UO M:=^6>#O0K^R,%2CA*B-8K;LO7('3*D)L6#'T;KY(8C>R M[CUV5G,J3LG>5K'/RR*(EL.*2A &S%"EOA^Q"(8ZU*P6#86O>J0VNA=X'B^SY.C;NGM8*[\K!EM8B)0J^NEW>Y_ET6Q:2*UQLTX;RSWW*-&P2\ M#S,TEB;IL-?WW6[5]?M."1D6J1P2^U]I/Z@TG< I:YD=%&M*N>H$@TFX&H<1 M$*OF:C="@R*W94%8QWR5.\W-NM7^QRG)^3#QCOCWWVY+9MR;4W#-]3RV(#K065V#DIGS @RV;U;#677D)1^$1HKK:(V-*R[@V,CKS MU*#G #_'L\L^AJ,#N/5>VA=Z:9'WTKY"+^W#B3-Q3>+,\<>L/*7F+&)/IEYK MGUT$A_45[Y'5V=NEM4?&BY<)(/I];< M:M?9ANFWR<3+'X:S'@L/W[\8GS M3I];W?5X_TWELO[RX?S0GCH[G/14KZ2]^R?'!YWC\\Z!U3R/ST^.#@\L(QP$ M@_RM=UFIIO*VCAT87'8'=*/GSC]U.AD!4*JX*,8P<@DL-#93[]WS M^ 2"UJS_.ZSX5C[;I11W2M_,L(SJ]*_!H(^C^48=%,RN/SGY_+L0$/"L=SE+ MH#"[CO2E,O<]$P\$P\S1C-F1*,-FS"AL4V59?:!-T\K1T@7FYR\C&SUK,'(5 M;;C?"%Z_FW,T'?0C\#TW!TT+R5IYRK/VB]AJ9V\T.> J&'EGK\I5L*E<.4/7 M613J/W7 RV.)VY]N86&7OH$CSH6J-L3@V$( 9S=HGY_;:3S87?0 SAJNU0OJ M\A!J?B9=/4IZ.F^&W%?]6:W4[W\Y.[,FX4#V:W8:>I;THK_%=%ZRZ ^M2DI^ MJG4K[^]W.A\_-@4A+!RXA%5N_4JY+RX^UO9WM&3+HH!AM%=E6.(#HWE?G_ A M"JZ8Q>9KU.QA70AZ_V55>%TS7 ,*\/52H+Y\7S_?O13BYIUCYW9/NX_./2^W MBWV19;?64OB[JW(W4L4O9H1(2#4*)<),*":@H!3C&,8:B?IZC&45QM$J?G"T MBE\X9PT_B%N(\Q9B;*J&W_KLJ;F8?$6([T%B+@!_58BP:/$75&A-:"P)$S@B M1F#.6<2,4%HI%>)I\0< +D;\68M2V&(<;K/XKU#9:HQ&U5;*DJWON%CFAT, MGC]LT=E=@_:KN.$126#2$(48$A&0F)*(28@!P9I*%MN9L482%C<1PA9GH$8, MRC7+4CE=$U$ UC)DL0I#37%, %>242 M0.C(B*BFQN_"X &C5HCKL&% E")X MC"3#]83!+:U';Z@6&.Z)/E9I9HZ;[]^4F?RFV@C1O6V$';$^/6"YUOZ#<_*: M5?%I 3LVQ;2,(18))35F!!L,$>/2",,!#D&L,%9F><##6XSR%H]P,V?@AFG9 M7H1>*$(+DA>%!"!,BU"$$=:(2" (@A)"!NQ71IJ](LW(KC555&S%G;YY9OS:8:JX_;LA9MQ;+QJP-384U+#0V% MK9)@P M%+&1C.D(H;!&L5[4I&]!C&'< K#.X&@ B'FWFY?/96D8,X316K8L1$2HF!LK MCX1!H;E1D"LA24C($C4*:_G#L(6CK1;&52H;]6&F#5$S3MW^WD27.^][N1G= MSCO8R%XF.FG*VF,]+=>';(_%'*X5X!YOW%KUD 'K=2K.:_=TN;^[77+;M(T5 MA@9A%(>0J!!3RH5&$8^8_8DIBB18HC.T%7+:PKRA@+CB*& OMULEMXL54FKE M,92&2"$,1A!+PI&,!8D5YIJ#:(G.>2NDQ*W>;Z>0>N?(8W/-Q:> %=VK+,+!L!"!BQ6.-(7'I%?N0^L:4:8IMT*PF\:[97)TY_%LSCR^:>IC4S7MM2H& W8[=B*(&DFRGFKV,OJ MLC20^00S#(66A &BJ)7&6(G(Q,0P!+2,PN<[+T ME:%$"@T'(("1 :,4PP['44&!$B>'0* %K\K(N++JZ MQ3AH\;"AON!FSMC-M^MV]GY/4^W*NS=BLMXT3;&I2O5:9_\A1XTFE&41YD!! MJJ'"D@BAL6: &3NAT]A M<")_K\F2[7(KW;V=IL)5=[$]=*X+#VB1O2(!%:E MUA&(0XAC9%4&0R)J%0BM*12@1O06I3*@EJMD3EE#\^)MG/W?["PV!^8FS9-B M-'N-SUHSF_E\]HOG*QA#5JOVH!ZG/36U#36&*-0:40U@A&5L(=!J&X0(:90R M""PQ50VB88OCAJ[,^T0U7E27IWW,(9<8 &PE,$;(:B,ABCC14BEN&%8(2Q@O M41N)6"L$6RJ73?%I>%-EPTV5!I*J6CKGET>+>J9.+Z*3%/HJ,1%58SY\EF( HIQ48+I@#1W"JI&H=*R7!Y MIB5QA='"%@319FBQ>!.LRU>%!*]4[)\LXQ@C:'0H%:$1)G%D+5,F@3(LE(@: MLL1U=HI:,((MP+=4QKVENF$ZL3'1X<=@Y#]K'!\'YQKVH,7J19S7/:J]7!5]Z0."P M<'-P(VY=V>8R,% HE?6-#KJ)D$DW*1+3C/C =2I:KV*A9]VK. -F/*UXL=W3 M[8H3C^X9L::8!:5 2>CJ@$K,*)*4,($Y(A'".E(U"087EG@K;$48MEA32X V M;)K=#O'=1EE=CF!BI*4&$8M"R3 0$022L"-089S;6K">Q>6> NU *0MSGWJ MSZVR8*VY.JBU>Y-F)9^F<=!->Y>[A6 MK0XL5TV#&Q'4PIO23$"$>0QD3(T+."&A0I1@LSRM [9 &+;"L*%1TM[L]U*Z M+#WD89$T*"+0%=6%%&&&C.0"JA@:AIBU"R!=HK[1@MLODJ_1/3*91,E[1!JQ M]+16O6 \#" M"+8T(*W M#=,"O B]4(06)B_,<,DI03@$',=63!"B6#,#H492TB4FZF:,M"#??'E9I;.@ M=C?D!G@0QHN'-&U"?SI9FQ84?[^KN:FFS(O:O5;58[3@P4- &H42$8IBS2V8 M"B0D9[%0#*O8?I5++%%&H;6$&NIT?:)D-4U/\>R$Z/6D[-IDWE3]9ZU>JQF!"W4IDL6#"D,1 PDX)A (V,6(A-!S4G,*5VB RMJ M481:$#0T,&TH['-Q&6RJ.D9T[B_5"PC=%)?,+U5X\%[ZI8S1F)((P%C%F$$!K M$E&&D4#48,8QT7&(EV<>61.#,]J"3:U=MH%KTE[_7:5<;X;^ZX?_50^_-W\> M+3QS\OGSX<7GSO%%5>5K_^3XXO#X]\[QOJO[]5YFP=O)UGO[:'L4L(>5IOWT M^CHIKBTGYNV>WK?LD_0N34^-*U$A$0!A2L(8 TRUDK&)(-,FBNT7$]=LB:TW M:'[DR;M>TK6TS_IF0GE*RT?T"MOB:76I0>/_UF,_M- 4C4-Q#>-?I[5-DI;K75Y-V)BV-D[S4QLLLQH^_94?0UV M@_=N1,;:,GSS/(LU=\\[=X\[OQ*9R=O]XBK-[%OU:-(ZK1B- <$]P6!'G9KT#<=>S7)8S[2;_("]%S47BC"W9&.>I]3S.=F][B.H$(P236VG) A#6, M)04A!P( 9)L*HYI,^X]Q[Q,Z83M@YA[Y(+WO0"/TNE=J,:TUG&6W<* M]E]>IFE53RO9]51D)]EY(0JC2\X]-5FIM(QJJ5QI9%44B^>6@6G$(R(CAH6! M!&(#YN-@-,K!<"%J]M-Z$5%K+/!8 JDPID!R#4,24HXH%XK&:*X9ZEF]"-^$ M=:E'YM.R;T3F6+MO7JI=CU#K(9/*H%A0;$0H&%;8T@;$@D-K4H5E&;5UF53S MM9X:&H=2,6Y9$$.+LH!0RZ FTH1!(N$R[:FG&U2+MZ"FJ'28Y_TQ"D%F[2:K MK!$((ZP(%8I$$#!)B*1$U97W6M3XHK %"6_9(7F4'CV]=#I0:SU21F-@E,( M,(9,9! ( 8FYXF2^1-[/I0,(<8NS1^F0E(T.1/$H-3Z+3%T%" P>T'KT!C>N MP[<8H)MA:FR*VN \A1[&)8A7-'7[T'$&&+:O'-U/3]@LG7D"79>\^ M((T&2Q4I 548"1QKP*UZX=RSUE:@A.LE)OE#(6B%D:_]O65K2VVM$S>.HFLM MH43;MP1*W"2%Z#9"N_"^M1=BS3.4@7N6.+4<<=C;K_AA!(54'"H8 8LZH=O) M13C3<8P8X41S@/02=0) 2 LSU$)-+;S7L,G?R\\+Y>?EPB(CKA'@5"$%,0-4 M @$I9!@P:Z)2L,P<,21J46J5:+3YPN+=U>/3ME+]ZW[7^6,M8\2)2AJ;L<\; M&\WS!OS\,*B=F4(D/:,[(NLEOD+65AV +1MM0(6/+X_^+!PH-%[<2R2&2PR@Y01$(NC M8 M4+'.S'8:"Q+I$GP^"X,L:G5#%> M4N0B,R+O9[=!Z7U[?&WF86D9/FUDH6QTXE3(3I$64&1D<*0X,W$[67TA6/[,H&,:1R&6N.0"H9# M01@,@949 JW6:QA>8@W[5RV0#5-GZW-;;YAK,2VNK)ZBTNN;S%R97IY\,\'/ MW33/?VENZJ(GTWU]GH;Q=/=_#LL_@Y3W*VGV,WT1+VKW>E6I$>X^<Q*4[B"_%C-/0"4"PQ(0C1",<4""(@5#2"Q.I:L:[9$[=P/R?$ MN 5A0\LL/E'N7K."YC'JU6#4$@%)$D-#@(A@E&!CS3\M8V",_8H!AG%-U:*% MNUYT-YD_&XT2*\Y$JXT[Z_LE2;+ M.__I)\7MZ Z74*+(J B'.L)$2VY4;"(-(F6TU0CGV\GU/#/?6ODH:@' MC2@'Y^6TH7+Z(J$T0%@Y!*%4$<<1CQEA,8Z1,E(90\)G+CG/%1]O33."6[QV M?^(6"&53 O#\/IH-CU9I(*D:-SEM&/T\JVWZ?J2IZ0%OA#$X4E>N+*^P:<8A M;J32J=.^[)I'66 AX_B710_,0C7<55)B[@);[9Y^V#"-D6#,6*U7Q5A'5A%6 M@B.E"4,T,O29 =GSZ, $MA@/6Q TM.I6G?@U;NY_U1CQ2@%A@=)/A!% F#AD M"F$588YBCH'4G -HB*A)0+,H"YBB%HQ@"S2UYMY+I7]*':L^_^=/]J"P7#$X M[OA@KPJ/&';[_D1=!Y35F$SV7+VH?."[P&TZ3-2,+/+&!$*Y* [1N[44L/TL M[+.+U+&"U==RH]VWTIU3AGW$24_T5"*ZMKGV0%EY9;HO>Z,Q(+.[JKI&9.6 M7-WI@T5Z,^S$X,AP4"IQ"%17Y);U#LY//YZ*2_,A,^)KV_YW+W2/4'/J$<=] M%W-;/6,LZ/9ALK?* ZW<9$D\-@1L:A[O.='HC@_+X-B,UNSLX8G8WKK>W=CK M=Z6CP*Z(;=_>B>YW<9O/H-(H++V_RH8/J[P;'PU^!J MT*?22S0T82H,K+5NAJ=&!WMG2@+&^S7:@JF^?#)".P*-=*9DN:F1FQR-<7FP M8RV"J\S!VI\OG)"F\7Y5PB>W-H0[$*1Q,#ST_JT81H]/QC=-=62^ILI,SW*AMW4[^1A8%G'3Y\EIYZQ]<6COM5PS>K5CB_N3$Z=6WLV?O_1$7]M92__R M-$PN)RG;EJZ;3I6=!\H)W?T>S(S55+\T3JV5=Q479;MV)F;5NPEW(95@ZA=[ MGJ"#/*)+SN]<']5FGJ[4/]*,QX->'FD3F=?ELU"._IAF07%E[+_,:BK7]HJK MO+8V9A 8JZ_H8+@CI_4BO?+)NN0B1WE9OKT'V'W1W+8M3 _7PO35)K%-95_/ M-LMGF^'FOTWED65"7).7)LXZ?^\GVS: !?2!3!0IAXT5$$8XUJ]+KCLB(6 M5DF!QQ*]E,S[,4NOG7?,7?2/I+C:[^>VAR;K_%#=OM,4VGEN[%\]OC6!":!) M1-TZ!,482JM5&,"9Y"RFC)/:V%@0@B(=+D;^,1"BD^S<9-\29=H_DGQX\'.9 M/F$1"?)8*X*TA:,%!]*N,G1DX9+L\67%:Y8;!B;+18Z02Z9C!A&*&(XPDQAI MSB 5'%,S_Q/7-KP=KU]S6 M!Y_+M:<>3N"Q+_K MMJ^;WKAU^4%3%ZD2 8J:@VH-TWF\9&Z,)A%I3&.("582X3AD A/*2*P!0H@9 M5K<]>AY-8D5BV (A:1&TX.HW:Y!$[QFZ9_??4]N+GN.7X#(3]O^DW-_O/40K M;=2F&%JK]]H 8+ 63G$!6$10JH@PJ:0%1!8)6EMC>@[%Y7?'ZL]'QJ45W6V6 ML>5E_#7*^)(MD3"*3$@4H ):%&2CE$KC-AV2KIW%\V1]F 88>@=1]ZH;(**! &*"=$04B*PLS:-TI$1 M4,::<6QJ%NTG5*3%+%PQ0%H$+#@]KH9-:5Y\5NAYFB4K(3&4&\V-@@0S AD C,2,< 6(B6%- M*.'B?4JH%6'6PGCS1<7;;B-[M ;Q]V40D;Z/P _,CQNWS)I[LVV+=.DU+XK5 M;?7H5'PV&F89(Z%BPJ VK@([%Z'!(:8Z1%8UD.%J%(,6B5"+AGXGNY?<+9/< M18FI81K%6L!5G5'+80:%+WC/0@OUDG.3;>; M]"Y;P:7IF4QT2]U$Z.NDE^1%)@I7-GWMZHFWB]:K30R8Y/>*12Q8M<<89!JO M!(<$"AUJ9&VHD (9$B(ACHBP*$8H785:05H;': +%:N Q!"9%& M*E0*2AQCRC #,= MD$6MD-"-EZ&5^2&>6+J[,8K >#,> M:\B@%V.1\\]XZ>'UC4@RI_.V@LQ86>BKHI^5^DAN]>%,]-1@RY4IR\S;]^9% MC1X2!,W:A-50J^S1O,$-M=L6UNYU^V3N&=QYGUU!)!?76-R+P?Z5%6:3CY9$ MD]KE$B,PA@ +C24B)M9(&FA,Q.IK=2]:E4*M$*.6-3N;,PT\4>J:IGIYU'B5 MJ+$DTYD\5H4)"U&:,NVHN$PN0FZDI?I"EWQNX7C[2JF:NG2^Z@8M?1V\X M"6<(S3);[5G3L^:J6/.5A2_4V@A')^?GP<>SD\_!2.%;'[FP!4NL]36%'U8V M3VZ,6V#M71Z6^8J/TGQ,WQ0P9"R26G*!(2."Z9#K2 )H*&&:O-0L+$FZ.W^G0P7!LBE'/@@*,BU!0S2,,J1!Q"(CD M,9,QU29^\?[G)WD6*$*MJ$GI418?1+>U[D(/4:\2HA:-1YPC&D,&N#84(\HY MP9PR)26/$ KEXW4<%HI' +8P;7JT6D/PJ$E^46_T>*/'#[\?_N8MRC3"O)T= M-O*A\_'DK!,<'N^??.X$%^U_^D(U6^7G7[=M.ES;'I:[2'I]J\\,%K_37O[! M6'7,5-==B!\F[_PH,F'UWJ0GLMO#PESG5G=T*F"6END$ANKEZ(91*#FE&!I% M)#8A9A 2I6!!"E)&%YQ3 MEJ,6;E$"@(?IBT^Q7CS8-1IN&0(N4TF@H%7-% MF1%'$L8$69,5$6*M4_#BE"1/@A;WC;PP^_'_YF MF)YX(TS/6CWON',1N.71YJA[CQ&S<>J>3ONR:Y[6[B5K[W]9Q' N5+=L()$> ML7./35&[83D"(2?&JI3&6$-7*Q81$&$4&4Q43.F+T\T]=0V6ARW(&[1A^8GR M[$U=CWW/MQD]T#UQ,7D6JB%C&TMCY(QFBVJ2*XF!P@B9D',8O[@*U5.7?\.P M!4B#L_0U"=7\FK"WS)IMF?GA?]7#[PWSIVNE'T2>J*J:<-+MN_HX73MC!S/Y$_V2#P&VUKJB#%H(,,&&QKS.!:A""G& M'#)%GYH@YM]#F M]L/_JH??NUR>KG;_H_QI="!LK\6E">Q\*4T6I''ECILHJQG/30 M>*U]I5I[(V)F&^@F>5A''3)YN^+QXY+%3^)27\U/[OE[4@T7'"@=QAR9&)4. M!Q$C* E3#% F8(WF^J## 3PGJ/]9/1LHX5,=' WIB"C'PO[!4F,226D_C6VS MB&WO#*PILKKXOJ&P%7+[#T>O2B5?;[5!CY.O R>7!QT:,QI%!AG$$*9&2$X8 MML@8ABK&4-=DY'C0H%\=+#X.^%*P4" &*>$X5IS%D=($J8@ I T.5]$S6$:! MM!"KJYOSRD!Q2J.O/O_G3_:@L+(U..[$9.^]S(*WPP,#NMR?KNNM,BXEQ',5 MZ?*![X*DL$]3]5K)N3&!4"J]MIV\M>2R/2_LLXO4L9%V.WJT^U;N01)."8^3 MGNBI1'1M<^T!5QX]G]T7U34B*X?GZLY"L+;*L)6#(\,AJD A4%V16VX\.#_] M>&I%XT-FQ->V_>\>>AXAU]0C*NFJGO'>C>=\B-4J#[1RDR7Q&(W9E)+7<]+2 M':?[X-B,UNSL697"M65OG'SCO;NQU^]*1X%=$=N^O0M$][NXS6>0:12=WU]E MPZ<,T'\@':&3A)J1*66D.CN4HS"TDG0UZ&.Y.6DH-M4$4BM1@U,[EM#K<(KC('=G^^<.*8QBY3BV/:G;WR@#,C MAX?>OQ5[PS$9$=5I<9T2W_%?_[N[>WIV$B==_7V*33(/HY%#N["T3C": 9_]3Y_.'PY/@X+#]^_')^<7A_GG+98%[ M4]:N/__RX?S0GCH[O$\'M\K&G1P?N*(6!X']=GYR='C0OK _SB_LQ^?.\<5Y M MU9^_]$1?VZE/_S+]]H=FK')VLVWIN@E2V:FCU!K<[\',6^D32^/66OA0<5&V M:V=B.KZ;J1?B:*NMCOXD#]K3->6A\K&\51J:L @=9JE?"-*9W^]X3S M*3\X?UXR&B_L\PH[7(NP.P?CYLJ49YOELTW)(V!S>619N#OAJ%EB]NJ%@?&Q M*^#9C%CAY@4"SX(49N$#0P(,,/8K P+&"$>8,@DXD0XQ M7O?6Y(9 RCI#8FN4O49H="?%EH/I99GKJ-B@RTE$K _J@.,5'2I M^'M_P-X7CKNKA[1[^N*>U]MWK&ZUY)/X0OP849!C*J,XII$UNC6. >$$2LPD MCJ.0$J)>7!5JKO!5S%J@2?5:5I3PUF.)QY*E6<1+1XY((1'+"!))(^Q<=TBS MF#"&C288*+I:TSJ*6K1V1^K60,C66MNU0;"-,,''Q&>5RRNU%&D<<(_$Y;^: M!99F4>*1.: &_FN 7!+*0X!TR+C"$=#.42RQFXO!&0H!X!BJQ<")#&71%B@4%9?Y"QDD>9/35[RTH48 M;O5%QNJV2[Y6D'F64EA]^FU$?AO18]N(R'.V$3UG%]'#NX0F]A@]>]O0V,ZD M5[J':(T;?^85CO7N EI5\^;9![3_J7W\>^?<-GNX)>C\XF3_KY].C@XZ9^@\[X$JG>X+#@L>F=* M_FNF_86_]?D.\W6&8Z-P4M]:YZZ=M55-=.FU9?[@O$C5UTWG[-4P4I9^'VXE:2A3U;9P:N/+BABL M;0GKW "B.TO]'KEW]LOJ)]6*0\>,H#5T\50D>M>:H6MLPKZX<49+HR5X=8+3 M&%C9V&GA(C,B[V>W:V1I/R4U4+*V8TI2JG_=[XK:%*$K:\6!B1.5%(WF\$9" MMN?VIW'[R?ZA9[+F-FHKF.PBW3+MTWM)&L3J:V?O*CEGH_F[,A9K-0AZ%FM*0C66A[4"A52AG@]5E&#XI3]'3@NJ77[.V*WK*!*(( M#HPR9?$4MXPYYHD?:])H!JN9;O67LLK\]0%>N'=IW;E)%@\\LR-:Z;.3B"PA MD/KAZ-:'\O?'A!##-25,"RR9$5S'(C8T0G&,,*O)5P0 1."/\V$P8><__:2X M=0&T:<^%9;5_)/D?U2IGZ5'^7(K!8@J$@!"W>&TN_%7CZZ+2CRQ&D%Z-@"]= MD&K"XQ<;2K0=@.($^\I>:;*\DO_1#&AA&%$CC0X5Q@B%S)A00\U"2*1$45W= MC)@%4:AAQ,/)QY.F@HG*#)<8"4 (Q9.0LDQHTRPD$ 6ZSABSX.3 M^R@9%TQRV!O$6WFU\/)JS9%'=ML]9(\@J:%$S/Y%KHX8 MX3'D1BO$(L. BNOVV,TA[L/PFODMDN1)>_&8U2/H%@GZTCFD9I^>]W,T1X"] MWC(?D#VDN%B[!_!0<8YAB*FVP!;S",4,0Q,+HNK2MBX"R5ZVJQB&I!5%\^2+ M]E#FHN ,D1)C&%D (TH!II)VRN(D&(\8J%B=6FRYH"R,U.(I&=T1V0] MJP3FBTUEB&:H 091+I0 &$@E" 62:$D)"V-) MG^M5N@]TGY6ZM($>X#S >8#;'(![ ;YQC",=61T-<8HY,]+^ M5 "+4T84@5GX-M"$B&W(,$M'FZ3RM6,N*B5.^#7"4=K=:6O%8<;MP[CV<"S M@6<#SP:>#3P;>#;P;.#9P+.!9P//!IX--IP-5NR_V-A]7:-)^VHJEGK?\<:' M1#:&7,W#],VCH6Y9I,+L]RGN4\RVT<#3W+>9;S+-=D;\^([=?+UBVS"TO MDG2NL-'#1V]:!4,FBB!%W)X@E+UXZGQ:)J+#XX^SA/._)DNUR*]V]G:]1'J)W B)?)8N M&RI!0L(U!P +802*N3!1K B/5(AJ=C(N6"#GFRN].'IQ? WBB"'CH="QU AC M2K T)*:AU&&$K6A&-:E@GB:.STH*XR722^2KE4A.,-,$&L!"@W$4,% M="'^&](*FU8]8U-6Z=V6!B[P6GF\L5 LWTJV@9XHA.?TFEJV+SU@%-BIS MG;QKGQ[NE]ZU#R(W^E3<.N6AG66B=UGJ$1/@^,4BEU44G*%M+#SNI[F]0J67 MO=)=7;GI1A/G4@I#BFF(1(@1PXQJ" GF((8RY,RL[38'YF0:G B/S-69G/+IN$0F'&E+"X$7.D((F0B5G)SQ.K!4G3(B #J$PH208DUA '!) M$!!$("O"C5]YA[P5$>3AP\/'ZX./%5@#%Z'+A$R:6+)(Q%QC(T$+,::2!QR0C"2_S][[]K<-HZM"W\_ M5?L_\&1F=G6JY P B28[C=5CN-T>Y^TG1T[,^_Y-(6KS=VRJ":E))Y??P"0 ME"B;EFSJ8LI&7Q+=2.*RUH-U7VJU)?>%QR-XI/!(\3*0@D480!DA#0C!*J2< MADK$$H61P(2QT(=*>+#P8.'!PH&%P$PE" *!.<.0A4D2*Q 1%&.%.(^)C^+P M^.'QP^/'??B1&)DBQ*&6+%8XHH11'84$Q&&(-(1@M;#AS92]C3WI4X!):3LS MCS"WSY6TY&"&.KFRC8B,$!I,V ]5^)H"+RQ0SA&%1;F/67[!?OQS3A#F@W; M:YI?82@%2A!B-,0("8X0IDI #6DHHO45I><>\-$[4<:SX%-*'E^4$_,OL@Z< M2##3D9$?1"BQ4H!K$K$8246!#H&2/J#"\^%+Y\,5;6N#//\H!'\ >R;2(1Y)31!.B^Z9T3/CCIB1 M,,FTT4"AE$9$A9IR##604#. F";KE[![D5YJSY\O@3]W8C>""4E83!F*<6AD M5<@$(8((K"4,!52K(]F][6W2F^7JWZFV?VOH M2Y/B^7)SE/Y'9'##P9>#+P M9.#)P).!)P-/!IX,/!EX,O!DX,E@S\E@QQ:7/6DXXQ)8@LP98()FLQG?8>89 M&DZ7T=WC:>?@V14&\O3\DNEY6[7!',96-N['U 0+*00DC*D$B<2)$HF .I8 MA"&"*$X27\W#XX/'AY>+#T@G(4HB$DMATT44CSA.0A)RRL,$HK5;JV^]+0HA M T1ZEFGB83/3U[>MZ78Q"J$"8P0AIKBH%4#"I* 5 B)M16_?"U/CQ" M>(1XR0@1@8@0$2>22HXU,"\@X@E&B# L2>([>7B0\"#QTD$"T9 J#B/)N,(R M2I(XC!62@B&(- ',UT;QN.%QP^/&G>;$40QDK.-$V^KW6M%($\PB+A31H0I7 MJQ_>DM9;)[Z/*?$Q)3ZTR).!)P-/!IX,/!EX,O!DX,G DX$G T\&G@P\&?3= M?K'3)(1-5H18,(X'J;..^XP$;QOVH5:>GE\0/2_W==SG1OR4%<7'+#>(.CJ: MYKD:B9N+G(V*\B:'(^G>#9W78^XO.563,WW!?C03$&PC,RFP%@!@10"7 L8< M2$@44#'V"0@>#CP%B8HKD3(0ADAR#&)*3=K M#B/*0 (HE1KT.F/@=M-'3 >00(\8'C$\8FQ/K5 $A)%.DA@D&(=A$F*N(5(1 MHH"$@.XB5^#%T^],.'?O@(($\&G@P\&7@R\&3@R<"3@2<#3P:>##P9 M>#+P9-!W^T4P9E*FH\N#\COSX?C'_B80G*I),,R*XFF3!AZ[I$]J*,YRJ?+9 M4/\"W#]!D0U3N:N!=S0E;VSDSRDFZY&TU[_CRG//B^:>Y:X:@^]SWTPS90$# MDF@>"R4%YAA2%85 QE0#C'$"UB[U^+Q3%CQF>,QX>9C!."21T H:R,!2H41 M)1,)M5 AAW'_^BAX_/#XX?'#2^R>>SSW](A[NIV^%$A%0JV%3A".8D01PY$F M*F*:$836EMB?>ZJ%1PV/&ON,&C]U@PT!$048\82*$--(<1QR+&$B8Z@Q%_&3 M)&2XW3IX8" F'<0)&*"D9V6;-X\GFZ67U]ZD[\%JOT0(J".$@^,4N^<((Z_&4=B5KXOOE[_9'6[&_ M=;=LK]J*'EJV93;E0[6KD6_4M-UEZ)LT<+82]')KM^O)7)Q-)\6$C2SI+,3G M)B@!(4*$1QA0R#$$0. 0B%A'*&JML[9V)#_L5%L)#%"4#!(8]=L>OH(R^G?R MOU1 V3I7_G53=/GB Y2'<0# VB)/'PY>%K'WC2P]=NX"N*44($%Q'"(8\8$]"\C@"(-,2H MM0_4$Z1%W8(R&$4#3,-!&'MIS,.95^^V"R\KHIF6Z7"10"!G B00TA)'0E#+(DT1W%3JWGS4(PV1 1A CZ >03V">@1] M,@0UJKJFFC LP@1++ PJZ8BCA,LDYDE7M^RF IHX$8LL)L[8?SSQ\_LTOU/E?LCT/S1Y.V[QNA,*>LRN_>Y'1J#]3R+@LA MALM98N ^&!0J3_4">] [W#&RQ#>L?V1O/OOLGM&\>A??BF1LG]_87'' [2H< M,&UF]Y8-O[.;XIZ56D2 7Z[R^C;E8CL2"X ELYH, 9@C4/49^#FXJN;E$HMK M,BQQJ95"ZZ^:6_[*D,GRN37'<&<^ORDF[3(M3,C>[>X.WMZ5:@.LMS45EF19 M<)5; /G+A:7T3!]9H#$2V:MW[H,@TT']T2]_9^_JC5F@]#9J;Z'_)?S00JJ; MB:4]^NWX]_G1F^#P]$-P_O7]^8GYZLO)\?G3 M#._L],/QZ?GQA\"\.C_[=/+A\,*\.;\P?_U^?'IQ'IQ]#(Y^.SS]]?C<#-M\ M<7;T?WX[^_3A^,OY?_Z%(AC_'!S_]]>3B__[),/_Z>N(3:5!7OEZV?,[%%M9 MCJ0.EA3DGW#%GWU?G1OF^Y!JA)^[WKSJ?]G=/L(JY\TO^$Q@$]K_7 MB[CQJN4\F1TWZ\? F[/BGE('K0=A%PFW<7:NDN':!K+>,T.P\J$K:WL\/,B_ MYHG67=T(HWS,\L"HM.;_7*G@VOSBJ@C42"K9"/$W8AU<6^AJV;:'"V#K4U2+ M..6)_H'/C)X7S9&%VM"F'<**&W[&8?B=X#Y7HD5 ==](VT/7)[Y%X?N>=.G;[1]P>E4Y%. M7B)D>VK?$K6?'9UX>O+TM#'1('MF,J6W#ZQ%Y\^)MLN\D)&SQU/+2L&6;HM6M"!U7<^NQT3@/WO E+M9-U]?ZH(2+**W] M;V#;1/#PB,9EUW/JR.D8(=B[UMA,S6*7%%*(QCG821"CF.H::< M(1K+D %&N4Y:8JD!1$]2X@J! 4+A "=T\[&"VR?/K1Z]+X;%=\!*ZX<CE- ]K'M8\K"W"6JAUPA F$-((ASQF*H&)X#!"/!$2M%3#>)"A MZ2FJ"QGA;2L=83S*>93S*/?D*[&6-3VFBFJH(R0QC&,6C>>JORDP]K\S;>7BY7_T!] M_];0DYPG.4]R?5XN3W*>Y#S)[=T:>I+S).=)KL_+Y4G.DYPGN;U;0T]R6R2Y M79L\>V/7K%>D_/.+*B9Y*B9*FL=FXH\@+8II>V%M[SS8)?_U)=KTQ-'#AVF> MCBX_JSS-9)G@/2<<][/#[RR7IVIRIC]FN5;I9&I^TPA.93%3",8QA9IA*F,6 ML5@!+#@@D"@H[@:G0F#^G63NU>I.O]NH3A6A 4SB_H:T]NZ(]2991U\LCQJ15\4(1MRH MISBAF,42)E IF&ADI."U3]).I6L\FWHV]6S:9%-*0Y5(@8U\"['$(D&,*2E# M*.(02QVOK:ENJ!2+YUS/N9YS%P[8*%2$49!$ .+8'+0Q@((F-#8*+*=M-;IO M<>XF[$3)@/2YLENO'<_[D&NSPB=MX'MLH)S971\$([7UQEH^J.0)@DJ>##6% MND[?'GX^.7*VO/>L4/(SN[&RQF&>L]&E$SMNP>97@VE&KK :O#+ >905YA,3/"AT8$2\8P M93$%)(I#'L= F;U*6IH4]"M*( 3)P S(8XK'%(\INU)8I";F'\/\"F+,8L"4 MU%!IC*G"',"U0>-E12AXA/ (L5.$>'JI0X80 1&C&(<"2X&2)"242B!AHE7$ MMP\@7FGQ\.'A8U_A@T:,04XB$6*$,3=J"X&QHEA&80)U6Z=(']?A$<0CB$>0 MF=D#2ZY)I#201H/!D!FM)=($,:44T;"EE9D/.?&@TI\U]*#20U"A %,9)DQI M1K&2,94RCHC$E!A1A8+56HVWA_8W4J:GX3"E;<[PZTBJ7$E+&F;8DRO;!\J( MKL&$_5!%;R)B?-C?T^%B22D6!C]F^07[\<\YE9@/VA&Q 6X:A90@HJ,XD3@D MG*DHT4K!"(,HPG)MG>LE!:GT3@#R?/ET?-F05[XHIS%<9(]GSX1$/(8D#"/D M(G$9X)!(8#B4@0CSM;.]7TX0B&?.%\6<*SH';X8[ 8YDI+E63")L&)+&+"8@ M5HH"IF/=^UH,$)(!('M7C&$'Y-.?[L$>)K:YSUN5K2,E1<0B250,3\>>7%##DW$Y/9N#3W)>9+S M)-?GY?(DYTG.D]S>K:$G.4]RGN3ZO%R>Y#S)]9KD=FU/[$W>3?G!=V4WW YU M*,TXSL;6&%V\]5& 3^]U>4+FZAUH>S+P9.#)P).!)P-/!IX,/!EX,O!DX,G MDX$G@STD@UV;7/:O*9#+FPDR9XP)F@V!>F.7V3^S8'^MJ,O(;4/$==";\%+O M*O!$OB4BWU8=-8?&E67\,?73(**)E)I"H3D6C"64*AJ'7,<:V\84OH:)!XT^ MK*$'C1Z!AH(R06'"B.V@IP5FE!';C@+2B""1X+Z75D$0#B!^ 04;/99X+/%2 MMB?RET;D?3LP(T(2Y.1L@K'0B)HS4_)(.GJRA1XX>(0?C&$LBM(Z!QA @AB,F M!!!A2'%"@/*U7SR8>##Q8/(@,"$BEHE!CD2%&">*4@BB.**)Z[TBHM7F/F^R MZV_@0>_ R@?']#XXQI.!)P-/!IX,/!EX,O!DX,G DX$G T\&G@P\&7@RZ(51 M8Q^R*5IK6RS8T8-A5O2GCZPW(N^5$=G'>7DB?_9$OMQ3(I\,(%5$)))1<"(XU3)C"*HQ '',0DRA.8HD2 82\XXI1'&FJB$JAC%(4 HB36/A4]_\$#1FS5\T4"QHC/F M]N4)!(!*(D"XH#AA,1/0"!+4_*NPB%74EW0'M_D'#PQYQH0,8H2>$:#L@!(? MUJ#30YB'L)Y!&)8L$2(6E"80RY@F"0A9A*W0$S&BUN[[ZZ&G']"SZU"(WHEV M/ERG]^$ZG@P\&7@R\&3@R<"3@2<#3P:>##P9>#+P9.#)P)-!+_([QDS*='1Y M4'YG/AS_V..DCU,UZ5FJQR/7]VGMV5DN53X;ZE^ ^R9NI89SB%*$@: ,Q9)A'4(68BE43(24 M*N0A\XDF'D@\D'@@60DD#(0PP1' )(%8898@)5A"((DA!UBNW>[G96:C>%#Q MH/(L0,4+_)ZE/$OUX)Q6@B1)3$.E!,5$N_P8+'5"@1 A MHGR'@H\5#RPJ!D M18CJ?5C"F80"LRB2B<0A)C1!B&DB,:=*2 &?)(TF?50XZH ,(!1^-Q!9@=$ MU*, >0]K'M8Z2TA"*4!((I,$<0Q!3!,*PX@0)!BD"O.^I/QXN##P9>#+P9.#)P).!)P-/!KU,U,%[G:CSG@W92*B 38+?62ZN@A . M FOMZZ]/;<6"]]'D+;,I'ZI=C7RC-N^'#OW)O6JN07AQ-IT4$S:R!-/TK%'" M0LF4(()B(2CC/-))R"B'(M&PM:O%VBD&L%-3<#! E RBA.R/5;P; O;)B_:, M(64'?/G7;5#F"P4Q"R97YFA6>5%B3@/%M*T:3.)0:(YQ B##'.!8JU *G#4 M6CQX1XE2=U ,#2B)/81Y"/,0YB%L#F%1'*LP05+J.,&0QBPD7&O%F5)QK-N[ M)#Q!BM8M.(.(#+#YGT#L(5CVL>EA]2O^+DD+) MD# 6BQ"'2<)$!$*DXP@(HF+MLEFQB[CW)+-%)W7*Q C%DA:'C#^>?/WYFE^I]KM@?A^:/ M)BNO6+([-SF=6AFBO,LOEC0?MI<#]\&@4'FJ%]:9W@G?'%E.&RZN??79/:-Y M]+\QN:* VY7X8!I,[NW 1M^9S?%/4NUB'B_7.7U?2H_LW?U MWBRP;AO[MC#T[??_^^#@\Y_RWYV]_^=G#P;N&RYFOW M?@W\">YB[^T-K%=X.U!T"W;L&OIV?G%R=' MYX/@Y/3H37!X^B$X__K^_,1\]>7D^'QQ57G%>7#V,3"$98_SH\/SWV[-S9'1PF3-;YI$,?OBXZ>S?S[% M!#^>?0DN?CLV_W\Y/@Y^/SN]^.T\.#:3_O $@_GIZXA-I3G!Y>N[3U]@Q%M? MNZ/:C&5HI0YA#C(G^]CWE0!12D5;XYY6"!-ZXL8U!Z]%.>-V-L3]TM0*Z;FM M)H8AQ#9Q9V/W;Y>TFG+?,JFKTS!6EX!9,29T6Q?8"5'/DCA:A>I=C,#H#.CN MPQ^_,0^7X'M",3T91O\)MT&EP2[(U-%D2T+3OM#D/9KCIA!]\R2X>Z)?3=)= MG_@(0T+?9NW7>:=<]# 0*^?F/DFMT<,GOP:'1Q/A82WOWXO"@G497[,(24V8PA!A%K.$,,@U)5@Q0"/9&N_^F(K(#V%\.L"V MY -]UGR_0VFK7R+5F*72^KB+Z7@\3&MA2EV/A]F-4D\G3ST=*FY7(UF*4#L5 M25:$/WYF-RZBX2([KTGC<"2/:\)8 "F8 ,$HH5&$,64,$TY!C*0!')2 EL80 M6Y!.P@&%8(#10^)W=H12JZ%HRSO<$H_HN7?_N'>#K!H*'"<1$2*4$::"\(C& M26+T"H1PJ/3:'18>E,J!!S0$ _/ E\FJ#^%+;_RY1U(Q=!5D8Y6SB8W0&RI6 M/*&,LM]*W4ZQL2]VF!5(>E:3UB=+636N-@ 4D1 RB+B*!292"/#GU&A_6A@$F5 $ %X#'"'$"JN58@QIR& M',4RWH4L%>+80,%#:K,\.7F]9!FKIX)4F<"@GEJ,\LKB$TD]0EVGR*NG-B(:E5,G$]JPGZH8A",U.3I5+K'+N03ZGGK] A^2DUP8^-^ M0IFJIMO#D;Q@/XY_C&WV\*F:-! :(&SP&7#-N,(R9HS$@D58*V)D*HE;+/&/ M$Z321Y4 B<$@BE%_P'HCG8U?A@SF,>E%8M+: (0C"0F(0HI#@2F*.=(8A1 Q MPA(SN]92Q%MKMDZB<$#I0YK*> #JFW39$VFQ%98-R0?"VKRFMGI'.FKX#BV% M?4LGJ3=\/0_UN8N[SY"'5:<_Y]FW5"KY_N:K(9.3T4S7/IS12 ,X.>!12"(A M:,PP,[IU2.)0(J9!$G.>[%9RPX,PHH.$)/V!SA"3)?ZB#YTX,F5L_U: M*I^8U(=!>5+SN3"/+4MP;/03(,BS_3A2'ZHR/%L]-$2XQT@3C3&5,9<44@PI2")B!0Q#[4( M0\DXW4E]!QH-2)_"B3M6T'VVKD\/(?L (;O!"Q"'DO,XUD1C"&(6113A.$9 M&S!(6GN,;KS(Q "%9 >U-;NI2!&W\2VWANL'A92EHZ^J:(O(65>/^ZS?KS! M&+63FNI:HUPH@Y(;_ 4,2RQBG H &0P$D:-9C'>:8Q:[V2WGJC1?9/@/'3T M&#JV@Q.(12%+DA!HQ;$1S:B0+(1:(HBA(/':]< >A1-69DL&,.J1S-83I.B9 MY.9]W=[7[;??;[_7'-<**/MXM27@#(O_OE 4$]JGM1\S/&N/,.UN=VZ MA2?LAQGCY.K*'!76E)C9=MZ9^"-@WUDN?93QYF%+/I#./2"\2D38' M/Y(I01C32$K,(V9T/"%T3&*!8LUQN*,&3XCZ8I+[*%OV1%9\6.!=*4/V)/#. MJ]7]C)/[6!-):_R+8@)C%@JFH,8T%DS',N;F%<$)8VIM:>U1\2^$#'"?PN1> ML!CFN;D'H6O+61<()CC089P@C(E27'*@9"PAAPHAN=M";A E@Q#WJ _3"Y9A M?!DW[^?NK9_;DYHGM><74M'O#/QCK968V"@+]4-]:@844EX9_JX(KLOANK.1E;4M?\?_SE-S=*4WN%BDJ=BHJ3] MXG D%S]H_+*99HL$)&&$K;R+L>2)464CS1F A"9*D9W$=82QT5E[U,B]8Y+M M;L]JS^][P.\KM=;MDO)@,0] MBO[PJ?3/(B'BP_'1E^/#\^/@Y#1PR1&'IQ_*%\?__?7D'X>?CD\OSGU"Q#-2 MJ9[61; 6-G]6>9K)DY'(K0_V@RK_-N^'4XM%S5.@/!F:32<@0PP*R0PXXTB$ M%%,>00 X59HF;2%\VVT9$X<# GKD:>B),[9G3@@/0'T&H/ZB#:" 8AE%-!$( MLTC2!"H59;N<*+NAG]E*#65 C C4&$<12PF$<=1#!G! M. 8MEZOF]B8C4K"3[42NY&.N102 M R5T BE.I+9E1D""N(HQC 5N=79LJ$D$'H1),@AICXR-;;S9.ZG \A,@WR1 M:+$S:, QBA72+)8 )X1Q%D8XIEP1B3B';8:OS>6DA@0,$M+C6+5UH,$KSGL@ MHGMMQBO.GM3ZME1[ +E]UI&_'!^=G1Z=?#HYO#@Y.PW./@:GQQ?!I[/S\^#B MS+UV$7U?SX\_V#B_L\_'7\PO>U+TV.?Y[D5M<;_]+WK[O7"[!\>HESB\<.M) MK6]+M0>0VV?AUM:<&F:%+ROU;'TT?I_S^^K=H?R?:3%Q-6I] M8S.OW?1&N_&DYDG-*]*K8)^\P=U@_X,:YT9H<(UL7/@DN\[,Z/_M/GCQHO*S MJ.G:(;ZP217F]5#9%X=@@CH;H2Q3@2G%&0F44WS!F<4))S*A,0@4$:4FR MV7QY*Y+0 >E3ZG+/SCO/4CL,PGLD_TA&"!$JT9%,L,9A@A56(8R@+2C%DF@7 MG2 B&@\0BO>>?YZG6M?Y?')( "<,DC@A24;P+Z2"V <6@1]8PKRA[AMT$PZ[-G4D<)A0C*E5" M,(^ H3H=A8HPA8%ASA;9??.R!XF304Q[5+32VQ8V(7N\5R.ETTF@\^S:4(56 M>6ZD$-L^?9@RG@[3R8VW,#P'=:B3A:$DA]*5=L%^'/^PZ*0JFFD 5$0 A'$L MDPB'6,6,QMS\ 25@&E C56Q%?/BWRC/)BJM7[P[Z@TH]$PP\"^W2[?QPAC&' M-Y(2$80(P%@!"B"%%&B"*-1QM+8UX5&.Z"@9)+[9TDOS0D/<569PC<4*2_Z9 M#G[*EH2SC09J'@=K"1SLCC3G[+1Y:?TFY*'1:$FQ6]J* TP?2U4 M,P:98T!#@BE$(=983YIMT?0,C7X' M!PCN56*YU_'VE;LVS$I02 J9C)7$'$/;X-,&DB"* 45A&.F=.L@3$ T@ 'O/ M2,]3[>M\TI^,OIF[9KE1\+Q^]XR$[IZ)# TR:P <9C"44@@)%<0ZB:@1'!(2 M4IU0 ;C".Y850!P-PK!'$.?U9L_"FV#AE6$E#V580 !/5(1I&#,LD*8")TDL M:!QBP0'?21 ^&L 8#Q#JD=^F)U$E/8OCZXV,\SE78Y;*0)61J*5E.YM5(&2&&",P3 MS$.8(*H!ARP&*&E)WMF\8!.&@X3T2*IYP:++/EAN/JAQ5J23IC3SQ%*,5P+[ MK 1NQ(Y3$5T[B$J-XCAD$941PHD.F6 P4@"'A"9AHM>.ZGN4.2>,PP&*>P2G MWICC^7@3?+QAIF51(@@@A@&!Q##A#$,J<<1)I)&4HK5_XM:<3##$ TR?M07V M)1I@9N$D8W9C?9QE 49S23*V*%U),)_F]-)T M)25&=T-A'"M%,9:,Q90H+5E$:$0U"GZ !H60 ,>H/D'E3C&?N3>SM]CDY MDF%H6!= J C6H4C"*.2)CB,9B4A3N%N!9!!A,HB3Z&5R4NB^7,MA/5(9NN= M'U2> M9O. \7)D06S6JB?9M/?V_13FA JFML9Y.@JRL9>S43=23:N1UE]4F]PN>B!&++"D/"'\\\?/[-+]=XH?7\[WN,72R@/HXB!^V!0J#S5"VM,[YQ1(\M9P\5UKSZ[9S2OWID3 MWX[EW>+R+56H2_R]7>7V3YA<>_7%A>S+0U'%B*??7.?6"+*=D%NU M!N],9)'>&^^:K]W[=82@NZ!Y>\5?O=LF?-RVW_[O@X/#D;C*\H.#=T>_'?_^ M_N0L^'!R^.OIV?G%R='Y(#@Y/7H3')Y^",Z_OC\_,5]].3D^WP70+1OIXAOF MCM_3LXOC\]N_,_OO/@\NSH*CL],/QZ?GQQ_LJ_.S3RG1R>' MGX+S"_/![\>G%T\QO]]9+JZ"$ X"JY \P0!^^CIB4VD.8OGZ[M.7''/59Z6 M86#0 *NX+4FQR3179[H2GCJ9*'DZJ1T" 51PF'#&D,6!1@D&H%8H5@)Q&3#@! MX[Y%MJW"4WVS*0N.H<8 !O_Y%XH@^CGX<'Q^].7D\\7)V6EP]C%X__7\Y/3X M_'Q6)ZT6W*IU?3=?[&J693/;V6*NGFF'Y4'U\K12@1MB9'*E-EDV. G@_E#9=4'-;PQ!_?D*JBN&P23*Q74]RHEN-F]I#*_S\;NGD:Z M,Q1A938SOF"%>;BS%AH]87[ZV:<8*3N5YJ83)68= MD:M+T\*>HNE(NZ^FA?F\L%9Z,]MT)(93*\('A?HQ94,S@4G.1L5U.K&B9/5# M^[O"7&Q4 C')R.4&'"S0FD] MCI%YO!J9,]X^W29B.K0R]U5L8F76-ZM(##^N0C&>2:GAIC'63[11FO* M L,@99_1Z=BV[YCF]C=CP]P3EM\$'SY_-ALGKD9&M+N\&02LR9+C(9M8G=WP M()O8RZQUH0BNS#%Q\*=AJ'1BKA#FMP=*ZQ(D@EP5T^'$%=:$I*FX&IT.@>#: MK*#5\*:%Y0RCS5U:17P<\&&6R8$YC NKVGUGO)GH4[#KL9&6)S=C5;P)[+07 MAST?J%'9S0!LTG,#-A8QQFI]?ZC)P*KR1HPI0<)5 KT#(08*S2]88<2MDW(\ MOYW\8Q#\R@H#$$Z@*1]OO_EG9OAZM@U&A1A.KMXTY^]VR@;%.! U0&0@P9"@ MF:X9O+)0HH?9]X7-F"R9J3"Z2+4C;U=SU3JD3[J0?C0[B&O3Y$K&OZWE=!YP MU&7 \;KXMQ[4;(-Z=H(:F>?_6\*A[VCV^K]8KVQX8+-[N]CU6A55L1-=VBE/T\UUS?\DC M#YG:4O=&-<\-F15F''0\NF(C822A0HV*U'FF2AFJ&"N1ZE28]V_+ M7;VX,N*K^8^)J]2HE-(H71F/G,E=&;2:?/11C T7U^F5OTL MY4N9NCM9;YB=&AM-C!I:/OI^$;"8*XAW-NDQ"'6';EHBEIHLVG0;;0?7DDY& M+[!9@-Z->72RML&YN:U!&_[\N?_*WIT_,RI[42?0H?Q6 MGD#7T^$D-2?"#WM "#:>M_^HSQ\CJE]>!:SM@KF"OJ"5EV;*RD9IP=\<%ZG! M]V ZMB>2&XLU,1AF$Y.VP\=9*6H[BCLJ6&#-)>7!E=K3ISS'ZC.F?.HP-6L> M7%H3HRWU-DQ'SH3YC0VGREIP1M5Y55I%2G-K51#.'$D&+>QL2N/(/:?/>@=* M?8\MHE@G"SP,>X?&G2RX$'LT]FB\AVA\QO]GT7A<@>_'S)!&=KW@)3*R_=!, MI'*QM&D"BA4W!Y/L8&K=-M94;<#-6L,M20\"SB8&'6\.RFAT ^@6OG]/19X% M7YP!I0V0L[%;/ /I;'CS;Y47#G%S96]KPY>F]E9-R[?30'ZDU^9C\W1(C!IB MXYG,B*_9'_:H22?!=\."!\74^87,V6&#YY1-*[%>LA*>[0^_&\2VMS9;-S'K M.WN(9[M MZ[G5R;L$2>_.K4ZN A@]@>F]^QP[>1?@'??"AGR;#1]@,&'YI>UD-Y?C'+"T M>\&*;#@M&Y08A1S?X64PTF*"-86GZ]Q_T>7 XS;I%H8&!S MSEAIE4Q7,_FE]9M/;!S..!M/AVXS!D:(S;Y;])/JVHK1\UDT1>-!65>GE,Q= M(*B]:5- +WV%]?)7 MK%P],TQA4-Y.HKA*M3LQ;/C&A%F5PQT#%NRUB^LPRY9-YL7T(:[--5BYD[, T@W U2J\OL7P:&\ M-MJ.\[BXFS;"$3]^:-S8'/M6U[)_$PA^^N-UZ:*@3N>ZG/P_/#+ M^<%1]H\#%!P:A#!3J>2FFV*BKG^^A4XK*:17^@;JY+5 C_!:/!VFHVYQP]Z3 MX3'=8_H*3#=XO8"8"X#Y117CU&!Q9E26"C';4?PS&RDS1H/C^PVBG9P-Z!'. MAK5!U#VE^P0[>2$0WM0$5X'/ZWP) MCFJ7]2?&L^HD.;FV0>[.O!<S5+8?IT,A?TVT^;[\RYQ>\]MGX[^3WPTS\T4I&S5XW4W*&;.M+=A^/E+6:7MQ/"=N-,L2/3_Y]?3D MX\G1X>E%<'AT=/;U].+D]-?@\]FGDZ.38YLM>O=L?D32Z.HMZ;"/J%UBZ0\*;\LPT- MF8YTJ""+I)(8,T%C'A,-1"PDEYH]I!_C*C0$$1(15T"'),2:1XGF2F%%(\!% M'-/[K$,](8A;(M-]^+-YYFIU[:^ZB+Q:0I&K-Z+#[J%':#-=)8@%16>E.'&/ MUC1CZJ9H%2RIN;FHQB#P!I'[$Y^V1+G=8.LV>-U;]>K6%./Q?=K'6GQW?QVG MX/ZE>NC,?V*O'SQ!ISRU3[ ]!_W6@JXC!>]L0=P18%WWXX:@_/:N-O+X>F!M M^1";1KW60*!5%T7KH%ZK$+/JHGX+,<&B7KG%UJ^#=M"YE])B*=W75@F;Z&JN[CMGDW*KX2UM)ES?! MX7#8S$?DL>^-<.M>M2\9K^HHOUC42S-3;RZ;":;)-2W_GYG95*;U,E;X_I67437.;A:M;Q5%]T3O]T;Z6-18W:R MR"[%C]; PU47)>OL8JO4NNJB.]'K.Q(_%K2/AV[JKYD%J*/,@%\^LG\;L: N M=+C+O6T-O%QIW 7K;&ZK-+OJHGC.H@^J)[BLPN"6JIJM82QO#0-;>15<9Q=: MH7G517J.TM*FA4-FZ753ER]OX;$8KV55@B8I:?9T]6&V571&2+Z0BS4H/6&SG7[$NW9!%((R!6U2SF$?.#@$\G@?J6#;^Y=U/+X/:0 MG]RTA%%T6:0RZ<(5;;.NU.IP<&.UL@-(?K8A_1\K$6%RE2NS:.8N5T4E(RQ6 MC5W(W5M<=2.*3A<*9LS7P&[(J'#%VNPU(]40CLPWKM;C4%V:C;EV>7Y&UC<[ M$)Q:L3!I^,0'[IWKQ^ ME "S 0[MY,^R91FZ(8%KXVB8;-87>D!IX&4Z5-6-4I+G#28 M8?N$NLPU9C&V$DOFJ:#L\M*@K%%I!D'.4JM/-;*<7 >.2B_Y7(;3;J\M5.F]=09 VQQ"?M[.ZKW2C"72VU62JI"Y"FW&K0Y MR[X/6K;AN_M9M?'5*9H6$WNU*\GICI%2Y;:EGM[YBRK HI[-(RY>$U2/M8@?0%=$U9"S8Z MQ7? ]0(\.D5XS(NU;;$$P:Q.8]._5'6!=UG]$UMQV]KS:V-Z414H,4>S-B10 M'0TV5W\FE)@3RZ:I#ZU$Y%1 X023DXG[V83]H2R!J7'M%G,RU>B;T9YK9]G, M1S8UL%6NMCE\9N?GE2'=[^E(S@M^#VT$6D67Y=TR]JUF@X=&4D MEA01V+QEL[T&RLJKUHI]:%=,5UX5;LJXV7VQ.H48P+5B#-H%O957W2VN]KAH MN?6R?%;$PBUF_G3(^UF:]=,::G4W=V>SD?!+\W'N2;]X9+!8S_:1:>57D@= #X9I ^"G[[N!O--5&_BV% M5MM':+\!KY-3&ZWEU&X7H%9>M3&W=O>M99_NEU46GE5\O20U\E]C-9R'[>?22MS M*>Y6N/.0YR'O<3,ZKUKA"&LK3,U/,VVC$ ]$9AW?ENVOPW-JQ*.4^*!Q0P'-Q7LZLLSU4&PMVNCS+GN&:A M%&NK+]3<8=#HC.6"*\J\&1OG847].K9=F M[EFPOAN;N&&GFO%A%9Q73M\YBXR,53I!OJOA-W7@O" V4BG-Y-PM\+C0C?G< MNX3VM+7J53^4F-:^HLE5=GL-W>SN7<<%JI#*1C\.@BNC5QOT'U@"L9IUEI>7 MS<-!4U7%@)1CO,E&LK6+@KU[GADZJ.OT7[.;RB,W7XFJ*'3IE+7DE5\75?)5 M&663+6QGN3ML.%PL_;P8[C5F]O RI)W;V71QW6S(L]N>#;#RJO626#LYA?]=XJ.R8$YH"?9-<&]FW;]EG2W6V -J)T%7<_NTW=M&#A M:!C9N-DRPH"5 9/N8+0)O&7<@NM=8T:3FR&:U9VU;+G]P)G'ORJEEC7:) 3\ MIK7\FAV\^E'U*C,,;Z,(ZI/7G .9F,5*Z&D9O6^O,")'W3I@4(8,\UF*0)5, MP:09:G%K4K='/!,8W@1MA36:&+GZT[W10SJYW=!:;K=NZ8_HZ=UN[;>;/[;6/;8.S8GDVEDVI7(;0^>B<)W\;;'U,E>5(F-5"UMA/^53 MIR:EN3RP OI-=K68P MR[,=0V#UE7VW1X_5H^[UQQ7GG^E7KAP7EIUS!U>(S/666$: M9_ET0>$-RV5J7VZ+@GC MTJ7C6;KT)Z/2'ERH_#KXH/CDM37>V>.S^?@Z[-IJD",VFM1=.FWP=9"^#FRC MGNNI;8]=7,V*[QA*_FOX!I@OA\-9?:7&CQ<"S0-V79:EJO7ATK1;IYB/;4:! M4R 5$U?!GU,CI"A7G6:>DVY7L5X&NYB#*J&P[6E5D]%2"LI="2:G]OZU*MOZ M,2^K8E5U6X6Z3M]^,NMWILN%_VCD<;N'1]6"'+K1?RGO7M9M-3^9_(M'2,U6V-0O"O\]KL?&Z.$Y:GV>&/M/A7 M_<;,W1W5Y[GE:&\M+S55P#,S0TWI@;T#9 =&*W$5O4QDS&G>UDYZO][ ME?Z8O!U-KV4VJ7[YZAT.W]"Z:FJ]"N]F>]B^.U5F_G]-1RH(09EW8$EYTZM) M0QEB$B'(0HXQ"AF%4&))(.!(0M2RF@C@:C5#6P5W]ZM).Z_F0AI'^";X.G8\ M5"9Z6N8R',ULKJW+Z6@%A4$3"4H84D-G3;$N!7/$Y9=95/"U[=\UR>&?N(C<#YUXJIE6^S631;63-3/9IU]4: M.4-4-2UWOUD6L!W:;.7J%;B]@+5W9&!SC=W YT]S6>[68U)E$5D3V-W1=[ M9IN85FU,G?>M3N J!B5[U.O@:(S9(B.J+ -3FB-G*>DC=WD=Y#"PC[4GM*TW M4C?P;N:'F8_G8W"U^F9>15%GOJXKK!;_?RU MXKJZU04)-U$7I-6PY&I &K:RM2L:]1N:A2 6/+X6^DIO6E6/?Z;6Z#8)+M-OC:H5E6N\!@;G@+D?^9OU,MN6 MZ+!6(_VMJU@@F98G&!8V@+AC[8=:\V6#2R4B\*0LB MF:%='OQFC@@C*!]58_K5:-'CX-.GHT&='UJ6675&M9D@?1?47;F7,O3!_+X\ MGAI5/=QN.R)RGJARV\,=K<72(AX/+7_3>KK?$CY7QM!LG9%V"NF= M@OG"M8+YVHTI*Z_:6#!?]\7J%+\7KA6_%R[MO;2F/6<[U:NMXG)=LTQ[?-_= M(CB#BJFERV66HOI(5-AX4:0WP>%L :S"-=C4(V3F!)+:DN6* M64A+2+5^,2S/I^H$KJ(E:DAU&M-"B>J["Y\:'9OEN1MCI7-6X76U#GK/;9H; M9(^T>OXV)*^JIU45CVZ2%K?Z:QV&MX3$.@#KVHC1*;0N?*I*NVMWH-I*WZE. M$7=A(_-O#VI.]WB(VVO'%G:*X GI"^G@!)3WSIDE\XTV36H-1]J-C M4J.%:##OG!?4342WU#MI;6[O%((6)GN!XUL$R4YQ+QCT>MD>V[5RW47$G?SW M>#\Z/6YQV3I9Q_%VDL>V)+[>4TGN_A)R1D.SD81.YQUE"_7_RAY&,[7M'ANF MT8ZO61E^WKRXV<*I0G*W^+,&-JWVT-5-;#;#'R#!OKN M37MCW,GXBI>F.Z^&D0[8LQ]BXBZ]E;B3=14OS8]D:5):ZMWH_>514 MW6*YZ>YVI8U^I#;0-M!6@' #FP=--<+)K2N]N,IR,S>;JV(NL9VT;^;!4\VN MWC.1PX:<-SI?-Z'DJ%I?)P8U M$A< -3HC8B "D&% -55:0Q"BT)P=$06D3'_:@]V M>U)#NBXPC;:J;56&T\RC M]*_JM2F#'AL7W%.'I$S4;:]/RWB^0/6R^;ZV50_NVY-?-+6\D60 M5#C&1"'.>"2HU"34#'$=]WN1('V3W+M(KQ\"-ZO)"&A.$Z% :%8'BYASG&B@ MD.:VR @2\CZ Z<<*[8B,8J:08E*"Q#"9Q"0)A8X ACI*(@VPZ/AP];17F_=TUMN2">7-UF:,+=Z M3SILY+X'66UAZSKYM,G2Q)C5N]#%:;J=5,N]9WDSUG(G--DI4H LS3]Z 'EU(?') M>E[\3F[\>?_<7FY>#X[U3DY1LI93M+WSZ)GM+,'749EL:F2L/Z>9_6N< MIZ),R"T[A->R'G-E@U+G62L3_IN&(I=^:YYQNZIJ*FT7;K-L@V ZLG69 MS',FJF[!8YUH#<&RI?AM/P-R2*=@ +)6,$![L]F55_EP@)9MZ+!YT5KA .W- M;U=>%?5Z\S8F _J:N ^LB1OZFKB^)NYM6.H"9FLY&-J[ *^\RKL86K:AR^:M MY6)H[TJ\\JJ7DNY?9Q6LJP;%>Z(&H9>L!OWW;=WGCM+C"JHZA:BJ=VH]_8TJ M<1FWY=;* $25NKA"F>9*3(:V_]P=96A4?SDHW=7S:FJN?)S1H*:V884-**RK MQ5H]J:DFW?QLC>2#?=&4HD[.MV@MYUM[R^:55WGW6\LV=-F\M=QO[2VD5V:K M/*]*"UO8RDY>JV@MKU5[O^"55WFO5^Y27SA2Y;X/I>B M7E;&))0L,5'B:I3^.:T#&ZKHA%K8F[8C#;7FO:2 O&[', MY<7@I_2->C-PG<+*> E^8X2\R63H4DM&61WJ[L1/(_>];FD"\H5*S3VDB">KXQ%U\O[$2[T_J[>BP_[Y.AXOLHZ']'4\%A;DJ,Z1=2\: MX+LWU3OB3BZ:>*F+9C5X=$ <'Z;6L@E=MFZI@V;U+G38.E^]8^66=-G(I6;H MU7O282-]N$[+)G39NJ5&Z ?OPC8+<;1OSY+[;<GHFZI:6 RJSHI%2^+^H*QSFN7I96K[3E7%,U)5M4MO%("U MGB_;"(15(8;F^_$T%U>L4%WR.=<@PTX&]'C.S[6FTV.V]H/K7UG7N)/M/WYF MD8/=EZ^313*.5]B#CED^,LIW\5GEYU<&'N^W! &). 4, :9"#"%(5(0U(A&( M$HC#.EE[+4L0T!$%E'! &<*8PD0"'",*PCC42:0;#K6*&'M($:V,M%5#4-S) MT!HO34%9O1,=MN^E&()\IY6Y%4CY3BL-OV5F!$"#M(&#VOVQ^W1R1<1+DT16 M8T4'@/%VGY9-Z+!U=*F38/4N=-@Z;_=9N25=-G*I[77UGG382&_W:=F$+ENW MO"G\REWHL'5[U2?R/2N,,C.T)^I8V0JF9:_3P#8TG591*&8JJ>LI/5*3\J=L M,LE3/IW,^WM>7V>CFK&+B5%YKLQAK_+"7F^#8DH90,D#9MN67JI@Y'*8K/VF MO+A\=!%DTXF-@7;/JYOE5 U>U8^ZN?74V964+2XRRR!U3WT3?$B';MRWIC1K M'+NJFY S?575T?10B4E9E&RU^;:/L!2D=^J%RD1:SPWPEH72@+KI/<-VUR?H:^]C)SDV7MU=?N24=]G$_ MTC4\2MRFDR[4M322?36A=+&9[E5!MPO7$-'5BE]>*??0K$,M=IS/Y)/C'V5- M^H]&PCER@J!;XC-]V\Q]Z/K&-TKLLI@G/!%1%(,"O/"Y:6YPT'<00& M,8WO%C*V$N5NMR&2L2:&I"'A DN,* D1(D@": 89PI:V<7"V#7"OMP$.**8# M1*.[VY"Y)RUJ&&W%DFLQOE8$;M>>=PD CK=L-FC:Z-_@RA2SH9@.2TC**IG> MYI3:#A,-16?!G_YXY>3VF+@2;%JH4AW1VGP1?,^F0QE<&7VK[(IJ\TH/.JD8 M:X-\)Y\;75J9[0%XW07E]R-(>J>;U\DM1M=SBW7RB_D*B:LWILY8*8;X,7>I=(6R&-N)&A0@@TPU@ QAF+C.P;P@0R%K>V M3]J=T/ME9B)U\M8&):TX3 8)QGT0>"6&@N,D 913K$'"@:""<:$C0D-"^-,* MO-O: HKC09R0NQM0V]+U'0/Y7>FW/I':)4WPXJ7?[I"=='(V)OLA@^Y9Z-A& MS^*DDRLR>6;R:??EZ^1X2L(5,9@G(P,QZH+]N#_X4H9$,7-**(43S 5E3"'- M"$MB'3-=\^M:P9=1J'5(L(;$3$/PF%.H&8TB&HE8"40\=^];8&C2R9.5+/5D MK::2#J3U4@)#?8;P0FRHWML,X743H+:RGN4Q4J/,EA#PH8/YS[_ "/Q\=Y46 M)FWKT/YP76\J9%P R'OYH"=AL4DG!W.RU,&\&BD[P*NW2;5L0I>M6^J]7;T+ M';;.A\6NW)(N&[G40[-Z3SILI ^+;=F$+ENWU#_SX%W8![/P8=F<1(VDM4@I M)JYL^*71%:ZKUG36$E9&F X6&L@J,X^R66TZ*2J[DNV$,F$_:EYUK6K5#VN* MFG6O8^/QT+:NJ\U:KH3OC6*Y[3">%K/;VBC;:5%>)I7-GDY'I0DK=1*(?4XP MSK-O:1E&FIN;CY1.)V4C/7O'@TEVX+*@72N]@;./7;.;0%RQT:6]CZLHK/Z< MVH)S]:3+J19O@D-AV^^:V9=FO;L-?!>F7,YUP597K\(RD]UW5@0_+;<%']>/ MF2GP7\RCOBA#FR(=IHXV#RZ*5%*$ 0D($5=02L'/+<+Z)Y8)O[H9K_.W! M=F%H&>LAU%N:FEW9QHH)2D,V<[\L"W]?&U09WMBH=59R[KPN)+/M)ME(*,N MTJRF863A8N*ETBIOM+VT#RP;&NW*TMS)LYOL4\ADGT>X14MS)Z\O!//RU[U< MN%:)=]4JSM?R7A.P&;4]U:;VVLO/>38R+T79S+8T"M]O&J: 4!(#P,RQ@1,A M>**(T#(A+!1HUL!Y+=,P 5!A&2$,H<8)9PQ$RL"LC"(4 Z'9TBRSA^QY)U)Y M:76=O=7060TO]]9JV+(@VZND]-#U-/*701DC.9P4Q70N"-2<&[][RPW MXL=A*:.X%M8S">;M]@UX#7_)JA-J-6AU0+JE29D/@:Q.2-=O_^LVC >K]Z'# MYBU- 'S(+G3:O'Y;7[=OPEN]*QVV*BI1Z0 MA^Q"I\U;:OLKQ;G^2CVS4_I09F.C\>]RCUM]):LN6NHJ>+>PH& M;?6/K+IHJ7OD(;O0:?/ZG2W_] =EJ[]DU45+W24/V9-.6[E?J>E-:G._,7/( MF?.OSFY[ $%P$/R:&&E^38/V88NNP=?>K?#!VQ+E\U966,-D1_3D3DQ;;&K M5JOE^\S\%?QD/:T(_/SQ\/R]>PE_?AVD"];/UJN_CEW(0GVY$09F5U="P6 3 M,L$R46!0=6P6N7)NX=9Q'F72-?9S9#,?[=%LM&8<+N*"I=>%=>B[6 WIPC?, M?5UDAUUOZ_ ?">M2GD6-N(:"]FF\'K6J1VV#0WACGB*4]7Y7F5FC;%+>WL6DS#;87#$I'62E%UW.EK7N M>^B^M'FS[:INAG-A8EI%;F78B#6SB M6N-S>X,&*?QJ;UZXW9O3D5W/5G)Y[7I],X<&KNR=W9![1F87*2'T( )D4,_Y M-#.LGN4'G_/,AN_,*-2%*L"?@R_JFS(@$]@8CLM1:F__NMP-RUL!SS,FS6+7 M'1 9=9K)EK7LS'"U-5EO3=@\VW3)LWY23M M4]X8$IK,5ZL,11.S;$S[F,MI*MWFIZXZXG4Z,;-8"* )6&D;B%]_')H_YI$(]\GCPL'IW5NZ%4%T9R(+[V^]ZPYGG5R'<#W?8?M#5U_V\K(W'K 1 M7;9O/;=@^T-77[:EPN8[\_X:/2SXOVKR%,Y?V,F!"-?S(+8_=/5E_?8@/@F; M=G(:PO6\ANT/77T9[?7V]< 9T,DM!]?SR[4_=/5EWB_7LA%=(D[7<\RU/W3E M96BOJD8_VH,/#D 4' 0?%)\X8PWZV;XLK7%'\PX8UD)TYDQM9U4)WI_.IWSB MC/DX!@?H_['WKMUMV^BB\/>SUOD/?#M[]FK/4EQ<":#MR5IN+IWLW28Y23I= M^],L$!>;4UGTD%(9CFU1) @\>.XW@._\/2O5^:6S MGSY+[VTJ?;1_,]H9&V?5.[SN[:O$@E,Z.!97KJ)W5[-P)OS\NO$.#NDS K[[ M8=,A7$YQGGJ=_LVLF.>+RF_G3Y=OOD3>\)X[EK+TD,/;*;:)[A?;;'_I_L?& MV&;+1G39OOO%-MM?NO^Q86?0/[QJT7[>WMZG[N<;;G_I_L=&WW#+1G39OOOY MAMM?NO\Q\IA4BW>SZ'1QYB85T4G55G1>QS?+G(&HH5/4\?DBO;B*S8PR12'S92S1=Q:8FB]>\7&P^.7T]/U)$Z*; MH%R% L"6[3Y60=N-76M/ MBG@SC^2T\*"_R+P^&F+E(;8>M,IGB/HTUAH)W51U6NJX(3.@5$6#IWJUOR&* M[$.]Q?*YYG[XP5$,ZBU1J[;#'ABOWG_\=:F'25U1/>4Z]M20LK]%K&NT-4?15C M]@LL'#^9NAE<+I*I4^*W4V5LZKM+A$8HA=M@9R',0E/C$!-_Z0@D9#7!51Z& MHP6\'NJN^6Y 5=^QH=@\[:^.3-OU<+C?PJMT.ETEZX08?L#9\*7/ /)G!/JD M M]+QJ<+!+18QL;K.5S(/\UQ(]CM)Y+N?>I^,8/VE^Y_[%'U&HJZGL^V'0@= M\C*7*G9W%.P4]T#WBWNTOW3_8X_J0-<.91B 5YZ591*EXTU).JNRNNJT2T!; M72A!Q/AL.3-O%&)$:UZ4Z->&NA4DZ,J_4GJ+'!2S"Y,7G;7^>V%CI^@,NE]T MIOVE^Q\;=G2FS/>KVI8^R%[>MJX\L4]@ M;564.FA09@%U*M"*?"N=O%+IG1U09RPW=?LR![CD#K&S,8*!$E)8_UTJ01=. M"?(*4:V(5DVQUDRH-4O,^UI7FIY:<:&36MG_/61NJD6>ASQ>9[KX5,EJ@NZ; M,S/S?<^FUZNI./MJX9O^.94^Y&1:F>:AK9>I5>SP=)&6F8HAC]*!:P6,"F[; M\'(*K[[]XJKI,_$J#7*9?]T& MK:+.'MW8QO+)I:K_;0VU[]KW;06!6Z^Q&E'OWLGP3>@\&.R=P/V7*+35+)5M+Y5F;)AM[9#8LM]VVVUU8\S;VF\AS[CIFMEH M9;E:C#?$FL.6UEYCFL5YG:)>M^E ;.VJ90*$.T-HQT5(13FU"&"=&VL3$,2?8 M6"8Q] TD>TR=W.B$]_;=IU<1CBJ3/OKPZN^OWO[^ZH==Y^7L7:6F[.EG[_"\_Y@TAIVW/<0Z;1QMR#K M=0"\L]7R V-KH^E$"$41 %0GDFA.I26,PH1@&0,54W$ FB8V2:R&+('4P4+H MA.I8":!@HIF-";LQ@V8_(#M OX?>6^'85'?5][8.I8A!DNC5;KCG/V6^"+3: MD5!MG5<5J[Y<](<]^N,=>,U^B'?8IALS9?9#O,,VQ7._R_W\#E(5,'>V.E@]K=>#F]H%M]A#AU&2 MUD^IV-MI]Q; V,:SNVR(=_W,S3-/ ,'8NLKE9<^[-)!I[$66O7/J'8,VT 4^ M7G39ZAA]%&8V8F[[G-"#L+Y77\KC@;:Q^$@3^-1H9_%X2>G)2N2'PS9 MB)E#Q,R1L]X:?;R=/.+-B#WQ!>N(57)\; MQO_:&H%^\>+5J]>O;SQ&ZQ!^_[?&9Y5E>J'FM3__$%NV9]'PYC4?A$INCS4= M)K5[4^Z^!?_1)\";4,B]GKIP+Z3867VUVG(E3+ZD_S2.,=6 M"!1SR4$2RX10S(5EB0(@XNM M2.0!A.S(3T9^TB,_T591Q#'3B26$0"")YRQ6,T")L@3TQD_>.?A_.C; M=4U]T.MJ2QZ."_8K F[D2(^3[5@M<6)Y++3E1#OF@Q&3!&B 21QC1CJZ2SZ8 MPOCD[=.9?NGF-\TN?2U^-=4'">M AH?#LAY2>QF)\]$0IXPU)8 CJ!PE*@9Y M'"L M8 HF ("1YA^:O$::'RS-2T@(9P@ HZ4SRE$B&$! ,R9BA13O&F6XIY+^-9+R M,0,-[=V&^PTQ_.IP8U94!VUEUW(ZOSYRE*&_[F+=4.@NS=Z/SN?N-KG'PNX, M00H1(QE3F,24<21!+ BD%#.6T)8\AUOY)"K64Z4M!YQ2 M)7'7K.2'T]8)G@#*1ZH?J7ZD^MT-B:% L51:6R*)E40(1_RQD5HIP1+5HJT? MB.I';7TD]9'4C^J.0RK6BO(XEI P!H3$2,=4T$0*)_-;4H3N3NJCW!YNW('X M>=]4]7!$]K-O+H/C3#I;^.-_[S3O0S*&A^P<-DR(]-KE1PD?HB6(8D*DY8FW MB))$,6D2QSEOD4UYW&8]',:3&,+A\LP]6#(LW6AD3B-S&C!S(I E#" -+8>$ M8"L5L"QNZK;LSIJ[+'1G8TLJ.1'1V('0% $8X)ADYCTH9RFP"ME8(Q M-S&*]^M*HPHT\IR1YXP\YPX\!S*5$( L$T(29(043O?AB$*#(8GC6\2JCFB? MT0EF9(+I@-ISC+QIY$TC;^JIB@\3*[!5#&%,L&8R]BG^""FK"8EYRX%:M^%- M7T_=SLB;1MXT\J:>>!/%@#%.("24*!4G!+&$02$((Q#W?(A[5/?H_?RG)(^^KZ92[]NNJ7:? M).\R25%/L@TG_ND();7776JJ:O,@FJ_D_0V.XD0@/P9X"?]05YT@3P$)?MJ M?R6Q26(U9 FD[FFA$ZIC)8""B68V)@RWO7+?0^2.&'EX2$'0"53P/J B74!% M>Z(+IY:ZJ]-I=N5X:!0X6:330IZ=Y>9,SMWSG[*YG-9'ZA11S,< M4GWHIC)%VS*_%MBE2K>2]0"$!K5363B%1=EYF- M4,GM+[.O=3T;6K-[6Y48EY\EWX))Y/_[;J^*%-^V %H9;^_>G2V5%ZZ,U_H] MK*;:0?UUED=SQZWFY[DQT86[X[R(S$P;?5S5\S%DE-V O(>VIX^'P?4;[Y+A MB1X$57_S;:,C#">1#Y,]7O0Q7=11O*P1Z=30J M9TQ(KC 'D' H$Y%(HS"3%@JME=B?H_9Q[DQ'WR/_EZ6I**OFB;JMIP]+$B/9(V-IX&]9@5&LF P%A 9>*8,(NEX3;A MS,024H.ANI="XW#P<&R*3NB0>-1X -L3(;F>NX\(&&,K#($Q))K&4B840,X2 M1S\$JY960G=0! Y)7PC&$T')HR>PT2G3B.PO\NS21/\I+]S1],H$;W$<(_@AW.B(#QA MA Z'*XY.E)'6!Z;B .WI&5LHD2&8(&$HY BQQ!L2T-RBU=(#$#::Q !,$!N0 MPC-Z/>ZM\/PJY^DL.G4X>[1@U&B+/6:EA..8$L"YBJWC759P*A")8T&(XVG: MQ/=12@(R5KAX.#<(FE#*)E@,J+)E=(4\$?+K.28BM'8RCF!N$$FD3024<:R@ M4< F4)#[Z F]T!JB? +@@.HY!JX&M"?7/ (_R>\.4XR. GH5#WB.S$"MJ'W9 M8T.ULPXV[T>LX# AM'#ZC08$$,N,E)1@0S6VG&,L;M'Q;3?3_?WC 9@LF3#J M=)HX'@Z;O2-I#JM2=^0C7P,?Z?G\"\@XL4[]84H0IJ7DL>8TH8F$6LBVH/#M M-;4#,0T,R 0-*5QU)*;Q8+H[ZYZ\O)EJ[_#Y_L(IOVEV=\\;[0R<;OW M=A&\DQMH^F;FT'2>Y='Z;X)C(.Z2[]QN<+TU:P;[0;DO*8$:=::^;PG&,#,4842(P, M@#=U6>AVG'.K>'_[[M.KB$3_^1>.(/HQ>O/V[Z_>?GKWX7_6VRBL /I\!>7V M2O[]"^L #=2I8ZAUTSNT/%CLQ/'L5J ; C3I9P]U#$\]V_Z MT= +NKRL7=NXNZ[?*'>_=_'\CCG=+K;53W.%)H&M_MV[XT++YO51>7^/[1RQ MZEY8].-]^X!\:!8V9<_=L/Z>BP5!Q_DE1O)84+J;-U# M[^K],GX/PE4.G88\;+?Q'?:@<\KSP[J+ET:60]S?:KQ]:^;O[(=*SV]VY]>" M"^X,%FD4(0GQM5R242NE$E#C5N_P87Q!; (%FR#*#NL+ZA_!'T# C]S@$&[A M1T;Z!Z5SBIB0C /!.2<)5 )C0K$_.CH1&DO3XOV%Z$!TCD$\ >+ !4?#HO,C MJDR#T8O^R/(_?>/CRSQ3IG@ S>CA&%Z_W/[F/.F!*!=^]]_,WI=[OU.[8%!@ M*!F&"!%&&*<6$*FATCJVMOV\L0-%G"<"HPF(#QQI.A37>4@58B2;>Y+-86E$ M8FDI8 EF@A$%J430"J5PC" 3G/4HF?&$TGC"V8$[D#P C1S38_%8"P)>I[.T M.#A5]1H^HO'TIUZ!>?:"$!,(A"Q M7'.*?7&VAD*8&(&6#C2'TBO0A$$R84.U9@Z2L7LL5\;($+X6AG!@ZC=(464P ME183@V/.$T0$H%H!&P/PHT 4I*1!44/$G\ MF^,DN3%_OW/"].X4?KI,X?_XZ=V+__[;NU]?OOKP,5QC/T:O_M_O;S[MR^F_ M*=5W_W([P*@]JW]_7O]])MJ:_;[O(7SW7.27']^__C4MRC*"[@G)S73C_43U MS0:K6F-;&^90D]U6LZM>AL )HJ7TV>30-SS$+EM8<"AS[H;D8?@?HG3NAE+M MB/^M_.X.,Y2+>;9CAFVTN2G'#Z&SWV)-+[*+"X?/@>NU)H2V"_6+H_ M+;66)>Q[J+TLH5^B;SWG=M]#?9US^Y/79.HQVP3PG<;$)]C]\VI,$\-F7D6; M5M<^RSR5[K>;N9P[B5GL^-X)O,VO:N0D7F)/S7SN=-^*^:WN;(7+6K0(^/F% M*^&@:J] ^L=G9DOY*D>\^KH9;?Z[2XG,IK?V6:SDST_T7IQ666SQUX'$2FF9Q7\_[F^^/MS$UWY'S?K]A_/96Y^EH71CB5< MFED19GR:Y_[ ;]_JX^?KU2WOY;6_='HE+[WOH?;SI?OEZG&7B;)1E1ND*I<\/57N?6ZLR?/0Z? 1 M:'.L"SGQ!Z![WF6BXAC:7#NJ[![/J?OGYB))L^A<%K4:<;-D7")5P*E2W)TN MYN=9[EZKUSH12B*5U (J3>)$N@W&-($^QU$+2VZ7AP [.0'!Q'$P__]M*7<_ M:$5%6*]7JRZ7Q%5X0'B64,$@*%N=8?EN,2^>TUO'Z^?&7WAI"D>V)=>X2N?G MX?YB7GW[UGR66I[TR8%$)X\@Z(D%17=CO4V7\KHD5%,C\^ W/U]F]CFA6B-5 M=:7VG9=O;RI)[^69^3DW\L]3]V,E=/?4L&X-\7;A*V++,;;1?"=H)N'"I' Z MOUT#$]]RG*[9N.LF\X[9.*X6USQE#7[KR[MT#SQ+/ B>2>L6YU25Z96\+G; MJ:F8_'2>UZ-40:9*V0GF;\O6A.A%^>V::GE>+3)D6&QZW5LR+FJ%TZ'034M; M:WRPN9J_&:D]D!K+"3K!#B;%=ZA1;K]EY.QGQR__$K3MS/IN4@Y/BF^>APN! MAU27?OI>/J_W9*, ?VLAZSB_DP)ZB7,4*XSY3<]K>M;(MYCW:>IVJ^LDB\/[)PUZ?27YQGX8FY_!)T5A_1]D_F)@SN'9A% M="E3ISM[O?M<3FW=YLI<7$ZS:V.*7G5:V"F: Q\BG ,[Q7,@_4K%X="EH7YZ MTO!=Z;N?1!]67"'PP4FP;S>O1OY$E**]B]3@16FG> %\B(#!ZJ7#<@)^6L40 M?R[=)[G#KB)JQK[\AXMT/O>Q17D=7#*F#A%-MH1/B6:KJRNT*&63%Z).W"SR M8B%G2/G#M9[SXGQC0[OV M&GE>)QNF]FYD:%JJ.S#IH9+J[MB:MMS?H >^CQI;YM9.ONK *ZM;HT)&6I)>.M)TWI2-EN M0=Z4V3C%#WMSQ+?TG/+W;72<[G33:ACM>^BNW7?KA>R5$W7'ZN*=78/>._LA M+?[\^=K_]!9VEK<)"\E]5WW.B0H),(G4TB@A"8,$(H(/D1DM.&)6)CB&1/JN MP$*B6'():2(383F_L7GU?K!VV(N^,OD^K?6@+GFD+F6U>]9I2GJAYE$AW68% M0][K9+[XWAS>"P#!7VMG0#5& MK76%-MGK;[)9'NZ\#,E/R_!;.M,A@*8/V"E[_U9WP(\;NT;OW^H.^-%NBQRR M4_;^-7< %+X/H%J3I_8]U"%YZO'UY,ZSJWVU8D&(MC?GOE=!7LNK6P*F&YU8 M2C5DK1%+NV9RW,[0Y/:0O.T:-XKOW+RK=@'KZ=-W[>1\ +MD8[IB$V_K4/?S MUQ5S7LL2-NXY?;#ZN%U(M!]A;E]2=ZSFXK=9GP_1.\3J3>T[>A4J6SA M PT?C#+IY\#'I=U'Y.@9.>"(',,\B.-0XNX(:'2,XSE:IW!3!+.WE[8?7G- K6"D MHZ^*CNJ#;G8$N8\QA5H6/"VT_@H4W)&\[B4C[AJ,;_-OM-:IMWHXWE?.Z#8J M>\AY??3.\:=%^B/)/23)A9#,@RF%-Y'942:P@YY&VAEI9Q17H[@:26Y@)#>* MJU%<#85VC@R-<9O&;7J(CO&(MQ[B%QJ7 3*)$.95X[+!G,3SHDY'Z_6,Z*JO MY]F%KTGP-_V1SL]K/'GU M14T7GA9/B\*X__0G^:51Y6F-E'&,%!,V)LK$G"D%F"224D6Y:NFWMI%N^H^U M'-^W1]:<(3]=RW[JF>_4W^ M,\OKFXJU1V!YRX$:X--X A!I:04W3#0^$NO_ZIC# Y[!_NVMM0#LFX)5MI5HSZKF?/TB_/SE/M]-H?RG,L$(J5(EHP M9'W-"C<"4&8T-LPD#/-OGO^?9:'H,+=W%)G#)>I>NKW'6GX[U8Y+E3W!IZ9FQ$ MHCB!&@%*D@1)CJU0C%$)&2:\M;_Y#NUR6!8CG0@,)C!&CUU9'&EX5!F'(%8/ MP6TPD01(I23FSJ05E@NLN (JMA)H2?&.H]:&SVW8)&9HPLE #Y,^./_9"@F4 MO[N=[-:]$+BUU\"^A\A]"H%;V[[O>ZB][?LQ*Z9;&P'L>XC>!U"M;>?W/=17 MV_G*R^7[-4T7>JO;0#:;7D\\^OL"O[KH+U\5_>7&3HV:EVT)YME<3B/M1K-Y M=A$NU5T))M4+?'\#FX>(^@U-" ^_RZWE_/L>BN^SRZVMO?>V_P$/3@^M]?S[ M'F+W@51[4^*]3_73*VIO,XZJL<;N1AR.GG1VOS8^-@Z)$*V?? M]Q"_%TITZH.UHZWN,4'5RMOW/23N!:I.W;A@AW9,C(MVU6\E]>-7A6/%I'Z2CM[RJ5Z M!T#HAV\_,+3>%$^\#<4046!H'2@>%PKQP?+PZ/N/-UUH..F#MB[H@[(^Z,7&_$W(?#W*=0 MS#SNR-!VI"^[;",/;D=Y^5]>O'CUZO7KX=24_[W,K!AL1?D*8 -*_+W-+CZA M;-]^EKNO<+68O[._9)GV)^Y]-/GG5)GBHQ/5C01?#1AG'$"$$",)$T(H2@T M-*'0V#IQY%YEJXUY?/*I>+>H6_VXN+RMJMX=UP",4LFM!40KD"0,6Q2[ MBS:V$K;4!SQ.]M&M\!VW%;X_1L9Q2+S[ZZ@G/;B>=%.0ZLY](-N:/K:J8H>/ M10V**P2ECADSU%B-XT9AB,TP86IS0A&DM6U0>F-&CK0W6L,LCA6'@EG* M"-0\\2YC'!N::$D2U'HJ2J_1F@-Z7V(R$1R/JLG("$9&L)<16*4@)C$"4B9$ M4R%BX/Z'L")&&"-;VM;O;R0]$$: *9X P;XV1K 5#2M_'[NC=&M#VWT/^8:V M]^AMV=K%>N]3Y,';@+:WM-W[%+P7L%H[6>]]BO8.K%M,H^4S'S(_F?/Y M_/*'[[^_NKHZ^9+DTY,L/_L> 8"_S]W7W]?W?A-]N9C^,)6^3:N9/?O]XS?/ MW\S*KIF>+Q213++/9A+)620+QY\=PXZ^_3_?U6RD;B9]7H=?B/*NGM)C*W//6Q<5L$NE4.[XW#UV1C0XM MD=>[':^:'9\$G*M7_?RHN-G:#GOO4^R.1'7O:79JO@]Y3T3PJ=$:>X4K3JR[ MC742WU\K%G(V][B1.LUAZGO(+^34-Y]WFS^_+M4OAT9GN3$79C:OD%+FCJ@N M+K-\[I]6[A79+'R;.F#-E\WKBY-2D$:_R9D\"P-$B7'*R.<:NS.'9WE-"$6E MJ11NQ,54^U$^I]I$1>K6[%!V-7&W)_ZE,B\QV^07RU>=1FZ9LS/?27\UX"0Z MSZ[<6_-)-;22B\)$TBD_4WGM;W4@7%BGQRQRWVU/KLV08^J M-MR1^?P\:O<:*'.1_O!VX>WO=_:_S76),,84_NCU/\[]4>QA\+_)8H5+2U1J MQDXQ$ 1S9I"5A!*>$ UD3&4,N4F@@#OOMYA]OLT6&_Z7V6Y M+LSLF^>A!_R6U1_]::YK##;UNDXB#[(5;-SXTZ!7.A$J\S2<;V/=!B]N8F8XR%II@DC@H(M4(0A(53 M1J0D0"AD&BT[RSZN(4\Y*#D5N!UJ.LU*-:%=@_+35?;*3R40\$OIK9TE:!5B MQA^+)H5-B(2Q) 8S(7P4'S@[^#:@;0)-N]'#"0-:7GN0>)Q;SKSJ^+DL,*ZF M_/RD?0U%/E\NP2'+N\3Q@+"$UZG?L?]QP_\FO;8WO_ZHSHU>3$V0\I[/_#S- MU)_?K)@5@AI"0A)G(0L2(REC;&.K,$1*089;3Z#<6*9Q+[WT_"A?F#;.)F," MB* ,N(TD3"!'W-8(Q]ND08(QSW_7T.#.HFQ+R7#85E/MYBD[J5/X'5Z74/%Z MKUTX2)GH(IVE%XN+DH:OO09^DPLG(944U.'OL'3>;[,;7<:4;W7U96ZVU$IPYHZ[7MGC/V<&_GGJ?NQTICV MM$S;&J(4:.48=\#.2;@P*1R&V#5,Y5MMUF:>.TS7%;'JVH[9.%[+-LY&;EO> MI7O@6>)!\$Q:MSBG9TZOY'6Q TY-K?*G\[P>I>J35VFJP'>5:MF:'R)R^:7\ M=LT2.*\6&;I1;=!GF\NZ)EV'1#WHGLW5_,U([8'46$Y S:W=V]R1=2W8 M[;>,G#;@V-U? MO,K&>VGA4XSA*8B&,;]:6?OI?/=Q3';"UD[?/&I^[,HI/_ M&MUX#./MZ'YP!SNM5<($G*RNY"4REN;6\8Y_JM[$#]/Z[!XJ?GN'^V'$@H=^ MJ/%8)GR Y=X<;W[G':4O5AK7ZZ"2_59J9.]EL'Z*#^9"^M(W9V2NU-RF*02L MTT/J=+WT&.<6.EL0 M#FR-'&PC6Y8^7*5PSV0/*T\//]=#L;[6R=Z=F\'N5%N=&+[,0J]#X?_Z%(\A^+%8Q9B<53&Z2 M:X=$/C5,G;M+-X2/7SIDFAD=@H)ILO!?>\RJ0O$^&JC.';=:^WY9;E@'F=UK MFS>LQ4)A3 B!Q#!%F(PY,((28;00B344W3',W*W6CVS+]W! CH>C3?-BWAU MIGG]XR+YIU'S3UF 6@,*1&,!$Z@M1 X6U'))N3).LV%:$6+5_EX3'WSR7BA< M^$U^\=SQJ5H=0I80Q0"BG #($ MG!D+D'4(KK54B-ZBC7B/<$(WP>F[*@-TMB3$,FG!+]5G=999QIZ:3Z(:%JL[ M/#C-ETLS*\*]COL[2I>7EWGFUB#G/H]R1PK('O#[ MT/3N,^FSE.T^PV *D M,88ZP0EWV"FE!I)(8+BE*'9,[QCI'S&;P)::_I"!<>#E$BV!1L+&P J"92R@ MLHPAC34QRB*YMQ;Z(/5!$T*WVZHL.7K((XI"IH=CYS/M4&#C='4'F%J,^WE- M?"[MI6,XZ6>'(3TFU*).";5('%N>=\J Q5]-!BPX07=5V-GQU77]M-3U7XVO M+ABHHHX[I;WB8Z>]XDYIK[BOM-==:2&W\JV66;-5WD>=/#L-2!)9QWBFZ=SG M@::S\-#_9/F?D^@7XX3*['KBY,%47A>IG 09^7,N_YU.R[^5(P+I'C+_6J27 MWMG6HSC G9+,,#XVUG1*;\&D_V3II=%6;?@2 JSXB3Z_=(KC3X%S:N2Z+JHK. ME#><.S[EJY;R['-5R]10,W)SMIC*>>8,@=RC5E[=DINI+WT+%5+N8U7=D\T" MX@9->)JI<.4D^E3JO@Z*OA(@?.D_ITZ?2MV"PB1"L5)MDM6#KR_$YU].31$J MI,HRPD5A[,(-D%I3/[I[1=%EYM^?!E N%Z6&=/EN]7OQ%]CED M?WHKL9K*.C0==H5=JDL4YWZ.N9N"V['$;6)-E*5IL-S">M\(+CF:E"LBI#+(H=F)8VIR+5\E[<4G8(; M7 0Z]5S4ER:[=2^!43("/Q=G6CXK/S7J3[V)Z4M-=FSDAACJD]X[>89Q-\_P M:K);=1"U'R%HY]YKL+/*@7/#)(1:(6V(D400BGQH""@>&Y28 U0Y), 2"Y&. M*88DYE8@A(7B%A)E01*#>_5=P)V4W=.:CDD2O65 M0'PS?1T:NY\*D:$'(;)[%Z0\* :/:/-P: ,?+]KTS?@JM8;%!RDWZ_W$J7?+ M9D)KQL,A]O=^A5X'H;Q#5Y^M3>K0$; -,KM?<5I?!6G'A,">C.@:.AV:N ME$T$2!(,!!>$<9,80)D!'!M&A 5WS97J=M "P!/,6PY:."KOO,>1?;T*OY$+ M'+H>]9&1_+WH6Q(6"XFL2GR=:6*D54Y'4!)KJ90TR3&2D C@$Q(?^'"G8='W M$96E/CG,P[&1?GGHC23]@+SS(:7)N->/8J]',VQ-%+Y.RZAF'6XLYJ,%UM^D M^E61!@*J4:'5477(@;/WTPB>S_%O6"2W;N6+%F%./;4U\;%C3%!"08-]NCC.B-)$BCG',(:0Q330[BK<, ML@EE8CC&]&C#/!7?UD,YL.Y.A\ (AK3$1,26<(V26$L%)(8*$2@2?0RO%J03 M1OFCI\-CVI>MX-9YZJDYDEYR9]@]H$:\-UH_4//B M8/,>C%93(^ZK,EC=X* ")Y8G&N$DB8FFA!L(N(:2"@8M5+=II'[_N, DY@.* M"MR1PA[6;3"R@Z^1'1R(]A&%,;4"(YL0"B"'$E!()'<,@3'34E[00TQP(@CY MZFC_(94M$A)+!Z)1??+]1B*[YLP_;D95*W@&QR5UMO#%!]N3>[+^H:%!XH8N M34UNNY%VP:CF'&#.M=&$F%A""R13@F"M,(V/XBA":(+B 655M5'+\]?3[.K-K$07-]K.RF*'H5C0Q,0, M6V(4XH(2K1BP!(@8X=9C)^Y864P0TXK'B4P,)HXD!%?62LR-)=C8F-RKLIAT MZLI#^NK*\]&?:ASZ?3AM5KE]B*S;B"A=[42S:TG5:.#*]]I<5AO?4/A^UVKC M_9#OL%WWJKLEG;KVD+MV[;E[M7&_J^[4!(B0L=IX1S7D78S6NQ-Q+8+ZTW^> M2AG=6.(\ECB/1/W$B'HLJ1Y+JA\3VHPEU;LV=3#>?6^1.L"EY]]'0$9^/05CW">:SUN47+A:5K MI6PKF*WW8CA6"M8PTRN&D9/T555DW[L)0WU*<#.FD!"$&#.Q8)#$!@I,)69 M*$-C !-^C(@ACL&$LP'EM XU^VKD! ,(&PXN^VH_C>.$)K$C5F,XH53QF,:) M(, **!/"6X[)[>%$&,(S MUP]KM^5GR;?.\IY$"'/W@]+OAL-17P_#4FL#T9 4PM[F=RC=<.\$']24VVB, M]*X2V6]FKRJ!_3K+F]KEK_5)J@VM,K90"B020#0D.&$),H9S:WB,-3>J1:OL MQ$!NK%OAP= LOI'6'P^M'X.P!8X5PPHJS!F!P @H$52(8TQBDS#:B[GX M;Y-G6A;GWSQ_]I60\Y8.5/Y^H+K43L=8DX['6#<(0#E%)P_ /U^J4//LLA9M MU94Z7[JD@;J0[.7']Z_?RS/S_;[P 4Y,9_72>UX.4< Z%UA$(2>F-RKTZO[^Z!GZ,SJM%A?SU MS:*_%M=*_55SM[]Q^'+3NEIK!^NU_,U([2'46$S PJVMV]R."O+IW"&$\NQ4 M1N>YYU1_"67.F7WA>9OWGST/%WPR>7WII^_E\WI#-FJVMA:R]GG]TXI6;U^6 M_;.<>I[]\=R8^6U*LRW6C":"(VT P9AQQ;22")G$6&-%2T_+.Y=FPU@E&"C& M !4$NE?PF,1:022LC#G ]RO-[G1>/>GKO/JUTNRDW(NH\)MQI_+L QX&O1_Z M';;L?H7*G4Y&)W<]&?WNY=G]KKK3Z>2$C^798R7G6)*WLR;:Z=9C3>=7AD ; M7M4N_M-V5UA3*5Q[2O:M#\13WKK3M?/\U_Z=YV,EXA!6 M/<)Y.%&U@69#U@UA@R/76_/+5(4Q#7(L[WKX;I ;'ON?CE4@$V02S MKX^='%$/?/R)8&-1ZB,K2AWW^NO9ZS%58E\NU1_AH]'1J5NC/#/1!W,ATYEO M+A7D2_.0A&C)G%/6+E&G? <3<^L*\V MHB]$YA;AF&L6"ZJ(%%1P9'S[>@TD5B 6.WTW.Q&9G\2;B%R5"%X-:C+W$H[=:@GO*1P[TP5() V$8*$BBAD!8D00)1C&UG+8VAW^ M9KK )W1 HO'1&6UC6&)T58]AB7&OQ[#$$,,2+]-"^2.!HP]R;L9XQ.@W'N,1 M(UX-#E2/0" ,A.L?.38Q:D@/?[CIAGE<2W0OT-^;W+<':IC'&DG) $#8NXFD M@8D0B1)0$I0PSD1RJR1BTLSZ(\NLOV?HYMJ1$SR@$TR.6R3RUY$*1RI<4:%B M&$MC)!"6$B4A1XB9!"@K$R@LNEUM>F0CO1]".RI_/]"9&[Q3 MZW#1^Y^[WS" *,D784@BF3B%"AG'4 M$@T3+A5EBJ(#'$$@<#R58#R5X)$C$'R\ M"-2W=W%DOD.FG8,HXS'AW2B$^VG0:]#,*\E]?^ M4.*BK"AT[/J=?9WZ&.+_^,*_1JVMA!0A+(A($ %626(3@C325EF)DAX/#H(3 MP.,)9@-*V1JS_T?Z?SSTW\Q/N#/=RQA1"0PS,$X(-RA)J#%$6D(I5P+UV'$Y MIA,!G_0)0B/1CT0_:*%/&:48Q- (! F35B:$4*S]ZHW]#%K#>+DP;]WD/UV9Z6?SFWO#>='4+Q*L,!(0Q,Z@ $ +(ZDR(!:* M2)/XU.;^G H(P0F SK':VSN\I40SHW"^6:"X4822Z6Q "4D-IP#!BE1UA"D M@,(MHOE0!,/9A',R4LM(+8]/S"A*A69:"!(+0JV1T'(KL"+0:"Y52UW=H11: M)V*<3LOH*&9&PGE$8L9(%\=5I^NL@;'$D1+YF0[TR0A!"4)0 #&TG$E @GEK:6" M!Q/QD$\XH\-A6J.O>J3-HZL3VS0I-;/2:DN5LUHU@I)JPF*9".74!0INUV>K M6^@83. 8/'IXW!\)() D6&I ! 5":0B)E2I11$%L>[6'43Q!;$!- M\$;:'&ES ,(2&R@-HHI@38C$FFO?XD(8&A,3(WF[=GA/PN0>@ZX',KGI&'3M MC><\"J%_GAO3].H98U4,J&3,F*DK=*("LN01*JE,=O!*"6>, Q',AG)Y!$) M%L*DT(F)B<**:" 2G &I232B]80ELJ6@YH"@_-QSH2YTB<0Y"6 %B@J85,K6XZ871 WMQ''5H]0&O?'BWQ3^[P5&@_(OO;U^GM0+G:W MR?7/S-H.2MG)T4X]5K6P-6@)D(;[8@U$M$%2)S'&%FLD+$]TCRVY\"0F>$+1 M@%C;0%I>C@3ZA ATGZJQBS"YP!BA1,1&:T*I3@1!A&(&H3"[3UQ00" M,(%T#/J-U#Y2>P\!BZ9'#V*H "06QS&!E$H+N20),BLH1CB<" MBY'&1QH?:?PH$CU6%,0H-I B142"N2!::$(HF! XH+S',:XRTNBQU(Y;T"9+*+8P MUE@S0RCW9WA0BQRM(@&MT3WV?4#.U.!CDM!(F$^;,.\K/!FC!!M#N4T(@4HE ME "+!2 )-+'@+<+S8$;"1,3>%3 @,V&DT9%&!R0\B:$6.GHAR-$CAI+3&#+& ML3?AD9$]]K; \822 ?5E>ZP9"IOS)G[>CR5MX8%L^'TP&ASWT]DBF9J[S?NI M^$>'"9&;V?$.9:D9"Y46"B((4\@0[3BO9DH92[4@!DC68\9#/(E)B)$,E_?N MV=5AZ4LC,QF9R?%UNP8K00QR!:F*)6 DEH0; SE05I(84!3W>,P@ FP"ZDT:?SVSZ%/0I[M'W^4Y)'WU>3J7=NUV3O M,4W<:9HD3#- -5)FZC=&N1T.F.D_5SM>?I[*PF'ORX_O7_^:%O-/_J%ONE+E M$JT ^.LZ6RFQL4:EDH4TO'VW]416\ZI>@UC)"7;3R?K]D%^VD,0\N[R[A["Z MX(?_(4KG;BA57;LRGH-Z2IMJ-SGSW:VG)Q?S;,?TMD!Y2%YZZ[7\FL[3LX#" M/^SE5IW(_=[T0CK1"STV6=-.TXSK::YM]-9&[MOYM4UMPZR/KUY$;V:?35'O M=H^0B#M!@AT)$M&1\(%U@@*_-Q2:2_[GPNVWO2Z[*44>!]+"STHOE#?*(NED M_>S9I5/Z4C6)K--:GMETYN5(E#:1).8]>G)N+),W\-Y=34R921K_)Z\AI7B#ZUH_SGW_A"($?ZXLU M7WE7C1N^AC]^%\F9KE_]^N6IOPS9CX6;UN=,51LSB_YK,3/EV&XZW.V4NC/;R_?OHQ;N_OWGY#(KHS=EOW[\Y^R4JKHNY MN2@7<24+![3";6*47-<3\&\[OQN+1;)969F[EF;9Q?A ML0!]/\EI!0"_IN4@,"J,^3- ^-S48+C,L[!3;KYN13I3BY 0[8=QFS@SY5=7 MZ?S[8?7(W]T#JWO#D^6HI8V0RFD]ZB1\ MZ0>YQ=,?5>HNI.[!C?7<2G:Z@ZMY2 [&))PU4#-#VN@E-ME1X:%0PJ'M0YK3,ET_4WI M[%^+-+]V>^U>/LOFT861L]77GI#0>)3U#NTQG%46Y M02.'T87GJIY;S*_] ]48UR>1!\,+)_+\?4K._-3=(G6JRHD7RM'#)-*+O-QM M]VRVF#L9:6J*6R>&2E"E;D UGT1IF,!DQ[VS ! 'TL74_7;W5+3G&'"/Y!*# M3G@(NY%+ W'5U,@\.$#.ETDBSK:JT;BZ4CM!2B=3TSI^+\_,S[F1?YZZ'ROS M:U>&BC*>96\/\79QD9B\'.,G[S&YG=4V"1M MNNK:CME\\QR*G[[WDUEZH=J6=^D>>)9X$#P+O39_D-,K>5WL %/30OWI/*\' M*>$.6>VF!F/<"ZDZ,I/K:C*>[D:(H/ MY&C:\"BV^%?>+^:ERM3N%Y\7/3DL#I;F]O0&LDS\J9L?>UTX.H[@O MA]&;6>FEV%.HD17%BS#IX&AQP[KM32^*U^G4Z$H1:?2*5(!1200A$A&I@20: M$XB@^VVPI2VIWP! .>9_PNBS5!=W S5O7G[>D>P[IE3S7W [LKI(869??/< M9HM\*U0772[RRRSW%D+#' B*P[-JZ=XV6#C]NA;35\:9M]:OM#9I?W>SCY;?>V4!+\?_Y/E?WH?DYQ.S9F?QHI^ MBH8SYH<>4;"3V1L?V^R-.YF];&GVKO3\ X33UE3=NT>\UX,KS;]_FN>[8OP^ M?+09+-H*0+7&G)I!L\T16@).]VRZ.(\^K]Q@+U-Y-LOGP\J)-%S_ CYT&=' 2,C#QH MY$'W7]'I;'Z>S:ZCGQTK<3K136QHR87^:\6%UCF0YTEOC;MR>N+8VE2[%Z^Q MI>EUA"NNY.]]3*RIDV>)T4?.FCHYJE@\LJ:1-1W 3+LT(0WD8SHO$;>(7B\< MAWGSYDWT_]Y/G#+TWJE&+7>]D-=NW'!S?9?G3"UWOL_3SW)NHE?_6O@@\.J) MF_6QS<5'2];8SA<_9.[R//KCQ+-9=]=_R@L'T!?921>9HLS9X^Z2=1? MEN'G7W]]4;/0T\69@TT$6VC,1XAWU8/@3?)M_53S6\^*^^.)2=G9GH MM'1@0H')6DI?\X8ZC<_A\L(Q<@B29]0/F)OR98U,I_J]"'PKE^]MCG721HD= M*?ONA/VMRARTE(]O>$)MK'?'K(I5"N.TR"(GH4SP,;@_SZ+H+LK%^$=KL,O5JGP2YP:(&R&JQ-EG,D^S1>%S[8K+ MDHMM/%"<1'_+KLSGD#<[G4;)8GX'()\F#KFRF=$-@&(K$Z2I %Q1H@WA,>%6 M8,49CF/:=CY<+P"=7V7;X"PQOC!+N 9P^7QJG^,UQ^9H;#_F/H8ZA M":,X@8@G"B,A"%200\&U\FV&$ZP!1P\)(P>=Y5J6>>_UFJJ,Q]X]X+FOQ;:*96_I@[X M3AGR50J^JUZ=)5RKQVY7*FRNKM^X@<#-326_*!8 M*=32U_,\VV#BM8Q/\R"_*T[OV_(59MI\I+I4YBROK;]:NV-KL^QJ*=5+=;6$ MS67 SVJ:;WR)T W.OU:1?E(MHS^%CG>*2_*.B-= MN(J#E3CUHHDHIPZ??;[]BUHS7+-%7IR^6!H@#B*O39(O9'[MK)M CC 4*16+ MBPMWL<1[]T0C%<=IAJ5Y6AM,B!:*O2JBKO5F M-]%Z]3OF6V^'+U)ZYBL*_!^A/L*I\2HW :AY6OSIU_[,O=R#Q1?7_6ET3:5E M78/;'2^2M%]XPW:H*+\UUKCNS=KR\/^7_.RF\:JP;G]2IZ!.HO^6G@VF,^-' M>>ETK,)S;8V3*U':YQWBI3R8^<^\TZA3;Z5 M^WQ KKC-G +AE_62H>UMT9"1&[Z:&M?6O5DORJ?>^!)*CSC!C17LD"1\GN\< M<%)[[AR7<7!-S+F<6D? 2T[8F&J(C=1UF%7!KK?ORCJF(E1INKO=Q#PG:!3N MKDIZM=-=U+PLW_,$XA0W$^(RN_Q):_;]9@UD<6[<9'-3Z6)I>$W%JH.D\+;^ MQPA'WWH]-WJ;G408XV<(,2SXBFZ#4\O-N+9H%X5GS34$BL7EY30,63)1V;BO M\6542C*_@,H[?H,_KE?A#K^>/'.B MM)B'/6JZ:(+/Q@F)6?2;*8J\J+EL ,B*ARZG]:8&1;?IH;ZG=S/<-ES1NYR@ M]6Q^*Y;BXF5^4@F*&@#EE5)<3,*M7AZ5*GN^%$=]L;Q@+)*[79$< M EV*Y*(N57(;=7"A^&U[:W95T74LFAOKY.Y.J)WR%OC]"VQV1 $J!>'O@5?] MO3UKJO+;PP%*O*7.;XQ8! MNS;Q=O'Z]XX"K!F]7'N-A^6.8&0E398FC1_+N9V1CY7-+N)=PKW\Q[+M2KGS.F+TI&RZ<$I M@C4Q6><,+=I4(,!68Z7\RBG8CA6<+94]7Z<["4Z0*V_X^Y8C\L)A9(@0^LOA M !"/]DFSLJ M-96WUK<.F15.:0A_>?/,^ ^7N7GVSX4^NZA[OERZ(5=7ZD,>RW2?8N&3)<(2 M0PC5^JFM(CS:&,=[/?C+D7+?9Z%THV["/<3]2^#7RW>O4:4?JF:!/F)27\[R M:]_KHO!^I!4T:R_,+;>OB,K <-"R^R3^3I%]?NS(/N\4V1=]1?;?-RQC.=N( M653>OA+1?.:KG 6?:17"@)/0@61I=CDUL3BO\CHN?%9/+29"GD_EG5W&[8/G MS_<+2O-2%GG'[L2_<^6;YEMZDF5!K T$(M%XOO N#\-DC<7N']][#!QO"'>XW?2!%C]:'7GTK8'2 MPOMX:U_R9,G)-NFRRFPHO9 M>[*O^9_*\GI-?B?Z(R;1*:HBCAU5$9VB*J*OJ,J[6:49TYJ\5KA3D_Z2%SC1 M>76>NIL=$DC].2W6MWR)8AY!M'$/7Z0S_[RGFFB;:CS1^SY$,^./Y/)X'.1D MX1,X'?<(3];(N72>-7!TG8QKA+N9 AN9)-M1'F6&_=\U<1NBTQ7 MR%T&+SW#="_3OD?;4MTOVRJ5TYU4@+LJY?4L6N9%-?FJ4YK7DH\<-%<#;*VT M!DF]R%)!N/0*??!S2F\\-7-MLGJO4=S<[!UKR]Q(16@HUSY4V9L/QBOVKW?L M2&XN?2NMW8-@4+&W'LFN4W1!'#NZ(#I%%T2OT852CE1-!!VAO*N:COD-?Q?X M0M-L#E>:T=5VG&B1+VL"KZRI02=E@^]*[)6O:["H'Z)OT^_J 4*XMPI;R)!Y M6U.()^-L$1J>.<7:MUDL-=$-1W$90@P9A#XT6@UFOBAS.:\:*;3%QJK!2@+? MF$&)[I[)+2?YHYOS]J3+ ,N=YRGGY>.A]L@/W!QYS=IO^&H"5^L"BWHW5FAQ MYAO2;>HP5;;0V\6%R5/53!9Z[RYD^H_4VV=_>'BM)905+^3L@^,5[MHG;S66 M33N:!_P@(X5**.<6$Y8HB;6$',1&@D1;V'K ST:BT&8"D%[D:QTXYC["K>5U M4:<"5:MX'J"V%("K!I"^4^7%Y;S,2@USKTS>+4_8COC RJ/3YC29-.,'X0X? M/UBZ4NK809^;L#M),G5_3ER5UJ@*6-@28[LFQD;6]5 MBMR*%L[-]9HZ6+*&.K/D.O@P@DE3&7:E_V7#!)R$K-[50U>E!A@>R8OYRMWN M.Q)[\Z,R8-;4K?#F932W(4U*!;;!O]R,E3--O,WF=)-EJ]J5&E/QMS+7I?0D MZ7^Z:[,R%FPKN2:U;P\6?+UN::4%V&+?.N[I])RR'W&R*-PC3N!Y-E-95=N3 MSQ=A--^-JE4_6P%D6^$-T]D T3;O#BZ@.IEGV:ZW5DAWR#JW'PZ+3 4DGTU4 M)Z9<++>WY']R5ESYE67K1F]AYF50OL2VVH'E#?-EBDL%R0#DD _D1]K+XNY% MDYV\Q>(HWN+];*Y71G5=AL2N/Y(U9_%MOE;.JC* MW+PJ:ZZV?"^,*7VNI7G;< @UK, *I\-9U,X"7;:<]EFM:_67-[RH]%4Y(CITWKOS17B\N:EP2W]C84S+*Y?)G.T]B^=::^ MM97E+M8,SC^]/O/ERB$IX63=K+UK/0Q;>\QVS+[THB4FN,=+$UW7)I#-IM/L MJMY\=T,V72S+C7Q0T_ON+]*9%TV^!68PLYT>'6RLXK;YQRV!Y^YTVLE?+L3( M_O8!J -8(>C+P;_D?V*?JM?0(P+G</T;-^@K_;T?*>^E86W]/Y0&LMV?S'96K M#6VK@^>5-_;:2;(\L+/%9>6^V8\-MU'.>DF+\<32B<:&T>5M3(B[94(<'!/B MGF9"W! ]-)X[=&(J/4;IJJ.0XEIRWQ"F4[Y>:+JL(?+1V6Q13*^?+6WOTMQV MAL+2@[/+W@_^Z\W(?)N%O]K^I:E?'IZR9AGLKBXI0W?U@*U.E.(\%'^;2"], M[8XM72I7QOQ9NU)"CLSVPUZ\A?(EQZ+\*4%]>A,\(G3"GZ.T_7O$"K6'4"? M;@7(VN9XD*,Y=[2:?VE"&PE_^?;=Y>\+K$Z>>PBV7/<] BO:)3PZ*I+#%">= M//X0;+G\#[,1VVI(?I9\BZA/ :E^?+=#9VO<[PP)_]]WK8I<>&.+FN::K2?C_2*IJJ^!%7]MV/\ M_RUSQ^O_R'QYY.J^C9JTF]K3+DTNWS;M2/6C06H&#^0O)ZO5K^J#5A)S4AT/ MN'/Z;S/O8)JN'ED+TGNXK&3C,EKOLU-*^W*9&%Y";+-.KH+@H&;NW,ZWP V4K-R$#@]]DY>IS!L="G:C9#@WL<)$[>N$9:JKW%69 MF'D='RCOJ-A&FF_CZQJJKBH":JJL2PS<;;[DU^?MI_-%Z>\,[VH4$L-VC4(FR5'M15!_E\K1IATGC+JB@A^$0O0E)B M^:KVIN.9#V#-9!W'"54*7MQ<^E/2],*M?%554$?"PB:FX9G@D/4' MUZQG/,IFE[AU\[1]7QM92MO,JTSA])E9,F@.SNY+2X899NEK1AH9[9LQGV5H M6___[+WIGF MB66IPN+B,5L4T?$1+DS=4?EQNB*"O;QGBLJJ#8FFT?E3-:<[;=X;GA,.R+'* M6T7G[8JSBXH1>LF6$=UW,U=:Z2/(ISV8K24ME_)RG!O7PQ4WTZ(IU;%43F;H M.PXF[[)@0+4A:EA0K72O'QNI0K*B5U\#[47R!8MM9^H'Q7@%'1134XH (T@Y\GU(2. MH0#!NFRC "VO6!6+Q^C.R3W$*BQH/5$GJJHZW=S/&&7*YXGWP_X?"R[%P:,Z MT)SJ,\,KTR$:>GL=W$#4S@!;R ML[I69?S,['[ >2,XDXO#KAI)ME!+KMI>>U;/U;K,C'H:CB H1GU<,S'>S7>) M3^*[?,IF8KR;_P8?RW_SNL@3*L5"A2<+&HZ,4,AQJ&_H!C?J)B=QB!>;%/P7 M@;.I/*U@H"E7*L@?!LYV4VBX\/CSN>KQ;EX1?.HD''CC3@,]4X/CO,%%_&3G M[L9E6=!3MC;&>#<'!3YUP]']B'X+1?P?A<'5UU5U2 MX,'J#@[B6R@=X/X,)V#$CP%;!H #P+4JJF['B9&F4E0MXS M@;AD"G-#I2))0I2NJ5R.$<4RINS$G^9K^XI=F^OV/&3V+-7W?1G+XU40Q&%- MVO,)[OGJSD>'SH6@J>D1,'/:SZHT0[Y/N;MUPYS6%)L?;0]H)3!Y-05UEGP& M<^DK$TMLYL5VPE#^*P"C##3A: ;XZD8E(2T71IW-<*[E\*/=A'-H5Z0+EWCZ MVV@XN/&3?LS&\)-L6I-F^&UNYC$!P8T,@+S2EC",>L]T <:S6D'=W$P2UO7F M!BQ18S>[^WY4F(/^\CBY?PZ:CXO0&5!NP,U1>ER.1N!3 )#\\\/LDH_J(99* M!S/?=3ZLWZ/)XFJ0)[^]4[W1[ZH_<;A:CEY:FS*;)L1 ]^E$8D<"NS"3*L$U M5?4MJ&G>@AI%KWB52TB52] *'@'^L,-Q<>&+5Y+1+B9\B45 #QT/QSF%;K!2 M/Z]?J9\?7:G+@7W[)Y1#=/;+$#YZF^\8&%N6FG:I4JBFD'_->N%=UHMPWN5\>;T@3&64^SOFZE-%:H_A-+,"F5]S:Y::MKFP MA;H8+5CNOC1O0R&KF>6Y4GV#5BV(5<=-A<-F&8B0D5^^:IJ_>'_?[QF5 T88 M9V\ H8%P+(2'#;+N'/=!9G]M>N?>S!*VO)?/-N>3RAZ+!''AM4@$MBS13B5* M"6%7WB(&S^-0D'M'\HR@25 MY32F9"*F1$Y=Q0^A,(=%[=6/Q0.@))F MIF782K R-7L7/HEH184F#[F1]?'!1MU_9BH8N7%^8[3%0F# JJ&6)MT9!< O ML&TK)M?V;QBLRKD.JOKNHJ5\FP_ MR#&KN"S+E-Z%,W?%7*&" MS!'];>]N29X693S+$Z3,Q[F:G99YR<[_NWK8RYT9YLWDY;\;]+.9=H[X"(\> MNR_#R_C@O"C%N^'HY_C4:_\V_/TYG[B+<38YF+TL%Z"J#5M&B#-8JK#;+#%" M2DYE2F3*&>;,VBT[W>RJ#8]K-.%R\^;W8;:/,6Q@UF6PP"&5RDQE\$-8W@)5 M!+()PB@KW2NK]*RX[ LVAFTH6S8-J9UK"< MHIA*TX][-8]DP \RZ4>W>BQ/.:U>U4G1G$#\ ]JOJS MYD ?W%=E5:F0]=6WV4+&4 EX>262J)1V8(;)Z_17ER]"R*$>YZW2\L@A-W"^ M-VM7N(*'BG3LY7V]F'O!G/H&3YM \X(PBDH-4RA+E&6/F"_JV*K@IL^Q[F2[0-#P0 M"M=.R^G&%\T94LMFI""X@*^K+9=RV;&P/#-9#&E(XUGWW&D]/I@FY,A60U^C ME%F6XO/")RMLJP'>E?[G!<-./CE3*M8PM_FZQI,!=!+I>9"4>8WC[GRH9#?O MD33GY5Z.3JP[CY:C!DMK;R6\JER$S2(4\W#$HA[RBMC'Q26H1(".\V6&_1T] M1-LT[%59K:'H<07!B$725^E-C=4WY@U;Q;%7''@YK0QCEC.8OZMK7!A#BP+2 MP!Q]%^/BPOJML20_)HT7)3"UQ'BJ+$^L9TXZS8.ND"!FD"8Z9=LV1=Q- F.T M4@0'IBV:6U73Z^>+5G<*2\ZHL&H^EQ4SX&5(KB0@A=SC;/GL.,HIOQF,7ZXE,8+T211_EWD MR;AECC#<$"L154K.0KJM#U1>*5GT316C<.-J!=5X!ZQBMX_>,)X_Q9$0)$M>*6TFM"'6I3A98@[+P$U?OAS\ M6X4C)XD!/B8?D-VBQ M-%86LBH6B02?DQD")@5! "*^K.(8A$X?:@3=W);5OH)..C7'A(LKP:6Q0%S^ M$A/PPC"FAA0"IZPV7L0TC!_FI=1,A.I<7SHE3E +)Y/27GO^>F"*VFBVR!N9*L3A M.+GM^/X0\GP^Q3R@?F&SB N;#[A;7:&P+,6P!M/A],(*Y,.I+DC89C7)MZ,X M5J>U[@K\7O1F"308'E,FM*B!ROW0L2[;)(#.PJ^:=U6!TVXXRM9Z[68NL5J. M@M^J/\??%YEAFY3M97E5EXE=NE6.\ZJI:RA OVKP\\I8@/?#P-9B , M);ZN/_SR\LO;3[]VWKS]^:"U9]NZ MFY;.F8-L8#C0Y\[^U64/-GPHO:#A#_A9UQ5+>-D'60A&BQ7?!X)?_*JD- ;< MF1>Y?!F&;X*H7JB]L+@PHAK2S2 >V#LXC,KPP9_TNP]\>[-2DLL0*FI M;SFGKMX+OPR49""^#"?/K1PY2R!"([P:,NXCQI?<>'?@PB(N ." MT@,G79,*#!D$4"S.*#"N)L5R9]KS$T@=Z\&69"-A!9/"KUW@SBSVJH"-NW&# *3Z MP#]_Q,1H=0]A#;F7(2O:Q>5XY!ZBHF)^^BSWNKRLFS>2B&;*'(=5(F*7JT*X M/XO6FL#N.CPR:M:SMA&%GW!5ACA8= D =B&)05-J8MLC)5V4V_GA8##,K:KKO%KQ"=GK_,[7X<8*27M*K?=2H"0U+-"P3(G% M J)#*<<*+]L&LJN$NP@KU,0G115LBJ,]R44SWVZ&X0U+T@' MMRP<4BZYDH0DUJ?,"B)54/<\M\@YGA(GFR,<^"K)\,.&)N=?1L,L^UBL*.B8 M/P]'H^C$?EV4.77VW7#TKESCL%Q5;RE/B,&2+*_7OT=%BH] M"ZC4;N.SV,;7!9H((FURWWG__O52&MC43AG_F=EPYHI+]3)H:3)MR%'(O;WR MH=?KS9<&]J[EUJ<4(%!,X3S5)B".8:TP)LV1]<-^VY^D_JP.)5[\?#NQP M$-W/6@W^N,X#L.#K]U<_7W\JC^''\DH".[Z\"^.\7F3Z]4SR^ \^/ M<&X;Z/:SRGK9Y_NP#_9Z4)U(-$XA1AB@(MIGHYAV9? MB++SDNZ/;,A%LHQLJN7T[_N3H(WI'[=:YFHH0DRXM#, 6:5=E'I)/1$4IT^-HU'/KQ#9=)W&1UBQ4]**"A3UZ5R!G+:H@ 1K$6,C"X*X@ M\@XBM8:F4 MC';"LE(0]*+R9%^XJ!$N4*='W$ 04! 7% M2/X//Y%9DM]E5Q M^]6@NB57@[R./V 6*O2MUEY(H ^#R #"*M'U%A MPGW#V#:BXNM!94#:9!"##J8^'TAARHI(+S!XSUX*=8NGOT RM3'AZE&L%G9? ME"F=LX+58:(>6!;R^.NRM-/"<"\Z,QT-JK2I?G^^R.LZ&WC]J9RGS?=,D50_ M?4?5-(Z)XH(IHW#"G!)AHXFT@@6MP"=<-M(T3E>9=F.@XPSYQ! _E4$.=L4' M4\GY@PO"=H;]RC%2EIO29R13H*,\R3 OCHW*%HH0"9GGS<>ZIU4J*<<0D/(= MF+%BL.#@\V"#*@NGAL3U;>5;!/U.CQ0XJ1HQ!A\=.N>@R^YB_MZI3(XNM3W70 MJ3TS*A%"Z)1#.!SA:5(3HK^W3CU__2=GH4[!M&1&O/_Q2ZX';BUJWC@4OB8[ MH*)FEYRT2#-!,!]M1Q"U(N',&I$@1FR0=#C1+)QA,N4RT;J!._+EV_!P.[*< MB?KOBU(N[_*-5FX/[CYB@#K %B6>2<&LY-Q31A.JN"3(D:"3(Z5YV8>Y65L$ M/:8.MTELTTW"*S>)7'0B7,HE832J5-IBQ8+DA>@$Z7L_15-!$-MX6D+X2"Q; MLOA.LHF%__#@[Q#J=&V)A74W':O P@[J]#YSKTT-6G?3L1*#%B-/AKK?*Q-; M'D'Q .C*$![]$",:1ED![F/P#J1FQK)@G7[/Q9ZF4"L??& ]2 J-(*V(SKX? M0; R5$(N2B9!)/ L#*4WB]"&/]#>;OPPM8IE>1]5G?5BP6JW/ARX1C,\E'.I M-OEI;@JBZ$W@!A3<(A.!R- M8W9NS$B:E"G]$% 5VW?G05AYX#F85=D?PN2+TE\/F'U<-IUG+>0V:LH#:)VCC 57U FTM%5',ZL+K"4,T ":D M;. EJXQT*DF4-?!)ZM$F9?/6A=<3;\&DP!.C#",IUCCH1-P(YQSE".E'P^OS M53I<;+V8QM:__?]^N_KRC\[5A]=O/WRY^OUMY^/[RP]K0NQ7"ZGUD]QA9>H# M['?/R%K_OAT&F0?7CZ-YP[A^OXA\B28;^/T>+WW?EFSD;\UHFFK,0O^]E MXVB]G>''V:$3&7H\>E4]YXM%'-L%XW.9[K=PML%^C.U&3\#1]/P5:A8%J5E. M83R\/TR?S%JB_T']N/'XU&0\7#&^I35_,??$/<7BII-YFT.PCU -<\JI*SB0"U0RUPN1;P*/BW3*;HY MQCA2V>*R5ES\-KN6>,8,D8Q)8@@GFJ8)96[9W,$0 MQ_*?\?E?'N[ST)FR.G^EOEQAW(#)?@BSB9?%KZ?+ U_!\^K WDX5C\7*_(OZ MBL?JJ^KUR[QZ[2) AB(^*](JIIO7G=6'!4,% ,05I60A *6HHFY&+J_?-0Q* M9-^5&?RQGFU1X6QX-ZT2!JN;NY;RH<4V8S"VR_P;R$.%$>-S7(GXN=B ?1_X _)NKO/'#:9)LEE?AF1:]#?KNAG.^Z+R>W,4> M<+$,7VDAJE%B1BXO-_V(*6_?@MUO\]*\[X9!,8=*]->CHE;WK-YY-=G(4:LT M(@KK%$)"A)&<6BV=1=*A9(.POB9R14I)-^AGRURQ3"VK_-8;:;)!?2@J(<>B M]OF" ZV49;1LC-R:$4+AP\[IX;B%VZ]G3IVE"NV"TJ#44VVH=V#Z59*EA$KL MH.AEZFJS?)NZUXQW14W,7,U6YZQ7=7:M#^L\YBYP'?0^K:4GQC%EC+3$>2H$ M=2R5ICZD]L"[ ;\@^T$P8'I\-).E *^.)'B)L3Z=<71<]GOE]_%\@GU'+5P M6V<$A4]MW@DCYHH6QY6,Q]7%B>!%>9H&:?L+'%?53"T3T 2W'B<)8=A*)3D6 M*3?<*HZVZ(^[8?A&A;;4Y#F')K[\U>@E(JA>HI++O8N\+(>B.^ MWOF"BG&\X=7&"ZV[Z5CQ0GO2P$PW*78U5U'$0H[X=BJ*[%S?#7IZDBTH*:58 M6M!59(VNLN>T:+(NF ATV7K5!]#KE;6VI1E[F&@BYZ:'6=E :NZ>;H%SNS'N8Y3;77H#\"=!G!U4%HL9[IT\Y;, MPGGGM&F'(3B)C M%B)Y9 O1CJ:A:;VWLE53(;N#) VTDP\J=DP*7T&(P2BO^!:O6OXD$FK6G:M% M7?D"IIR7!XD?OLRK2:]>S\X/U@FE)ZU=OP8CS+TU/0'C$\F^>"?A;/8;=/X[_U%I4= MS##BQ([HVHC4=3?)-N"DR0$G^AD%G.2Q!'.8\VU>ZJZAX2>U@PQG MPW[/JEQOA73!F,8:'E!4"@>]+S:, !%:]"3*"M-%]M-J(MPV0G/])NZP\V2O MG=\I*!1O&Q6ZO90Y[JQWBC+%VX29%J>Q\>-X_>XP8'V\]EQE@JT/_*_QV5!T M Y>"+F7_^U4\QQ6@4#JBP\=B[N'T@]4T76G':/S2JL&<#B__T"[SC# M<@S;OY&O?6-1[Z)\8;&QG2BT\C(6"T7^OHW4_<:K7I09.4P ^[O"0CJ&5,,R M/WUY9TXT&C 'VZE5Y- $LDRZVY#,BCVKI:,EG-8R[9F9ENS/M&?ASV@7?+)\ MT!+#KL00=[Z5@"LWJ,!(*?_WVAI0KU^_??ONW98R<:Y"[\OT@E2*A,$5X77Y M9]MO)FB:H)_%7C<.5 85)RMM[<4MJQJ]+TRG%.%(1";V<3JA*?8(:^4 M98Y1N]ZE>#4 _^_G4M-_7QATHFT?..O:?P9^.EQ7!-8E24W,U=FD\4:<<<2# MN94L6TO\[TJ,'%QF"*D3RX-XL EB#A.1,NM2@;CR*6>B-GJKE!GX+#*#B&[* ME\L@/2.9<69(]R[^:0ZD^^0R%PT5>1V.KZX_O(_E9,K&18V%=].5;)(0/NB@ M#B8K-R"Z)D(N;HA,O>-"NB!"L134^"!)$>(2$6>6DW^W@EPEY5\.[)L9W1>C M.)A E;B+14WH34,%:D$I3P&$M?Q_3OX_O'XEM4L2E2;8$6:\5 @+C:5+%)*, M^SVQTHF8'74E>3H:UP[,?E[T%%M#(:BT2$79&FI_)\(1T=5GU^_'P,>R9V6L MIV?O>H->-A[%H.S& ZW-%[U!@KANT O6\##FPA*^T 2\2:)[GWD\+;"7ZH0G MQ&I+,?1:2K26V&J5**LI0W:Y">168*]@Q%]R-@RGP.4<$Q;#.9P>S5'29355 M+1IZ%&S*XT\ %[;BZKL75P>73=8;HI#P*.68.24U451A;HTTSF!1(YNVP::G MEDV,HVX8W?_HT8V%V$^3[K-+Y!/F\:(/&3W8X@3C,^<:_ M>^_VLW()/ZE%._!)0J1U5"&I>>H8EJGPV!).4I<8(Y"L;>JW$)*_M_Q/$]25 MB#93_N\N!QJ'35N1]CQ]TRF376@G$98+8'5_-_'T^76IZ;MF*.R4QEGO&,=Y[8+ZH9=4%G; M!?59=D&=L>L&F:3UU0PJ506RWU4_9[#++)OD/;JR./2Z]-%$8:Q3E0;ZL=ZH7BM,3%('8,OMS*>WT M/.F@6]6+., ;ZT%>%7UNK^<=)V>SFE1T]OS-L^5MEHFC,7_S;*.85M,ZVPCF M7WFZK+"9;-Z'0X^1';:>9T_D41#B:62*@3$A%F2$DH6='P*J@1[8V8^'WN"# MI'$<1"(?.HWCJ,?$SMD6E]A=8#NHY>7]Q-+ZI#[P*:!C7(552@DEJA MVR.N&,"8-%Q(Q+W6"<,I4L98X93Q+F'"INNM]9L6>ENNYV\G(^"8%Z_X!5H$ M\*>5DGMD8#1>;#8M&V,J-K\.00&$7J.-DICE>C5*8AYT4 >/N3Z#Q#QT/ MONS]^?*V9P,U_51T/&<$6>:4H(;)! NB,%.8.YT$.8SXBU#YO+VLC]>>JB U@/##+33'(5#N5&2ID60+8+,$210Z[M K%<%K2[@1TX\ M\DI P$G*''':>RF,D#;U6C@L&H4?\84\<#QU"Q^;$>ZR4[%XO%NU^!V=_55> MK#K[+Z%C35#,5CKX+4DL58D0.*AI+BAHV"A/I9%:*^Y8>@ '?T EB:3<$:PM MH]HJAI"UQ%%EI/2IWL_!OU.1?"P?<_#O&DO_)38SFC:5BMY7: ,7$'_1)ZYP MW'=4L2W3MDYS14OG:X?F'54.Z-M?OQ\[;.)^7NZ="K.3;0NS[U!0_IBS)CN5 M-B?XU T>"G\R-,!2]UFXIOQID]X/6WOYYZ.Y$G1! 7EOZ>N>)IB=H+IE@1'W M:9#R2'>%0H[OHK NHMA=A>//.[\^U*[I'FHY-E\ZD/?R=L) M[;&-Z$(F>VUC3>G8R_B%NEA991H].'1$G3=^S_%IO(!PIQM!!# #1I\!X(!]CIST2,"=3]A M32[0TZ/MRYN;D;NIM4>>: 1786=[@ZQGSC:": ,[O -M)]P6::/Y+K7: ME;VN-H$>=]XX$XU[48>>P^=SPZI&(QX79.]71G@[_+WW!A;FZ29;E#=HXVH2 MKPF5F)/$,&:Y2A2QTF$/Z2R,UIBW,":[VHUW:KB)NT&K[]*4[&<[WD9+."@= M7I"CDN%NMK@#U#YHV6T]NY50M4",I282%9$*$VHE4L,0-D@(1H71"5$*$26H M=EBBF@ZY>S AK3(AV;0L^#U-HK,@<^!QW6.0V5G@+I4BUJ*@U7,MVWH]=' GT3N6C. MSZ/FCZ:%'/8P8,>5D@TZ#8Y[[#W)XV"J6T459PZ%4>Z@>)I7E&GGM):)%(Y@ MY['COB:+>(\#8+,2$__M1D.KLML7KUYN+_B/K9SM4U-Z7X5DYS=MC9!V?=/V MX';WU=N2RY_"XFV+3/:8T[;(9/=]VO:$V_U-VYYP^Y#$0:GO]$*K62:C%Z]^ M"6=:K6&]M>\L6_7T##LMI>>4GFU%ZAO:4@RS)D7(:)%J9JW5 M0DF./>CRGY4LQ1)3YTW3'.A<:H0X])AQ%GJCL5^ M<]CQZL.[HS!@:RQY"M2[+V LJ7I;S(@LPEHE">>>,L.11JD61!+-C6.,;M!6 M9W_,>)R#I[5S?==VKF:S\[;<_&4X5OV5Z-$1:#IC42(985)[:2TW5BCMK"%I M4M,;L46/3\4P^6XX\J[7FB:;S;#%+DU&,Y:M]JY+4XF0$!YQS(P,?X1/$A=X MT^O4H&/QYVXQ9ZPKQ(%-,ZU=\JF0^3J864/G&P)-BB3"C#,C#&)I$A0NJ@U. MA:2")U+6!'J=SSA)+MB!0RY;XV1KG&RL<7*.J5= S,2'XTM1C0A'S"JEF?.( M6&P2BKWRNH683]E >=\;/1/SY+K4IN>L,X9=C/?405!&I>9,:>DXI#<0A2B6 MTJ7<&!S4Q69!4$&[A.U9,*>AILZ]Z+/EE<.92Y>894,<:XD*)Z 2! G)/-4J MX9(E@9^,H<:98X69[(1CDPM^9B=[:SC= L>>6C:<6%!][[:\3?)2UZ6BEH6? MBG34C7)7R7/*7:TGRUF3S>\VP6(IO35)#"/4&$\%8MPR[4B:(NF""44-U$ N. M@@S@RM"T%K&>VMY*#BP#GH*]=3/*_%Y2;#G6'">(82P8\UC)!"&I+$ZE0-Z[ M0];S79EB*RYX\HQ3;!L@9QMT(C7]\'Z21]+J$!4E46VKK-9KT%ROP6/E!F/YV>>DS)[6 +M&C)S& GL&,5*AGB5E5B9$)=B) M \LX\Y(Y*72EH@4I=3+!BBS"4^Z!"??D=/BL'3:(&1P[J5XDBR[H3**O4JX MER+\<5#N0WG.$\DY$IZG+JW-M#BM,DHO^)GK/9W#:?+04RFAR(9I0[^FTSJYG>Z:<_7P]\:%R&-:= M5R>K',J9%IPHGVAMF=!(O3^;_GJ>K$:EO\[+N+G*VKD8Q MR?-R,KX=C@+IVM^"UCBJ[.G'OAID/S_,89)/0(UU78\D8X&B$I48+YGC3#KB M./7>IY9YMT&DU/JN1S*5UI@D42)53"*K=0!#J>(XM200LMNKZQ$A.VT>?:SK MT7]-LG'//^P2R%/7^"B;W-TIV*FLTQOD+!0['^GA9-RI-D/*.L-Y__C1&A^M MWY(=]G&_%D!TIWUD1V]\=-Q9LYUFG6S1^,CT51;DN/'C>/WNG9#6=CB:ZY6T M?;NC+1M(%G.R-;^\H5N"D:Z8OW MGT&MF>O-U*G8QO?J]UBS$YOW?JS;F_I6C_MLV.E)!#T+$JG@W:=+(EO[0[84 M;@??R--Z1B+:[ S]+IU%SN+#*5I&;6=K:)!L($]4-#S)-G2-DD0M0;8=OT[9 M\>M$H_CA'TZ-?FS9LF7+MA-@%:><;0 K6FJV_/A=\F/;O7#3[H4M1WP?'-%J M,BU!-HH@6\C40J:6'YO#CRUD>O*0Z=A6_])_"I%DATNE.V(II;D,AFUNCW?_ MLTQN6),'L4M0[T8Q,LL1,N^'W]PH_ZEWUQM7(K $22AB%#-E"6.(2DHQH99C MD5IBY0:%4 X]'IQ6)$-;%<<9,ZX^':A)43;M1O]_8(58)R8+T MD2IH,DBKE&BE"*[57 Y.Q%@>U(JP588THH+U1&1NCG5$>:THMTSJ1 MDAIN4TNM2AS6LBGRZ 09BZT<>MIRZ+O1QTYIV:GDT2NR6I'5BJPCBJP#EW[Q3E(K MO93*(^:IU 8Y@C1S2@5%3#?&0=;J8.>)%&IJ.%!3 WD0)ES+E"HM%$NT5(@S M:-/)M$_"L;I!:["C<=:7;\.U1SW>^*BO4TZ>5B@/PYI8CE-&B6%ALP(4PPP3 M8XW7X?=SNNPVV:I-0WG81=+X4)[S09LSFFZ>O'WFT<@;+PD7QJ, )A!+4REI M8JU4FCN=DH36MB X!T_M9I]!W53N69[X6!"C80I-R]J'8NVG$PHCD$%(IL[R M<)XR(0D53@:](J$^]>>,9:[(@)6A,/("+Y6*;1F[9>SSG-G-BR+!0;W!7'J/ ME&74"RVUU8;S)!6)1>GI39B;@.7-ZY6C]EAON;\IW'_D PL&4V()DQYS[SS MX2>1ICSQE !KUU9F/PIJF3#/KM&&("I4D6E+I$D*( M4+0Q9_.ID2H[#U*17A!]."[[/Q\ G=ZT^P M$$=3/>_6(I5ZPI#RF@DBPU'(+7?8&RFPPK78]U1FY]N16Q]FMZGOG5W41=D] M+=\[Y'=8CJCQ"6-(^J"E:.HM(\10@E!MQZE&;=:FWG=^01OO?7]Z,8=MNL6I MW?D!D%AFM$X$3IE"3MG$<($#6Z,B7FV%1BMP'A2UI)'XS!,JCAE7*=! ME6&6.6&])3Z $4(33GF#<,=NA4>1[,JDM9:TDN1[E"3G#__@!$N98)EX<)]X MJY -/RD3P$JJ4N::(UYV56O:TC>M;&EER^HQD7F&)D@1QA@73-B&68N6] M5]);UAS)T>HU9XI(J>^HU,:B;!6+HA/DJ9 *035P915)K!*)M ;RGVWM 7TB M)\:[X61TL% 4?E%7<_=IA:((A9&"TH$.2R:8T0%$48L=DB9ACIPS;FBCO=HT M$D5P<.78% M,<2$\DYSSI@2B0B0A%))H*A'DO+3)P>ODB'/Q,3;RHY6=IQ/=APSC(53+;E@ MFD*/:Y-@*:Q,;2*1Q<[S,]0'.JAAA:;=!#6T=VXK4UJ9^7+<*SZS73.KUW$ILCH?T/Q3\<.)T&"G&;< M!Q'=VP[\;3SH:V7-]RIKGDI(@$^T=))+3[AG-*7:8.NAM1[# M6A!*KH:*KE8W;) =ZM%("8ND"GI?ZF1J&3*) M]I1JAQ*E+#:I7!4I<0 [5,*3+GDJ_L56TC14TK3J83.6Z4E$:TB<)"(AS,J$ M,8*1Q)HIFE*!X9=$'T\=I!>\+H&UE72MI#LW"[?JX$'5P:,70J&I]H91PAQE MR'IA'.?<(8J&)1%C\I M[XHKL?!EW-,O8=[_)-YBHL(&&F48"3H^MLAR(YQSE".D29$)'NX,A]QXT[LX M\ /PP*N_Z5'G/XK!E#NW:K![#)/O-,RT'&8=+?S7)!OW_,,N 2B766?H.[^J MD;GM4-SM "MT.^-;-W*=;RKK_.5Q;GY[=]\?/CCWV8V^!AQ1KYI]& Z^N@R@ M!_!Q%F->JM^_'F;C#\/Q/UQ@/3.\&0#,J2"R374N0 2FDW061)&L!"#]RXY)7)8#2= M;1CU;#G"+]FX,W)]%98,"JUD,,S.,%^,L#=JW+E5-O#FN).O:Q>8-FQ@+^NX M/^^=*>[3KE-YQ3#(BH[J?"M@X$N5X\#.O1OUAA8&I^[O1\,_PS3&KO_0>=1! M>[1]_QA'\VXX*CZ"Z^9[(VKF%*4*(QZ(0$N4"(]5BI%V1-L-&@AL3 HK_;7T M@I)%?VT'OLHN.E]N75CZ,-&.5[T1"/6)@[7-(HPO]JL3'A5$,K!9^&_D7.EL==8[%0Y23;!D$CLI M'5&I82SA.DE,[=FZXP[LS8Q654HA!- ML:4T2+2T#JW@Z8KB$Z\H%J*+TV4UK1M$30:BI_%\BX>*3$F7EQVO']%465O?-YX_O/@9A^_/(J3\NPU\S M$+XF^'3I$;G!,G_&7 6NQ\_^;OR@FP4J]',X0*PR5Q07P<-G)HSZT;QX19*% M0E-UT[L/-[S4L 0OE0^3^ZFC^M_40[9BG:J*RM]N1^53"N6G0+@(T&S-UD2< MFW];8F&$ AJ^+289PYE+Z)OK3[6HN/CJ12"9QZ96?#UT$/ 4J"3[,6K^ $<-.5'?_L/-2W^ M5:'X*M5/)S+W^_QO,W9=':QE;IV=]-VUKY>5GX($#'>-"U!W.; +G_P6A%)V M":*C-WZ($P&>_KD?OGHQ$PS4<)]8H5.4:D8MA_)[PGG'I4Z@U^H&$5@NB+A[ MX+/1Q-5)$9=Z:SD.S^.:$:(4#:B"X23Q$G/K.?EAOS_\%O%,),)L:P+4C,90OEB4:0N[4Z_TO=W?^U$P' ^8RE)\Z3;IVUK 7#S50G6LRZA%DC#6=E.%4%ERI$J>.:4.$E2ZT3PG&<<&FU4#9@OFW# MTIJ@>.,NP:C+6-LOMY4VK;0YN[391DU.<&HY4\*1E#$:;E_W/S_S9 2R9.R=2XA&@< M! 23/''>$&DL<3CQY];[=BV$T-#.-0U%4[4!0$_53/=N./*N=QX =IB%;%KU MB$KLXE/2N \_F>=P5$S9HP8M)AREFF-KD=+,*J(X8<)$O"BMP.?6NG="BZ*+ MV!.IDMH\#FOD8%O1UHJVQT3;9.06JW4]#H&-($)1AA1%#".EL%,D84)FPZ!R07%WYW0.R=D9OMF=N0+>(S \H6LSO.CXD?6JFGG0[4FV!,Y!=8/ M^7"R_I3UK/>()>?")8Q(B@53S'DNJ50X"5!7ZH!P5S>_:QZ:Q=V4RJYD#8V\ M/#&G-V]$IY4]1V;DI@27-W1YSB[GM@&Y%"N:"&L<,IP1JP1%#C&M4F:YH[)6 MM6\FM,4724-]/_O*FB7\FO][GGJ0M+::QMJ[R(GK0^+U4=IP^*;]I43I4 MG;],<9%@HC%"3'@M&$L(E*7V5F":U/IVCL[S.Y5-(UU,4#K"KE4-P>* MV:THIG.@FI&=IUDS4A,BF*,&:@$SY9ETABB5"L,3*;%/SF ?65E;DEPD:$5M MR74RJ)!$JT17+IQG/\??]X$4ZRO3O'BU4?TP=P,PX9.['X83:G#SII>9_C"; MC&K+@.%44J43DS(=I($SFB6<.ZFE20F6.CU &3"BK$2:X\0RP8QTRB32,X_2 M\%,X5E+\F,0^H!GDP_67MQW9^5__)@@F?^W\\O;ZET^7'_]^];IS]>'=]:=? M+[]<77_H7'YXTWG[^OK#]:_ABS=O/[[]\.;MA]?_^&F.7+8H4K5^]CLLV6ZG MZB;$,RT^]\E]=6%,V;O1\.[MGV,W&@3)$8[/8;@-^/']<'#SOO$7-[P)8.860!'44\Q6EI[S*M%"8RE3KIC15AB+&&>F[MZN^P9;3QA>?@7%"#ATXX@>S$A N' M@]D9M !KC+OK_50V^_EE-)S<9]?^1!99H*:EV :I99H85$ M 7*D ?%[9G']CB\5D)=5I!!8=@56B = P O?@IJ8N<&+5\.!6X8)8%V^CY6$ M\T$7LPZ'^Q\!E ,\Z/?+\JM0#0^D!D%_#03>LYT[9X'*@\C.QEG\!O^U&P%# M;]P9AM,\'-]0K2^<]7/; T-[V?OSY6W/6C?X*5\: SW5?&*TYXQ2IBS&J7'2 M$^L)M?+%JRP(\;XK-JEX/)ARLUS07X0-'9?##V@CLFU'/W1NI@S9"= 8$> MJF$J>8'![*?#%>);SVT[L.CC)>G6 MTRU+QI]36;*@B:PH[7ZV*EVE&6"Y).-,7E0_:>MVK>:SM@9@DYCM&"[AMG3D M,UOHM?WQFMK\KK!1@8D* M^C3 1?_9&]^69JJW?YK^!&0%F*C"_^T7]6?%*($%]F#II,1P)K 3G-O$Q@AG M95*,U]NQ"TO']:BPP4=S=O%A;IK^Y^>Q&D?W[IQY#*[+&>]@+I&4IUW:5$_H MV>."6QGT/,H'GC(P>3_IPH0VTB>)=PHS*I#$7C&F$X,Q8Z+.2[;8A:I)T@5W M*6-=D3SKTBDG1(;-@7]9KQG@[WS2]8PQNT\:/REFL#!4.\$,2X346*8!-A'B MX-?$'AL_!&<7=ETM#8]F8"BZ=@>M7W7>:NR<2-PR--3 M )M8Q.Y) QML$T,Q188)#AA'"R(XDLYK1ZTT&Q1)VDN$YNR1\P6PQ>%,1#CM M2M10E-.:B%H)T5!$E5B7*L:LXX*E"$G"J4TY5LRGX:^:;,&#(JJCB0/<99)V MT[9KPZ/3>8(VG?<0']BYC+%[K7'G6>B,)\= B54J38Q-K4\9)5[(Q*0\85(8 MS;E:GQ>PG]"+)%Q0\.$$'NDF+.FB9Z!1MDS[!)CVN!R*H(B!X(9HG;" 1R3C MU%NBO.=:"J^/#$N.PJ$D$5V$Y9-GSU,:?+8LH-,8E ()?,YV(H4=M5OUYHK= MUDO9M!(1&U7\:F"-F@W'_83Q%$VQ\"A!3K.4.9QHCU-E'>2M*YS0VI(S!\13 MOWT^@'1F729P-Q$-A4_-K$C82I]6^IP6&%*.J:8^48YRQD4BF=$&)R)E*5'4 MUY1V.2@P/(BH23'N(OG]U6D])W!D!TO'.8S\.\YX#EB%Z[N)_S[_2AQ37DJA ME;.4BI1XIID26&)O!*94(V+J6C!O#\T.8;T2W82D798TM&G4&2OKM3+FB<5W MGWC:1XZ"3+6A6"8N84XQ3811/.5!WTL])@>)MSJ([H8(ZW+>T 21IU4J;VU- MA1T*,?!CE?1YI%#/XV5Z-&.:*F)HR@63WBJ2!B4B$+94B"&\WF2QODR/1C[1 MG/(4I99I9Y721BB=ZH0CQ0C>JTP/WV4;TB.5Z?D(3OS1^*';N>^KP3@6BW'_ MFO3N08?:H%I+1XT/6+!E_;KOL%E[%2])=]DL=LVAKKSS#VBM/-:__ MT4(GQ^D5T!:&>$X$].+5&V M1-*E24/;-36J*UHK*9IEUFN$\W1#&9#BU&'/D"94,9HF4DM-"<<&,R2DK;'Z M8TQ.* -X%[%G+0-.B+ : Z-.E?G8!O!>(E1(Z'=0\*88=JE,J&)4S1P M5F*=,C6\M.Z4/QXO8=H5@CYY7FHM)Z=+QGN.BM%S3U8^'G#0'*-$6.C,))BB M0B.2&&F(!CL'02M[^ITXR2<172Z29LJYUKS1,,LQ)FM9%#ZW!)T=A6/)62-6^+P;@E>.FI:W8W!]\R(T9Z[6 M1N>S/ W<8DR2<,M(BK1D.&4J"+\48ZT)5EQXLCUN.4@.BNAB+KNHILEH(^1> M0T(B6M9M/NL>B$\YED103Y .^,10I0TGF"JOJ&,68N&V!BL'XE,*S8!)0U6* MIQ2)4AN&?2Z8ORX\O)DZT=K4AC9^I.&+=!A,HZ6%BMA!N9.,)E8)(R@G6@5P M@P1B*S#-0<0APZQ+<4,MR5NR2Q)S1EFF.5 M,IL(GE+JC:=T5<#*021*T,^Z:?K]290E[)7_NU=:V6S%RM6K?%&7QY(/8O9S M_'V?0V]]"LB+5YMDEET:$Q9XG'U4#[ 8@73#)Z.)L^][2O?ZO7'/96]ZF>D/ ML\FH-L5,84*H]B[!D#EIN$@\Y9*RU*?.DJ3VE-PRQOKWSY\^=SY>/F/RY_? MO^UV;SONKRY^OWE]]N7K[>3[K:XL87L>S=A;O]([;,_QV\H?=1 MLN[U9#0*_#*7S,@(U)KPN5!L5=3?(0+YNIR0YO9-;*I1 M^3L6 ]\9SQ^&P7U,5< I)BIEC*>*>YD&#5E?H_T"&W[2;LJ2;R(86 M#7MRD7]-@D?1B&.&=W>]+ L[FD7CSFCXH/I@TFD3$D\BA\X$,(+6T_NIH('/ M00YDKZ=T<#FPGTHBJ!%%6)@4,Y4:0A@*/S N-,9)JAQWUAT1:^!N@E%7\(8& M^;2YAD^8=ZVO.]9U?^J3'3\MYK]2>1-,P[ZWXM-7Y8SJ3&*$^-(@@VCF@J7^D0Z MA"%22M4W/3G,0<^3M(M00^5,J\<_83[9FRDT31ER0@GF!;.:2Z?&4<\P>/VMP]0EVAJ52E%C;CQ8! !CW80WM$UCJ[2W+'E(W+"2_Q1&G >T M8#EQ#"&KL70Z,2J AQ1I=T38@+LT%=T4-10XM%K[WN;^T="[Z'%2_8YWK6/^ M1)*G&2?^Q\KNOW-UHD=J9XA@7&N!&4N$0H[JH*YHKR0-_QXQS5Q2B YJIN!I MU?@GS"\'8PZD)(5U)GSYSG%*=W[*K M>N..:O?GO1L$?#A--1B.;]VH(17T&JITK.UCUE"U9*]QGQ597 -1+B=4+PM/ MBEW09JQUV%FFF%76I50R[%F"4TOL$9$%EEV6-%1X;LEGC3S27^Y M_G+YO@%PB#6R*FFE+-5WDW=Y_I78*CVKMA)-C1/9:!687F&!-+-,2\Q0&GY/ M$&TT8=I$U19Q8Z)FV@7D[0K94-CI_?E^B5TE/^[=PV^5:7VYJG+])T:Q7G=3@U& MX^%]>:@4GY1SRPFL+(/TYO/'=Q_5C?MYY-0?E^&O&1FOJ66R](@/$ZA3DC_C M;[ MFU%_-W[0S=RHY^:G M=Q]N>*EA"5XJ'R;W4T?UOZF';,4Z55G];[>C\BF%C"CH"@$-U6Q-I*[\VVI] MJ,YM,)5_* S])WRH[_]AWI5[DF%OI=I?(GF MFUYL\I?AT'[K]?M!'E\-QFIPTP/AG&5NO*;&I!$<(::=QIXQB:Q&CDO$,5?" M$8]K\=B6)0&1$5XS)E)A)*.$2*$9T@C+\'RGD#]MC4D\K3'YR_7UF_^\>O\^ MUI:\^O#E\L,O5['4Y.?/;[_L7EER_71W6*,35)8L2:B.2ACAR+H4V=1+%OXH M;DB"C F070?<7MMT=4LJ2:W@*CPRL08S*Z$IF]%2**V\Q Z31PM'KE^^'=;\ MT<*1NVK[7VY=^+3?'WX+IWXGKQL8Q%??F7'6,;>!<\,C>H/.3;$;!RP8N7Z% M=]B61XLGKE_A';;E^ 4CCSIGMLNVTPGQ-(*; M?W;A(0-@1YONXU: $BM4PZR]2E-$:%#M-9,V$10ZLB>82TT= MU_AX*C[M!I#13<6! ZU/&=JYGI5.Y 4!Z?JB,QI^FX[FZNY>]4;0<&%193J9 M$)H;T-FDSN%'L5LLVIK2;U!8R.@GGUK/GJB7_\7Q<^F0CPEY')0=TG$ '04,?=$RT M%YN'COLSUX Z(S5VY\,\VZ[L&8'0/@$6YY-A!QSWZ3'/NYQJ7Q=$^V6D!ED_ M*H&_J-Y@0:8&69I:29VTQ#!ED9).,J(,4=9[AVHCT \M4S'JINF!,\K/'BO2 M*,1T@+B18VJB,_USG.T MMU9>DY1I;3"W1&'F@\KJO!32$VMB:[6%OY3LZ6W0?)=QED>J2V5B5W=$;N?N0R<)MVQK<.L+G+,O"F MPF_WDW!0J"S\,.J%HP4^>CT,BN7@(=!2P'##0'3Q4Q]T32#5B2MO';AQI_10 MQK+*/3A!>KX7K=N]P>R[Z+[L*/.O26_D+&@,X?Z2JHK716=>^M?BLJP'*W_1 MF4ZBEP7*'7?4W3#PP']#K8G)&+2+VS"\\-W8Q;Y<:A#VK-]_"*\L1^E[HVS< ML>IA]@'P_H]\:!EKZ&U8%D7*X" MO+'?^R.\ZS9,&9Y],YWZ]"5=8.5PKH<)Z[!GX;+PE,X@ABG +0J:?IBX_#Y( MHC#(B\[5_&P"?9K^Q$ZG,X:'A44MWOX 'P_B4L?OX5:C1J,'L'_/[7[E78' M8%?"%2!%X8$W(Q<4OU'^L%[8^QGU=.%N^+#S;3CIVW+^(V>&-X.PLQVX8[:L M@3A'-^!IRZDP[/\D?*H?BI6H&1_0M[,YK<^/;$IBU='/WRB^W0 MY927/S9>-1Z. P$50ZGN5""]82 .N&Q8\_Z+XTF>=!?)(Q8ESPX']$GDJMAE M=O)(4S)-#5/ZLXF6+#^ M,K\#@^2S=W8JL_:]5:Y<_\KR==V\7>.]OY\ M>=NS 8?\E+>GITX+HY2G"6866VD1PH0PI@.BI!"! %S9=X6J6SP>R"QS-Y&4 M G&5E!1@4N=QA20/&+SVGTIJ_2T0:]6*%!8J2;%PE"24)88HDU)DG<*:$HQ, MLIT5">.JHG+UX=T*5056!FQ)WX(F%W#@BU=!!BVI+(MG5>/P2(0"I=9Y/YLTA_//V7&G>5"+S-S?&@0$5.Q$(]@&.M?]O25 MI$E0%#G#' <=$;F@,"9,,D&1H2)AFNYCUWN93#>$/^XLN4#+^Q$XI!\Q\%J6 M/7]'[;DNAR^JXYH&D=0&K\76 S%I[UN?[R][>? M.K]>?OGR]M.Z<,;')/CZ6>ZP-.2PY]/Z$VJ?&2X-]D!'U/6@$)1$E(+R]:V[ MT[UAYTU/W0R&XTH#!Q$Y[T;1YUZ9M\! MG:HWR(;]K]%GYWO]'""]LXF\4D%:!@.UH/' MLPCG:9A_52[/V<7J@O^K(?4J',9./A_OGQY.3"WP]'+EZ\@./_H08YS>0_KIU[-6G@?:/?+?*3CS$(Y9_Q< M\#!5[)ACNY 'B_H3A9. BNOKS]M4,NEJS&CPU!3<;#^B$L&N7+ M/=YJ]1?[4$^IX?_]W)G10XS!#U^]_\?GJ\^=ZW>==U>!1EY?7;[OO+[^\.;J M2WG-I[>??WO_)5YR_?'MITOXXO.RW3QGF:55J/$)SL>KSFS4U0FOS199[=W; M\G182&Z9CQ:WO=&Y"O,*+!Y'':1E M^"IH!D"4X?2^?.9^UKD8\9E5U M=N'[PCJ;3\+$33=J$MX#VQN^ [M$KBO%P\[VO \'T!W85'O1ONU'P[MX,91C M,N.%X^?D1/_BU7^ZH/A\=?WA?5QVZ+CH1D [8-*]'X8=>3GT+PU8M>P4$44S M6=:9 &7%MZ1NN_9J%KF5 ]/*^[HY7K@P,>O B (BPJ[DU7/_!R$)ZS]'^ +1L/[2*73RU]?_W[UYB66%13PM0?@"W[7 M8:/B?DR'- @C<8,@=V @L#,YEX[!&@YD=;7W(]Z;@P0[,W'CV&+S.T@G*8W 5VIZMX%.#4&9LZ)N$!.66#VF]N7 MN<ZKFZ,#_]MN MT!DSD$7?E,ZJL$S=W0>@,7ZX=X4Q=7[8LX$&F10&D+FL2FCSQ B1&G^XF:.E M=);4$EV@YG"[R>\9P0>WPSXXHD;#G$+ZO?"*#'P,[@9$:8XF/VK1>6^4_8HZ!+3U/$X9YN,;[B MU;_VS&@8U!/("^W.F\J+_3\,'QPI9_DQ=GMB>C0,<'!VBM:.NSQMI],/QRI@'#CTPK'W#8"S M'YH(?L)7 6C?1]P2SN'',$QQA$!81A6S5&=?7!EQ>-68 R\-RL6-RE>N]#F& MT6>W/9^[/28Z8.P@L/,HBMP!![ @K%/XQ^3&E\RY/^#?/@PCL-"CITZXKCAX M75=_%W_\VGHK@3?7_)2M"K>VB'+FH&:3."M(#^"\ 2T!QI=>-MM4'[_NY!&@9C? M_G;9S14XX(??+CY?=-Y!S _PQ)L !CN7-F!B,+#.[GGW)MRCLL# $&:2=1*, M?OCCQ_P@!)&56V +.^STV?&N4K$"_OQ\^>GSR]?#WU^2SF5@H##*R&9U2]'I M9 \!RMYMMR^U=IEYFJVUS1S>##,?ATW2I3#L^-&+5YU6)BP\II4)!YY,D F! MY^?8X2C$$CE^%OFX?, GQ\?Q4.PF^J!ZAY)1O^_>KWEY\?[F][_2*@ MN#@!+\['B:>V#&817 >%SE:4+ML;!=6F_U"X3H-*'K0V&QW >@)F["Y@_#MG MXX;TRPTI+?"WPR#=@GZ<051?V( !;$MA0BT\V+=.]<>W'8@>!YM2MS,8#N:N M'8Z"TE)@J&PNF:E\;;6#4*'-C=Q8]?I!S8"U[F6W4:V+&L3,?3O39=R?]]&F M&!9C9KR>33.Z)6[5($CG,]K9ZZN[+N5R66>&.7C\*0\B"-SB8DH *$ROA^ E M&<"_6<^6ONN5IJ*3T>$F!K@-G];M+-O4"CE?V7Y;['NX-)H?2MNO*87+.%KW MV[RZ TB!>6*Z",N$#5O+I@Z%BIR)IN7&'8RBD^]K6J[ MW9CWX,#K%7^;.;P>\F>"G$?RKZ JORMD6V!9%R87GG&;!1X#U]UB5-^WA47I M#4S@@RPL.9B"58SC*]I^Y$[)@:OX),,WT?72=S=AN>[R2*[.#V%=.A^&0=GG MTUXAK\.:],:%(_%U?"-H2I'G*Y&6^9](IX-""\I^ZKP/PN$F_O)C#0<6A%IF M,IW"3G8R@IU%D4/P,G@PLCS*?#B+P>Q\NW71'S*.+MEH7@+W<"^GTT +@39+ MQVDW^HN!^:?I.!UUL@(R6DKGBR1^!&0\&WLNR28RX'_1RDUTW7[L*C=A>=/=/ M-SPW_0W! @UCO"N8"AR6T4T'ZQ]&I&[BR\H@M?G]ADBJPGE]J_+':Q=V*0\[ MZX$_#FZ&D?WLHF,[&B^LRTPX3"%Y*TC);]T: OL6+YN&%4?Y'(Y@N#M/ P!K M[91$>OFT*]/M5L:>)QKEWQ69.[6SC5[/?$95?NKY/#MJ8>JC (M 5YFF1^6W M_H!_S!.:('ICZO"<7XV=&"">)3^0'W,^J#RM6[ROF),K%JCOOH*\7LGZ.7.O MY.W#T"PL:4&VF\F&1LASL"V;6TCVLW-GWPB6+PP;/ F0;3. F'4@,-C$,)6 M72,FGHM%C/&+4\Y046H6;A6(+P2@D,U\"GF@(^0%S04S] 9? SZ8^B- J9H& MS\R9O:=$$*"T_=8;V Q"06]AI2,@[ZBO 0M/PR0#?@B/ 8U;@;H]CN;ZO,A= M3.0LJ2P/KP4>*6,< [D$ZNZ97C1PYO.)C!,FKTJ:#UBC%[!2J55,@4*,E@27 M04 ?\*Z;84S$'$U7KE\N\D7GS0S^K (PU068PS(1\XZ'PS_F0T:GGJ,XXG&, ML8D[FY6SCB&E\/4L_O-^F.>B@L]JNBYY@.DO446*#OL87!N>!5Z.CZ/AS4C= MY;$(=P&;=>Y[_;X:32-X'[^O##J8#X]J/1JML>4\QI9WX*,$KR1X:V,4&AC1 M9V'54.,V%XRY_E33N_>1:;>&RY:7OA]>>C_\%CEH,($(T/R$@Q"Y,_),&W1U MX* KT09=?9]!5^W!T!X,NT[FDPN*$L2T^9'*QJ,)' [NW$=#"Z=:KEDQ_F9P MS6=P#KB;G@%%OA>^"8)^,!R$HVLTR_N<)0(%W>2G)P.T=EN12N95M(3$8@E5 M=Z MW%OP,)PZMP?CT;!?)/\IR'AY*.R499QNCIE@NT=W4(_-N/M<+H^](HCZ5Z!* B$-8(AMD:K]F0XS\E0]]2"JL J"^$EP+UYX$G,2HP1Z8&8 MAW?A.('R,Q -4_74#XM\@]QX&Z1HT'"#A(+TN2@_@+G"X5,XX*>W32-KJFP\ M $=K;BM7N1\J"IW>76F!'Q5B!8KCA$5\F(7A%P;K(HII6,DSZ.B'/-K7_1E3 MXI:*_I9_K(N&\%*2%57KRM342>[,AP<%V5V&X7=SO[)^F ^]AY0)-\HJ$X%1 M3@7NQ1((G">I>E);_]F,<4M-&X%X-D%X&7IE/P&N9[CXGP&AKT9N3*% M?CB+;P-W4V]D7\(!_M!9EEY%D @4- M/BHGR4$ TM5G#MX,LA,6A)(IG>( M% )>CWY][8IT=U\O&;)QD":E+(2Z*T&^F%MPI?6#C"S2W0N)4XJQ>%G/E6ZV MZB">.>C?Q(AZD#@D#R5SW:B*^6XA_QB _",P-">!_$P]6H#!O,VN,RM9Z%0KT>0>9^Y[)DE9GW^KV+-9E^B&$JOBA]ET>YI=,H MM_WT[YS@:[_0B]061DNUQ,J%T>?]OPJE*$+><7+;!KOG.LWI4_]'N(9XJGO ME)G61 97^RR*<+J,W2*2IO+.Z6OR213B910[P$2@\A=&+\1TW/6#*(((_\]D MX#H4E=Y\F.-?.DQL>/O\[.?"'.G%7)+4;_=Q!?/0&%C:L)\*@HMF5;<6R:!; M)8&0 ]3YOUAXS._/XCF("!3R+*?[AWL%P?B&@"DK, M$\M5/C ,Q.%'13J;% $=XWE-&9 @O/&N6*!9_>5"LYS&.\'P5B];J6EV(:0J MCGKVFABF& M[Y_$I ;7.1J==I9Y9#+M1O;R*KIT60C J!I?'2MA3175^\E&- M[<[4UOAC#&,%E)S',&2!1)C$F @T4RY]>_N=4&@A2UDK+0<19+(H%:LK)R>?))1E]=-0%QO44= MI:B\!A6&A$,#\R383)5/,PQP6;O=G[KLGM8N'J="P#_S7/JFGP[MVQD&X%1Y_?NS>+@-/P M?9JE1U^J\UJ ()T<7X3/L^)RH*VTQ20@%#=@]H%%84!FTZY22_]?FL QA@0E M[C=4*3$ON[<%&2?(0%/#R+I15J-X[-%U[" 7ZXB?CL%>PJVZP%X4-@KL6DXQ MZV/R5CC8M-PKS5CYH8!YR>D C\3A<05)'5.@@!, M6V)38B(X_,)<5F1^5S1C!_$*3Y#)0IGX'>ZI?T?5+6XL^#'A--W[1%A'"_A# M,1"J:OCS.+%,2OJ<$\ $M7A.'K)%VJTN*XWZ]X@QP>']%E/4_;!'5EL19]S, M0/PS5*%1C&*K[2AA+#$-/B@^JP_[7 T3A>,(1]XL$$E>;Y-@:!EUEP*R,><> MXPJ.2>-(>8302!+9"Y)%B@I?9JC>L09I46)7H<1>M2BQIXD2N_/RWV.7^?7, M>E$?I[:T=ZWEROY&-,[A,U5XO.=(SDE#B2H&THNJ"*[Z8'>-8=C/(]7LQ=J+ M>[Z0A0(@42'W=Q%LQ1G7BI UD%4%J/_B^2T2Z==*&_4'9>EEC.Z>A=S3.[=C MX+YFF\NF=K4+6X@N?Y/3.W$=;WUQY5NO[,M\%25XP]7:V.SC1BK+/]LKDW[? MXXXT]\ALA>-^A:,F"=W'* E+TH5WJKUTGX'='Y?V5%]EYU;I3GVS[?S\\?/1 MN^#LY/>3#U].5F?SO^9VWJR;]+)%N^]SON(PEN_=G:G?AF;2]WO.KF@PO?X5 MZ1Z&A]V7#[TL*TG%/=],W^U9NN]A;+Y,[^P\)H%^H%7YL;V4UGXI/?$;Z(=? M#L.7N_N/Z7"VMTU[VSCR^^2OENO<(VMP$-=\8!_R5*[YZ#VH MI W=QN=;O5 M[5:W6]UN]3UL=1M:=EG*N4GLAU^#XX_GG\^IA^S)_WXZ^7!^/6:;VGX)RW/ T\^8&B\]4H0A9CL63TI2/*OAU&[N-NF V MWQ7<9%_YH:S^\,5!B]EJ1?H[$NE7CTFQ4CV65 C[@NUF2Y4&T^Y>U/H M1?AJ_\7&15G:L-UW)F9[ZZR[;7V-5K;O9H=17^X[)= EVDJ%7.4+&TJN*T)P[<5]R+#!541)FQQ8N-78 M'\KV"W?VUQF0N*;P;>(5N]$':./&MOS,W+&BO[O8@U<%(_4OE>SP"N?^&N?5%:\6G5XXT,M]WP MX'"=:8=6F%M=N&;Q68?Q_1#^9 OB;*D<-D9];ORJM6+5BE4K5JU8K7T_-V08 M3TRLUF $KCG8^N[C^7GP]NSC>QUP_?AAL\*K+9[P[F.?6X?ASL%3@!DVSOYY M*]\M\7*[U8].E8'>V@L/#S8/;W\?4VV55*ND-L$\;6.4FSR,)^:>M6+5BE4K M5JU8M6*U$?NY(<-X8F*U#B-P U&B'S__=G(6; DD]'EP^N'XX_N3,/AP\GFC M7*?UHR-:_-.5<867>^OD>;P&?.7[#S6L_[RT$*O;R>@31^BUZO9J==O=;=5M MJVY;=7NOZK:-%F^*A[HAPWABCG(K5JU8M6+5BE4K5ANQGQLRC"?C_YWPT@#GA2@YNZ]Z$6HUI>'F]>D\X%FOUEAA5:^[T&^ M]Y\L;?;SS2)Y:Z7[MA'@_?#@Q>;U!_W^P[VMY-Y6<@_6F;IX0+'=;-JR-LZ\ MP<-X8BYV*U:M6+5BU8I5*U8;L9\;,HPG)E9/+\Y\FO:SB0K*Z%NP)0T2GP<] ME:I!4K8^W_?C\S7'XIY"%7(;9]XLV=[C?WPRP8&7%N!>BB!VES= ML8[PX=JZ>WQ_C5*>;D^A=./&=L?=?C9W*5M1;?7MAHR]%>)- M7=]UR^W&#??A1'43K//]];--?#CY'""P>*."7PL6:OV749Q5O;%::=_N+"[Y M[*&#&S>ZZM:Q,HB+?K5)W7WV'[+@^A$$L==_CM*'22A6=YB$]P,CY[_2 OP0)C"GIPVP^T^C.9'1K&YP>B%ZF(*YR$"): MRW]745ZJ/%#@=,;!^RCOCX*];ACL[NSN!IS*-?CLZR3;?A^E MPRI)1UD!*Y<';SY]"LZ/SLZWC[/?MW>#H[1,A@K&H(JRP/G&6A*_I'#.XN"\ MC.!O\%R841*-X;G98%"H,NC-@G%V:49RD8VK"4TGJ_(@*W&,N1K".FV@5TSA?^@7O-6#G'PL^G>< M%&6>]"KZ>!_&5'0"7BD], [-X,A25;KRJC\@-CTX*E1 MA_B.QH]$11"YGX/GPUCJ[UB?P&GAJB^9G/883\VS75?#P)$\>+7[XPU4R" ; MPP'$/2_Z(Q57<&_ ==JOQGA@FY=O*X;O1+G<-EE5P%X4S_]R\^7BZZJOQGB] M]V$L?_MAYP?Z6>YN_GD<%058BH.2/F],@-5.;_(?.+S='0P$NEN"$4(3&A2[ MW5H/.SMU2,X]!T/70S]V'V]]<>5;K\P)K13YE8?B45;YS8*\C8&BMW"DR)0: MY4H%$_C$J&CV-AYP4/XQ?FB_;PU,H*W$7D-BHXLL1\WXTU:5#O0/]^8BWZ>4 M/%3NZ?M1M[N/7'C)>7J,HMK*Q%W(Q ^_H$7:[O]3W?_FQ&YP/(K2H6K%HA4+ M1RQ^?,1B<=^&39E-5Z?+6&$/[Q%7XP1<*%:UQBS6A@"Z;KY7WRV69OTKTCT, M#W;72;^V-O!I>W >"_K@@:>_'^[L'K0GHCT1[8F0Z7<1A[-.>KCV2&ST,#9+ M6O=>K!,R=FU1O8\EV!R.PSF/;0,[;KY31?&7H!%AL$'8PW7W>VL*DVQXU=W# M52)T#\+=W2?;:O-A2Q':L_-8SPX*T]%9O5$7/=!^$F1OH-G;7=5QNV^:V;MJA4?7.S;4UXX@T2JRL7;_V7L%/+ MMPEIJ4T+N#Z*1=L+]W;V'H_8KS]TVY[31YT%V;P5VG^YSE1Z>_[6.;8G<.(V M8DUVP\/=3?*5VU/V/8WM$1R @U?K3,7?C?BWWO0FNLQ.T?"&2=B&F=[KUD/K M(N3I;E+JYH')>.ZM4V][)![UD=BXR[@]$M_Q )X &=7WLE5K'\ 3D)5&2][^ M>Q%Q65,AW^KL-<&#\'.-E$>"XY%A-?+67$8%$>3DB9 @;47/@V?=3I=7SSQH MD&>3P! HU)Y2R(>1?PCY09(); 7A(@?)-WCL(AXE_/Q6C][WTMV+*U[JT6+! M^&-5]/.D!R\"7U+EP?_\Z7!W=^=GGS6-?MF%,?;@_7=#8]0?JR@G*1T9)PN\ M.$VI([_1DDJ_-(P];\X_O?T$+M-KV)ZO1_!__,OVBL+1N<=\J"8]E?-S_HK' M2G]YNV>[@4V]$ )OB7:'P9S8H%RU6W2_XZRO6#>,U)+00[I!HL@A"8\:HA/Z#^Y._\#2,Q5\_.XD^IS^@W. JY6;5(DCW-;6=\> MV0G#P/;7*!CE:O"W'_[T&<],-CB&3X'0%* X^,?HH*AK6OR*[KUJ6I?;4;"[:^:&G__)% M>Q[:\]">!]O][^63)W):9V5\>^H>9LDW[-2]>/#0T<8=ND=42; !]&D?EV:[ M-P@BVA+>; 3A33,/=;AW\$B80+Y[;IA6@E/R(_9;'XQW2Q]XUVN&+PXVB>VZY6#YGLYI>RA78D%ZT7+]M2>P/8'K6J&M;KB[LTE>]>8P,6V2 MP[U)YWSCQO8(V,ZV]C>.8&4SSM@MG7O[[T4D"0]4>*O E;;,!HM\;"G%'314 M$@9^)5](Y2_$A!!AT6Z9K?2-+O$G3/-D$N4PVB JBJR?1"5\[C(I1\%EEG^% MT8WQ-^XZPN.G55Y42(<0I<')ER,:^D%W9^OK_?7-D!O_FTZ?@_.CL M?/LX^WU[-SA*RV2H4CB,11D4LZ)4$^93D,>Y7SM3Q33)&=W[*4K5. Q4!).@ M(42P3#"_")WY3T;CDI_Y6P18'YRJ_2/K,V=!]^7/P M<3" '_7#CHHB*4H<]SG*0!G!M'"ZGW)%FY>J@BNJ<=Y96JCG=T/W<'>U[.=J M/(:M#X-?5:IR@6 ?Q9,DA8G!1B47*CCY-E4P]C66MYM1#IU11OXH%8_2%K\W M_[T(A;0#'P%GY:LJ4?3Y>&[QE_D7DTD"VPN[]CQTJN+[63[-X)'P(A#T8GW[ M*10K.YU7FJ2$1+Z[_V/H<:T4UUB[>U1/[ID#+97VDVDT!CT55PJ?H4<2%E6.9S]T=X;F,LVS@:*?87(#I=:X)\UG[!26*LF9.@'NAS*OA'\&1!%4 M%TU+2A](/?,2K%&P;C9@??)0[R?F"<$8J7Y 7S[;Z^P8.IV8^7=0<@9)#O?& MORO0PG"\X(,D7W"71?CN:DQZV7\D_&*89?$E/$S+#SS)E;"BZI%>3D DW.LY MJ_*@&('@H@SB),J:8'<"/%7C[%(^,%7Z"V"050U?"/I117Q%\.1>EGV5S\&0 MU+>^DC]@&0O_H1.NIU.URS=I8+!Y*J/'B4WJ'$"!QT..7P1>T-F18+_WK@CPABLTQ3.M@JVY,(!O9NJ=;*J\*@2 M&95R1P4BG^+=7WC*#)8XP0HWM(3DX_QI]P_R/+!?4A0/%LI8T=X4^/,X XL= M/CR!W_9*2]_"E%*XK.16*=A]L;>;E=: M4B$H]&!0T5_H#JF*A-R&#*X>4MQ%&#AFJ8@/:1>8<)6+*8O^G?N!'+&),=2D!WW3-7(& 3\1GK7.^W41\\2AXOZ>78C)>, M1UBCJ>J3A9"UD%.CC7C+&C\*/\&CP%2K%QLDP8SO-(!C&<"Q-^]5* :7K?FUJ/N(4K*9O*UE+;P= M:V&W92VD8;6LA==2B' CCR+PZ[4R!!TW I<&M5&%Z@)OYC+!FX.VA]44^ K@ M>\QT;&M0P?6;DB#2KQ0:NWCKXM-ZLZ /HP$[%OZ(,E' :9V!KL*:?44W/'P$ MG8]2%#$\@IRO$C[ GF0UG<)M!&X.6@FI%Y0<>R83!UXFX.K@>] VCU&6MO(VB]\4<.2N N T9E)-6$;##["Q+$V/N,^ M'RYWU5=D'5 L5?N48!_H5[O& %QZZ5"Q%?!L?\]AZ&U^NF++_^\5W&Q[.^+T MPD(]VS]<];N>Q;-GN';A9-I%=F=OEH0>.8UFVNLW9@S&@V!EQF+>8$A(I<@6 MR1=^[6O/]L2H=-TD,YE.\&6*AFT:X#+3%V(UB##RL-CC"NFW[Q1]@.5)C<7& MB!4H*+BYT7Z-)G# 2M^)0C%5]&AX2C94^+,[?9H"& =Y10+';B-^%,]7,L%@ M.%@($CNC"%@T0]5$L86BHJ@XSR7D=X&!EN)WTPSC:AQ'8XL$;,]+&CRIBZ+" MZ'9"41MS N&U:)ZZZXE3UQ/CQ] SX TXHF5N:DZ?!X-VP ,UK_'FCT-&QR"Z MB)(QSBRT ^WA,/O@-Q6@H"CC C8GS"F*'G5!,5+V M+>B?\ TPL8K08GHNLPTZ GA9\S:H9 MLCR=,7NNS>+A!SPB&N,E/H&#NJ5B@UZT4XH&Z*!"YP U D8G=!IE4]!'9(V MQDW%,1D^QCO?CCN>'QZR*-+MQZ?4ES,Z3B2L#G<,.#P8/B_L$>+5QY^![*=X+' M79<8/(9/Y[V;08+9!79R2#4D*$G3+"])]%@@KV-1+YY9)+:6ZS;=S9,'\F0C M+W?SV$(>:QPZWQ8,&OR[/Q)D42Z#87)!%SJ?!(GF:OG'A5ZB]MQD*EDWY39\ M>YN37?#=@<*[M3!I(M("0F@OID:#)L&SK[ZI?D6:4FPR>#5>W_@ %*P0^?5G M-MC(\YME'$?PYRZV&XRBA-F#TADG7U'LS+V$T7TT*$GY95;3.;<4*;T!$5%K MTPTG;#2950".->>&4SCT"@Y_P7E>Q]YT[3^39$ARO ASM"(Y4Z"^)07X B8E M7"BK:PK6\H4_[X9@0P]W_!K!!M_8VB9C"S,5218+,;=-KJQP.F\0AUCDKQG$ MST-X.0^C3S_9P#4H517LZM-X];+A/CGG,TD'Z.]3C!QCHKD107][P4:#ZX[N M6S)/TA1U,J9^Q+:M*9&KQM$)_I^LHCVL\B&'9^'88^@/'-UJ3&=.>:/C.Y[= M'8DVO5:4Z-)^G+UH'2>/S#3M>)*S$XL!FJ 0WX'D4Z13H:_IKX&<^"9MJ.W7 MNC7"&DI_"KU7N3.-U8E?K8I%9A@;D3K0=C<7!EM>GQ"NP@4'W*-1[ M<)847P,)=NH7RZFNPZCXD.NP'"Z;;D6"6@$FB!J=%GN"7KCQFF1Z@V;SCRTX M2<8!JIS M2AP^R/I?1]D8(PYZ!?C5=[,!O/0KKSP.B;!7;^'HP#.V_R$+?GT%*7^>CV$U M:37N5'#C67Y,@R-PIHB*-_!^>X81@ 0-,##ACH8OQZ58@CV!.U@L_N)7%=C#D) MCWJ4DO FC(0.?Y:R.(#& 5TVSC"23^D_>MBS;@<(D\U0F*R(V: MY*"!,'Y$5@ZH,9.,B:,9^UZ$1XN#3_2$,_N$<'Y8$A #K?,/JI+!HX M(PRHB]1QVAB%RUS$>($7@BF=:7\$ 13HQY 05X7Q6R'_ F8&=@^\$(**].I@V]X\0F*R5%L+@O=IV)6EH\Z?40^D*3@ M8Y?6)"SSB"V_G ++R':+RD8'9UCXT*JK."R#>IFC8.:7$O$31QY#?8BH[45C ME$QXRQ@16S@Y4MSV3/._M/'#L?J"59=VI?@KLHA^5!KO[(O$.C\FN*E='_U> MNA,N$ T;*RWGL!_TCCXX*&S/8DAH3'[<)/D6@OQ>VJC0& U42OYSI!4^@:^! MF<:X@AS*(X,% 4Y#_%LQ2J;Z!B)S@EW:PO:"2R^RI"^?9C]Q 5C;F:@[_R.: M:D/^/@8-@/O/L2WR@ ?;LALP+O1+HYSB[A*P)KT)MCIK3;(V]G;VMJ+G6_O/ MMY+D.;[GC(F049#/05G:J-PYR$Q.HPM.OO6)_SHXXJA ]]7>_CI#7'\H;;Z3 MHE*(*R+?TT^[>]@$;8)CY% ..1]\UFR$+]"8!L',@*07%CME9-5YA(YUX0H/ M\^R2(*0FX,5'C/6(%WFN@2CX>8PS)$'&5U*(8\"VH!M+P*W)Q=&>4SLZKL)C M8='UILDAY()V<830\] )D;H]N60%3(P#@])5,HY%B"F)9V6?+&W$"MHK"\=& MMQ'K('?^HEEU,(@S>_5SIA-OL,FD-ZLRFQA]B_!ZO\FBO0+]1UBMN+1N D[* MI6)+HP&WW0E.R38BY]9810;^S(=T0UX*JKC7')2W_RNET);G<>XU>2.GG1*$5XL2W?D%AL+9ZA:1RDA]4?%< M#31=F(LU]+]<#UYXD2P=HB#(MZA5-TYA%:#\@I4!PA)2N#OM2TFIT+)2+2.M M&9X^138=ESJ 63)6" LO5)KPP>)'B8)Q7N$ZHYW@+<,CT$$+2=8P2PU;4U-_ M9&NQM\Y>=_[6M:P:<>^S XM-T6A];BT.ZHXK &Z%^CMS*_*S7H M?CT KJ.[Y/W:3)M;_%!4$ZS _0_"S"3Y_E7-.*-2:"1<4W#]%CUSZX'CZS71 M1?'%L.YGKY.N=]ZNVU:W?@;J(2VJZ"[-86]B6VNJ.N??8'7\"C1MW<.&@=R5 MY% .X(4)X\^]H*FVOV'\7CA_V630R;JWR7PRJ+HC"NBP>,\E?R0I*&E-+"0R MQ1IBC-"5CCX1UBZ-,SA;?7X(.(-D=1I_!N,?>729XM5/0%,/F;?/54N=X(N) M>>B\5-,*! L0>N*FZ?0"C+]/_OQ6\ISFH MBZUZ_04E9OQNLU$E2*&!?%C%0Q>E,+V@C(HNA):(GN$G3PXX'UVMBY5M!0F*:175LK^'2\) M9D0/>2&"LK77V?F1ZC=S+ O57WQN IJP$L=@U@^W?P/?IIJ8!N_> M'8?S2!+]G_48P!=)BBPW0 DSH,ZU3BRIJ6962?OO!O*)5I&WBGP=BOQ4EYB> MH6L46+WNHH^7H#M[8 P7ME"5'#%6=1A<25,XCPHSAQH! [8.GF4$M',,2D52 MS$QYF%1#D]Z! P^:B8;7B]*OSC5HH6BT(X)/_9FP3[H.QAT#D^GU/(M]C^GLH5# MRF,*H\<^,U*#FKNMEG.O";>H1@?E'$M05]$0?8;57I3WB$ !Q1%%L*D(2>X MA0F15)<#D<%HUQ[7?9$]SQ'@_K!F2"S+,6XKEI8S9-E9,I,0+S$BC8'% M6:W:AXN/6JW8:L7O5RLVJ)].0^BQ%I'3D$2*;?W!3K.H/M=PM.>-'3^TP- 0 MA/\?NB@WIU LPN=,$C034_$4X;'S,#_^S]&SK'2,L=D%IU'KA/J1!@5^^&-= MM>SSGQ9^JRV^JK55]^OOOJUBG*P;91&Y&!>-8F3*,>LX/$(3D*2!6^2:)AF\,A^<$[L MD@42176836?N,P4X2>-H5B11M1W.&Q@2[)81+7:]VV/>'O/O]Y@+8''&AWRU$T%>ADXH(%Q>&//( MAZ-4PE3E0C6!(-(@\V 9B*O'M(*!@L*G!5C"Y27U*D!&)S0?=!UB*0R%H'/F M:YIK=J7>PJB2GA@6S!B%H4<[7W7MK!B3 RR?+E9-2+ QFJC-5Y,MI&152,E>"REYFI"2UI)H+8F;3N9, M31$IGFI6*;QU_B#8+P()?[YFK..M31C##RH=*:!.C/E@ 0@X<>OA6,B08>^^7,N'7$.0AC.K\,^:]4#D6 M++CXYJE;$C%=BYIG1,T.8E_EVYJV:TO"]Q12 M=^FT)&S_W"<%,T58$2'+ZIF-[BMC <[%Z/M(\QE'N6$,HUI]NF29UM?PF2'G MBZ[#:B F6\XOMB"Y>6W2,1:/9\%-><=8BIHGH!>1D.52?B(L1BYG4K.C8NO_ MX';EW)'.R]:8G>Q_(&T)0N<%UTWU(,2M*D4:7*ABGM_+HCRFM \L,Y.=8K$! MFO04GV6XD%MMY51Y@)^$QAB1YR-(O< [-P$9[U7QT#H)[E\,+!_6:)C!0:.E MH$%IATDC^ZE*DB1G0$#P3'@4QE0A@N=N48[':C5?@ 1HANO!M1&6F(**>U % MX0KHN@]RRU0Z$LQ1E#H+XQ0(FKD/8?&=BSNQOL@/K VW\Y<)?;Z %UK2T M]=_?P"+S'WM[R\Q=V#N$(=_2R/-W)5=&$^7AL@4(7$2FO(1(9CAD@C8;F&9)4;,I M0ZLLT1GNCP@JRO815_MH.JVTR. J3/NS,$"P55Y-R_[,6 &"9Y*2J"OKMX1: M: E')E=%D1F#5_X"+)/^[R(;PZKA-A#YHOU1H*!L#N7.R-T9X9>$IR3'XK_0 MHZ)<$>4F23MJPK"$3;,6.;,X66P_(R:PX9F0&M@^1N&6+P "F;$C!Y*]T9K6 M-L4IXS-%M0XM96WU/1I2C.19Z(B7AQU[#&@\-3T0"A>ZL[I!FL*<[F6:9<$5 MZOYY_G?S5ZI]UWP,8O'O-YX/X\IBE!.NI,.]XW]NGTDIG24$Z&C&IX\I@V>P M]P?GNR]9M@A=C<*\\^KG)1CKW(-AAQ[E!8G&T>?W[E*ZG3XS&=QU$%"0*B<^H4=%-*)@F^12XX]X\HSY+>!T9SG=V-2 BE424C^4A21=S!QH M86F$TQQC;GUEZ[)E*1H8+^9H 'W]IQOYB2W>-%%S&8KBTJ* @\UZ9ZHU)_4MR1*.E\:YILNLX$AZG#F)$\ MD?F)B/&TV:186O'SC1 M9#DL,CG:N^?E M*IGT*HS&>.^@LSCA-F'$N6E,9U?+Y1IXP/=C/SN$=CVJT!\5F4S7]8< M H7-$F\ZN'W= ?PTY8Z_N*&GG=>=%_A']E:W]T+#@AN!*CHG'Q<5D@6:V8(A M9F.Z9 XNYFK2!@+WJ9^!Z@2Q[_N1&M.@@(ZVQQ)$E9\-I/=586!\^DJ\RO'> MWL.+F)P%/G-8KLH$_[K#C0D_R-UIFJ3B7R^R4IO8&!B6'T7_".D1K YI;/R M37/3D==1!!F OP+BMM>6&,Y&F8SY7N+R5V;NY#5$KK6HE*;#1?#LY8'.D=XU M67\+;;L*VK;?0MN>)K3M=C< )K&,;[C8K%DA/&EC^Y5.,2#7>**87U07[&NW M16##CG7#VI,BODT8"#W*1?'/!KL#2_@)V%"56-1UF:,CE;)M-#%!##_HO-5_ M;CXHX2D*YOF?@GL!8Q]@[:$_!V!@)GQ,_!W^C3NBNO5PN"VYZ4<5> M+X5SYQ_ON6FN3;=&^_O([-'2UB_":UT+P%TA6I& 9N!IK\*7.Z_"O=W#14)* M%C!F]R9*="F^!WO;#QV'[-E^9W?'$R+#UT\$/1Y)#']AQP'_,$*N=/EGJ(IN MKGF2YU*XO#Z.9\J\.R%7.CL0HTYP9#%U"V8K'N&UEC,$8<00NCM]:=RE 3 4 M9JNQEM:8[>F5_,&Y42Z( -/>>+2>LA^:MG2=\GME%NS,)0I^XQ %'UU&>6P3 M8.R(1NR?8)]/+.QWDUBD;UX?G;TY0J/PC>I+4;HN*G6DG3-2S[J[G9=NV^N( MWNCN'\'''-IZU"'\BI+X9T&G(CS+8S,!R;%I?@$]8"H!G.LY&]9!OIRTQ]2B7B/< M0^(J!<=!V_2P;AM]O/X0+C0).VH[Z4I<=4<^66-&9/U"[7PP:S'", K7;-5) MUYP8VRV8$*^%9>L/RM*#L5T7N1;,]^2IF\R>">Q9FO,XPK\V0",L%NN"WO.W M']BQ,F.NP[$F21R/%1@U/%_CAZ&M;^'O"P".S6^".>'>_NV'[L*W\D?OYZV[ M5\Y5'!S]4EE\O(.36(;0#(A/'\) MY'*YN,_,'IY@;4A9?'@FRC7Y16+==_7V(K#6+YG-]N*9P^] MY*Y.H/R-F?ZK-4Q_=S_<>_5J(\7N$6B8-:N1HZ:>9:G2$.3LDN(8Z'M2^UMH_,?FBA0[9/(@ 0H0U:(V;OIZP ME2MU5\>2UJP';AOLNJ%A'NZ\>KEA@O$8],#&WOV?*2NS,0>_O?\WZOYOC!_O M'X:[N^NT]5N3X(Z5P#M5%'\)?%7@P'$W3-^WAL && );W;WPQ=Z#YY%N9@K< MQP*LGMG8!"6SCXNSL4;('SX*8(.$ZLIU6[\JPB JE@+=;H?OS#K8M,S%HUBT MO?WPX/#P\#\95OR1..P1#NO.7RA\$ M]]*_='_*B$"_7!E#$QU@M3Y!*2TE'B)^+X0PY:V\@JK#+[ H*593(1!$5# ^ M P[!6.E2YSY2:99P^7X+@SRZM Q*8Q7%3 JIN1*_X>; I&)<&JR'M&52\#D# M\T^FFJA'R,KCJB\$F\PD>)$E_1K<7CZ/I6?,-.WCL_W.OHLMYC-:@[BZ^[\$[1I* M>5TBI%:(/0Z>[79>F!?$2CH4"OT#G4:7]XJCPI&T+?3J-KG%Z[-NIVL>9QH> M8BF&/L0=OA."SR,X^3C)PLR+].@TRH6U/AL,D%N$&&C@N2\:GZN'Z:Z!U1\; MC:G5)?PGWTBOH(:_AM1H8"W?5OPDY3R)X=4H0CN=/6?IEB*CW5748L-<;\) M ONPZSZ,:V20![:F;WDOC;Q%)5<#F_H$YX+ 762B-.3 C=)J $J*1/S*)?1H MF_&6GG()A326-H+);RJYO&@K7EL:QZOKSRU[>D8T?T1 MJGR7KA!+LKH=4]#L,KPX54\+=$M@U 67_)BNH&S1\F.HP 3O2KER21\:YD^V MX&K6I^94=@I)UFUIU93F.3R"R!JP.HJO3YS;IPSD)Y'T[S$6UV-AD/.!$\U- M?4]%KKGB6R/-@L(9HB8SE8++R YHJD>,_!=ZP,[?+9GV=8J"2'RJ(4D&E;XZ M8[$/]W9]]7$D17^<%:8E*SY_I-@W$FJH]X;AVU"+OH%O546A2QN/0*IG1<+& MLF&W/]9<5O29,V)?I8]\-":E)IJ2E23"/F(]Z.YL_R-TZ9A*,LYL UDQ&\#A MX[(H)NG&\%^AZM5.%&BF\V:I]PW10B'\'DA'."[4)>TZ/=V4H6[8:3E3?7;8 M3[F*TSTQ>9;"O[F$]&Y5Q9LT;=UZW,*^F MO&WPH0^PT<'NW$ZO>7NC((G_]L/QQP^?SSZ^.S_Z\.;3V&H+TQT7LWXWC>K!PJI:9 (0FL%)SNXS-G84K?;M_ MTWCWF[;YOCL?[;Y;V) DU^ZC37L.P MGS5-'/]3WU2_HG!P-@ S2W$%NO=5YZJ1SQ!7!=Y+%9GJ1$!/74YD>$1MHOF. M*?PMOP2;!G:&7U$/E<=VR?KNDDW-DH4-W)Q%T-V+MKL'6XH9F;L'L?QD;+Q% M4[^"M(R9 )F^V!!LN1\,I;L/S38U#%42 \?& ,(-Z-Z_P6OMO]!O[;J%M0XS M]5:8=CN:MVS9=BU: 5AGL1>(QH*G4[/'5]L:]ATLQS5E).@+]&27J]&EU.TI MQRB'E6(:!J[XGQ*AKDMI[9CMWH8E3$&0TT;1F(H"_UE4$PR _:?.Y&7_PTGP MFX0O6T?H+-UQX;2(@K\B:W=.N84G$PJY*O0U&SW)JY"P9EG\"',,J%+ MB(5*M"W,J(6:1]PC6'!,<\V M0JYIY)XTNV-5&DH> 3_7F_C?WG/!Z*_PX5%P;7KGK\,JGH[//P>GIHXNO?/S\V\E9S]T>?3S]^N/?(RBK/3D6@C 1OCXX_?SS[/K2#YZ?> M[FEAL+#) -CK:DHQ/JMYJ&D6P6)S07ST%)$M6_BL]E)$@>1)\17Q7=3J>2Y# M78C'T8^H:R#\X5,$2N0T#$Z1I;1[%&HU=X;/>&4NE,A[]10@K?1VW,>A<@:^@E,@1,40RMJ#>JY0$8@O-TF)GV#M5$ MY5E5F ZYR61*#6007_7Q]],WV]U73##+ _)D=5$6WA,6/>F2 M9$1Y#-3\%WP&IOZIKPKE%?#KMNC@:YI=ILR SOD$#FW;#V"_,G\!I"7?Q#8$ M'A<9,5O3<;VR4_ 56RT]M2P&7^]XVYWB@9&:+UJD9HO4O!/(U'SC^AB38TSB MS,[&&'0"6E*DMBWNP M,P_F3="3&<''QKJ22/H.<=Z=/Z*O&?@^QDBAG[+)?F#PCS8P9W_H=HV\W=I:"-XDT3#-8.C]X#-RZY_;G<&OB%BX&^HR_A/3/S>.PRM: MIB6W]/&[TZ/@,J+6OO4& D;>?CO]??M\-ATE8Y!5A]V_H]M,92#\+A9:\K [*':/Q"8$!NAH MRR#=^2.7/C8E=V8GK1--5TD2WXF2+L7>D#5> HM8P![AK0V&5<)M;S&=R;9, MK2\F'UD[.J=;J7\8R-3KE=(Y0"7D)VQ1ZVX:.I]>LF6YB2@:9IC9QD8ZW(E! M]Q>L;?P5[1BR?*XA!#>"6'08MW:?UZ5DF6"L\\B>7,!D65+00-8E1;S.W'<5 M>Z'-BT;HUE&:[LQ#_%8OSZ*X0;M%DPPAM:-9D8 ^PS+/D8K&Y0A=-RP9 (,W M#! 5Q?$Q79HY43&!P 6Q4,XZ[M[]813YL,*>&*5238K5*_OD9]-A+K()Z,VH M-%WJ7,L24E])YD6/BS9;1!+FN)&8G M%9$1??;KL0 PSJ;LX96J/TK!$AO.Z/'N]!.YSBD&617XY43VD'6%^2ZMH5.] M:FI?ER@1<^2=;CBP"%0*B]UG+VN/!Z^%:HH[B.PVVXY^5*&TWK%K8S:*7L'W M.#?3BIQ6L]J#-X"46[2N:'$$#3GW[N%2','M] O%.%[\O"D @MM-!JX5.F 8 MG*?6WBBCYN;CXTV!**NK7""5J_FB'B+&N$'<0)4S.B5S($NW5/UZ:WC#_/6B MA.#J#E![OMKS==/)6 E7KUT9^1@;@A/APMRT0:WMA:#X3CK$>A#[&D#Q-$6 MRCCJ*6S6]R#':(T-DMOSUYZ_FTY&@TSG6%(85(+L^[0GRG*X,E5> M2"]O"5P;4Y#R'4[[8..!S<5RVT/7'CJ[/NVA>YSTD49$*E?-%Q" A_F<*(5AP%_:,]B>P;O;E>_J#&*TP[GW MN#+>V)%%-JXXTL\,:#D>U#@9$#:^1!+;!(Q1"ZU;:2WN]( ]2'[8 >ARH3MB M"C5+,:;S,#-\J21A')K +":$40=B'0UG2(":438J,R4P O:QC,+Y=6RLH2PDI7CW+= M,60#@H/NSM;7Y]9X=*X_=R,]=$TG.!V8J;)LP>6'>W>19%6!2TVL8N[T<0N9 M5I5QNC!/QL4BJ:WR\#=F=3C&:4%7!KAQ4YA(.>@$7+3.N.*7./ ,,7B]]T%**I>44:IL 3U%H-R6EN%LV6RO5A ,(O6X!P M"Q"^$;-G, !_O=*84U4HJX1!5PR2M EZQ7K%5P:C*)_,=S7@3]KKRRDTR?$J MK931PU?KQ/!*B*76FO-H25VO$15+ ;&1)9D-&5+$2#0'L02#(B87> Y2TE!G M 9D+5V00,RVLXB ARZL#4YFYRTQ(WZ;57@FLZ\[?APK>I/"C7MS15 EBFVU@ M8P:!TO7E/J8OT27LB .2\"",7%_]<&=:U!S."LNPRJS_U2O9"N6SM""6YBPF MN9$$![)FN2L@2#"%.P$^&M;\7("@XNPHV&3PNVQ!PI.5<(U-A*+)M=)14DAN MF65(IA?Z2.#:YW'MY(1H81%8'+74\,X(:+E+AO1)#96#/_<_.0=#A^&F5,CF MSE[@A",#?6N8#XY/!L1'$@=1F%,G7S2?H*V4EY$Q'6=2JB3$[2CYSNJY9AM7 MAX&@DS0[JX"OU+)@)F+8Z'6C$D1>ETCF%"ZJ3G+G[A0JY991UVG2X$LM;0Z" M$JV]HFE$%A@I#Q)QN-U+CN&0$5*RQ,->&!8HY#\A>YLJU;2PD1[\"BZ3@X_6 M<$QN,)Q<*"&6,@!R(;#+L_%8=SP9P]VO!%))BP[/0V(JT0Q%Q7K/_%J6WMT\ M]'R3/JH.;#C Y8 S@;#W=219SU6&6"]J4%T2N*JJE:+JI%JM+PW]%3NS:V<17J'_YPQPW05Y8%B#' M%=>*PX8M/&5*/HTM*3!-/W0T4:LU%XF;-52HN")1*FJVY5"K=[#A8S MA0-L=H89^T=9+NT[I'T3634#1;1.V!N+Z)VL_G%;'*'9LU2T.L%Y-C&F H5G MI#E5?;3:VO'<4Y@LG4W+6E>P;)NFR7A<30I8K[P7+5DT7[X.Z;5J/*692I66 MQ3#A<^6S[*0/<^*FOXSRN+#Q"5DEL Q]*\-YF)FC8WGB ,Z6[.B(A]=?"-\R']8@0Z5>7W?U&/26&!M=&WB\1^@[760YTHZ9*D#' M7_!+C80]@*U5+=8<0+$'F^$&[AFF@\7GT#L0KI3X?2[T.7$4CJ;=9)U3^ Z) MP> Y#*WD>]1#D.D"/VYI%;G+YKNT@GS3[DE7#<'VP#F>L$85M5;7C=Y)#\U- M""LB.0$G7FFI 3SUH*6$K34.,L:P_+Z.PUZ$(K]:V1J%AAMCVA1J-CZ48'D# M;VJ,EA4G*-SN<\1Q4%KO"^D^-^,R)IUB@JQZUCP_9P7M/N%'FBXOS8[$,?XB M>'UTAH'@SQEK\R@@CC_+.FV9+IH[]ND7FE!!1"'N@7\BY_9;ST#K1T:F%PDL M0I0W#[E#O??P2QR@AZ\T3VV"H=]1=JFHJ*[G]4@9:QIU2..W]L03:>.:2]=.L+%3.^^Q@N M;4R(T8VB-:CL=X"AD-J>Z\O<DN7%NZ;N3J^IT[?4 MTT DD/A'1Z\9R7)KT"/OW&&_&U)M$C3SWL6"A:[5!-N@N,K*.R1S>LL;&T=- MFK1IPSQ"49[8DW7N_<:K6P("JQT369K;]M/7G^[=WJ9"'B85 M:C+AN=326-P7K-ZSD&=^R=X/Z\MVI MQ3..1J']_VBT(FV($"C.9_\\ 5A-8&JNDA-F0SZ4D&F(CC[\?GI^Y#1(MH$\ M5[2]>-PZE>0J=T%MXKD5!NV789RP:7S"^6A?[*^E;A=3T_>=W MQ^1B M3JKQD Z+NSA]#_KF<*Y>+6N<$.2DK1.&"F8G/F=$%4YF>8P>TJSP:_A M1]WY!944P^\DG7/EBE!,5CC1L*E\2"%E^87$)$.;_>5-6B@*;D2>R+0H.N2B M;S$Y@^-5.LCMS-P5)'_SQ](9)ULQ/(V#3# 40A$8;2Y19$EOD60M%H] $JW- M& KG.UA%K8T.)X)GMXNBVC:IRD%PYMIBS4M<59N27_N8!F]5+Z\P4;U/%L]. M:'G:WBCL:*<][M_X*./J+X9FP: @VB:1=G,'_8F^1B([;M.K! M0FB=,-6MK\P.R[@YT6TPPA)&JE*-C'6E!?;J(@%7WS/FM,F :&2) !@P!G<$ MMN@FW=CO7#YY\&+?Z, LBT/BJ&-;[C@K)@K%CYK*Z0C7M5=K%)D5(QI;9]$$ MWX)D\@0*X*B?UL>)=TXTGI:EBAZ()B[I Z%)TR=;0B>"$7"07>ZB$>IIB'D= MG4&DS2,<#H%9S&)R78JSFF8#=<,T0>.2Y"N2>^J+C/$"W16K3_ZH('X3D$DZ M4ZBH-6&BQ=%*?+(6S%T +:;0I0E1.W:_1K:9T9X.W_]T.OS5F()I<#3-DW'0 M-2=!<#$18X) 70C"+/M:8RM)@[]7J0JZ+_B;\SCR*8P(F\H50@W$5]B2X1A# MVD.6>8"K=*RQ?=C4>$SPDGQ.2>M5Q!7U(-A.K)#6C+2W$^^-10O*M/4R7BMS M: FI)W?"C>C.7]]->)X0[8^4SC'31IK0.+?@*XD#.XU)R+F!,[5D(W)!-4$" M4279:4_5,]VXW/VY-9[+D3+>\X!0B#AS73E"<6E[R>1R M 'K!98]ML%,IK6!*P\-S*'AM5+\V'1+6(0J;BE(+;I6CKBQ(MU^.E-<1 MSP<5!;!;$49X/<0924).WLD(.+:I:XO+B,:@SHMQI"] EYD"(R)]0[?J.#ZX M8],,U//,;0\FO5)!V%EA.^<7=?=5E*4.#R49JTN)2^E4UNA)O1B*;,4B_M#K MD8;B>Z]08XV*>-V1@!7$.84.@\//Q@H-R MWF)@V8+%KG%4M%-\U6 R+WBBX[R>&];C_ MJ;B0=#P8/CL+)K#D3'K[[RJBWU@=UN M)BFA\E!BX>YW\[(Q+ F)C;MH6JDV MGUUT*Q!SPKU_=E[]W)QL7J-O<,3P!MEFMM8)3#>_VHO""&2J/[RNX>)! MHOYUIZ\M9OR<48S&(K#'&76_-KD+KENDAL)9'CL>."PPUTN$FO*5%$&(2IQ[ M+O?U4&@DC-.B[LX%W0E)2@A*N)#283F:"7@#QC5&FET=L9_9:/2(/"8R-I,) M+I^/,P[!@$:?&K4]HJ08!%D/-+.\X$V*J# RBM"DJR8BN[I1+ALOM=O(O8$( M1M%D"\TL)-]R%!OCQWZ*KBQ)BZ>>16X=GH'N-&)6\B2RY:^HK**9#J:@.84M M2CSKN88_Q74WP0GLH%-PR0R/HFD((5?4H@='-8TZNSZB'C JM96I5&JKEQWQC4="AYX.,\ IPV/@Y2/9<*/#YL+_Z_/20]+FK$)H>QC&^KW MR/!A%19YS.3HBMEGNJ1YJ1ZSVEPNZ")%516>ZF>3@EP)#N MK]XF7R_9XY-W73>QXP%(Z^%+R_:A8YWX,YZ[VI*.[R[PJ@ZN\!">7DN*( M3/S-HQ^A\=;2SB:1:NHRR2/S(RBL \FE]3RIT\;WR/WAWQU2DDQ96@'G&@WI MQ)*XEXM;WN\_!!_,]5B-=0&A=9I#6_1EG4:Z/#W'$<.8>$#Z3!CC!YO^H,G5 M<@RTRK'4U-C!48FKAB[CR5Y1UW"SF%$"D_ R""76^G*6I$"D?"H1Z[D3[GS' MZE3.-SKI'/'M29]R2,$3!)@VZ FP[&$90'D^@G#GJ?1C,V5AXQDOD-=.8"&2 M162NQM!35 65S#I4"&A&2?K.NX+)AH YE14B/'Q$0Y]*Z9LQ=MCM3KG&112, M,X[=Z/CI.I7:V578H('"'!E,KV!L"T/V*-531_TDE/V^\"XZ*74KN"HY1<3C M5$F#6))"GT8 W^_\2CY$A%:)P$']ZG://M%V;(%[)AJ25K !-T_'A9:PXX(5 M#U4DX1]X/PL_0H?SS[!25[Y8)@5]&*%$F://,;86?%5J2E6G?\Q%#\$?+IFO MPPTVSR^[65#2@V*M^ZP,&")CDAA]#%; PK];D4?NL]'W^UY%3Y ML C+&#'%G@\V;*S1KITG[E"T''7<3_MG:K85WLLJ'.'Z-QF<$=3FW0,1Z29JDC M!%3T3R>#KAY*LS2P\CAW./8^1T-S5KN]'>:\*N5NUC!<.*T3C7+P^OO9NZB^ M)J5E 9K#SMG%[<\EH/$E<1Y=1J9 5C_%6/(LE>M&RGIE;*[1X$296,O--\3$ MQS!3%+*B)>T_X< M2%97SB;IOZI4;P%?31SJ2?XCD3H;X>F#)(+%KF 'A3?"VRB]23D"!Z2#!9;> M9YP&X[Q7-!:K2 ?DK&T4@L_;HH>5M-=L"#JE,.$^-[*9NGU$ T.9-D%7& ;YC3%%-0RKW$,6R-4*%>0NT&[DJA;LI351V[L&;&I!G.W3B-0F*]*GX&@(*ZZ M>DQ!Q<(TF_@&=*X\AE[Z+@+0L!S(7$0"7A2UWFQ]SF?.^U?2"U)-KW9R&@,; M;1;Q0;*(^SMM%K'-(MZ4 H1 4X.<3=#QC.%\8+0,*6@(NCMA#&3]"JR[.XYU M-8XNM58P/AD%$QT/RIJ]R,F8%(XSA2A-375=('BAK%ES-?!9X3E_3!>NZ9G% MY=/1'UL#PJ83!3Z-/6'M* =O9HTHCOH80RQW3+5YFC<'%>Y#>SZ2!IU6I4M( MSB-U6"HQ64!!*Z?E-^8+&;3E)1J6S81^3?'Y>EUPO0JK*0OE!KBN1W_Z".*+ M<^Z"Y@#S*P<7@]L7WH_K7P0ZV'-AF0:@W_6B,^B*S!5[. -O6$69\2@9I4%H1O)"3IX%+#N:\;>]-HIKM M>+XWIK,]FN+9*6Z F>#%Q'28.)V8CQGR#T9<\\$-EIC[=WXZWNZ[[[9$EDZV MFOHSZ8IJ.W?G(90'0J"M^))2\B+,G :-)+J5:1)K5ZF\%DW )"4^HYAR]*99 MFNL/T(?!.4V5O@+PHL W?V)&'R3=<@O&C["?44SV_'$DI*KPZ?JOJ;2>E)4L MF;=0N-48+0C 7^T+7>;N3G=GG?+^V]P P50J$SJ_DOAU"YM[RIR$T,%,4SL, M;ZY<;:SI-AF\S$VAP-PA,\0QWYTR5C)&P)E'KXS>K"EERV0BM4.U@$##$CN5 MH[I^UT'E2>DS^@(4IG'A'/H\XM,F46P$TCU/B\LJ=14@6[__JO*DB!.=W&)^ M2/T"2N7.PW-U]OTR*;P6$U[ZC;!15Y9C5E'G$Z=*>[#P;^PQR;?D,=)5)%X8YPVX MX<3Y'KPZ_.GEJY].CDD;+AR ^3Q2V(R3K^A4RV],1P@*UO>I=3RL,M. M\7?Q"&#Y)DR!6(A&=F-6E$&DM_@\+EM)1W5"P__"3H\X=RZ')4W&?;Z[ #0, M,U(QY2;/Z>Z#6W3NN[9(F^D]!#>CR;0-.;6N4W'8"1V+&WLTUT2#81SS[\.R M'?X$#)4;@]&6QK8U%,7.IF#-59$%V2[:PN;=-VTM21C9G=ZEZXX+Z[D?F6=1 MT$5KZ93]T:"S5I6\[6+*2B3 ><'+4'W;!ET1$5CGXDL5!ST,*WPUN MAKI+P#9E$_@*&Q!9KO/]'D15(V$0K+^:B\PQWC@?9PP==),.$?]H4]L%S M&P1?(BP4/J8KM1GG '^=/WRA_YFYO28T.Q^0H(@&V("7TA5.8*A)GO%%[G;8 M'6<$DMWMI3H=U.85.OKX2K@GVO34]I9^">NFC[?F[(@&@^0;7Q\G)!3SV0*M M@4T_NIF+5?*$F#+&:<'5-J1HQM]=8:(;6XVZ9"CE47_A9 M],4Y2ZE=7TY:Z)5>1$B 0:5YO6T\E2TLBWS.UI+Q8#O!R3=L=D57TCB[Y-I) M>4+#>0RVCO'[P>ES'?NM)9%R O^!\ ZV>0X2XC+EKYN4K3N+(E/#PO*H]$ M(+QF2" 4%X56>UDL@"CO5T*^ WN%*XSF0@7>E3"(1%Q;.A+V8MI%N#J4P?@; M0A;V%760V*/*D BKCH&-7F="KYND(W#$O$%LQ+T(J?=P5307A$N]Z#V-M\9[ MSH1;*J32)*6F AS=PL5+N(2FQ=B86CC:/^B81I,=)*VWM$7(-RKA$[#E41UR M>P4@Q&^C7:7748JVA?9<=T(IB:Y!1"8T),<26&]JGM0GV2V3!HEB&'V4Y]10 M41:[6<7*I5'4)N;48Z5)V+2%],$].CC1?%^QYFBH_$2C!76\Y>3MJ)SK+ MF[ZG/]PX0(%0<"#GEK<2B%B"W'&79%$>P3R^!:=7V>NNZ8>!:"K"C!KF46L% MIQ4HN2CX'3RX]HS+03(\*R+'NE%@3:NB<B?T*I)QB+&9&=Y= D=7 M)IG@ /)-?4.F,Q16;LRZKK >IHNM(VP^7ZGNT*::E"+-BCE,(^Z;MD@Y,BL0 M9GMA.:N)WC+;CLWY8E3JBI?;2@O^L2; BZ6)XMHH47/G8-7%?+1MT/_Y M4_?%SL]7/?<6N42J-G^3%/V**U@HRP?+/1-6:'.<,&[L)%;.;&+EH]F$__G3J_V7 MNS__2KMZ++MZ[#'PZGH;?(8,3+[USDA@+:T+QJQLZIF&9H3Z,1,S&;IY'4R/ MP0.+%&B@FP%&XG5;2)F+3?6YG8CQ4UPV93@PZ>,3JJ2L'9MI5B06YD,]P)WV MGV[H5HQ2;* Z(^RA0;6 \T2DM_/L2<(4S/7+(;/MTD7=Y]ZD!%FR23 *MLBE MERMIJ\?T 9W@#XDN#!/B]Y:.$TGSOZ_!X)(95B1@=99!?S)XO<$,_ +JQ1[G3RA%L92\!,F1YHK&3(Q,.T MK2%7H<,<;$_EGIIEHC:$]2(4)%A%@??Q+/!(F)R0C>%"=3@L^E$Q"@;L1V7, M/\KP#N$=L)N1]<8TN%IY)7NVH#1U.+>1:S1POZZYA$$6L#TGAF8U:I!,)R6U MOAR56,YK\$[&2*C&:1A)%FAY]D1=G$U*]>O"0298H7,>>@TC0:' MDZES*_R21\'U]H@M9E(< :46109"HC7I0M88#:R=8<5:/LURQE[;2ET,!AL, MEDR)H-\1MUJ58UG;:!R#:4"HY3%J$%;66=5J<7B::YPHA;*X:P^=L$^ M(LO@/>W+'G=AV^78_SA#?O%(DB(IW1:X%A,DYL ^&%0/7VE_C30D'G8&A6;4 M(@J^\:Q[V'D%>A_6WT!_*7R$ )K2WC2F!RXU"Q?,K+^W]@YW9=M4X-@@%2MY M1QW/I9OJ;W?U?>2!5. (,- &SSBK3+Y[-&N0D/(B9R%([(2<9,<4,?3:$[A% M*R($-MD0Q>6H"JEGP=_-X=AV@J, $18(C9XS+-2"5YA1:KBIH-GEMPOF+ :0 MVX8G5H,(?UB\33ZOCI(EAP^^4ZEDF#@VJK@>128/EQ>1@LB=DRMZ \+?A*&! M8Y+]?EXI(9H&%1O6%B#CY#J&J^ L(E*_XMMX&LVX,X*#GRV(*V2658%T[TT% M_)TRQXP3X:S37F%4I>36+GC.90[XLB7R^_@5022R8"G!%"?YR2HQ)J68Q(19 MI!+G'@D>'A#*PVB3LMG_XQO/GLTEW0RZ'L>KJ^*/[%*\$Y;5!#O&Q-GC&.0 J;<(TEE$]O(3&U MDJC/#RQA6CL-"P:5Z-#M:C6!8M9=I6PJ#H8W4%\1)2 M$ZG"-:#\^<,W$HRZ*NV\D)PY>J8O;3[K)HL&PWHMKEW:&UV?@,:"(^@-%&0- M?];U5PML'<>%%7] $W(YC9WJK%WCFI$'ZY)74S*LD /*N:^D.HR;'=2;S\+G MB?Q?4X08M\.8@#,7'YM-T0>H4BX=LR5KA5)?*?'AR(68O'A[,9^$8*=C;3/.^9<^&0J8A[%CUKG/UMX<+(;Z*;].B&ZUSQB/055+#"-9R)TY ^ MAON""X#@]_ 83XU8WE-3$'-0NP790O,94^#>IJ/8G\WQH[R32/T_,9YN >9^ M XC/=J'.:?%XF3AM0"Y?5<@UZC9BZR5ZLL'!T)QPSK,QMR'F8F[N!9 M_V2LN$A7B^].O58-?[WEL MZ!D]-Q>%"32IZ/Q)ZO,W]35JJO_KP1C/2'KLUN Q7[NT(C>+/^%9<]:,L*/U M% ;@A,5%E:E,%_DD%D?Q+\C#HGPXSQUS, M/4G!EN"/78XR6:U^-C%P;+PAFN9L0J$F;M44"=6G'8."FO^^B7KM+P\J\6Q8 M]N%V+L"R@??_[8>='^CG*2I2^7FUXHJ JRN"^?(*'J=7F^">K[$:E'/U"%[= M %Z^A.>O9V#]G_CGOY;Y+_7?ZT_^M8QK10J[+W%LQ)((-K,>4IE-;W+<*4OS M I:ZC*\QA*@JLP5#6*R&KB4!\V,1)) 76,> *$-PL 2Y3Z;GHO.-*F+*.0*Y M#PGL2"YBAF6!?H!#%U_Y3^.LQEQ);< 0SN',R.SFLQS ?: M&@"3I L#E9!_(%@(YKI&AYHS)QPFIA-D_"#DCQ"SC''CEY)R*;F+\?$HFN(C MNEVNG%"QTQ]%4_1P!$+G+O!SE:0ILGP[2;>GE#['$&+3O /K.Z('ZH<=3&.S MF8[;-SW6/D%"/5+K!PZD^G>%IN?4LC6@<2J()PHG8H].2J5Q_LEMIAQ1FL-N M@^T8BQ@7@FJU^J;5-X]8WZ LBS(0V 8CKN0 Y?H6IA0$A0%3->5 M,(XV?C[-,0%!: CI$:RCQDM"<=8W3TLTS*@J73ZOJ<$=H'&NW%R>O_B2XM?Q M8*Y6BTPUVSAAK>^D=IA%0Z($^!GC]J\.M6O V%%'38SBAROB1(5]+)'[CIKX MQ+AS_&>6:U.]64\A,'.1W&AT<7IUFU1LY"U-DE.Q$XU'\KRASJ#RSPL>XRZA M27@+V*08T3&^5'YQV9*M?TP!]85WSK5(7QI!&B9)A)T#)5UO>>@*OQ[\==2; M!>QAIUCT+T>1*U39'^S19Z'"(V9_2I)8OHG%E M\C@7F<'\86MY^5'R"I+(A17!-H_U">/GL;QQG!#[!(O''S:7I0;7\O,AW@MQ [QR@W$&9P'KC!4L_;.7!QH;U[F"A&>AO+;L1[=C/]IM MV8^>)ON1+\Q(8/JW'T[^][?3UZ>?SV&0_V=[^RCMC\"[V_X%1P$VVAWZ)X_& M(SG87^B1R(CR86]K)PSP?YZO:#O6NTE^/GD?O.C*_13["=W9U7NR]> M[-(_N_L[>R^ZN[OP[\.#@Y]Z^:@/QWYO]V#_Y?^OOG5WMKN=43GYX9?N3J=+ MX:C]G__,5_H]B_>J*WT?A^ N]KC1[[S)QL,513DL\K.<.@[NT\;%*&]4G\F_ M]G9"[B!'Q$&Z+E8^I5O,'>@RH9XJ+XE"8P3?3EQZ!6PWDO:9Q^1==$ET@,'? M.\%Y"9^_R%!+-$;?MY+4U("1IP6RR62"Z N>?!LEO:0,4)CPYR501L8Q9K8O MGC#[/=\097 ;)?SP>GW),UN=>0N=>;!WL&MTYMZK_?VZSMP5G=FJS(=5F4>@ M(V/2F!^R3M 596FZEKX25/AJ"O LZ8^0L_)=)SCI8=L2Q$\J4PP7-.EG>2,7 M9DI+C(=1F&:2THFC59DW$NFUJUM@M\4&??-JYX7H MFR8WJ55!WX<*V@![I;O3[9Q^6)#O:U7,?:B8_WU]]BXX39'9HZ^"-UF_PA#) MIIW<^Q*V\^/?'F4R\*$%Y'/T#6F$9W#UE$(14(F]/UE\<_*VU7'7D9\W:D!44ILO-.M6<^^.7K=J M;EUB^B[JJ?&F2^C]R=ZGLY-6K5U'7CXA<5Y:WLMM:/_=A*V\1H,A[ZDKHBH; ML;I-R.L;U%[-SWUN+4H#/E\5+CLG.?+Y',$0"V*#6K@:1K5WSW";4R6WS M%5Y;<;=JQ=U>6W'W-"ONELCNC8H\I&CO_/37#T>?OYR=-)7MV3\^S)@>I//? MIUK/^Z9>VU@%I?Q@DBGUP>PJNBX$NAR:: M'OF ='A ?N7*YRX'VP%V!MN'W*+'Z].N8SO860#-N%$@8,G3'BP$L! ]_=!A MH@=;VOO.GF_"KKX!]_8OP?O(U O=021LX;SJA8>FX- ?]0-._S7\_J?B)P/^ M9^3_=RO1]Q%!;9?NKO7L8F 6!E[)O?YNE[G5N(=*6O[[]LFQ&[N\NK(U2:%I_8E^K%28L,&F6X: M-6H*/+!JQ;&FRH0,T;74K#?RJYQ?R2'YAHB3_[/[D_MOW/Y>%L]^P7^,RLD8 M_O%_ 5!+ P04 " #+B:54^+4TD$H) !T-0 %P &)R:&,Q,# S-S$R M-E]E>#,Q+3$N:'1M[5MK;]LZ$OV^P/X'KHN]MP'L1"_KD4>!-'5W W2;WB1= MW/U(D93-K23ZDE('6XU_QM"_\V&)!WDHG2"$XJM4]>:T6YEGPLR%M9TI)) MFI,+E=>55*7ID].2[39][>^-8G4ARHHP+6@%,FHCRS$9O?G'\7DF<[@VY,/Y M&5P*$N]ZN\ZNT^E]HJ9S+<>3BKA),B0#XCF>UU5A,&CFL==.Y#!5?$[2,5.Y MTD>]%YG]]8BIYKDXZF6JK 89+60^WR>_7LI"&/)>S,BY*FCY:Y_8DCXQ0LOL M@-C61OXI]HGK3*L#4HGK:D!S.2[W22XR*+'C[),7COT=]!IMN+Q:C-CM8F?2 MBOV"$I\;W1;,! K9)ZG*>3LO#L*J&72S!I!033 MZS7U24K9I[%6=[L%:+1=M,1V\/$SUXG;O=M6FI5UH])AK>S(ZOSQ]>WIR M?'EZ]IZOC]^/+@9GO[\;_8<W7:)^>23:CFY-TN&:5"Y_,^K)%&N:2:T&K_OCI6- 7OP42>FREE MX%*.>D[/WD\IYXM[R8]Z?_(T<%@2IC1A+'!$1,,H\MT@98(F/ @]Z)938XYZ M;RX^O'TG376)LA_+?\PDKR9XX_S]WLX$?S<>\;#2KSK^$>[Y0K>%\!A'NL)U M9#1?#%"IZ0%Y%#?4>^7N0HS@=ZC1('^C&IOLJ'=+W&V[^WH3(Q-Z)8@65U+, M,'Q-I"&_U517:&SD7$R5KH@JR5NE"^@T^(VHC)Q,1)%*1=Y(.@9?"OJW4:UK MPGS*$N?S;BNVW# M>RI&_)HB\P(C+>;D4ZEFN0#>TV]L63<6S!4(*Q5P+.A-94EH.2=U6>E:P/# MNBP! ].F$)[!]I&Q991!D2:J@$A V/9,:B"!T*L$:: 8D $RFX#S)Z;&_V[$S806K4R<3R%-#KP. M">-,5A.8KYD*9O5%N5/05'&8-3PA6*-TWEV5[8&K\!P>"<=W,A8$:>C0A$9! M&O P3OC0<:)GN-Z- O_)PU60;)DNW5A\'[ *S:%:=^IEF4%$HIA1P37+:PXR M 60=\^X#0"5&L2F N&-L,_S&_RV6#$K0X.+X!(%]U>1"AWJ'-J#GU" +#NZ ML>HQ:B8DR]7,5J(\+<9@IYK"N!0+FVF TOT.,,U"MS7EMP>;GNL ^8M=UQ-1 MX ^=-(F<*/69+QQ*HR1YQN;=)A\\%6Q>WK+<7U[$GAL=F!9];>:!L49EF81; M:].GA&IAP01HD&A78.5$&+0Q:2;8')L5$'8Q].(]EX;ERM30#P.R5GD#HZE6 M3' H-N0EH(8+0&4#C=$U)$+E6)!C"&[G=0XM7)\.W.%+L;,*4Y3D#GE3N6-O M)>:590-N'(Y@0.Q@O@$=JG;O<;.=[D 9#(337H4^M$"&O;\U<([<6,0BH,", MH\ )/0HIGALP/_4$#4+N_"1P[G66:N-Z_QA'\)+N/!%/P(6!00 $EH#>#=@^ M4F5&:W/_+DA24T&6(S6T5]4:!$!\O)(&@S"V$J65@UL>-^&[0P'6 W5.+9I; M&GR#R'[+%K!20B@'U8S*);<;KZ9.C>22:HGSD0UWMQRE1$FU00)M?:&Q;-N& M;&4$Z%>YP9.'%(_# ,WS+@8!AYW?I8\>EN]1?HTO<6]H^V:T[A_G+ZW[P!_ MBA.0B!P<"-6**G@F;U&75. GP M8'(*3&1[W$3*?&S(6]>9A_W8!+-[>94VGH%Z AAWS0)>ZKJZO,:W RWZB@^ M2WWHLK/ O8KL[KTWDBYV0:S?:Q<&U#M X5L#;!9$\,]SALQC0[C/WF;0MF8CP!\0]3$#4(S5&B'5X=<;I!;* M5%".9\H@R\#:D#^:DRWR$KJLYPQK$C+P'!"/5SJW\V 8'MB@(<)9;U4"6\=CE:=G(G.3RD\C;XX.5]OW_>\6V9Q\Q]7TJ0NZ'OI\% MPV08A\,D\%WX+PPR3MV?Q)5\4XU9]-*5]&]B)$;P+IQOPB4B\ 'I MQMI^P%(U6G-9*6TV;29B%UL/(Q2%K"HAOD!74H5O;$ ]EZ NRB0O ?1 !PRR M#_B+^Q8+QR7^J"7,QCJINF3V2&%GB[8+4X_%+.9.FO @\I(XRH:.DP$!")E( M@I\%M=M* )[,=B$>K&$J+@'/N/&-6^A,"@!@R\Z7VW8S03\AW6YR7TNX;1)O MC]H7IVH/@G6[I=:<0FP(JY1#1R.64773 ?PFC]"F_B !< P9>K_A_ 8-MBX* MJF$![-Q:KK/Q='*[^+S(J!LF#@LHC8+$B^/(XS$%BL]\-_62X!G.S_MY%LY MVS,-,:\/X!(V:BO=O'#2XKC?T%Q97JG\2B#7+>FX?8U&MX%>%--[TEI< 5#\D+S#;PV8#P2.(BD[ $S>(@=HR9^A[0&6I$PV'+'E*D E1]JJ] M%9+S7'S1NM;5^6I[>P-6M4_^1>=DV+=OL-_YH#=-)/C"1-I7K >IJBI5+)>, M>--K8D^ OM=4?WGAAL[!GME;?[GW8=;]1!YM,]]'?Y[?2?OG9[3]S^AD(D5& M1M>"U;B72\XZ2>4'#>220U3ZMI'C>W_.0K[J@Q;OAWW0TOF(I;TZW,/OD.Q% M^ZW5_P!02P,$% @ RXFE5#>)GHCZ!P HBH !< !BU:_U/C-A;__6;Z/[S+SK4PXX0DN[3;$)AA(;3I4* A MO;G[4;;E6(=LN9*G!["RR+#V]KY_W]' _MHD\^N9O M /V8L]"-<&R%E?RHOU?\+B?_WFS"N0AX:G@(5O7@DU8LU"*<<#@3*4L#P21< M*YE;H5+CP3 -6L5>]W.J@CSAJ85 Z4@?5^%<_ G@9)*'S;> M1>ZG <;.)3]L1"JUS8@E0LY[\-U8)-S !9_!2"4L_8@1-S'C1*0'OI)A>;([,M:0*A.S$,\L!PUPYQXVT)"6ZX4^XI+$A^SVGBS@ ML^!FHE6>ALV[K^JB%"0/(&%Z(M(FZ:4'++=J,:6+0XHY7^F0(ZU4I1RY'MS& MPA<6WG=:W?[>JN*.^KZN'O>>UFG%R)=4ZLE@-!Z>#4^.Q\/+"[@\0U\=7IP, MKX[/X6QX<8Q#'%V>X8K!Z+5XO/I]=/W[\<48QI=P/3AQG+YO=XG;\<\#N#X> M?3J^&%PW+_]U/O@W')^,Z4VWW7ZIOO^3&RNB^6<+TS@:>G#.9IJG 8=?6G!M M.4^GBAPD]5!5FLB#C9GMO3JKG18,(693#II/!9\1&L;"P&\YTVA1.8<1SY2V MH%(X4SK!?2IU3E'MA#2';JCH S#'35!Z2!B 4YI4 E& MME7%NGL+4AYP8YB>TY*$W7 \MT;35("6((!Y@"=+EPGP*%H7"(V9!5>C\QAD M"$$%9K$(8C Y_;<@ S.N>4F$Y$B$D9@L* O-A(U13I/QP/%)=#/D4(4H[12W MA>#/Z]IX?:.]?\1H'*)%1E[*[Z'%<#F^UK7W(HW02QDE;1P',@^1)NJX)JR' M9A+DV1FJB(Q,QI=R:<52+WT(<6C%?D^/;=QV[GAP-3VJ#$ M-?(_%4586FDGX1"8YDZEJ!OA8SF$,@-'._I2F)B6T[($0Y#"D)Y#80*I3([[ M*#BUDH52,ZT"'N*T@1W48!24M%*T>'D,4'#4G*E0/;'TR'FK!T4K!T5X$(E[UP%P!6'NQO!/ MRD)E<"E-Q@)DZ+#1;KCGC(7AXEDR8PX;I]=79^=XU)@V?:D2<29"&]-#^Q\; MUXOTLRQZ^U8?U4I@? XKWBKB'YVC+750+MRSX28[84H>&#!9L695=@!?I#!M M'.VPW0WX*$K!M7RL"\;&"KG5X/UL3D-N\!#T4Y!$U*BRZ)I$0I-Y3O'$P9EQP=MBK#D3^\%;I- M&2.CY9)19D I'1/+O(D[BBQH; M#&P##/C;"0,;9[I[:+!YCMP8%!!(IB*DX&9&I>2>=V$ '3C75 $3 # =5L&( M\""8+Z2PJO&^Z-VLC]QEY MFHIQ%02YIEBIE;IKJ";*6)RG]B[2,J@;^*/H#,(.;KE?OM^C$"$D8 :]L[F4 M(\#(=#TV:K^E^8+-W8+)F)G%K8%RKX,0'KH:Q:FGK!_F(,4-EV7#[AP+9=$1VT&$P1QA*2?B;KI^5T_,_54HZ1L4O[!4)?)E2>95'..;V>Q*C(J6PE_#-?GU'/F*U^#MM#^C?[L;ROKST[-/4BR-QS^RA9FC^Z*'O*9X7%-O@ M+=^^ZWS??KJ1^%P7^=_9_LU46V.JDUCPJ/:]XV7M&CBXY4%.#3OX)\[!E<82 M%*UHO_IE^$5?_'5?[8N_I1C5J+]'7VVZ0?EEZG\!4$L#!!0 ( ,N)I522 MI 2AC 4 /H; 7 8G)H8S$P,#,W,3(V7V5X,S(M,2YH=&WM&6EOVS;T M^X#]AS<':U/ AR1?\I$ KN-L&;(XM=UA^TB)E,55)EV22N+^^CW*DNTT:9&W [G294P',\;Y>%2F4M M1RT7I!](NH)@'LI$JH/27I1])=!FE;"#4B2%J41DP9-5%U[.^()I.&.7,)$+ M(EZ6(8.403/%HQYDLS7_P+K@.DO3 \.N3(4D?"ZZD+ ((1F=+NPYV=0@B'7HZN8!]Q W:NZ_=IUQ1WV U5T[SYTF[H+'A]2W\/19'9R M?#(F4?Q2#@RD,CL;GL]'1->ZF MHV'&<<=IP?@89K^/8#J8O!Z4YOS7K6 M<7NORL (4L8Y=@I&'5,:E8B40Z90B]QFIF6J=$HPG1JYXV;37#V9NUF."95+ MFVQWIQ>3K-US(E.B B*8KHRO$K:"06CLB+5[&<>)*=MU,=?P3LA+U %*=U.D M[EU]Q) DWS(DD0O28B9_Z#DE++^DE!:]#D]*'V(?-\C0:M5;[BMAM^(.EXS MK).0$:?N^CYU<5E"M#XH'4W/CT^Y-C.+^Z'2_"6G)K8=Y]<[YWS[;0M7WZC# MG3*&?5KP5B#W,_?>JBJ?6#/T+BOAPOI$2)*"-2.7/7B0XE(Z=*MW8&.=S6]E MXX;*2M=P74\77\VE=<,\^*,TP3 .Y6*9V*C<1*IB[U.NF-U_:.O9VSC9)Z\ M\X#;W*>O-M&PC>M-,.W^GX MI-%J-!N=P.VTB==N4>JR=D3HNCW=[CP!)#1Y>S5=%FVX\(*<]08VC866FR#C2) M)36CJ>]4BZ_+#D5!SAFR!P];:KBH/IKPBUB;UCTW;/G->L-Q73]J>X$;N/5. MV(X<$CZE0&M9W+>YZ>><\B8O7^VF1^AF7=QWK:"YWG3]KY5ODZ)QFQ2!-$8N MBD-'9=W=Z N\Y15HF7!Z9U'OOZ&MZ1I,.)871>&T"J/ ;D&_S*^?@E%?[+DM MI_?@EOQ^=GJVT>.WT3#F+,+-&F[<#+]@,(XBCH>EK!J=8_'@%,O'HZD9/O%< MMQ6$C7KD-RAK^T'3KY,VZ9 FC:+.<\UXKAF?D+9O0??>#MK*TZ]9^.$IN51, MA S^J,+4,"8NI)56/.>X1Y?CGDWU9$RU+D?;5Y'= M Z5BWS!A,GO"O/7VTMJ]W*FIKCS5=E=)W*)@_9"DG(=)E*G:G.BI/GS4_5+WA;N\Y+B M_;"7E*T81:M?LZ]A62-_\?L/4$L#!!0 ( ,N)I53-)MO#Q1 $ZJ 1 M 8V5M:2TR,#(R,#,S,2YXXB;A!S\\NF?__CXKU[O"KN8 M(1];RN)!T097ZG1);"#ERF1JP$>L?'AS)/XHEXPBBQ%KA7L]4?F>GW-SC1VD M^(BML#]&#N8>,O'%P=KWO?/#0U&Z(/2-29W#DZ.3DZ/3TV-@QL8.=OTA9?J6;O%\R.&SX]%,4+Q/&&APQ]Q,;QV=G9H2S=D$)#I*1IXG(? MN29.TEO^ID*2^-UA6!B3 F+^@XNAYQ%W2Z D\$_H]CS&9XJ4B-7XN6KTXX,3Q;*%.^6S-\/+B0-A! M+\;\=X_A-\!J3,*HC4L $L6'4(6#94K.1H\=QTT@9F9:R5@$-$(]S'P""GXT MJ,,G$\M$=E.QH(H9V*V6RL++IE)!%>*2-@MEHT53H: *MI]7'M'.'"10Q(>; MJ9X[55BM&?.M.H,HV-BKFQ-#SAG@,O92.Z MH$(IGB?UA_9L#O]=:V/ TA@JQD2;JG,="#HDFR#9IPZH8 TTY!:/**\+:+9> M*:ZGN^+:-ZXG4^TST.E?-&5DS#I\F^&[1NX*<]V=^=3\FC3 MN]H#>T-?"NZ[G<%59Y^5XUL*!D:8VXRXHG.C.5EP(F+X_4\OZ@4L/=Q,$RX M:5,>,"R^:+/^5)\(1TM@);[ 8X M!"+^4J'RTZS*I]H7;7RC=:I-J%9W09L^99%K^?BU0KUOL^K5QZ#>N3'MO+W4 MU%+@Q#=US=\+_RTSB72^=I6/YCC$EQX5^%EBRL:NF+!55_A=)CS?2HK4):_ MZGT6*PB+K_6Y])%>"^=)3/?:6,SUKQ5U+/VI/A1V*9$LBB/JKGPLMGD7?@A4 MZDD%%C]GL1@9XZO>7)M>@W=T.>]TG=!U.!?ITMC)+9[8*-JCR2NHT/R'K.;# M.0K6"F'K(C\T&:GC#H $ %>8KACRUL1,;%J)C3&3NM0AY@![6(2.9K20-*"O M@.LL"]>59EQ-U5.@^)P(WYI^UJ0(S&C@"G:IK MIT,:I$5RTR/;.+$$\E6Z)'93!&R94* MN#Z4Y&645V$W'2BY"9HD+-L/RX#9I&4JH2G+Z73@[)5>2(+7M%+YAD^3I$*E M!>R=MNC,I&9,G32(XN(RZ',CZ4J$ZX;D'9#[Q>9)?!O7*H.]641>:0][Q_R= MH>P:_"=-I %]F7'4#?FKS&*?=$)G$ WS"JFIHI*L=&XHS294@MXX/]%!W3AZ MOJ+P1;IYS!4G?X@5G[(=8!\1NTY87=W&\\7;9SO$VZ\5R;$2L:RD>59>15QW M5E3;BH:(L"_(#K"Q'!(70?B ;-WE/I,OOC0PI9H-/:\]G32V)\&V(OE6Z%+9 M<*XD6._,JKE9B4/A$\QF:\"WO@WEU7I>@WG;V& $CPHPJ4@N.]MH;AL0GE(' MS]$];C"]Y%1Z7LMXW]@R0A85R6-G%V5YX13L6\_VSPR?E6:&.US*4L,I9#)/ MGR(Y?%:1'.[PJ77T+SUS%A:7SI$Y1_XJP:MY=+##<;\L?PK>QK6^6Y[_["GR M_)VE/(&EI-X'VJ7JT]G,(Z(UK"?C@._:5_=.4/EIU]2,DE=09@#I4ZZ5L%:> MD^T&?=W=O5G@.&C++ZLF>^K=OK/:NWVOE8B5#N+:$ OOS?"RZWY-VN< .Y-( M*P);\*-$#'60UX5\BKG/B"G?TP4%PLJ\]>0&F*LTAF:M/(>99%;O C-YY"NR M&'&A4N:A9+8K;N;:V^0% MK2N$O-1%J^&5N2-JRL;".CR^;C6WYB&V?1X_Z3VV]>:>6_'UCJ7\%-[D6LI+ MMH+XV L_[M:WG/?8@VRN9N_)*O$7R<..' 2,B?6W$0O).IMO>S"![\UU$P8V M]/+3'AV[B)B\2<^/%<*/>_3-B=FDYYA![K#>RL5T6G*SI1_<7 Z^FW\/W'L332.QU#N%[_>&0;$5[;&27T9&\#GT' M?<6U0EV)*]5W4%/%E>R[*"SZWB+TN#GPF[B="4:/Q]Y#6PXQ0:RZ[L8)P&Z>8?PCGY"[0D+()HR;& M%A\RZJCFMX!PZ8D:2_#S!]BC\)4;[J-,/"'I?LTD=>)06#D0>W@"K2R1S2O4 M$I8MPON)01:&+>(7:PO"'0Q1@;@Y?([N83"+._7&.(EY,4EKI+3PHDS(Z"I> M=[6Y$U! &1Y[Q".,.$XB7XNZ-:)7 3R%D _FZ[6TU5ML4T\41L>/KB%>QBPA M>RWJ4/;-#T^<6]1!Q/VA@UX+Q)7[U\2R;*PA[F<$*R)HH2PC#),(WEBAM+CD M?>.)G*9\?6".[_U+FYI_)L3=HXUMC?AQT?V9'I@7)PM^K$YF@>?9!+.3S$J5 M*6GA2A6J73R0BH?6>,XZ54K5LE4JYM!P,02[)"0?(!\G?8ABFJ0TXE+Z=AA7 MU@W*E+30N&(US^]H)10Y-.V"0EVMF-S&4%TW@"4*PC%&,#>6.8,C(5^S:JW) M2U2D9.)U[%?\L/'9OA)__75-'?%#.\A]^(QXN6;V:.,[+XSA!DH-=43+NKI MK@7H6<4K?X+DA:WR3"[&X2OXC^7A2HQ6.#9L #-)4-L!V+7Y5OH&Z5<7''US(>1)J_4N9[9+F-V'XC\!:B=(X MLSY-KVBUJ'^ N=:>Q<3D*X.02< \ZN,Y56T;IJ4^/'1$S'+),#+7,!3AWQGV MD/CAZ\0A;Q56O/!G?'+FOZ=LO'4SYY;=1^8^H\%J[8<":OW5 \7JKJ MO:!Q VV(-9VX7]?$7*?B6]X7I\$]&Y[-UYBP4-#T0-JA>LIKC!C_L5:QN: C MS,E2GK\U6TS4LM4@N9;]#2,VI %+ MR;]3_9HHO2--GD=)N@$UB'<8#99_OGX0299@(?<1GLD1 M*KTH$!P\T36O*VVB0LO&?U\BODG%Y+G^110MDT3HV%B&W Z1*4=E_>#7D)4X\533DJ8R(2"8^09M[1AU".B8D* A41 MZ4^Q25?AJX*RH=0>V'.TGC(D^>S'9GFB^R1RQD*FI&5C(+K\)/FR_8(&?O+: M#B/PQ=QOB0.7>:';;@VT30\;$Q5):NQR]&AO:N"O*2-_8>O&M3!+B";VKKAV M#TL+X7@"9HRGPJ[SU/0\[?\_:S'>-4B:4D0E7_I_9B77[O[O@$%B"!?/==^] MYY9I7O)MN#FO9FP5M/"XCF1Q?D?S>4\4M);W-;B;!=PGB]K*OPCK\ME/EK21 M^[0#EW>CD^I:$\RD@R RNYOG>>\P[=M6"S64/!0 77*>?"OQDC)&[\(S+_*G M(;#8,MF\UC+$1<<+=FJIE2=EQ*6.CS]?(-)^QO(+8D1TM'6^HIJT?5O :9ZW M3HAXB%BPZ+GR%0@5\ 0I Z=0XIJU6PFS0&M$D9L.GC-S0#E9"X=W$4)Q&*N[ MR>,_NJO=RGW/ 5ZBP/9K0%VWH5:B/A+7M3'>MRF74Q-/Y\*SA2\E;1([J)(+ M#G$"<8B-Q!OG5I!_V+60\CN?9:H\#!9=IC9#MCAIZ3B$R\U$YN<>].5I0OCV5M.3-T/P(,Y%- MO'S(YAKO$+,V\;M'0K=HB8%-RV!QX&GI;GCDK#*>?>+>VI;*E!YUZM;6DZ/C MM_#W+/L:2B5I"U=KPW')(N#;;&>EJR)LH6S[&FQDJ8$P0G&^'L((<_NXZC/V M\5)6_GU5< 6$OI@#GDG%!>V_&/7F3BLU9Y^6C$YYX65XU=.G_P%02P,$% M @ RXFE5$Y53R=L$ R>D !4 !C96UI+3(P,C(P,S,Q7V-A;"YX;6SM M7>MSVS82_WXS]S_HW,^*[.0>3:9NQ\^<9YS((SOMW:<;F(0L7BE"!2G;NK_^ M !*4^,!C05(BZ';:22)R=[&[^ %8+![\X:?793AZQC0.2'1Z=/+N^&B$(X_X M0?1T>K2.QRCV@N#HIQ___*?\81IBC!_NAQ,[JZ_'PVFP??_NF/\W.J<$^33PG_!XS)D9U:^?^!^/*,8C5F@4?WJ-@].C19*L/DTF M+R\O[UX^O"/T:?+^^/AD\J\OM_?> B_1.(CB!$4>/AHQ^D]Q^O"6>"A)-2ZP MOS[2,!?P8;(M2TG!?XUSLC%_-#YY/_YP\NXU]H^$BOPUH)"<_+5&+VPZ^?CQ MXR1]NR5E@@*-Z*W9S'NC4>8_2D(\P_,1__O;[&;+S7WR&)!W'EE.^+O)F>>1 M=93$=VB#'D-\%OGL"5UC_S9 CZS&D@#'ESA!01@S?5+9R6:%3X_B8+D* M\2V)]V1&O93]F#-=8=&X]F)'47QW!IRCD \S]PN,D^[TKD@MJNNQ!K$.4T-N MV>]2B?@UP4R:GY?)U6YE3UIN7G)(O%)I(8\B""T;R N+66GI:#Q'\6,Z)+-( MZ FA%1N:WY],<)C$^1/NBY/Q\8F(&[X3C_]S%L<%?X;H$8>G1^6'29!PZ_*' MDYYUO5A3RH F5;GRKJ3Y]EU_!FQ'DJ^XJK_LE5"__*JL?0&D9[1L"*)>+HC] MLX30>A0G*";Q>KE,I8W9F+#,^>>4+%4N)EK="_I]&I4$C!(R*C,2ZF-Z>O2> MQ_8O.'A:)"+0[Z_"^,C"(Q+VU]5OZ^ 9A;R+.TLN$*4;%K/\C,(UKM2D%8]P M$Y#'P;IO8JT>%$") BU_=0@M^71CACW,]&8S#H9K17<%(,U[+RVI@Y"PL$V/ M!+T@ 8 /#@'@CN(5"ORKUQ4?[AF(I\D"4]VP9<$A7 ;BL@XN'M+48QGG&-IO-OK)JXWI4F * 4SM!2 MNE2C<),4]:L5D(/:A.I#5K>8\T5/@ H'T0K_&&A=JG0;LQ35;A"15[Q+$?(E M7I$X8/%9:L17$GG2<^Q2?2F45=3/CCJO#Y?F&'>4L$XBV=R%*$I8U,.G2"N>>*NG%""DVZ!2 M1^I275H8I:A?O82\SH\=JO/":A73]SXAWJ\+$C(]8ZY[LJG4.Y1BF-':2-^:4.K$Y=3)& MA#N8,2E'O+G2&SF08,32F4.=V%6X6!D)0(A)'C!%TE?NP )"*DD>S <.%@8 M" "#7IJ @DO3CUL2/3U@NKS$CXI,NH8B'T=E%*[6M]D<0#5+A8C:_;M#N5!9 M$$< D9'*!:GMZH'/J9A>5-%M$.'I_()B/U A6T92@7:9Q+T*-5NBK5(INX/+ MQ8JQ5ID5 ]/K8QHW\F2*NK>U40<$@*RAA#-*3 "I=4&-TWBPLT^'!J,DX!:! MGIRBS\T078I#Y16IR,J@Z&3':_UJKUVM5(-A@!JM"[!P6U;,[ZM M/\+^%:(1/R-TYGGK)3<,^Y=X'GBUP!S.(#P%87 5!-;& F !D>E@('?FLXD' M,PN%=RCP;Z(+M H25%T:-5#EJ6T5E:LX@)D%J'RE( ?CD@(PT^UEI2,:-Y%' MENE!C:\XF2T<@,$4;8% %-AAT3: V73F#7=**,* M-8%PE(S 54@8C0'4NDR&;(5K/* IGW&:8SWSDTDT#*T_3*H^NF6_#WFR?J-72=2:972=Z*N*N_Z/';$M6 ]G]@L?8XC%F753R!IJ;:'D114_34P M>1T0J$6E)E62E1U14LB0-2)95W/XBN:J7S//9.>JURS WK6BXI8=$82S;)T'8>FOZ1X"1J21YTJ]PA[5S/H8B'HN[]Y1CH\:BNJ:EAMC MY0P_XVB-\WJFR$M^"9+%Q3I.F';TZM4+U_S2&;Z?E/WOUV=]+21LTT4-)/37 MB'5U3+KP1ZDM2DK+4DH-2G$PXW!!XH1'\Z(7J+8GU>MM;KGZNE]+IG-1+Q(S M:N\*-A3>]8=KI:^)WH 27*M"LJQXB=G!TWLS'&/F(GX.^Y*I&9)T@[RPH=;? M 6BW/9N6ULVZMC'06/<&80(+_W ("_'(DU#< 0)(^LBH'F>-SAM-D_>#CE+EFH# MC. =2D<>(F<&26GN20]#A;BTME"_;Z_/'475%4O%FC* 0/'.UIT+Z#$O, MX"('\FXEF%$JE@X->U+(P7,C>UF,=!!C.EMLH%&1,Z"E[]VMMKU>?UBYAR^= M0@1>>F%P>D]?^4&!\@[3@/C,^7R?!K[$V=_L=Y:(O7KU%BAZPC-F\=5\CKWJ M P;>\\TWALF;:!MMG[&^\EEV X,]XZXK C/V M>M&*A[&?QB,P4ZO3#F QXE(6F7@'!^#R&;0[ MM$F[:]6RIY1(>IIO1S0T:(",;8$-E7S948*^=^#DVCV0^_5J%08,Q3R;M%R% M9(-K72B0.N])3-1# XZ=^6UZ%U-!G6[FJE\]SY]L=_SP:<=V.YEZEX^*K+*S MITXV-!0 #6Y1_>H2NCQ)Z/<<6SJ\K!P\Q1'4ET'$/#A;T;NAAC M=(6YN+N\IUD2:1'_EZ?O!]5?9 3 >CNX04BA?@;5!O,U#:-^OB9E[#_RFN'T M(- #85T]WP'&SSXP):\)O5\@BL]1FG)9\C$@A: B)&LJIA*KV8MQKIO6 81T MYC!(WRW1I!C=V6L@O>RS[RE$<="YHP$S>,6/2DKGF2!:R54A$MJAX<[&]!;@ M,A0CO9+[CYC >HQQ,R:0ZNW@#08*]?GGE>(F.5P-HSXFD#)V-Y?*VQWKTHL) MPS./57^<'BJ?SM.-E=D-ZU-6@:_8EW[BK M1E;&^F2CG^EU=Y9-.'0?IEB7: M%,?\9EK(TLI]#_N['%5J!-]^D[".*N"W^NH ;*2O90^5]$.%(M0%'>!-4Y1L MKOA')& ]LK@9"4CU=G#/=6;(=%XT;AJURGA]]@&]U]5/3?6 MO1AH6!-PKDU$?O>;24"I1U">;#!I0\/J3F=)0<6"CB'EYU)&O][I MY=]%KK<3$.WNY@P=[= 08V-ZJ\5B;3&R YI]3QTOQ;6IL'M^@-3;+_(9J(<& M(SOS6P#)6)"#%WK4P5__!K.Q1U*S*#LF&>\P4@_Z6Q$G8T0)0YA0H:/S ;.ZA2KL/(%>K]W&[TBQVR#536+$IDREN'C MT.B(3E$G*TUV^4K?&&-Z4NP%J=7LWR$6I]7.EH0FP?]DTBO$@I3F8)U:'#[HO28)#/X@08S"H%S(T8';BK+T$C/KR7?P@\N /P3:# M$/A,K!TRY$=D7:KO.G9E=_QMOP%E[*9 W,K^R< ]-%2U!L_Y/I-_XM"_)O1;[7(T*YXP8&O@2O:0 Y67 XTEU)S MJ84QLYDI>4G6C\E\'>8C>'5K$(!T=SI90SHT-%D8WNZLLJ84P[=%#KA\G*]; M;"[YYY;"'N^1V&HB.^Y8?[4=>8NO^HP^A!XS]/(%)9@&*,P^)L,O\Z3/DGD1 ME*%JJ8:AS]OF)%5$&IA9N2UN)S6+!LS2G)Q("[5_(?17GM@D'HYAZ#!S5.&A MXW 8'V!#80#1B7-R>5_H?%6V008#94*:"_I@JI0-*!5TH-62.M>@8/6M@A M;O30Z)7=H*I9L&G$:T:4C'?(8#+ZHB,^3?&-%KLJ8-/5-EM_30CKW'[U#:@H"T=D_Y:Y5 6;REVI?K MX*E<&R,>7D@+9!:X&P SY7Z[N*P[YR"P3(OM(F"B.D^G5\',7,<;Y5-0*P59 -CA: W"&2(R_8+984& M YY6IG$-*[GI_++&WR1:S?C?(&(U#CI,Q)H5[."QI&+B!I#N@))+TFFNI3=, MNADBI*;L0,^X%!&!*YVT=HLRYZAJA?;E.3A(F(Q0S"UMV8#0\,7X5LO4MI)JWND/12+]KF$5%2+?P!; Z'B:PE LM=N-)?\JR_B<@&-40I*B7TU M2C>07JH58F.<$L)<9!6R-5&.=YC5O6*-=F,UVX?EX@XL'4K@1ELA1BO6D.-P M>"=NS[!:_:88?&F X9+]LW&.2 ?&56L8;6LP .FH_ M"QKJPAW,IRILJ*#20"7]E*@3A]&;( MF;&/L*,6[\U5PR)T5%"7'P'=3PM[H,C'H!8EHY2WH#+E$-$#M+LE=-2E.+CH(8PY)]$Z-O0Z M@@>QI(!X<:*RL;X,>4T$.IM>$ MMO M>FL[@$>M -F7"CI>.-HADVG$,T_KT,V*-1. ^WX:GV&D6^H.+'V23<] MB[%,PS*D,D4B7O _'E&,?_P_4$L#!!0 ( ,N)I50#T]YH%"X )P+ P 5 M 8V5M:2TR,#(R,#,S,5]D968N>&UL[7UK<]LZLN#WK=K_D,U^3AS[S-R9 M!*2HYM0D$8%^ MH+N!1J/1^,=_O:ZR=R\ %2G,?W]_^O'3^W<@CV&2YHO?WU?%AZB(T_3]?_WG M__P?__A?'SY\!CE 40F2=T]O[ZXN/\_NG],,-RW>W=W/\5_!N[]__$3^]^X< MP2A!:;( 'SZ0SKC5]]_(_SU%!7B'D>;%;Z]%^OO[95FN?SLY^?'CQ\ZOSZAC +X MY62+B]N"_.L#;?:!_/3A].S#+Z#K]]==?3^JO MVZ884"H W6*[;E^>;ANW&_ZU_E=2OL>#_.[=9I@1S, ]>'Y'_OQV?[/M]QP5 M3W4_+-=%%*U/2(,3 )+5R=5K"?(B?-] +2M8 Q]FGL],3D)4%^84@+#Z0GSY\.FV&^G\3 MZ_.Y%@ M@,C^*84?8[C:T/X9PN1'FF6S/+G)\7 M" >SH@!E<0G**,TDR(_!*B4DG7WZ MI2%(!JH6N;,XAE5>%G?16T1 Y@G^!54@N4VC)VQ(90I,Z%8"KS?> "Y0M%ZF M\4W^#-&J5A.,YRJ&.5RE\258@SS!$\B;R?"K(]%BYNK?55J^W6 ;R\OT!=QE M47X/BA*E,9[@'DH8?\=(>[]\RU,CU3+':8O5&O1\3<;6,D-,R-;(KE:K")FH MEP10+6)O8;XH 5I=@J?2@#PF&"V"+N!JE98KS&9Q 3&O^0+;#)X"L(;A?Q/V M-],\%=)%E,6_Z)"LB6@2IJ;@1Y.5VDZ6,$NP][512@.:!<"TB+O)7S"?T,C2 MAC"T2+D'&$P%# CI0] 35[K(T^(_U'/4"C'?Q1I LPG0U.,MOWZ1^+:VG;K*5!G7KT^U2K0'?OT!D.O MC,.6OZA/LP"86\]%GV1E%&:N@3ZA Q FCH$^&3T ]F=D^J?UB7<'6(OH>;D$ MZ$M4XHV&%FW=_K:G>,N3N\-IW=6$[GPJ=SN)VYN^+4W<%K;TIGMYUZN&T_7" MV@[7SM;6=.$R6K+,%BN#9921 M,]J')0#$H4,8UQ*4>&K,K#$A0N&($3>TZZX,,*X#9\31Q"L-<>RVSJ?6 B&$ MUR8Q0C&ELOEKF]#M(7R:ER=)NCIIVIQ$F83P.T M+'H"V>_O^0VP$A'V60U.O/'3;/^*V5.!]^-QV>.&][GA9?BYR\E.-V:HRQ.> M+BBL9N;0G 2?$5P)1QV.ET3 MT^&)<;1=,Q*"=D$*5I:O<0D+(#6B/@M$U)NC^O:>K"_D88N^>-LMPA8LEQ<% MD;9A-,+\Q;,PR1''5YC#+HF-[O&,6*D3%;EDIS"U0(=C"<60!-OHRE_\ZLI. M>Z_QD&U"Z14F>N<-G0/LF8)6"L_5*^8 4Y_F$7JKV<;ISD.-A82L\MU5'61FM E:T M,9YDE80!IQ'P?_@5\%=0&\=ZW($4HHG]<<+W>C;C^YE=<5Q'*R54N MFIEY'A5IW!.;L$W#/J=-D&*4X6=ZTXHMVV MV@OALGE2%^\63B/@7_T*^)\@72PQ/;,7[!HLP->*C-/\N2:UF%!69I<@ Y2JB.<0Z@4L MROES+U>NT07FMV88>M^"E*Z(_G$Q]GI3>7F.DMZ# N"!6<[RY!*3EL$U(;Q1 MLL%!E43;[:F5L&V0\E7A3^8\2PB-RM]SY/,!U+&E35T0DGP_2U:8L:).''X! M;$50ZT3/9"4[!:D:6AR/ZX@L6*HLGB-^=5V#*BXK5-\:+$J2:%[?T;A9K:,4 M$?XNL/>R /UPD4;/W40BWS-(W='G76J2D8=-MA^ M#E+H(US(N0M= %1\GL.,C0=#CS7(,=X_TW)Y414E=D_1U6N<56370K00_Y<\ M1J_LA!<="-V<(0>J)^5A(9]:HX:#:YCGZN>6HON/9]T.8'_LY8,U'E^)O MI0Q+>1,BNB6\AEYW*JHZCEF>_A9G$$OQ]_=X90";'[#4P6MYE=6]?G]?@ 7Y MBT6Y%JALR13_JR]/_-.?=P@F>*V:HP> 7M(8S%[3_N0O:M*,#[N)2^D*TFU[ MTN[*$TKQPY1W#8C(F@W 26:N>+]T[CA,[FJ-VR44L\&0XA!82Y04B*&E#B\YD5\XL;G&FV.*2*&',$[7 MZQ&R.-59EA:R%.@P[/8SBG*VU3*^-./0^1*RB/DL2(NR R*,_.1;3"'>V#.% MQOS6\-S[%K+@1&Q(BZX'9)@P_(^3'NMXL_3=R^6ID;O6$Q(BN,WN?RL_V!/O MY[6NFSQ&("K )=C\R1KM>YAEUQ#]B% _84NS]RY?5JUWD,$OLS&0RJ]5@Q_& MC3-^R8NMH7!K8E!#X16Q"$P#1CF1B88-083AE(VE6HTE$NU+NI1Y0A0_Y&6-L]EOZNUS+Q'IFZ1=*^Q^H 29C: M.,6(2MZ3=4#&\0;9\0:9LKAVBE0\PEF2U!Q$V5V4)C?Y1;1.RRBC%Z1(\&%% M4E-J%6P_&7,/L!=>I"5H8CEW *4PN0O)OJF*"J07-8I?!M*:Q^T_ZP4B5#4\SM>%IY!6A*GE!47L "N'44P M A>D[EL>)W)6A9=4S +;K/EKB"ZDX7J@#BE,+;8V-DKSM#JN0&[[TE.. M-,&TZJFC"8C.N:8JB" 5T,)HR)Z.JB()Y8+Q\0*/] 6>O_J[P*,OUTW.!=$] MF)/)D7&K1ZIM7^KLMH'>\U'A4'SA9P12&!E*/=J8=T.$;6@],G8;?S=_Y.0( MY;AC"IH%N"Y2Q@:XY_(>W)/Q*W'6'2 SD0LO ND)/9S;0*T\&6::.O?[,$_) M<[JZV%SA."MML3*!]?**+-T,LK8;98:5F$*5:KO=40K;ABIL%1:E!#\", QK M?B21DPJ]\>U9T*(9#6:+4,4\SHZ4<)E@PDA/O0$F7JH8>Q97[4=G=/E^H:J&+NMR,[T\\&%Z M:D WU=COMWH@0/0:KKV'YL8?%;:&2^%U96LXF0],6X/.>3G;WHB-/+EK42NU MGDNWAI__G+PU%)OQNZF9P3/271:Y>DGQ,X +%*V7:=QZM9$4+(MA#E=I? G6 M!%H>NY)F8UW%7?1&@F>D\%T;+U&)U>N4D 0GIN.7=^U?J M1,^))#O92W"Z0 [JK,% K43R[OF*6Y%(Z.\5KY.N=5$ &7Y[$3#I7#4<50> M;#=UE@ANO".ID5Y',9DG\-8/+Q:$TA4AE%W/7KG?MH*+=+^]40?=L=!3$ 5L MAK%7G7F.F>D@W4%F?O.2$:&L$\H\ZRF##)IVN#;@"JG;",D#=MPBE$)1,@6K M33^)HMO&;_*$O#9 .2ZEU6687-&%ZJ_0)J7C6UZL08P9 GS<'VT'14\OUT M215,64)Y[IAGZVV@M8SYP/98SH,\ _^2%B93*(M:+I%"6MC.DBB4Q$UN\,=1 MP:[,*&[4$W._D2_'<-12H21C'?'RH+9%W($B\UUE&Z*R,R?KU/L MD,9IE-WDY)F..BBDO^6V=**XI>\\RC!UX&$)0/D9P6I-\HDIQ5N+NX@V=ZIY MFW=;X!JU, ?G[ZR6)>[YCQPDLW++%B=JH-.5CIA25T_SAC4M@49CU9YT3$DB M?.8K;L]Y1NI%4SD-Q6!Z!82.'Z(_;0_1N M0);QB<9<.Y\.0#<$O-I6B"ZJ,/+B=GR]L3ACA6!5N@R\45&72<.P5CTI]1&Q M[D%)D=!.I=N3^W&"W5E1UQ@0Q MT2L>PC#FN)9KL?WK_TD!PA)9OMV2E[\8;IM:I^%^0MAIK]PYK9'0<>UD$84Q M"VU)_%)?']Q:.RLEA#&P^7LD%2%S;9U53GKJ-U=/[!IP%Z8=ZZ4P#TBQ78RR*RNP1&L8OOX#7K*3*@/S9T.VF+>FG #? MIE;;!3YI&H +&W(ZVJZ,R3;1_F^*3;UJG;^Q 3""WA-@LK/"B3'YO0?GQLK, MUT %Z70O;]CDQ\+Z*.8C9$?S:[0"S*BL;'.A\;2;^XOZ3Z&D7%O@CIC%U4E$ M(5^[VY0=I(H.(N+!*"GK>" 0+14>(WC6TW".&ZY6ZPR^ =!Z I0901YM1R-! M_'9![9@9LQF4YW)@7;F[9.*]9Y/W9HZ"C(?'^%.4!YE%U418E' 9&B<^3RQBV6;[*I M0L8[9C %L[4=73 >;Z.E1;18(+!H%LJ&!\YI@F1K>CMMK+6W3$)#<4/5D>BF M$^IAKV^GC6$-93&JR=IX87E-&GFVBW*Y\=+PO$4XQ/\E>,9B6Z0.A*XQJD'8 M8X4T'S%;2JI%21C.]"Z1OZ;'7T;*FV*5'^X^M2 M%7SN$$RJN)RCYAUE1C!0 MW%!4,$-CH^VZVL)JYR]>*Y0RE&>NK0HLF"T!LV#ML90'03S_P1_DF3M?51%*=SRR HSG)W.U6N\C/(%P"0F(&'G3@B:T+0) M9A-/:S+?^J 4,QR!MM(AF##",,_Y"T"/2W!!SL8!8LI3U*09 G:3$.4IP/B_B7>+"YT6T1"[W MQ(B2T/T^,S)[1I@4]OOOC$\T\;KSR==#(J-V"85,=$3'@U6G,7=@^#/169%R M)#7X0.74^A"TE'@,R,NH!<'->WU7%8)K\"5-D@Q<\1[D$3>BNQQ.HY E),68 MM+1XT/RY.[=1F>8S[*CQ9D-^ QI(9C0(6:*C#$E+DP7)9ERY /''!7PYJ1.U MT=M&F,T_:EENC'3SPY_?'GJ2V_W0,$9^"%DR X*E)4%ZM@N=3YQ6OWT>W6W> M?'V+8 DSS&>Q>:7<+3[I]]B]9_)?$I9!4B>,ID\5(8J\VWZ9%B1)KN*7"%+O MN'T[1;ZCS]=B:BK/08[_4A("9TE2JP9Y=VGWVCPG7U^O=W>$Y'M[FIHT5 ": MCDU[8I/'OWEA1A&OFYP2#M'-13?T)2KC)9XO.M\!(E-&M #S9WHAKF@WD#-- M*RC$1FR(8A_UV.4H&RN[9>+<;)/$M(+V[P_5T[] 7#["F@$EM9> (Z7;0C@' MI,#RX^5*2X44A)%"I&]FUJ9L:Q/S06FOPHCYF&1#R:+B<' !B_(>Q'"1I_^] MV_*(597=1ZR5_3Z'H(#"<;"N:WULPZU\0&K%NJPGTU2L1#XNVEG5F+&+$(3Q%YXG#[SGY ME^@U754K]CM@K&_T^:_N-U^E$1B& ,6$#T32>HJKVRV,A,5.)/X^+;X/%FWZ M6.IH0_I8JJ"AO7A)]P2!$X$6-V+16WB/)TN,,Y3DK*V+?+#UTZT<<&'HZ+&B MBPL5LENS1:Q?>UR59<#8+D1\.C9%,IKR)LE.TZ#U1H%+S0EH #2,.&=3\JZX M!S%(7\@.Y"LH+RJ$AI%,F:8TUTS8-&A-4.!27A/$0,.(&)* T_SY,X1)^[+H M \SZ8<+QAMOY@-\P:!V0YE!E+N"##".T1W7T+GHC"BJ> ]B->M;?;Q2TS*4X M4[?X/KAVF"Z@]9\5P!4WXJWY/H*VFFO\6'A6<77O!F+_MD<>!AK%/'=))J61>"9)MSM6- M?G-_861IL3-51,BV4$5Z:-C*T@=_D,HRB T'HRZL2+=-?1%&Q6UH3#C5 AZB M#!1-+ 7OBIA1=6$;>L60W284IY,W(4 Y[L3R[\*NKQBR888R36PW0X^PC#*F MS,6-AEO,3J,]D+H4?ZIBYP$-P]09$Q>GQ)-$2[YW&4C))RW'4J*DDY)/&5K) MIB'Q&*6<* MRJ#J$DJJ0SB.(#TX&Q#+=@_D6E.U&&L=BL/ ,'ZHRJQXL=@BJ!5C#' 8<\5# MM5YGJ:QJ2+:F^X:QUF&KAAJS"JHQ"MAG M:_(-I54QJZC_P&VU2L88/ G<51 MGN1\1!88?Z46R.-P\^<.34P78+1=,P:"=OX<08'DH#QK;?$.(1+1"B#YRUXU MEO# [_$O8Y:#IREDH5>G*&8+KAPO,;'!IY_5TW,[@&"MMV7#! MM=VJ4Z=NE)3]-14HUQ$JWPC-S& +O\EV6\5J$OB**<&7;%R%!2NN(!YD*,M8]VXT$VCMA?. A1&C[E)^'<5@MB)SC5 UA\V8NMEN%JZT)5F3 M%#-N4T^#@)1! M]ENQ[1'LGSER&-.S1M W1MTH",<8VR7K/B-8%'<(Q@ D]7L:YQ A^&-3?ZE( M,7J07$-TG>81]I'R!2:N)V)+T.B#K*;0PE49NP,EJ5K&2 WO3W&+%[8I?L0. M\/SYCPBE)"AX'Y7#W8;[HA("]K34 MH N/BM[Z@P?L>6S^?(? .DJ3K?;-\)X.]ZA6DHN4!(21E4D(85^T0F= #-<@ M(2*J1YXO"I #JU1>I,L((P&1WX I^ "2#T5"'NC :#GH :RA M^$,J"=*EC)LW-M:,*=LP<@D%\AM(5RIQ< AP*&+G68)3"WJ0#^==U*ST/SU9 M"W/]U*3M+K&/. &W,,HWF1/749QF>$_ 3!>3:=IP*FX:A&/%SAM3X)$OS6[. MF!AD&%;YV8DAI]#7GA'F)%8=H<0PK@=W::+.0OS&S DZ7^)Y4H* M2K#2EF,?4%^(82VI&F(<+#4>!W,^OV<_'J[29Q>[D.GC:>T5F"O4XY>G$ZUWQN6@AF'TW:7F'B1@ MM2;,;8+UHQMB40>F9\WN$/*ZKL2X=.8J1C\YQ6KW.PS5XHZ$ ^5JXQIZYI-=OKWZ=Y66;S?U-=OT!9"W M61^JU2I";]ZOOSXL(P3.HX*\'KM:8R\HVF@4(J\RUOG/;[LF30[8[$>$DEO. M35E[ .G-<@L /18:W)+6HKAXA/,G+/B\_WP/YSJO&9#!.*H!\33K6-0C:&D$ MVQ.4.7EUA0!-LL+POZY6ZPR^ =#0QQF2Q0*!!0FU;1\AYZFY-7B-O"S .PCE MMSVN]NW H5A>(_:PW$=I>B/**O K"BJC0]#3/\+*):+W'F;9-43DHRU[E4)B:J(C M2'YNJU210$"&.$)V&(_%6N3NGR!=+$OL4K\ %"W U2M <5J .X0]"\+YLVN[ M5"3 OLU*$W"T9QN2"]K6I5D*X]%@4\YG25)+(LK&]YN3X+)DW2.XCH:L*(_P M;':$^C!JE=0PB@\8\IZXXN0]#I)UOLUD#Q28&DRT*+@.!E8D5UXDX$63X:U@P)Q MW%OSX WF,,V+-*[#A^[VZ6P\]K?C?3R'8[X3R"$\1UU N6$A)5Y=?D."/^.& M>"9Q:E9"')9,BH/C:$Z2XQ^>*7&H#J2RE"EW--96W-!\-/*"NE,S5$%IR2KE M4!Z-5$\ZX=FL'!..*H29$G\-T3-(2Q):B 5\28Z-?:3..$G6^*0['9R M&86WJ$KST:F*&+!%%S(;[*VG;M.J[6.6M6R;F'\.ZW8F*P\6;I,7:N6AYSR- M\3S8DD]IZ%K(;=FZ(O*CN9M*+$"+5V2'>(F50F;'<"!-.;O29Z6X:OC/YH M^N92"]#XE1FBYA]"[I39K+=.FR>[_:SZ6NCMK?N*Z(_F;RZU ,U?F2%J_GN> M+<5/%',9JE/$:O> >1SKSV'C3F047JA.F@]JT9Y?K[,8FOQ:,>I+.8-O/Z!. MX1_M46+)V1U8X/UT^ NTB#9&&PF0?8Q'"U-:NS#LS4FS=3: M/)=W>BAA_/VF*"J07%8(SP8;(FM^BOIC+P WN%*O#8#:B@: PS %TY%SH.D: M)%%%#B%1R=C']ZRP:296MN>9R$Q0CK6PQA< M#-9"%@P,1VN3&OOPK(U),[6VT#.$Y,,L3L(.7/CV@X/'L(/"N(=H90.*J8V% MD)_S-,[94Y\S5@E$/)F N 2)U7(&THA,$]TE$!V.^4TAB8 2W25(IP89>NX, M;Z!$+/X!,PR&O+9*'GVSM0RJ8W1199>'\7!L=5+9!+1XJO! K3?TU!<=7B_3 MES0!>3*5[;+PN;3<+KZCW6K(94^LMLL!M=E]S5=A<7J?%M^O$0#U8ZN@*%W; MK B?"YMEXSO:K(9< K=9-@?49CUGI,RR&CI(V"R3^28O^H:GUJF1DFRG@S ! MK1&RK\>R9-"G%?8U=6,3"YH_;PX:9U6YA"C][^%9LROXI@L$'_Y!6(/K<0]H M >!33&W,=\*&*6>[$M2NK6TP_AS6Y^V; *R0A4>J#7N:W9*;_5_B=*,'%5B MINL<3D?N* ^-9:]TB.;G-DXU*01DD:.$4S/TG;82+T%29:"A5,0J]PK@(^&L M;W>VX5)#LP?7I65%6>;4GAR-K@,#LD[:8T7=;K,$<_NA][&D(_.O42J&9\ M2#JD;!2$*4LX0GY;RFT ;4'1CGLGJC_[;QUY$A9XCJJLU)'6@ -Y>?VY>Q3) M]G:_OO>2Q]BRTQ= L)Y].OW+%\#*E95HVKG9Q&OJR?GFV Y4XHPELPW W2TB M'B!#F^-(<+[*TZ>JZ&/]E2E#N<8-KV.-@Y.C$G=B28Z!FM(:N=*4;2ZTRJ E MJLBACG4RI.HYB+-QL3 :AG_+_$;/J;O?#L_#%3'OS,7M(34T?._UM7;LY(G0 M_7*)PKA.E@B%/Z^=K9]&E:VDQ[*M_QTZS I1B?"'L8?84U,8[ ;VVAA8NZ)) MK4&XN9K$'BSLT2Q9Q-5JG<$W %IE"YCNXVB[9B@%[4(]1S&93Z'\R"A%=C5H M(KHJH"6,"1A[U'"%R8O*FLU;@HIP/G1>)5HV RML>7B.K?S .'-SA22$L2_B MD,A&J,,E PW1_N]V9$&-\]N3MR!@['69(0\L[Q8 +P^;O00'PJ"VQ MNW0)7D &UX2!YDH 4]0*/9J1DNH1NCJHLZVD(%+@PY@+'D"&@2X^@QR@*,,$ MSY(59K0H2>&;%]#0S)XGM/K23;U:W] 5RF0HE%1+$='0/_W'26\(;_$_-U\8 M'SJ#"UY+D">[]/#.\&*7>_64PH^8_I-Z6*_^7:7E6^=4H5TN\!*449H5[P,+ MC_73R;]AAE&+;L)&T:E$?4^V$K?]M"EA@,P6$F& S!R)Q>.[:K6*$%:&9XA6 M&Y?I"59E6Q]:U8=G3T2=XT%NK1$0.E::0(**YUC3'VAI5,?#/:8DUW.?)JEA M.&?;Q*#*.HGUMO?B>OY%9;_#Y3W((:+G QEFW]> M(',*G/V@J%N36' G>7M4E#A?;_I]AISN!3":T./N<-.:F6W5Y M"G.C]UQ;^_QF%IG"$.6QNS!1&>Q'XW4BQSTT:QD>&X/7K>H\I<$S7AHB"3I3 M6KTD"2Y-?Y2$H_V[D^@>3P*CC#8S09 5H@UY;_'+#I)/C-7E_,#">IP2K,IM MCV&9=H,@98OMF[Q$:5ZDL9.@^S@B2V%W$:*?S/8=2&<_0N\B=FC63) %Q*T' M1?R$#?V$"P_=OB>7VQ[O"5B\4L$%(.18401FK]M\:ANU.4VCA9Q&/I MI0H!GL.>&2:0C<_MD!5NJ,WZ+I9O=>S@#X":45RE3A,F.*B) MA/8PG#%@B)JP;C)CB";\;;V>RH0YJ%R8\ #5T83-);2')CQ@B)JP;GKB1$_6 M2+%[_C9D6.<=&SO()!^W,446P(LW5LUW2ME,9,".6:(F_+<]>D/'\D@PJCTZ MQ&"^0/,Q!%U=TI+QF:W2DM)1*55IQI?A(LWG)XR2&E8G1H4"UU8PN/"E_5?F M=&D]MEWHT3J@#IBQ[C:'575T+RU2LN+\?M@DJR[J_AFEL KK_IBEN^?)-H=3 M.:>J)_,C+>#9^W@(X19&A4_1$#C;7+5*@/;PNWGB;./I_8!\+1A\;&M!Z^,! M:P%O"*;2@A9^AW/!(VXBF T8GSN:T/Y\R+K '8;)M*%-@6$Y(I$^7,,*\=5A M^+6M#>VO!ZP,W$&82A?:!!C6NCF^L.)[F&77 M$)%.MF1AA-Q4;IK(0YU\Y?7=)'/>AL24YN]1MHQ2YS79V1,?W)SKWMV@SQAT M>1F58%O4V.NDH$/==+.&&G7':<6YS/=RWE'C-["MD/5W4;:0-IWZH\;;:OFB MP_D+0J-T',2T$HH<[4\@'CD+X^60XZM"/^6K0L'-!'9>$ K&_,6O!05Y#7A: MKRG S4J .Y0#F37"&,J?8"]B_.1*\#-,S7-!WW8*9YK1I,OY7*-,UW'"<2CG M?9IUE#DU?/PE^*FG^ZQ<.%./)EW.IQYENHY3CT,Y[]/4H\QIR*_-V!@0O)%\ M!FE9(="O%N=QWM$AROFDHT;4<<9Q)>%]FF[4V SH@1NWN\U-1>_I S5=O--% M8RC>XZ1@(*=]LOL!)P&]+#/!ELY3;,13Z.-HUR92VB>S[C,2]+LS]K=+GN(. MGL(*1[,VD=(^F76?D9 >E7&Y+?%@V5S,4VW?C_9M35;[9.(,7D)YH&7DPK7, MA2>=\JS*<"4KL2K #:#HJK;5.1I=!S9EC]+.^R![4B*5>6GVP*I$J"N;Q8(0 MTLCYM1]"][/"O/!^2-?=C[4?CJ9PK/UPK/U@L?8#K^!8]PH]ZT8]H0:@9XA6 MY%VTW>_L$F6VX-&B9N;P0MW6&M:0L#W24]2:L$"SQYH4GP% %Y!8IKK(I7F$F41]E%591P!1 9XEN8 M+V[3%Y#,B@*4Q6!/M[5F,S!;(]8%XV_IWPE[AD!4B%EX*NK7;GNC9P*B&3D] M$)YF/&-M@5;&K#V1Z9)$)BL]4L)P7'NT]]B4T]>13FP-Y78Z')V4&Q='6LA% M'L9]^#L$UP"5;V3I+\G2^.\J71/GX"OH:YM,TV8LQ4WW6+,4QL"6/HE1AG%5 MNN&/L$O<5:1QU\)>_B_Y#%Z93LN.A"Z/HL:A#U61?,1LZ6A M6I0$"?_GPHH[*F8.>\1!GK-;VQ=E1Y^>T".8@RTC$H/Q+LDR@=[+4Z\K$Z MV<;(*<]&9]LDL0/G8^VH\O#;>7QK;53>4)[#CE+P -?RY@/<8WD/3SN\2YSY MDI>1R,6O:FD)W5E!:2FQSYX1)H5YAL#Z1-,0.I]\1?9'[1(*F>B(C@>K3@_H MP/!GHK,BY4AJ\('*J?4A:"GQ&)"740N"FR.ZJXILV;^D29*!JZ@HV;76A8UH M(2Y.HY E),68M+1XT)S$/:1LZS8JTWR&'37>;,AOT##/:A"R1$<9DI8F"Y+- M0$ !XH\+^'(2PRHOT=M&F,T_:EENC'3SPY_?'GJ2V_W0,$9^"%DR X*E)4%Z M.BF()&5#=P@F55S.45-=CK'5%#7919D930YD@RG!O]V])1NA/W^SH8>0W%!4 M,+<9H^VZVL)JYV];*90RE&>NK0HLF"T!LV#Y\U2-I3S89_F7,VLSJ2UHX3Y2 M6=3AO$G4D,CTH)C?NN+U[#>-VR44L\&0XA!82Y0!9%/-XMIQ*NZB-[)F8&KQ M+Z@"R6T:/:491@&VC_E0VNQ2\!G"Y$>:91CU35Y&^2(E=-3+F%7$ ZVNL0.0 MK$[(BHK-'..]RBN\HD8;Z$79H&ZD0?[O*2K ?_Y_4$L#!!0 ( ,N)I52@ MJ+V/VZP )R "@ 5 8V5M:2TR,#(R,#,S,5]L86(N>&UL[+U[<^-&EB?Z M_XVXWR&O=V/'CF"U+;FG[]@S@PV*HLJ,59$:D54>1\6-"8A,21B#@!H 55)_ M^HO$@WCE$SB)3*HJ=J>M(O(\@/S]SCGY0.+?_O?+WD?/.(J],/CW[\[^\M-W M" ?;<.<%#__^W2%^Y\9;S_ON?SO_]__U;__/NW?O<8 C-\$[=/>*YI?OI[?W MGI\VC='-[2K]$Z-_^\#OWA'AM-6?OY+_N7-CC%*C0?SK M2^S]^W>/2?+TZX\_?OGRY2]??OY+&#W\>/[33V<__N>'Z_7V$>_==UX0)VZP MQ=^AM/VO27"G[^\6B+V8+\ZUW9[!WYZ=W9^;N?S_[R M$N^^*UPDER6,E,U?.NV+>SK[Y9=??LRN'INFBCR.ZN-MIT\/H?SY1:&/;_$] M(O_]>+M@2O_R(VGQ8X"3:_<.^ZG)3#QY?<+__EWL[9]\7/[V&.%[NAX_BHYJ MR-/YA3R=L[^1I_,_*LT_#G'O@4!I$R:N#^-GIJ_K:\?,<*>74(^6Y_(2\BFG M%,%.W^#("W?S8*??\;8I*.?7B1N- )6NL>$WH-]KBJL^^>DZ_:MA M%[\D.-CA76F9Z.;$SLQT%FPSS4?=X;:AU2=9)(RZMQ.G6C.-]VY\EZE-,^&# MZSZEZL_/?L1^$I>_O"._O/OIK,@;_Z/X^;^F7]QHMTG-3%^\N+20W=R_?T>] MEG@)N:?6M1^;-T#D&[<0X3@\1%O/IWCOI^9)V8"# M=Q_7WR%OQVOO9#\A\AOZ3'[]__[MQ^H6NK<]C9J=YT;;TK?T3\']%"U^W(9I M1GU*WC5N[3X*]ZQ."26>9?%H,IV_HD8SE(2((_^C.7ANM^$A2-+2[2;TO:V' MX^E=G$3N-FEC5=BP!"ZGX5 4,U6#0EIDA8MOOK"S7KQ?+JX6L^ER@Z:SV>KC M;$-^ZK>^?C:;!+ M?XD.:3+SW+MT,)2DOEYZ\=8/XT.$-VGFNDC=^9-.J[Y:FIQ3UP)#2%6[JFQ- MNC4KE;(]_9#@ 0HEJJQOV!X7S4I) M,>G.)P\",T0V;*AS-JO-]/IKPNJ =#42S5;PO*WKEOWE 3%E@)%.]+=2N@=B@]/ M3[Z7^F45^:A=S28;JT^XW*H+<;C4U:T73[J&\#0[ \!$&8I/4-;(SG ^$%%R M-4A/2-DT])6*Q%)!6%/\'2GT]HZZ](!;7+2*$O)L4 VM8@IH#*@CQ-+^8504 M06T,G;UP(ATU;(I#<%X@5-N8:E;YX=&88P MQ2N:1,+I(V^9_G?SV?_/(O M9]GX,_W'SY.?_GJ.W 1]2+GPB'X^FZ"TT\^SRY>IA?T=CLI?T_]-G_(3WB;> M,_9?[> E%U@4=HH 0*3S?\\:T-@7 _W59NW!2A!T!^* M*-,)@$RH?'+SO>/,T,]I5 5]:J/A=*&HU5$GL\T(",(2=,I9P>?BHG%:\'HQ M5'GF'290VK_;CIH*^V9R">9H^ M7<" #HUT"[U040N,Q46[XN( ?/"C8@^ V! 3;Z+P'L?D54G7O\*"X"AHW(R2 MS,8PK&"H!YY#$%N28 E/P9$M3[5&Z!Y;$DY%/=[EC42_4/G#D*,0B6O!.*'6 MKN]&O)UYG$9- G4:P1"GI597H4$W(\$6FF#%$OJE'@*:< M//=+.?VLSRV-S/>&T8%,K^ERIJO9-?J<_V+^329%<*B1N-MORO3-52@2MV[7 M(&5W.R_)1ETWKK=;!#/WR4M+MW7H"V^77#G!+T9ZCT\%M\H0LTV,'3:1T7Z"E+IBV?%U"IB:<=?B) PEH/ MNC1R3T6:FYPT[TH,69*1I/I>S"%AYN&)2?")DV' 008WFR!C:1#"SF@00V\= M8JPY!S",F9V!V/WW(4[V.$CB37B+R9/ULDT]U2!I$\[<^/$F"I^]'=Y=O'Z, M<7H;JR=R4*07/$S)QKOL]276"4,:31P3A0X3@ZD/[Q1LZ:;-/WZ8T636J6G^ MU704T@CY<#R(M4,>O+5FI-1U-Y;$5T8J6#^Z$;YPTULAH]UTJ)MM%[K%Z1UX MVW0@O$["[9\? X]LN_S[P8N]!*]Q].QM<7XJ)'E4#T&FF1=ZQ[-.B\IC6(<, MV/K]U1;+1W-=.LR/Y)%3B:*8R&83[*7>[(4$B_+"B'QDI8QQ0<[))OH=82:: ML9Z!%3GH%OOY6=D;]^5W+WE\#'UR$OQ5&-'OEYU/^FKJY@9U37!Q7M6V=,SF MG;3,#-T]O9$,P[VT.]FU&&7',T=I7"7O<'VII%'BOAC?G06 2GJ$' (/9K13 M5 M02&@A.]S+-<'5#O/ M/Y##U]9X>XBRW1?SEZU_V.'=5=HC)&P=DBQJK>[G;A20SPFGQ4<>V%[I"F@? M5=1OJ8PN.BT-C47Z? .-7-K=Y,8YS=:=^G54-;#C.Y P?ICEJ8B%Q3:S;\'AVQ*-:V?=(86)NFF%&TU(=(0$,U MC>2HV%(G2I7FLVGH,]&+,L6G'7N[\(<+M%3H@4;5HP7 $-KR^F3CY71/RG?8 M8-G4"1,I2YUFPV3N!?PK>(!>:8R2-3O-$!E7(1(W0N36];?DG>DB1&8"Z35< MALJG-%1F4W/H>R_(_S)^S@0H]N'"9!=ZH#$R5P\8(.O^VD):N+5"2(]&8>P9 M6%4S0;G6;S25!-NI\-3L$AOU+I;N'E^&>]?K[/"2;,XM/NK-M82HRH#^857' MEGI8::E@!8P)(@W1Y[RIE0,;"A"$%*=WE@QY*TDQ+]M6##(NCG'2F29I_%BR MI_AQ*$CW?K T#N/G$0][S:H$QN]Z 7$T" MK+/@BJ:&2KF>(F5+]@_[.XF5[SF]9#;C9FZPCD:@7FS$ [CC"!KJ=&P;IAD0 MXZ_U#K\UL8+[WCWS6=)027W7G:(!O(.!8TI;M5K?'F,,^ES^;+JHZ='/W/ C MU]$6A"/&CAS:M48P MM14]>FJ511V!;3:5\4+K./M[?SY<:B H:W;87U3&E( MI6T[Z;B22Z5][XA"W.F*TH<4EX%JII15T M. S;8BQSQ!U5IO?YK'"C;UX=7^3 M C'U*ILJGP:[M?<0>/?>UDT=S?>Y>L'#3>A[6P_'&_R27*0^_=D"+82JXL$. M4S60=$.,0Q(3P \>>0>K=]:+]\O%U6(V)3EN-EM]7&X6R_?H9G6]F"WFAJMS M$#2&\*AHAHXA6NOA9;AWQD-0R\/7_'\%P492J!E6A$(P 41@1D.HD+,H$11D M%#E96[)47D>=%:271467W@I]1B6R0)Y"62F+YLA)#OLO\9?M(7K.^=1,\O[_'G?+;C/&B M8\_(M\ADCT=<;^HRN MR0RZ7O'ZR<&D\/6HW/VW2]I!RA)V[(31H@ M!]BQ54-N41!:4:=?=?H;DW)6G/\FTI(BUZA^7DK9[Y$PQ6J=Q;)8!/^^7 [_@;L>;GAK\2#^ROJK#A\7F TG&$S1;96\!S)?D M%8!)GK%7RUEZ\7:Z6:R6:VM>-N\'KA"@SUNT5U'3H+^Z?P2B MG'A5,@<_ ]O'_." T)Z358H()Q &^)-@O7N\1R"@SXKU\&!TF,/-ZO8R#8MQ M,L];">5S3W4Q5,FAS_;,\QK .FOF=T2PFYT+9KLKG^7D4YI.8H^9K(9EIDX: M*M-.E8FL9:(B[7KE$TD^Z'_1V. M5O?98<#QC1MELR6IQZOD$4=5)F&=% BAJA;.^ZL"H&=?XQK.+ 1P1\3R0>J= M7 /*OTUNTUS&8#"&\*#H!I"^6ML19IAWACFCE/.DJJBAWNCDS%F3-*87["RC M"B?9VL 5@+W/ SV V_H,X(A.GIPW>3)!N1;R\D"N9X)232A?!B(%:*:L-M-@ MST&NMI&,M?/9$I*9W?=<.?\!$^?9A6[S>K=Z+:_#18Q<(_2"&4VY)+-K,JU2 M,+]B#_%:G45G4_?Y,AF2-V7 OJ['"BCG_%O$\0'OV("FM>K"NMD*#MQUO9H@ M3C$A"?2.9 GW.$].^4?+D)0V"01270)PY: (P_+AB8B"\YJ/4*N7>C[ M;E3[QOQZOI4"K]]>RGOTY^^9>_M1*;FZ /*1T>T<]G$Y3VXGG6_!)O\VJH^#7] MWU3F"6_)1Z_\5VNHR=ZJR.EI)NFZ&Q"I6JR@4YY]I\>.%]6 W9:L.K#>$KH6 MK'1KK0<[9I1JPI8TO2ZL*&=Q;4CI=%Y]2.\=08U8"7'KQ+9NHR1ZBO C#N(T MEBV";;C'2YRL[C?N2Y=$HI85B=@MAY.(I1O^F$JA+0&3N-)DP\+-[?RW^7*] M^#1'UZNU^5T*P@X.E7NB0QB64(LP?-UZ402Y2T%D9P"$\J66J@7*FZ#OK\,X M_F&"TK9D.CEM/4'3)(F\NT/BWOE94D]K9&SZHSNP@&,OK0 @SO ^AO01!DF4 MG;E]Z\5_;D@O=L(SK]$Q,M,;#:8332UL4<.QP*<04]!I7$/D(OJ<738^KME1=N,&C6:TC1^D":6 M?!-;IJ>Y5*%VB8@O1R$^:5JZ+6+.#8[(#^X#/A-1A]*4Q9U&4VCRU)1K94_7 MCA)]VN).]0,IPYZB<'?8)BAV??,;2"5ZFL<=1H\(R%.3XK*GH]TB^ES@8/NX M=Z,_Y;(/HSF+1IWFT%1J&=!*)[HM)4K15-#2TK&=K;F)A0,>R3A])2!:2Y)+ M-JH5FPCW2I(I[30E<4LFS6HMP1EVU*V77&TS:KQJ2K,K/1L.5)+H9RZ-J!TB M8M!1B$^>EFZ+>'/M!7B1X+V0-IV&+-;4&D*3YJA:*V?:5I0HTQ2FSAV0)BAK M8QMENGW,8PRU-P2$.B!:;XK.(*.S?I/3ZZL?G)!F&7AJH/O\T4EDR3 M(WS-6E$#N*(H,M,?,MEZ8IRM&69-LLU/92-$6KT=)#%7"X=#R?!:X=&U#=G? MP'C)@]>H&V$;C>!X4E,+6[!P+$BRHRU8!5-K7OW@=B&=!XP'SJ1 K3T#_AV- MII%_BY]Q0-E:2[G6P/GQ&@B\"VV:ZH6F=C&BZ^V/$;YKF6R&]/LWNYZ5FF?RU(PFNRT,?)OY3KC9#4 MN Z"UII&^(3;52[&;%OF"-N;(CIE#:Q*N;1>ZR"9\:!I8*XU[0*ZH\;_>3-? MKLT?2<;HKU#N&7>A7&_91G)7BX;N!TW -.6J?5^DX7P<75XXS6[GY&.5?C>; ME0]Q$NYQU)DLI>=HN=9E?!.U'HIWOG[0;"YEBLL%"0U.V0C15M+LR/>2" A[ M=5.+2'S!!J]D;)ACV:47NP\/$7[(_#K6Y-DV8M:)WTHRQ8.3E!G(.RDKD.Q3 M,I]G4FD&C&BC" 7W6I**4>)V0"O:LHR7CN$O)UGPJ@AU:*= _ OT4 MSIR4T<"FG#5G>LDB0,P[\4F1 D$)KMGRW8M+?)-"IJ<=P7@KSJQY^S MPQ]^LJ0Z505-.*A'6X254] @KHI-6PA\X<9>O'Z*L)MZ^,F-/)+2;]VD\^J, MJAB5PCPQ4 ZS#>DCL="F/(L%JISL.HJS!BC-KL]%$Y0.E4S7M*HX8;)6K@]Y MM&5K8/-69-46XK;C"_5E'141J9P+]-*.C)'QLJWTRSO2:AS2$E5-)ZAJ/$%Y MXU&"B'2&%;W/(R,MGUOM>*^'[R-ER[6\@!0W0;9=BTV,QTO)K=>22N0X M:<$>; 582/.1OP];+"O/11OV8O,]W*2V^HQ2*7)2O&S(::5GS=)X+.T:[4_6 MMJ[V>/7\C#9>/3^)\2H-/M+\9?2L"HUK*N39W+%K+:F_A'THW9:2(W0EI9?. MI9T1R=PR.8#*#4T=(O]$(_+9:1"Y QIY&M-Z5(G$I0(%"C=MFB6P\ OI_$8U M>FKXYCE=+33Y>GW%G"/H7*^6[]]MYK+:&=D"UI1,U2M%6A&.NK5EX':)N0S3E/2(?\LSIWZM6L/&]U*LQOK=,*,3WAJ1SY05NL/6" M!W2/K5KCZG8A.ZC3GCU&D-_-VM%/X[S1@%SE83 XZ*=98XV]X< M:(KF@=^KS6'?IPV0F[6PBA/=;N54.K0NX);J6++MI#W@YL<(B]YO4R=Y)*5UI!*SF9# M4#+65>LC'\6*/-DZPNUA#MH7+=#.,K)1>YA)+E9?\,A4EV&3IZO9%K(LW3W] M,R:B9E2BU)N!TJ12K(\D'1OR%&F)=O>RD096[BBE="R3'_1.X+&CDF!SHZW5 M%F;DR_/>]L9]S?X9><'6>W)]+D]$0E36L(5 .<0RHX]1 HOR_.(J%O/^N!'.,0)%C,&3TB*?7/"_"N<.'0EFLL6=H@6J-RDX:<=ZK41_ M=]DG[!NE%,C4 ^MM4>5&0IXQ"S M$K%J:5D916+:"OI7BL04'1*49EJVCN#S_9,?ON+H@YML'[W@H7$]7Z:3([R" M(GX D%*D)R!(F!XA0,A[T2-@R"IWRH9DB2YKB;:UIE9&"Q4(BJ.'(ABDHHF$ M3HGH(NV9==&&G*M\B[?A0^#] [>_GZ8DPX\A;1D]X:)I983(0#78(PA0]#C' M8[ C[),]&@2'IT-]!DC$+&?WH12AF^(2W*79,TG3IS#VDG@:QSB)E^EC/T01 M+>7SFQW)R&HVF']TQ:J4>\;172A:^.":XI.-(^J45[,#])MX(:Y+C$,.(97(IXB MO/6R2=+T;Q]GLZ7!;KH/H\3[1_9[-\)*BU315D)D.'^$1F +'VE[ E;)J7'J M+;/0[-::&*>8/";"_GW689Y0NL5"26M&#Y OIF-6][-P3PK=_,L3>:F;?>UE M_>A&^,Z-\:[8MQ*SSY<'4%8=/S](V?#3Z0>8!R4^A">"L^V'&G#F__%QL?D# M+9:S^7*S^#1'-]?3I3VKCS# #'7 HW-H_@"]K3/U!WMX G'IHNX]YTLT$-I4 M(Q-+VUBAB6[?2&SBN@(2G#@6Z-'I1$*2 ))]8I(8%SV#$EUQKZC$\]%<6)J[ M4> %#_$-CC(O;T+?V[ZRPHYDZ^)A"UL/#!L"_1IFC.0L\M@OH\&Y#N.8'&:, MLB9F:2W;Y6&O?FG24B!8IYV4#?WX IM7DK0U$%IG:>8H6E7XFJ"\)?I<_)>( MH$S&<)6K!WN,:2A8\!F=E&K[1SZ'L16$\D8;1@ OV@#3*M,*6FP%3(U"K\XRHVE" MA19U2:?XQRD6&^TNYG"$TA]\AI2/A4.0ADZ#]+B_Q]MD=3]_V3ZF",B^.[<* M9F[\2/YO_O>#]^SZ9!+H%J>$]K9DEBB], UVS1]J+=O4TF>AI*4."T,I#>\3 M:#C0YAXWE&BRZN2*R4&-N%"='9*%\K]C\L'*;2IG. !I)$(X&O):@0_>6"-H MZKH7TP'7>\;'UY7)39&=E\'6\_/M"M/D"N]PY/KD5+)#ZLEKHS$UP()H; 34 M@1I! N@@'^ #)H0[X@ YW(IS5)2=66'^P$!(C'9B'1A(:+%MD/)N+ /PU;;8 M17:2>\$A+6Y7::V?W4=,OSO&A!:L5FX,ZZ%52QQ3]@-^=@W4+_6@UL^24QV/ MDI9UULR_ "-8&.$&P4ZGC[;0S^X24I8GT;BWEF]JJB=4I3EN:98 M]G'C[)W!;PSMA;!3HJC9V=W\C5.\QM&SM\75WJ7Z[J9E&#RGPT&\FWYQHUV\ M(1]JJU\GVYZ68?('KKT EY\5>!5&Q4^DW5F[<#%BO*QO1C8^- Z/ZB[HR,^$ MY]R8/KY#SN_8>W@D,]KNY46F3@/7\&B=LB5+[1]>I$#=RH262E-V32 MD4WV.WJKR&&-*P9#YVW6_I6F7&A%#D78/+I!@8^QA@&R?N@>$8C]L'5P(/)< M7UHS="=&Q@U2OCG+KW5<($WC,88(*HP8:;0@*3Z;5-I&F9X)FK]L_<..'&:6:YH@8CYMEZ#7 M-&16'DS0U(*O+G\+DQU"?8N3G0=C^:A@^O 0X0!Z//KDLX,S@G"&T4,76JQ9Y@0#JVJ0E<5+CUC)4ZT<\\1^6AZZ M>@7M:NYFO,D+BDWM$Q4-F]86ZS4O3V*ADN*PF1*\[<=7/*= 8]HWCKEMROA+;S,T7M*T@L8WC@%N/&+* M.?DE=+QFR?>,^9T8*CSS%BUIS1LT8NLS"/OBY9]-Y.[PCKYRSFE2@I[:9"CF M*4I!(<_6ST4\2\PIKZ#T4AKUME:M=_(Z,91_Z"W,4UHW(,_49@[Q5ZX7?7+] M [YX/?[YFX>C]"$^OE[CY[0O7KQV):\F5#PD6:&!/)$S \D<)8L\+BDHK!)0SGY.C%5+%I U0_8)9,)V8&)77^I MM5HOV39QY62A^"MC30N-%0Q+L5E:GX#45M2+_8!$8[=J_S)(+J.&RG5Y^Q90 M?G5_Y05NL/7(UV?C)#ID;N?GZ[&H+B/3ICA?!HK:/"M:*"UA4(K*0CUU"H?W MZ-@:U9I;0F I>-"(*]M[#,+RQ*E$%=NS@* 7;HH>,AN$P7=&;)-+9,S])( MQ.\"!G>Z0E3*L'3;Q91S:::<2S/E7"-3SL=AROD@IIQWF7)N,5/:/2M@"J4+ MQ$PYEV/*N25,R>I2?(W=&%][[IWG>\EK^6F>RP->XI=D\P7[S_A#&"2/G=%K M3_&24\KB0XFF:!#\%:Z>#G!YV4>ED^+A9\,$[8N=$*8_6U16U-3@=R\O#$ 9 M["V=OL:A<7R6#H5R,93)3=!1)AD; M\T9?W1 YK)C9%#.9=KHK9RJR/W%(I@+(3'DFRG9*(I\T0D_%1;MIVH>6_3./ M"NM&R2RC9A*(S"',%$7;"4H;OTWH]

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end